data_2mh1_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2mh1 _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 77.7 m . . . . . 0 N--CA 1.442 -0.854 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -82.61 8.48 62.0 Favored Glycine 0 C--N 1.308 -0.999 0 C-N-CA 121.432 -0.414 . . . . 0.0 113.168 -176.03 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.404 ' HG3' ' SG ' ' A' ' 25' ' ' CYS . 12.4 pt-20 -90.13 156.67 18.19 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 -179.393 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 5.8 p -107.55 161.7 14.61 Favored 'General case' 0 N--CA 1.409 -2.503 0 CA-C-O 120.739 0.305 . . . . 0.0 110.767 178.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.444 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 19.1 p -127.66 35.7 4.47 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -178.622 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 29.6 t -52.36 -37.31 23.03 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.987 0 CA-C-N 114.81 -1.086 . . . . 0.0 111.628 -177.559 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -68.95 -37.52 83.52 Favored Glycine 0 N--CA 1.443 -0.846 0 C-N-CA 121.068 -0.587 . . . . 0.0 111.94 177.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.477 ' C ' ' HG1' ' A' ' 12' ' ' THR . . . 157.05 -20.53 0.43 Allowed Glycine 0 N--CA 1.44 -1.035 0 C-N-CA 119.472 -1.347 . . . . 0.0 115.483 177.646 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.477 ' HG1' ' C ' ' A' ' 11' ' ' GLY . 27.6 m -155.89 164.86 37.97 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 -176.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 40.3 m -94.71 164.65 12.86 Favored 'General case' 0 C--N 1.283 -2.312 0 C-N-CA 123.688 0.795 . . . . 0.0 108.949 178.536 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 39.7 m-80 -93.5 -30.86 14.81 Favored 'General case' 0 C--N 1.302 -1.477 0 CA-C-O 121.163 0.506 . . . . 0.0 110.008 -177.595 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.487 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 20.6 m -90.13 120.28 69.22 Favored Pre-proline 0 C--N 1.304 -1.395 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 176.836 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -71.05 -3.56 13.11 Favored 'Trans proline' 0 N--CA 1.485 1.022 0 C-N-CA 123.258 2.639 . . . . 0.0 114.285 -175.626 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -89.0 -11.94 64.41 Favored Glycine 0 C--N 1.269 -3.19 0 CA-C-N 114.176 -1.375 . . . . 0.0 110.117 176.453 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.487 ' SG ' ' HB ' ' A' ' 15' ' ' THR . 34.5 m -103.68 144.67 31.15 Favored 'General case' 0 N--CA 1.423 -1.817 0 CA-C-N 114.761 -0.719 . . . . 0.0 109.25 -179.372 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 14.7 m -112.7 151.33 30.34 Favored 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 179.5 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 52.0 t -89.14 118.69 29.03 Favored 'General case' 0 C--N 1.277 -2.549 0 CA-C-O 121.531 0.682 . . . . 0.0 110.318 -179.34 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 63.0 m -116.54 63.81 0.71 Allowed 'General case' 0 N--CA 1.407 -2.579 0 N-CA-C 104.54 -2.393 . . . . 0.0 104.54 171.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . 0.428 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 40.6 t90 -36.27 132.43 0.61 Allowed Pre-proline 0 N--CA 1.437 -1.082 0 C-N-CA 126.404 1.882 . . . . 0.0 113.592 -170.144 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.428 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 2.8 Cg_endo -90.31 13.56 53.0 Favored 'Cis proline' 0 CA--C 1.547 1.139 0 C-N-CA 122.882 -1.716 . . . . 0.0 114.849 2.039 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.6 m -110.91 144.46 18.82 Favored 'Isoleucine or valine' 0 C--O 1.204 -1.316 0 N-CA-C 112.877 0.695 . . . . 0.0 112.877 -176.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.444 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 76.5 m -86.19 152.14 23.06 Favored 'General case' 0 N--CA 1.407 -2.578 0 O-C-N 121.164 -0.96 . . . . 0.0 110.693 176.287 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.438 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.6 p -130.83 -176.89 4.14 Favored 'General case' 0 C--N 1.291 -1.951 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 175.164 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 14.4 ttm180 . . . . . 0 N--CA 1.416 -2.172 0 N-CA-C 106.107 -1.812 . . . . 0.0 106.107 178.844 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 81.4 m . . . . . 0 N--CA 1.429 -1.489 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -76.13 7.12 31.35 Favored Glycine 0 C--N 1.31 -0.881 0 CA-C-N 115.877 -0.601 . . . . 0.0 112.853 -178.165 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -90.56 150.18 21.85 Favored 'General case' 0 N--CA 1.417 -2.122 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 178.823 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 6.6 p -109.7 154.17 23.25 Favored 'General case' 0 N--CA 1.392 -3.372 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.439 178.031 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.478 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 20.0 p -118.06 37.28 4.03 Favored 'General case' 0 CA--C 1.484 -1.575 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -177.807 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.8 t -55.71 -35.64 39.92 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.971 0 CA-C-N 115.002 -0.999 . . . . 0.0 109.912 -178.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -65.7 -26.26 71.99 Favored Glycine 0 N--CA 1.446 -0.693 0 CA-C-N 115.354 -0.839 . . . . 0.0 112.587 178.244 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 137.41 -22.01 3.23 Favored Glycine 0 N--CA 1.437 -1.249 0 C-N-CA 120.849 -0.691 . . . . 0.0 113.917 178.782 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 12.1 m -150.31 158.99 44.76 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 -175.624 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.478 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 61.0 m -95.23 155.94 16.52 Favored 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 176.467 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 40.1 m-80 -88.72 -18.61 27.47 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-O 121.178 0.513 . . . . 0.0 111.194 -178.613 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.543 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 34.0 m -101.14 124.77 40.31 Favored Pre-proline 0 C--N 1.297 -1.684 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 175.316 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -68.57 -13.68 37.85 Favored 'Trans proline' 0 N--CA 1.488 1.151 0 C-N-CA 122.974 2.449 . . . . 0.0 112.907 -178.2 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -84.55 -12.78 74.61 Favored Glycine 0 C--N 1.263 -3.525 0 CA-C-N 113.311 -1.768 . . . . 0.0 110.525 178.633 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.62 ' HA ' ' O ' ' A' ' 26' ' ' THR . 56.1 m -103.51 126.28 50.57 Favored 'General case' 0 N--CA 1.403 -2.792 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 -179.153 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.451 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 1.1 m -89.23 144.03 26.4 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 -177.77 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 53.7 t -88.14 103.26 15.59 Favored 'General case' 0 N--CA 1.421 -1.904 0 C-N-CA 119.602 -0.839 . . . . 0.0 109.887 177.764 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 14.7 m -104.82 58.36 0.69 Allowed 'General case' 0 C--N 1.285 -2.231 0 N-CA-C 104.473 -2.417 . . . . 0.0 104.473 174.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . 0.437 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 42.1 t90 -33.98 132.9 0.38 Allowed Pre-proline 0 N--CA 1.441 -0.893 0 C-N-CA 127.133 2.173 . . . . 0.0 113.495 -169.808 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.437 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 4.5 Cg_exo -89.31 11.32 59.45 Favored 'Cis proline' 0 C--N 1.322 -0.859 0 C-N-CA 122.851 -1.729 . . . . 0.0 114.981 2.203 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 34.8 m -109.68 143.6 19.49 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.765 0 C-N-CA 120.166 -0.614 . . . . 0.0 112.538 -176.458 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.47 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 77.5 m -89.36 147.92 23.8 Favored 'General case' 0 N--CA 1.414 -2.273 0 O-C-N 121.7 -0.625 . . . . 0.0 110.984 177.21 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.62 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.9 p -132.74 -167.31 1.88 Allowed 'General case' 0 C--O 1.195 -1.796 0 C-N-CA 123.923 0.889 . . . . 0.0 109.206 178.069 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 98.8 mtt180 . . . . . 0 N--CA 1.399 -2.996 0 CA-C-N 119.048 0.84 . . . . 0.0 109.51 179.083 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 4.0 m . . . . . 0 N--CA 1.413 -2.275 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -88.92 -5.75 73.25 Favored Glycine 0 N--CA 1.439 -1.165 0 N-CA-C 110.123 -1.191 . . . . 0.0 110.123 177.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -78.77 147.93 33.16 Favored 'General case' 0 N--CA 1.428 -1.558 0 CA-C-N 114.92 -0.64 . . . . 0.0 109.438 179.689 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 32.2 p -105.01 155.09 19.29 Favored 'General case' 0 N--CA 1.401 -2.907 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.271 -177.178 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.624 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 30.0 p -118.8 41.62 2.98 Favored 'General case' 0 N--CA 1.428 -1.537 0 CA-C-O 121.614 0.721 . . . . 0.0 109.228 -179.104 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 35.4 t -56.57 -36.47 48.23 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.919 0 CA-C-N 114.933 -1.03 . . . . 0.0 111.075 -178.366 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -91.7 3.93 78.66 Favored Glycine 0 CA--C 1.519 0.312 0 N-CA-C 112.025 -0.43 . . . . 0.0 112.025 178.338 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 83.17 42.51 7.98 Favored Glycine 0 N--CA 1.44 -1.066 0 C-N-CA 121.753 -0.26 . . . . 0.0 112.847 179.231 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.3 t -155.09 151.03 27.84 Favored 'General case' 0 N--CA 1.431 -1.377 0 CA-C-O 121.286 0.565 . . . . 0.0 111.227 179.219 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.442 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 82.9 m -138.2 145.85 41.94 Favored 'General case' 0 C--N 1.286 -2.166 0 CA-C-N 113.812 -1.54 . . . . 0.0 108.105 178.696 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 31.6 m-80 -87.18 -39.25 15.66 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-O 121.61 0.719 . . . . 0.0 110.162 -178.505 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 16.0 m -78.52 120.85 82.55 Favored Pre-proline 0 C--N 1.305 -1.366 0 N-CA-C 108.785 -0.821 . . . . 0.0 108.785 178.208 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -72.98 -8.42 22.22 Favored 'Trans proline' 0 C--N 1.365 1.425 0 C-N-CA 122.802 2.335 . . . . 0.0 113.127 -175.501 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -92.97 -6.66 63.21 Favored Glycine 0 C--N 1.265 -3.369 0 CA-C-N 113.45 -1.705 . . . . 0.0 109.881 177.725 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.479 ' HA ' ' O ' ' A' ' 26' ' ' THR . 98.7 m -109.57 125.93 53.05 Favored 'General case' 0 N--CA 1.401 -2.898 0 CA-C-O 122.532 1.158 . . . . 0.0 111.106 179.202 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 3.5 m -100.09 153.23 19.39 Favored 'General case' 0 N--CA 1.401 -2.916 0 C-N-CA 127.153 2.181 . . . . 0.0 107.688 -175.283 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 53.9 t -85.27 117.59 24.3 Favored 'General case' 0 C--N 1.285 -2.198 0 CA-C-O 121.466 0.65 . . . . 0.0 110.364 179.001 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 21.3 t -124.55 74.88 1.36 Allowed 'General case' 0 C--N 1.282 -2.364 0 N-CA-C 103.197 -2.89 . . . . 0.0 103.197 172.47 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . 0.472 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 42.9 t90 -39.56 133.88 1.28 Allowed Pre-proline 0 N--CA 1.431 -1.411 0 CA-C-N 113.858 -1.519 . . . . 0.0 113.096 -171.063 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.472 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 1.4 Cg_endo -92.38 15.27 46.72 Favored 'Cis proline' 0 CA--C 1.541 0.868 0 C-N-CA 122.874 -1.719 . . . . 0.0 114.695 1.958 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 30.9 m -115.63 146.62 19.82 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 N-CA-C 113.986 1.106 . . . . 0.0 113.986 -175.696 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.624 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 70.0 m -83.8 132.93 34.79 Favored 'General case' 0 N--CA 1.402 -2.846 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 173.309 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.479 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 2.5 p -135.55 -176.57 4.33 Favored 'General case' 0 C--O 1.182 -2.485 0 C-N-CA 124.057 0.943 . . . . 0.0 108.654 -179.779 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 57.2 mtp180 . . . . . 0 N--CA 1.407 -2.585 0 CA-C-N 119.515 1.052 . . . . 0.0 110.009 -177.407 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 73.2 m . . . . . 0 N--CA 1.431 -1.4 0 N-CA-C 109.665 -0.495 . . . . 0.0 109.665 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -88.41 16.9 51.51 Favored Glycine 0 C--N 1.315 -0.612 0 N-CA-C 110.741 -0.944 . . . . 0.0 110.741 177.65 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 -90.35 150.63 21.81 Favored 'General case' 0 N--CA 1.432 -1.354 0 C-N-CA 124.018 0.927 . . . . 0.0 109.881 -178.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 7.1 p -124.58 151.94 44.15 Favored 'General case' 0 N--CA 1.411 -2.384 0 CA-C-N 116.186 -0.461 . . . . 0.0 109.869 176.025 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.491 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 27.0 p -130.9 41.12 3.4 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-O 121.446 0.641 . . . . 0.0 109.989 -176.507 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 19.4 t -61.87 -32.94 55.64 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 114.965 -1.016 . . . . 0.0 109.533 -179.317 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -85.79 -1.61 87.08 Favored Glycine 0 N--CA 1.442 -0.943 0 CA-C-N 115.452 -0.795 . . . . 0.0 111.78 178.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 109.4 -10.14 33.18 Favored Glycine 0 N--CA 1.433 -1.516 0 N-CA-C 114.81 0.684 . . . . 0.0 114.81 176.059 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 1.1 m -137.55 152.57 49.59 Favored 'General case' 0 N--CA 1.43 -1.471 0 CA-C-N 118.773 1.286 . . . . 0.0 110.198 -174.708 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.463 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 82.8 m -106.92 136.39 46.84 Favored 'General case' 0 C--N 1.277 -2.546 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 174.469 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 33.9 m-80 -65.54 -44.44 86.85 Favored 'General case' 0 N--CA 1.475 0.778 0 CA-C-O 121.236 0.541 . . . . 0.0 109.816 176.884 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 55.0 m -83.33 112.48 39.35 Favored Pre-proline 0 N--CA 1.43 -1.447 0 N-CA-C 108.852 -0.796 . . . . 0.0 108.852 175.197 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -75.87 -1.39 11.34 Favored 'Trans proline' 0 C--N 1.359 1.096 0 C-N-CA 123.337 2.691 . . . . 0.0 113.781 -174.716 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -86.69 -10.64 72.57 Favored Glycine 0 C--N 1.27 -3.084 0 CA-C-N 113.971 -1.468 . . . . 0.0 110.356 177.14 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.456 ' HA ' ' O ' ' A' ' 26' ' ' THR . 49.9 m -105.92 133.5 50.54 Favored 'General case' 0 N--CA 1.419 -2.006 0 CA-C-N 114.552 -0.824 . . . . 0.0 109.537 -179.053 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.419 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 5.8 m -89.86 151.88 21.54 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 108.299 -1.001 . . . . 0.0 108.299 -177.693 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 50.5 t -88.52 104.71 17.07 Favored 'General case' 0 C--N 1.292 -1.93 0 CA-C-O 122.021 0.915 . . . . 0.0 111.331 179.604 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 42.6 t -107.51 65.59 0.65 Allowed 'General case' 0 C--N 1.285 -2.201 0 N-CA-C 104.22 -2.511 . . . . 0.0 104.22 173.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . 0.444 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 56.7 t90 -36.24 132.63 0.61 Allowed Pre-proline 0 N--CA 1.439 -1.018 0 C-N-CA 125.884 1.673 . . . . 0.0 112.668 -172.171 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.444 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 2.2 Cg_endo -90.23 10.76 60.48 Favored 'Cis proline' 0 CA--C 1.546 1.117 0 C-N-CA 123.017 -1.66 . . . . 0.0 115.294 3.09 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 30.6 m -111.34 153.78 13.03 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.0 0 O-C-N 121.561 -0.712 . . . . 0.0 112.466 -176.611 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.491 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 68.3 m -92.89 135.37 34.2 Favored 'General case' 0 N--CA 1.397 -3.078 0 O-C-N 121.835 -0.541 . . . . 0.0 109.617 175.044 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.456 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 11.8 p -116.45 -174.21 2.52 Favored 'General case' 0 C--N 1.285 -2.23 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.836 -179.558 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.383 -3.784 0 CA-C-O 121.523 0.677 . . . . 0.0 110.901 -176.79 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 71.9 m . . . . . 0 N--CA 1.439 -0.996 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -94.93 -2.76 62.45 Favored Glycine 0 C--N 1.308 -1.005 0 C-N-CA 121.227 -0.511 . . . . 0.0 111.869 -176.521 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.434 ' O ' ' HB2' ' A' ' 25' ' ' CYS . 1.6 pm0 -83.82 141.74 31.13 Favored 'General case' 0 N--CA 1.426 -1.673 0 CA-C-O 121.488 0.661 . . . . 0.0 110.87 177.001 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 22.8 p -106.83 153.57 22.29 Favored 'General case' 0 N--CA 1.404 -2.732 0 CA-C-N 115.279 -0.873 . . . . 0.0 109.765 -179.603 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.447 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 19.5 p -122.01 37.59 4.33 Favored 'General case' 0 CA--C 1.492 -1.277 0 CA-C-O 121.389 0.614 . . . . 0.0 110.268 -177.876 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 16.0 t -60.06 -33.99 55.04 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.204 0 CA-C-N 114.734 -1.121 . . . . 0.0 109.636 -178.646 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -87.73 6.62 83.17 Favored Glycine 0 N--CA 1.439 -1.107 0 CA-C-N 115.258 -0.883 . . . . 0.0 113.087 179.647 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.452 ' C ' ' HG1' ' A' ' 12' ' ' THR . . . 142.18 -69.01 0.44 Allowed Glycine 0 N--CA 1.438 -1.189 0 C-N-CA 120.131 -1.033 . . . . 0.0 114.502 177.384 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.452 ' HG1' ' C ' ' A' ' 11' ' ' GLY . 20.5 m -157.04 163.24 39.27 Favored 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 106.748 -1.575 . . . . 0.0 106.748 -174.851 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 98.3 m -94.76 158.49 15.48 Favored 'General case' 0 C--N 1.281 -2.384 0 CA-C-O 120.808 0.337 . . . . 0.0 110.493 178.58 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 16.1 m120 -84.39 -26.73 28.15 Favored 'General case' 0 C--N 1.31 -1.144 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.845 -178.64 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 9.1 m -71.22 112.87 15.14 Favored Pre-proline 0 CA--C 1.556 1.175 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 177.243 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -70.8 -10.21 27.28 Favored 'Trans proline' 0 C--N 1.362 1.274 0 C-N-CA 123.293 2.662 . . . . 0.0 115.257 -172.101 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -93.3 -6.06 63.18 Favored Glycine 0 C--N 1.258 -3.753 0 CA-C-N 114.309 -1.314 . . . . 0.0 111.124 179.121 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.501 ' HA ' ' O ' ' A' ' 26' ' ' THR . 60.3 m -108.49 126.01 52.43 Favored 'General case' 0 N--CA 1.422 -1.834 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 1.4 m -95.16 143.9 26.22 Favored 'General case' 0 C--N 1.284 -2.268 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 -178.203 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 41.1 t -87.65 125.94 34.67 Favored 'General case' 0 C--N 1.285 -2.225 0 CA-C-O 121.593 0.711 . . . . 0.0 109.879 -179.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 6.4 t -132.22 71.41 1.47 Allowed 'General case' 0 N--CA 1.4 -2.973 0 N-CA-C 103.426 -2.805 . . . . 0.0 103.426 174.53 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . 0.491 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 55.5 t90 -35.69 132.87 0.53 Allowed Pre-proline 0 N--CA 1.433 -1.297 0 C-N-CA 126.319 1.848 . . . . 0.0 112.95 -171.281 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.491 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 1.6 Cg_endo -91.95 10.59 58.15 Favored 'Cis proline' 0 CA--C 1.539 0.729 0 C-N-CA 123.081 -1.633 . . . . 0.0 115.381 4.053 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 34.1 m -118.56 150.03 20.88 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 C-N-CA 119.511 -0.875 . . . . 0.0 112.438 -175.177 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.447 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 64.5 m -95.66 148.56 22.41 Favored 'General case' 0 N--CA 1.398 -3.047 0 CA-C-O 121.704 0.764 . . . . 0.0 111.331 175.933 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.501 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 0.6 OUTLIER -135.47 -165.23 1.66 Allowed 'General case' 0 C--N 1.284 -2.242 0 CA-C-N 114.518 -1.219 . . . . 0.0 109.975 177.851 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 3.8 ptm180 . . . . . 0 N--CA 1.389 -3.491 0 CA-C-O 121.746 0.784 . . . . 0.0 110.554 -174.476 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 65.2 m . . . . . 0 N--CA 1.438 -1.029 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -96.25 14.72 64.06 Favored Glycine 0 C--N 1.314 -0.678 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 176.534 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.423 ' HB2' ' HB2' ' A' ' 25' ' ' CYS . 6.7 mm-40 -81.21 149.76 28.92 Favored 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 179.132 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 18.3 p -123.49 150.75 43.54 Favored 'General case' 0 N--CA 1.401 -2.914 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 177.198 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.481 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 30.1 p -127.22 44.85 2.83 Favored 'General case' 0 N--CA 1.427 -1.578 0 CA-C-O 121.231 0.539 . . . . 0.0 109.588 -177.103 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 38.8 t -57.62 -33.82 45.75 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.059 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.894 -178.37 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -81.09 -31.49 34.71 Favored Glycine 0 N--CA 1.444 -0.83 0 N-CA-C 110.803 -0.919 . . . . 0.0 110.803 175.474 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 124.84 14.89 3.31 Favored Glycine 0 N--CA 1.441 -1.006 0 C-N-CA 121.507 -0.378 . . . . 0.0 113.613 178.41 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 12.7 m -139.62 153.77 47.42 Favored 'General case' 0 N--CA 1.424 -1.727 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 -178.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.463 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 41.5 m -122.59 137.93 54.74 Favored 'General case' 0 C--N 1.274 -2.709 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 175.194 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -66.01 -52.44 49.24 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.043 178.188 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 32.8 m -73.39 112.53 16.32 Favored Pre-proline 0 CA--C 1.554 1.122 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 176.57 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -72.86 -4.64 15.74 Favored 'Trans proline' 0 C--N 1.36 1.178 0 C-N-CA 123.438 2.759 . . . . 0.0 114.868 -172.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -86.0 -14.77 66.37 Favored Glycine 0 C--N 1.257 -3.822 0 CA-C-N 114.388 -1.278 . . . . 0.0 110.358 177.416 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.534 ' HA ' ' O ' ' A' ' 26' ' ' THR . 22.0 m -103.95 129.94 51.54 Favored 'General case' 0 N--CA 1.419 -1.999 0 CA-C-N 114.952 -0.624 . . . . 0.0 109.658 -179.163 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 4.3 m -95.85 156.48 16.31 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 124.346 1.058 . . . . 0.0 108.151 -178.806 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 42.0 t -83.04 123.76 29.78 Favored 'General case' 0 N--CA 1.423 -1.809 0 CA-C-O 121.61 0.719 . . . . 0.0 110.987 -179.299 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 32.7 t -133.76 69.93 1.46 Allowed 'General case' 0 C--N 1.283 -2.306 0 N-CA-C 104.526 -2.398 . . . . 0.0 104.526 173.831 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . 0.491 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 41.7 t90 -36.53 134.59 0.6 Allowed Pre-proline 0 N--CA 1.443 -0.821 0 C-N-CA 126.258 1.823 . . . . 0.0 113.93 -170.702 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.491 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 1.9 Cg_endo -90.12 8.83 65.17 Favored 'Cis proline' 0 N--CA 1.456 -0.705 0 C-N-CA 122.679 -1.8 . . . . 0.0 114.261 1.277 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 35.9 m -108.88 158.66 8.62 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.928 0 CA-C-O 121.415 0.626 . . . . 0.0 112.548 -175.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.481 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 84.1 m -95.41 135.52 36.94 Favored 'General case' 0 N--CA 1.405 -2.7 0 O-C-N 121.733 -0.604 . . . . 0.0 109.829 174.453 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.534 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 10.5 p -119.35 -169.46 1.76 Allowed 'General case' 0 C--N 1.286 -2.168 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.83 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 10.5 mtp-105 . . . . . 0 N--CA 1.392 -3.326 0 CA-C-O 121.878 0.847 . . . . 0.0 110.442 -177.447 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.711 ' SG ' ' HG3' ' A' ' 27' ' ' ARG . 78.0 m . . . . . 0 N--CA 1.439 -0.978 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -81.57 -3.47 90.61 Favored Glycine 0 C--N 1.308 -1.007 0 C-N-CA 120.99 -0.624 . . . . 0.0 111.944 -179.501 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -89.62 160.06 16.84 Favored 'General case' 0 N--CA 1.437 -1.096 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 179.602 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' THR . . . . . 0.412 ' HB ' HG23 ' A' ' 9' ' ' VAL . 38.0 p -113.88 164.07 14.25 Favored 'General case' 0 N--CA 1.406 -2.647 0 CA-C-O 121.109 0.481 . . . . 0.0 112.271 -174.83 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.498 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 26.1 p -131.41 33.8 4.03 Favored 'General case' 0 N--CA 1.426 -1.663 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 178.034 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.412 HG23 ' HB ' ' A' ' 7' ' ' THR . 21.9 t -57.7 -35.52 51.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 114.74 -1.118 . . . . 0.0 110.01 -178.766 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -82.27 -4.77 90.08 Favored Glycine 0 N--CA 1.444 -0.782 0 CA-C-N 115.684 -0.689 . . . . 0.0 113.063 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 128.46 -24.98 4.87 Favored Glycine 0 N--CA 1.444 -0.771 0 C-N-CA 120.231 -0.985 . . . . 0.0 114.344 177.497 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 15.3 t -156.89 173.03 17.61 Favored 'General case' 0 N--CA 1.431 -1.402 0 CA-C-N 118.277 1.039 . . . . 0.0 110.446 -175.689 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 57.5 m -101.77 175.88 5.41 Favored 'General case' 0 C--N 1.276 -2.612 0 CA-C-N 114.527 -1.215 . . . . 0.0 109.977 -175.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 51.0 m-80 -97.88 -38.32 9.48 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.046 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 33.9 m -90.03 126.12 58.28 Favored Pre-proline 0 N--CA 1.429 -1.524 0 CA-C-N 115.505 -0.77 . . . . 0.0 108.979 178.33 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -72.33 -2.34 11.55 Favored 'Trans proline' 0 C--N 1.358 1.043 0 C-N-CA 122.693 2.262 . . . . 0.0 113.416 -177.383 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -93.07 -10.09 60.08 Favored Glycine 0 C--N 1.271 -3.054 0 CA-C-N 113.836 -1.529 . . . . 0.0 110.311 177.176 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.522 ' HA ' ' O ' ' A' ' 26' ' ' THR . 80.3 m -104.09 132.37 50.4 Favored 'General case' 0 N--CA 1.42 -1.926 0 CA-C-N 114.96 -0.62 . . . . 0.0 109.472 179.478 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 7.5 m -101.49 156.43 17.47 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 -179.736 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 44.4 t -88.16 123.97 33.35 Favored 'General case' 0 N--CA 1.418 -2.066 0 CA-C-O 121.409 0.623 . . . . 0.0 109.961 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 8.8 t -130.82 62.83 1.6 Allowed 'General case' 0 C--N 1.282 -2.34 0 N-CA-C 103.463 -2.792 . . . . 0.0 103.463 175.121 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . 0.537 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 35.5 t90 -33.28 135.78 0.29 Allowed Pre-proline 0 C--O 1.243 0.732 0 C-N-CA 127.827 2.451 . . . . 0.0 113.821 -170.335 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.537 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 4.4 Cg_exo -88.4 4.98 69.71 Favored 'Cis proline' 0 CA--C 1.534 0.507 0 C-N-CA 123.004 -1.665 . . . . 0.0 114.812 2.183 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 34.1 m -107.82 157.66 7.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 C-N-CA 120.26 -0.576 . . . . 0.0 111.913 -176.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.506 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 93.1 m -91.28 150.33 21.37 Favored 'General case' 0 N--CA 1.404 -2.77 0 CA-C-O 121.305 0.574 . . . . 0.0 111.086 177.063 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.522 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 16.7 p -130.9 -178.65 4.9 Favored 'General case' 0 N--CA 1.421 -1.895 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.624 179.765 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.711 ' HG3' ' SG ' ' A' ' 4' ' ' CYS . 34.4 mtt85 . . . . . 0 N--CA 1.414 -2.241 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 -177.798 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 73.7 m . . . . . 0 N--CA 1.446 -0.66 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -77.78 -6.24 86.94 Favored Glycine 0 C--N 1.312 -0.778 0 C-N-CA 121.212 -0.518 . . . . 0.0 113.163 -177.262 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -86.14 146.94 26.37 Favored 'General case' 0 C--N 1.308 -1.222 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 -179.398 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 24.9 p -104.39 161.43 14.08 Favored 'General case' 0 N--CA 1.414 -2.255 0 CA-C-O 121.013 0.435 . . . . 0.0 111.891 -179.401 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.47 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 9.2 p -126.63 34.72 4.75 Favored 'General case' 0 CA--C 1.492 -1.255 0 CA-C-O 121.271 0.558 . . . . 0.0 110.27 -178.858 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.446 ' HA ' ' NE1' ' A' ' 22' ' ' TRP . 5.7 t -65.43 -28.79 45.27 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-N 115.273 -0.876 . . . . 0.0 109.46 -178.698 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -79.76 -15.83 78.58 Favored Glycine 0 C--O 1.241 0.564 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.512 177.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 125.98 -18.39 6.63 Favored Glycine 0 N--CA 1.436 -1.361 0 C-N-CA 120.519 -0.848 . . . . 0.0 115.217 175.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.5 m -145.67 158.14 43.88 Favored 'General case' 0 N--CA 1.437 -1.092 0 CA-C-N 118.764 1.282 . . . . 0.0 108.172 -175.341 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 62.7 m -99.51 170.85 8.32 Favored 'General case' 0 C--N 1.281 -2.372 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 175.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 26.9 m-80 -101.37 -18.82 15.87 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.468 0.651 . . . . 0.0 110.621 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.565 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 29.2 m -105.58 124.83 35.0 Favored Pre-proline 0 C--N 1.293 -1.888 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 175.561 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -73.29 -3.26 13.38 Favored 'Trans proline' 0 N--CA 1.486 1.078 0 C-N-CA 122.744 2.296 . . . . 0.0 113.098 -177.735 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -94.89 -8.03 59.47 Favored Glycine 0 C--N 1.27 -3.134 0 CA-C-N 113.38 -1.736 . . . . 0.0 109.839 176.419 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.613 ' HA ' ' O ' ' A' ' 26' ' ' THR . 85.0 m -106.12 125.75 51.37 Favored 'General case' 0 N--CA 1.419 -1.998 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.168 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 7.4 m -101.55 160.42 14.46 Favored 'General case' 0 C--N 1.286 -2.168 0 N-CA-C 107.483 -1.302 . . . . 0.0 107.483 -178.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 42.1 t -93.11 122.58 35.63 Favored 'General case' 0 N--CA 1.419 -2.013 0 CA-C-O 121.305 0.574 . . . . 0.0 110.911 -177.352 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 49.3 m -123.99 67.69 1.04 Allowed 'General case' 0 N--CA 1.409 -2.483 0 N-CA-C 105.03 -2.211 . . . . 0.0 105.03 171.644 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . 0.526 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 50.4 t90 -37.27 133.69 0.73 Allowed Pre-proline 0 N--CA 1.435 -1.177 0 C-N-CA 126.091 1.757 . . . . 0.0 113.23 -170.157 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.526 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 1.9 Cg_endo -89.52 7.07 68.27 Favored 'Cis proline' 0 CA--C 1.55 1.299 0 C-N-CA 122.924 -1.698 . . . . 0.0 115.905 3.32 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.3 m -109.52 151.47 11.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 O-C-N 121.581 -0.7 . . . . 0.0 112.421 -175.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.47 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 71.1 m -86.52 147.34 26.0 Favored 'General case' 0 N--CA 1.405 -2.68 0 CA-C-O 121.297 0.57 . . . . 0.0 109.954 175.395 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.613 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 31.0 p -132.6 -169.99 2.35 Favored 'General case' 0 C--N 1.294 -1.829 0 C-N-CA 122.758 0.423 . . . . 0.0 110.257 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 95.9 mtt180 . . . . . 0 N--CA 1.391 -3.396 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 -178.266 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 88.2 m . . . . . 0 N--CA 1.427 -1.596 0 N-CA-C 112.323 0.49 . . . . 0.0 112.323 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -89.88 23.41 20.43 Favored Glycine 0 C--N 1.316 -0.554 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 175.555 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.422 ' HB2' ' HB2' ' A' ' 25' ' ' CYS . 8.3 mm-40 -90.38 156.76 18.01 Favored 'General case' 0 N--CA 1.437 -1.109 0 C-N-CA 124.181 0.992 . . . . 0.0 110.005 -177.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 21.8 p -126.16 153.54 44.45 Favored 'General case' 0 N--CA 1.41 -2.443 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 174.23 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.432 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 21.6 p -124.79 33.75 5.15 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.781 -0.574 . . . . 0.0 111.005 -178.442 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.434 ' HA ' ' NE1' ' A' ' 22' ' ' TRP . 22.3 t -62.03 -35.98 71.57 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.867 0 CA-C-N 114.786 -1.097 . . . . 0.0 109.193 -179.835 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -71.33 -16.06 75.23 Favored Glycine 0 C--O 1.22 -0.733 0 CA-C-N 115.094 -0.957 . . . . 0.0 112.336 178.747 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 132.66 -23.65 3.97 Favored Glycine 0 N--CA 1.435 -1.428 0 C-N-CA 120.242 -0.98 . . . . 0.0 113.696 177.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 20.4 m -157.08 162.27 39.47 Favored 'General case' 0 C--N 1.31 -1.116 0 N-CA-C 107.114 -1.439 . . . . 0.0 107.114 -176.483 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 52.5 m -86.45 140.15 30.24 Favored 'General case' 0 C--N 1.283 -2.301 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 177.163 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 44.8 m-80 -72.0 -44.21 63.83 Favored 'General case' 0 C--N 1.315 -0.93 0 C-N-CA 120.746 -0.382 . . . . 0.0 110.892 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 27.2 m -76.34 121.08 84.27 Favored Pre-proline 0 CA--C 1.556 1.195 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 172.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_endo -71.24 -1.48 9.69 Favored 'Trans proline' 0 C--N 1.36 1.169 0 C-N-CA 123.551 2.834 . . . . 0.0 114.683 -173.45 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -95.06 2.32 65.9 Favored Glycine 0 C--N 1.261 -3.619 0 CA-C-N 114.506 -1.225 . . . . 0.0 112.003 -179.122 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 32.5 m -112.03 140.77 46.43 Favored 'General case' 0 N--CA 1.426 -1.674 0 CA-C-O 120.908 0.385 . . . . 0.0 111.674 -175.253 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 3.2 m -89.91 145.19 25.31 Favored 'General case' 0 C--N 1.315 -0.909 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 179.324 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 43.2 t -93.09 105.43 17.53 Favored 'General case' 0 C--N 1.29 -1.991 0 C-N-CA 120.073 -0.651 . . . . 0.0 110.369 177.547 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 2.3 p -113.97 65.69 0.66 Allowed 'General case' 0 C--N 1.278 -2.538 0 N-CA-C 106.274 -1.751 . . . . 0.0 106.274 173.444 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . 0.517 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 49.2 t90 -34.83 135.34 0.41 Allowed Pre-proline 0 N--CA 1.446 -0.628 0 C-N-CA 126.985 2.114 . . . . 0.0 113.512 -169.933 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.517 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 1.8 Cg_endo -89.93 2.42 68.04 Favored 'Cis proline' 0 C--N 1.329 -0.499 0 C-N-CA 122.929 -1.696 . . . . 0.0 114.725 2.875 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.1 m -108.1 146.35 14.13 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 C-N-CA 120.259 -0.576 . . . . 0.0 111.95 -175.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.432 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 72.3 m -93.27 141.59 28.27 Favored 'General case' 0 N--CA 1.396 -3.162 0 CA-C-O 121.4 0.619 . . . . 0.0 111.5 179.341 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 1.4 p -109.14 -169.61 1.51 Allowed 'General case' 0 C--N 1.283 -2.313 0 CA-C-N 114.736 -1.12 . . . . 0.0 108.683 176.079 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 39.7 ttp180 . . . . . 0 N--CA 1.404 -2.73 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 -178.478 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 61.2 m . . . . . 0 N--CA 1.437 -1.092 0 CA-C-O 121.136 0.493 . . . . 0.0 110.049 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -84.98 -4.45 87.01 Favored Glycine 0 N--CA 1.443 -0.882 0 CA-C-N 115.699 -0.682 . . . . 0.0 113.978 -175.219 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -86.5 169.45 12.81 Favored 'General case' 0 C--N 1.309 -1.185 0 C-N-CA 119.836 -0.746 . . . . 0.0 111.064 -179.637 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 7.0 p -120.36 155.52 33.22 Favored 'General case' 0 N--CA 1.401 -2.911 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 178.402 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.484 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 13.4 p -119.06 37.2 4.2 Favored 'General case' 0 CA--C 1.484 -1.587 0 CA-C-O 121.043 0.449 . . . . 0.0 110.571 -176.648 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.7 t -57.69 -34.2 47.02 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 CA-C-N 114.926 -1.034 . . . . 0.0 109.353 -179.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -70.62 -8.51 63.4 Favored Glycine 0 N--CA 1.436 -1.321 0 CA-C-N 114.964 -1.017 . . . . 0.0 113.557 179.172 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 144.21 -54.07 0.58 Allowed Glycine 0 N--CA 1.441 -0.979 0 C-N-CA 120.67 -0.776 . . . . 0.0 113.962 176.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 14.7 t -157.61 173.33 17.02 Favored 'General case' 0 N--CA 1.425 -1.72 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -176.226 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.484 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 35.6 m -96.21 137.29 35.49 Favored 'General case' 0 C--N 1.27 -2.867 0 CA-C-N 115.342 -0.844 . . . . 0.0 108.759 -178.158 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 40.8 m-80 -70.47 -47.74 59.13 Favored 'General case' 0 C--N 1.319 -0.755 0 O-C-N 123.199 0.312 . . . . 0.0 111.43 -179.168 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 42.3 m -69.91 119.56 72.2 Favored Pre-proline 0 N--CA 1.437 -1.079 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 178.774 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_exo -66.87 -9.82 26.14 Favored 'Trans proline' 0 C--N 1.36 1.134 0 C-N-CA 123.458 2.772 . . . . 0.0 113.927 -175.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -83.3 -17.27 67.12 Favored Glycine 0 C--N 1.265 -3.392 0 CA-C-N 113.787 -1.551 . . . . 0.0 110.412 177.252 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.495 ' HA ' ' O ' ' A' ' 26' ' ' THR . 47.8 m -108.55 126.68 53.2 Favored 'General case' 0 N--CA 1.416 -2.173 0 N-CA-C 108.096 -1.076 . . . . 0.0 108.096 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 6.8 m -101.22 148.04 25.57 Favored 'General case' 0 C--N 1.274 -2.701 0 N-CA-C 107.459 -1.311 . . . . 0.0 107.459 -175.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 50.3 t -90.78 106.27 18.4 Favored 'General case' 0 C--N 1.275 -2.653 0 CA-C-O 121.702 0.763 . . . . 0.0 110.662 -178.156 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 31.3 t -107.67 67.09 0.68 Allowed 'General case' 0 C--N 1.28 -2.426 0 N-CA-C 102.9 -3.0 . . . . 0.0 102.9 172.81 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . 0.51 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 57.4 t90 -39.39 133.59 1.23 Allowed Pre-proline 0 N--CA 1.433 -1.286 0 CA-C-N 113.405 -1.725 . . . . 0.0 112.326 -171.356 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.51 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 1.9 Cg_endo -90.75 12.17 56.75 Favored 'Cis proline' 0 CA--C 1.543 0.967 0 C-N-CA 122.723 -1.782 . . . . 0.0 115.812 3.721 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.0 m -110.66 146.86 15.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 119.071 0.851 . . . . 0.0 113.007 -176.419 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 90.9 m -86.53 140.64 29.71 Favored 'General case' 0 N--CA 1.401 -2.898 0 O-C-N 121.679 -0.638 . . . . 0.0 109.327 174.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.495 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 2.6 p -135.6 -177.3 4.61 Favored 'General case' 0 C--N 1.269 -2.92 0 CA-C-N 115.206 -0.907 . . . . 0.0 109.084 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 12.9 ttm180 . . . . . 0 N--CA 1.421 -1.89 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 176.883 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 3.5 m . . . . . 0 N--CA 1.44 -0.937 0 N-CA-C 113.55 0.945 . . . . 0.0 113.55 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -103.93 18.39 46.62 Favored Glycine 0 C--N 1.313 -0.739 0 N-CA-C 107.724 -2.15 . . . . 0.0 107.724 169.806 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 23.2 mm-40 -80.99 170.85 15.73 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 113.605 -1.298 . . . . 0.0 109.552 -178.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 16.8 p -122.57 156.5 34.1 Favored 'General case' 0 N--CA 1.402 -2.827 0 CA-C-O 120.791 0.329 . . . . 0.0 111.062 178.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 20.5 p -128.22 38.24 4.03 Favored 'General case' 0 CA--C 1.491 -1.294 0 CA-C-O 121.41 0.624 . . . . 0.0 109.601 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 11.1 t -58.62 -29.89 40.37 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.007 0 CA-C-N 114.426 -1.261 . . . . 0.0 110.709 -177.16 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -74.1 -22.11 78.24 Favored Glycine 0 N--CA 1.437 -1.256 0 CA-C-N 115.849 -0.614 . . . . 0.0 112.544 179.028 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 149.63 -36.55 0.99 Allowed Glycine 0 N--CA 1.438 -1.226 0 C-N-CA 120.207 -0.997 . . . . 0.0 113.863 179.672 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 8.8 t -158.3 173.65 16.36 Favored 'General case' 0 N--CA 1.423 -1.793 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 -178.429 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 63.2 m -89.75 150.54 22.25 Favored 'General case' 0 C--N 1.268 -2.937 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.134 -177.277 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 13.9 m120 -90.43 -12.23 38.06 Favored 'General case' 0 C--N 1.308 -1.203 0 CA-C-O 121.177 0.513 . . . . 0.0 110.158 177.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 10.4 m -100.37 122.96 48.13 Favored Pre-proline 0 C--N 1.305 -1.335 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 176.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 96.6 Cg_endo -78.39 -1.85 11.97 Favored 'Trans proline' 0 N--CA 1.484 0.949 0 C-N-CA 123.232 2.621 . . . . 0.0 115.926 -169.186 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -102.5 0.02 49.84 Favored Glycine 0 C--N 1.261 -3.634 0 N-CA-C 110.001 -1.24 . . . . 0.0 110.001 178.221 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.424 ' HA ' ' O ' ' A' ' 26' ' ' THR . 56.1 m -118.65 134.15 55.32 Favored 'General case' 0 N--CA 1.402 -2.854 0 CA-C-N 113.75 -1.225 . . . . 0.0 109.041 -175.429 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 10.5 t -109.89 163.86 13.13 Favored 'General case' 0 N--CA 1.426 -1.651 0 C-N-CA 119.584 -0.846 . . . . 0.0 109.639 -178.74 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 48.9 t -92.96 125.06 37.37 Favored 'General case' 0 N--CA 1.387 -3.605 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.117 -174.495 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 46.0 m -128.75 59.85 1.54 Allowed 'General case' 0 N--CA 1.397 -3.121 0 N-CA-C 104.557 -2.386 . . . . 0.0 104.557 173.211 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . 0.41 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 47.7 t90 -31.8 131.49 0.29 Allowed Pre-proline 0 C--O 1.247 0.931 0 C-N-CA 126.851 2.06 . . . . 0.0 113.149 -172.452 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.41 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 2.8 Cg_endo -89.04 6.62 69.08 Favored 'Cis proline' 0 CA--C 1.537 0.644 0 C-N-CA 122.872 -1.72 . . . . 0.0 115.242 2.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 28.9 m -107.76 152.24 9.54 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.004 0 N-CA-C 112.855 0.687 . . . . 0.0 112.855 -176.223 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 94.5 m -88.56 149.4 23.61 Favored 'General case' 0 N--CA 1.402 -2.836 0 CA-C-O 121.452 0.644 . . . . 0.0 110.986 175.71 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.424 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.8 p -125.37 -146.72 0.35 Allowed 'General case' 0 C--N 1.285 -2.236 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 173.761 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 6.6 ptp180 . . . . . 1 N--CA 1.377 -4.077 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 -176.5 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 58.5 m . . . . . 0 N--CA 1.43 -1.471 0 CA-C-O 120.764 0.316 . . . . 0.0 110.999 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -107.94 -6.69 32.1 Favored Glycine 0 N--CA 1.431 -1.661 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 174.853 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -69.59 151.35 46.06 Favored 'General case' 0 C--O 1.25 1.086 0 CA-C-N 115.169 -0.515 . . . . 0.0 110.948 179.389 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 39.9 p -102.62 163.38 12.25 Favored 'General case' 0 N--CA 1.408 -2.571 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.072 -178.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.709 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 29.3 p -129.38 43.42 3.14 Favored 'General case' 0 N--CA 1.425 -1.677 0 CA-C-O 121.465 0.65 . . . . 0.0 109.485 -178.839 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 58.3 t -58.42 -33.14 47.07 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.862 -177.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -90.03 -0.95 76.89 Favored Glycine 0 C--O 1.224 -0.528 0 CA-C-N 116.211 -0.45 . . . . 0.0 112.109 178.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 86.72 29.18 24.53 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 121.823 -0.227 . . . . 0.0 113.217 177.752 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 7.0 m -148.52 155.08 40.67 Favored 'General case' 0 N--CA 1.436 -1.131 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 179.196 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 61.1 m -133.04 156.87 46.58 Favored 'General case' 0 C--N 1.279 -2.464 0 N-CA-C 107.572 -1.269 . . . . 0.0 107.572 176.862 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 33.3 m-80 -84.1 -39.42 19.53 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 -179.787 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 16.2 m -84.79 116.62 66.09 Favored Pre-proline 0 N--CA 1.429 -1.507 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 175.415 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -74.72 -7.67 19.61 Favored 'Trans proline' 0 C--N 1.358 1.07 0 C-N-CA 122.433 2.089 . . . . 0.0 112.758 -175.444 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -90.44 -6.84 67.88 Favored Glycine 0 C--N 1.268 -3.239 0 CA-C-N 113.233 -1.803 . . . . 0.0 110.143 178.368 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.427 ' HA ' ' O ' ' A' ' 26' ' ' THR . 86.8 m -105.28 125.91 51.51 Favored 'General case' 0 N--CA 1.412 -2.361 0 CA-C-O 122.407 1.098 . . . . 0.0 109.679 177.269 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.435 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 6.8 m -93.59 150.72 20.2 Favored 'General case' 0 C--N 1.276 -2.595 0 CA-C-N 113.125 -1.852 . . . . 0.0 108.603 -173.641 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 52.2 t -93.1 105.77 17.82 Favored 'General case' 0 N--CA 1.409 -2.493 0 CA-C-O 121.866 0.841 . . . . 0.0 110.904 -178.374 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 31.1 m -108.68 79.61 1.25 Allowed 'General case' 0 N--CA 1.391 -3.405 0 N-CA-C 103.569 -2.752 . . . . 0.0 103.569 171.074 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . 0.505 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 54.5 t90 -44.31 134.51 4.37 Favored Pre-proline 0 N--CA 1.429 -1.517 0 CA-C-N 113.322 -1.763 . . . . 0.0 112.919 -167.976 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.505 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 4.0 Cg_endo -95.64 22.96 26.79 Favored 'Cis proline' 0 N--CA 1.458 -0.561 0 C-N-CA 122.969 -1.68 . . . . 0.0 114.597 3.15 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 29.9 m -120.68 144.22 30.25 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.968 0 N-CA-C 114.057 1.132 . . . . 0.0 114.057 -175.712 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.709 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 56.1 m -86.05 129.87 34.71 Favored 'General case' 0 N--CA 1.414 -2.268 0 O-C-N 121.791 -0.568 . . . . 0.0 109.616 176.212 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.427 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 1.3 p -135.78 -170.82 2.71 Favored 'General case' 0 C--N 1.287 -2.119 0 C-N-CA 123.541 0.737 . . . . 0.0 109.828 178.439 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 70.8 mtp180 . . . . . 0 N--CA 1.396 -3.145 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 177.729 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 96.4 m . . . . . 0 N--CA 1.431 -1.394 0 N-CA-C 110.209 -0.293 . . . . 0.0 110.209 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -85.65 4.01 86.36 Favored Glycine 0 N--CA 1.447 -0.581 0 N-CA-C 110.788 -0.925 . . . . 0.0 110.788 179.677 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 74.6 mm-40 -89.6 146.82 24.3 Favored 'General case' 0 N--CA 1.421 -1.909 0 CA-C-N 114.79 -0.705 . . . . 0.0 110.816 -179.511 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 32.6 p -123.71 150.81 43.87 Favored 'General case' 0 N--CA 1.392 -3.335 0 N-CA-C 106.185 -1.783 . . . . 0.0 106.185 174.4 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.438 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 24.4 p -123.99 38.35 4.21 Favored 'General case' 0 C--N 1.289 -2.022 0 CA-C-N 118.63 0.65 . . . . 0.0 110.254 -177.521 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 13.6 t -61.76 -40.48 87.04 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 CA-C-N 114.494 -1.23 . . . . 0.0 108.306 178.791 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -73.78 -22.24 78.42 Favored Glycine 0 N--CA 1.441 -1.032 0 CA-C-N 114.902 -1.045 . . . . 0.0 111.022 177.127 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 120.4 -6.94 11.57 Favored Glycine 0 N--CA 1.436 -1.302 0 C-N-CA 121.255 -0.498 . . . . 0.0 113.876 177.211 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 6.1 m -136.51 155.25 50.23 Favored 'General case' 0 N--CA 1.429 -1.492 0 CA-C-N 118.047 0.924 . . . . 0.0 108.936 -176.336 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 57.6 m -113.99 143.33 44.92 Favored 'General case' 0 C--N 1.279 -2.463 0 N-CA-C 106.154 -1.795 . . . . 0.0 106.154 175.676 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 33.4 m-80 -68.09 -39.36 82.88 Favored 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 119.053 0.842 . . . . 0.0 110.656 177.395 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 9.9 m -94.1 113.19 60.04 Favored Pre-proline 0 N--CA 1.426 -1.671 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 176.358 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -76.33 -1.89 12.0 Favored 'Trans proline' 0 C--N 1.354 0.828 0 C-N-CA 122.668 2.245 . . . . 0.0 112.534 -178.727 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -79.59 -14.41 81.26 Favored Glycine 0 C--N 1.284 -2.33 0 CA-C-N 113.105 -1.861 . . . . 0.0 108.936 175.166 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.543 ' HA ' ' O ' ' A' ' 26' ' ' THR . 63.7 m -103.14 127.33 50.47 Favored 'General case' 0 N--CA 1.406 -2.653 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.115 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.407 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 10.3 m -89.9 148.86 22.9 Favored 'General case' 0 C--N 1.279 -2.493 0 CA-C-N 114.876 -1.056 . . . . 0.0 108.633 -177.129 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 50.5 t -84.64 115.15 22.49 Favored 'General case' 0 C--N 1.269 -2.897 0 CA-C-O 121.461 0.648 . . . . 0.0 110.453 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 16.6 t -120.26 68.24 0.84 Allowed 'General case' 0 C--N 1.287 -2.152 0 N-CA-C 103.728 -2.693 . . . . 0.0 103.728 172.85 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . 0.45 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 51.3 t90 -35.92 133.08 0.56 Allowed Pre-proline 0 N--CA 1.441 -0.904 0 CA-C-N 113.108 -1.86 . . . . 0.0 112.969 -170.417 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.45 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 1.6 Cg_endo -91.63 14.46 49.62 Favored 'Cis proline' 0 CA--C 1.541 0.855 0 C-N-CA 123.145 -1.606 . . . . 0.0 115.343 2.517 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 28.9 m -115.65 152.6 17.3 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.019 0 O-C-N 121.182 -0.949 . . . . 0.0 112.36 -177.629 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.438 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 59.6 m -95.73 139.32 32.14 Favored 'General case' 0 N--CA 1.403 -2.81 0 O-C-N 121.77 -0.581 . . . . 0.0 109.543 177.123 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.543 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 20.1 p -125.49 -173.29 2.79 Favored 'General case' 0 C--N 1.29 -1.989 0 C-N-CA 123.119 0.568 . . . . 0.0 111.345 -179.157 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 53.8 ttt180 . . . . . 0 N--CA 1.417 -2.095 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 -177.619 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 98.1 m . . . . . 0 CA--C 1.515 -0.39 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -107.19 5.64 36.16 Favored Glycine 0 C--N 1.31 -0.892 0 C-N-CA 120.465 -0.874 . . . . 0.0 112.443 -178.295 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -88.73 166.43 14.06 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.779 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 24.4 p -112.49 163.25 14.68 Favored 'General case' 0 N--CA 1.415 -2.194 0 N-CA-C 112.15 0.426 . . . . 0.0 112.15 -175.79 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.443 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 21.4 p -137.13 36.01 2.55 Favored 'General case' 0 CA--C 1.497 -1.073 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 179.58 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 15.4 t -60.8 -35.4 64.15 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.084 0 CA-C-N 114.719 -1.128 . . . . 0.0 109.4 -177.867 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -74.27 -17.27 79.63 Favored Glycine 0 N--CA 1.44 -1.044 0 CA-C-N 115.132 -0.94 . . . . 0.0 112.935 178.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 141.49 -33.43 1.98 Allowed Glycine 0 N--CA 1.435 -1.402 0 C-N-CA 119.992 -1.099 . . . . 0.0 113.795 179.848 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 9.0 t -153.58 172.8 16.64 Favored 'General case' 0 N--CA 1.424 -1.745 0 CA-C-N 117.771 0.785 . . . . 0.0 109.845 -174.726 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 58.1 m -94.75 176.35 6.31 Favored 'General case' 0 C--N 1.274 -2.687 0 CA-C-N 114.475 -1.239 . . . . 0.0 110.042 -177.391 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 26.8 m-80 -100.55 -36.43 9.18 Favored 'General case' 0 C--N 1.307 -1.243 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 178.588 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.495 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 25.8 m -90.69 121.86 67.69 Favored Pre-proline 0 N--CA 1.427 -1.607 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 177.179 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 15' ' ' THR . 13.6 Cg_exo -69.66 -3.58 12.22 Favored 'Trans proline' 0 N--CA 1.488 1.157 0 C-N-CA 123.132 2.555 . . . . 0.0 113.458 -177.506 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -90.3 -14.22 59.08 Favored Glycine 0 C--N 1.255 -3.949 0 CA-C-N 113.719 -1.582 . . . . 0.0 110.283 176.458 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.562 ' HA ' ' O ' ' A' ' 26' ' ' THR . 57.8 m -103.55 129.97 50.86 Favored 'General case' 0 N--CA 1.396 -3.128 0 N-CA-C 107.575 -1.269 . . . . 0.0 107.575 179.254 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 25.1 m -114.78 155.5 26.61 Favored 'General case' 0 C--N 1.281 -2.389 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 -179.13 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 38.2 t -83.48 128.15 34.28 Favored 'General case' 0 N--CA 1.409 -2.521 0 CA-C-O 122.251 1.024 . . . . 0.0 113.065 -171.477 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.8 m -128.26 65.32 1.39 Allowed 'General case' 0 N--CA 1.402 -2.833 0 N-CA-C 104.401 -2.444 . . . . 0.0 104.401 170.149 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . 0.479 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 37.9 t90 -33.67 134.87 0.33 Allowed Pre-proline 0 N--CA 1.442 -0.849 0 C-N-CA 127.433 2.293 . . . . 0.0 113.918 -170.92 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.479 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 4.6 Cg_exo -88.96 12.01 57.51 Favored 'Cis proline' 0 CA--C 1.544 0.98 0 C-N-CA 122.894 -1.711 . . . . 0.0 114.403 0.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.7 m -114.38 150.49 16.36 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.889 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -175.254 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.443 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 95.5 m -86.14 151.6 23.53 Favored 'General case' 0 N--CA 1.41 -2.435 0 CA-C-O 121.74 0.781 . . . . 0.0 112.206 178.39 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.562 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.0 p -129.27 -164.44 1.4 Allowed 'General case' 0 C--N 1.298 -1.642 0 C-N-CA 124.609 1.164 . . . . 0.0 108.331 175.559 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 17.3 ttm180 . . . . . 0 N--CA 1.407 -2.603 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 -178.277 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 85.3 m . . . . . 0 N--CA 1.433 -1.312 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -80.06 13.9 23.53 Favored Glycine 0 C--N 1.314 -0.675 0 CA-C-N 116.117 -0.492 . . . . 0.0 112.927 -176.382 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -91.56 162.13 14.66 Favored 'General case' 0 C--N 1.306 -1.288 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 178.762 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 25.3 p -114.74 163.48 15.42 Favored 'General case' 0 N--CA 1.411 -2.385 0 N-CA-C 110.374 -0.232 . . . . 0.0 110.374 -179.739 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 16.9 p -134.2 41.2 2.98 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-O 121.229 0.538 . . . . 0.0 110.185 -179.036 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 23.2 t -59.94 -29.89 44.26 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.042 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.619 -176.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -83.09 -8.14 86.02 Favored Glycine 0 N--CA 1.441 -0.995 0 CA-C-N 115.769 -0.65 . . . . 0.0 112.903 -179.786 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 139.82 -39.61 1.49 Allowed Glycine 0 N--CA 1.443 -0.885 0 C-N-CA 120.214 -0.993 . . . . 0.0 113.777 178.2 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 13.5 t -155.6 173.23 17.01 Favored 'General case' 0 N--CA 1.423 -1.802 0 CA-C-N 117.354 0.577 . . . . 0.0 109.649 -176.807 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 32.2 m -91.87 173.11 8.03 Favored 'General case' 0 C--N 1.274 -2.713 0 CA-C-N 114.815 -1.084 . . . . 0.0 109.578 -175.048 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 36.3 m-80 -93.27 -36.63 12.47 Favored 'General case' 0 CA--C 1.496 -1.097 0 N-CA-C 110.059 -0.348 . . . . 0.0 110.059 177.017 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.463 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 17.6 m -84.63 124.26 73.38 Favored Pre-proline 0 C--N 1.297 -1.675 0 N-CA-C 108.131 -1.062 . . . . 0.0 108.131 176.304 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_endo -72.86 -1.53 10.58 Favored 'Trans proline' 0 C--N 1.359 1.098 0 C-N-CA 123.05 2.5 . . . . 0.0 113.425 -176.194 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -97.63 -4.05 58.2 Favored Glycine 0 C--N 1.265 -3.407 0 CA-C-N 113.964 -1.471 . . . . 0.0 110.152 177.782 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.463 ' SG ' ' HB ' ' A' ' 15' ' ' THR . 60.3 m -108.66 125.84 52.32 Favored 'General case' 0 N--CA 1.409 -2.518 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 178.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 8.6 m -91.45 151.39 20.82 Favored 'General case' 0 C--N 1.291 -1.959 0 N-CA-C 107.74 -1.208 . . . . 0.0 107.74 -177.213 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 46.6 t -90.17 127.73 36.18 Favored 'General case' 0 N--CA 1.411 -2.415 0 CA-C-O 121.388 0.613 . . . . 0.0 109.565 179.501 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 22.6 t -128.71 56.8 1.63 Allowed 'General case' 0 C--N 1.28 -2.448 0 N-CA-C 103.688 -2.708 . . . . 0.0 103.688 176.001 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . 0.446 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 56.6 t90 -31.2 131.91 0.25 Allowed Pre-proline 0 N--CA 1.446 -0.644 0 C-N-CA 127.009 2.124 . . . . 0.0 113.347 -171.314 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.446 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 1.8 Cg_endo -90.37 9.68 63.07 Favored 'Cis proline' 0 C--N 1.323 -0.811 0 C-N-CA 122.883 -1.715 . . . . 0.0 115.074 4.091 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 29.8 m -112.32 153.01 14.04 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 O-C-N 122.043 -0.41 . . . . 0.0 111.927 -176.2 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 73.4 m -93.39 158.78 15.56 Favored 'General case' 0 N--CA 1.416 -2.15 0 CA-C-O 121.487 0.661 . . . . 0.0 112.42 178.05 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.427 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.1 p -129.81 -175.04 3.48 Favored 'General case' 0 C--N 1.31 -1.145 0 C-N-CA 124.519 1.128 . . . . 0.0 108.562 175.679 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 20.0 ptt180 . . . . . 0 N--CA 1.384 -3.725 0 CA-C-N 119.407 1.003 . . . . 0.0 112.138 -178.027 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 72.4 m . . . . . 0 N--CA 1.441 -0.924 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -88.03 12.98 62.52 Favored Glycine 0 C--N 1.304 -1.201 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.025 -178.057 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -90.23 154.67 19.56 Favored 'General case' 0 N--CA 1.431 -1.401 0 CA-C-O 121.096 0.474 . . . . 0.0 110.013 -179.289 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 35.9 p -111.65 158.53 19.16 Favored 'General case' 0 N--CA 1.395 -3.225 0 N-CA-C 106.32 -1.734 . . . . 0.0 106.32 170.449 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.604 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 28.1 p -135.85 50.86 2.07 Favored 'General case' 0 C--N 1.283 -2.304 0 CA-C-O 121.502 0.668 . . . . 0.0 110.056 -177.66 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 40.3 t -62.43 -31.0 50.35 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.36 -178.568 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -74.45 -26.36 68.08 Favored Glycine 0 N--CA 1.446 -0.638 0 N-CA-C 111.338 -0.705 . . . . 0.0 111.338 176.701 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 122.27 0.18 10.46 Favored Glycine 0 N--CA 1.443 -0.875 0 C-N-CA 120.657 -0.782 . . . . 0.0 114.219 177.021 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 15.7 m -148.81 162.59 39.51 Favored 'General case' 0 N--CA 1.432 -1.372 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 -179.664 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 35.9 m -111.82 166.78 10.9 Favored 'General case' 0 C--N 1.281 -2.407 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 177.841 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 36.0 m-80 -83.43 -38.89 21.31 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-O 120.923 0.392 . . . . 0.0 110.022 179.223 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.575 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 13.4 m -79.88 123.85 83.54 Favored Pre-proline 0 N--CA 1.429 -1.509 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 178.979 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_exo -69.81 -2.92 11.03 Favored 'Trans proline' 0 C--N 1.353 0.809 0 C-N-CA 123.009 2.472 . . . . 0.0 112.898 179.504 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -96.47 -12.19 51.83 Favored Glycine 0 C--N 1.27 -3.134 0 CA-C-N 113.752 -1.567 . . . . 0.0 110.449 177.17 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.575 ' SG ' ' HB ' ' A' ' 15' ' ' THR . 62.3 m -103.7 130.63 51.22 Favored 'General case' 0 N--CA 1.415 -2.198 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 179.659 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 9.6 m -109.26 147.7 32.2 Favored 'General case' 0 C--N 1.282 -2.329 0 N-CA-C 107.928 -1.138 . . . . 0.0 107.928 -177.625 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 46.2 t -83.45 121.15 26.8 Favored 'General case' 0 N--CA 1.403 -2.777 0 CA-C-O 121.629 0.728 . . . . 0.0 111.073 -177.434 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 25.2 t -123.58 72.36 1.13 Allowed 'General case' 0 C--N 1.279 -2.472 0 N-CA-C 103.417 -2.809 . . . . 0.0 103.417 173.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . 0.48 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 36.9 t90 -41.24 133.71 1.95 Allowed Pre-proline 0 N--CA 1.444 -0.729 0 C-N-CA 125.893 1.677 . . . . 0.0 113.411 -168.343 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.48 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 1.6 Cg_endo -92.23 16.81 43.42 Favored 'Cis proline' 0 CA--C 1.538 0.705 0 C-N-CA 122.826 -1.739 . . . . 0.0 114.655 2.113 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 26.8 m -117.38 151.13 19.3 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.863 0 N-CA-C 113.95 1.093 . . . . 0.0 113.95 -176.11 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.604 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 82.8 m -86.21 148.95 25.42 Favored 'General case' 0 N--CA 1.409 -2.506 0 O-C-N 121.536 -0.727 . . . . 0.0 110.928 176.459 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.497 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.2 p -132.72 -174.51 3.48 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 175.959 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 3.5 ppt_? . . . . . 0 N--CA 1.379 -3.975 0 CA-C-N 119.524 1.056 . . . . 0.0 110.43 179.368 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.627 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 88.7 m . . . . . 0 N--CA 1.442 -0.852 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -92.42 -16.75 48.55 Favored Glycine 0 N--CA 1.44 -1.096 0 C-N-CA 120.454 -0.879 . . . . 0.0 112.866 -174.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.627 ' OE1' ' HB3' ' A' ' 4' ' ' CYS . 1.0 OUTLIER -90.15 145.94 24.66 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 122.447 -0.443 . . . . 0.0 111.056 -178.786 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 21.7 p -109.83 157.04 19.6 Favored 'General case' 0 N--CA 1.417 -2.114 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.485 -179.209 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.48 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 19.5 p -126.23 38.85 4.06 Favored 'General case' 0 C--N 1.303 -1.422 0 CA-C-O 121.169 0.509 . . . . 0.0 110.589 -177.05 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 35.5 t -56.12 -35.48 41.97 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 CA-C-N 115.106 -0.952 . . . . 0.0 110.722 -178.427 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -95.4 7.85 68.97 Favored Glycine 0 N--CA 1.441 -1.027 0 C-N-CA 121.089 -0.577 . . . . 0.0 113.053 -179.483 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 152.1 -82.06 0.18 Allowed Glycine 0 N--CA 1.434 -1.477 0 C-N-CA 119.186 -1.483 . . . . 0.0 114.425 178.369 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 7.5 m -153.44 163.89 39.15 Favored 'General case' 0 N--CA 1.428 -1.57 0 N-CA-C 106.867 -1.531 . . . . 0.0 106.867 -171.153 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 76.7 m -99.13 161.56 13.55 Favored 'General case' 0 C--N 1.291 -1.95 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 176.188 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 41.7 m-80 -92.82 -16.51 25.24 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-O 120.99 0.424 . . . . 0.0 110.837 -177.839 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 10.7 m -72.49 114.89 33.98 Favored Pre-proline 0 N--CA 1.438 -1.07 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 178.814 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -70.17 -9.02 25.01 Favored 'Trans proline' 0 C--N 1.351 0.709 0 C-N-CA 122.806 2.337 . . . . 0.0 114.213 -174.204 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -91.74 -15.34 54.94 Favored Glycine 0 C--N 1.261 -3.623 0 CA-C-N 113.988 -1.46 . . . . 0.0 111.234 178.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.552 ' HA ' ' O ' ' A' ' 26' ' ' THR . 82.9 m -118.7 125.29 49.35 Favored 'General case' 0 N--CA 1.415 -2.195 0 CA-C-O 121.639 0.733 . . . . 0.0 110.795 -177.687 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 8.1 m -101.88 156.61 17.42 Favored 'General case' 0 C--N 1.293 -1.871 0 C-N-CA 124.666 1.187 . . . . 0.0 108.521 -176.734 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 51.8 t -88.64 119.64 29.3 Favored 'General case' 0 C--N 1.297 -1.707 0 CA-C-O 121.503 0.668 . . . . 0.0 111.851 -176.696 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 21.1 t -124.76 75.69 1.45 Allowed 'General case' 0 N--CA 1.417 -2.097 0 N-CA-C 103.541 -2.763 . . . . 0.0 103.541 171.11 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . 0.539 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 57.2 t90 -38.0 135.79 0.81 Allowed Pre-proline 0 N--CA 1.436 -1.125 0 C-N-CA 126.063 1.745 . . . . 0.0 113.058 -170.809 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.539 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 1.2 Cg_endo -91.47 9.54 61.59 Favored 'Cis proline' 0 CA--C 1.536 0.618 0 C-N-CA 122.862 -1.724 . . . . 0.0 114.958 3.426 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 25.3 m -113.86 158.09 14.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 C-N-CA 120.102 -0.639 . . . . 0.0 111.725 -175.442 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.48 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 53.4 m -96.86 143.06 28.12 Favored 'General case' 0 N--CA 1.388 -3.528 0 CA-C-O 121.838 0.828 . . . . 0.0 110.442 173.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.552 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 7.9 p -128.19 -170.13 2.19 Favored 'General case' 0 C--N 1.273 -2.742 0 CA-C-N 114.466 -1.243 . . . . 0.0 110.994 -177.558 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 19.1 mtm180 . . . . . 0 N--CA 1.381 -3.914 0 CA-C-O 121.459 0.647 . . . . 0.0 110.77 -169.179 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 99.1 m . . . . . 0 N--CA 1.444 -0.737 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -87.64 9.83 72.24 Favored Glycine 0 C--N 1.314 -0.671 0 N-CA-C 110.581 -1.008 . . . . 0.0 110.581 178.459 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.409 ' HB2' ' HB2' ' A' ' 25' ' ' CYS . 6.2 mm-40 -86.38 154.16 21.39 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 124.14 0.976 . . . . 0.0 108.735 -179.64 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 9.2 p -126.82 153.94 44.97 Favored 'General case' 0 N--CA 1.41 -2.452 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 174.062 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.438 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 25.1 p -133.94 40.38 3.08 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-O 120.92 0.391 . . . . 0.0 110.862 -175.825 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 18.7 t -56.48 -29.17 28.29 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.182 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.345 -179.075 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -79.66 -17.19 76.0 Favored Glycine 0 N--CA 1.445 -0.7 0 CA-C-N 115.612 -0.722 . . . . 0.0 113.392 179.562 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 138.03 -32.07 2.39 Favored Glycine 0 N--CA 1.444 -0.828 0 C-N-CA 119.775 -1.202 . . . . 0.0 114.543 178.874 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 15.7 m -152.32 159.13 43.52 Favored 'General case' 0 C--N 1.31 -1.123 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 -176.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.438 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 32.6 m -89.95 165.66 13.94 Favored 'General case' 0 C--N 1.285 -2.221 0 O-C-N 123.767 0.667 . . . . 0.0 109.599 -179.295 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 14.0 m120 -85.16 -48.98 8.61 Favored 'General case' 0 CA--C 1.503 -0.842 0 CA-C-O 120.884 0.373 . . . . 0.0 110.142 178.079 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 29.1 m -70.52 118.93 69.14 Favored Pre-proline 0 C--N 1.311 -1.077 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 175.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -72.35 -5.1 16.49 Favored 'Trans proline' 0 C--N 1.365 1.421 0 C-N-CA 123.134 2.556 . . . . 0.0 114.164 -173.534 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -90.42 -8.43 66.1 Favored Glycine 0 C--N 1.261 -3.606 0 CA-C-N 114.008 -1.451 . . . . 0.0 110.35 178.703 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.432 ' HA ' ' O ' ' A' ' 26' ' ' THR . 67.9 m -107.98 127.39 53.72 Favored 'General case' 0 N--CA 1.409 -2.512 0 CA-C-O 121.41 0.624 . . . . 0.0 110.663 -178.464 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 6.3 m -90.16 148.63 22.85 Favored 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 107.969 -1.122 . . . . 0.0 107.969 -178.241 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 51.5 t -88.97 102.81 15.45 Favored 'General case' 0 N--CA 1.412 -2.332 0 CA-C-O 121.501 0.667 . . . . 0.0 111.183 -178.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.1 p -105.65 64.89 0.7 Allowed 'General case' 0 C--N 1.288 -2.097 0 N-CA-C 106.225 -1.768 . . . . 0.0 106.225 172.244 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . 0.431 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 56.1 t90 -35.74 134.31 0.52 Allowed Pre-proline 0 N--CA 1.443 -0.821 0 C-N-CA 127.358 2.263 . . . . 0.0 113.586 -169.652 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.431 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 1.5 Cg_endo -91.28 10.01 61.09 Favored 'Cis proline' 0 C--N 1.323 -0.777 0 C-N-CA 122.823 -1.741 . . . . 0.0 114.188 2.474 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.9 m -110.81 150.0 13.44 Favored 'Isoleucine or valine' 0 C--O 1.21 -1.019 0 C-N-CA 120.212 -0.595 . . . . 0.0 111.846 -176.426 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.424 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 69.0 m -92.93 141.29 28.58 Favored 'General case' 0 N--CA 1.408 -2.539 0 CA-C-O 121.44 0.638 . . . . 0.0 112.45 178.808 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.432 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 1.7 p -117.83 -177.18 3.19 Favored 'General case' 0 C--N 1.292 -1.903 0 CA-C-N 115.016 -0.993 . . . . 0.0 108.526 175.534 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 4.9 ppt_? . . . . . 0 N--CA 1.387 -3.602 0 CA-C-N 119.669 1.122 . . . . 0.0 112.298 -176.521 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 63.4 m . . . . . 0 N--CA 1.443 -0.794 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -89.21 16.62 55.33 Favored Glycine 0 C--N 1.315 -0.608 0 N-CA-C 110.201 -1.16 . . . . 0.0 110.201 178.408 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 7.8 mm-40 -91.53 151.44 20.75 Favored 'General case' 0 N--CA 1.425 -1.699 0 C-N-CA 124.433 1.093 . . . . 0.0 110.153 -179.403 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 17.2 p -126.4 152.27 46.57 Favored 'General case' 0 N--CA 1.405 -2.675 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 174.746 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 24.7 p -130.37 37.67 3.84 Favored 'General case' 0 C--N 1.301 -1.513 0 CA-C-O 121.153 0.501 . . . . 0.0 110.934 -175.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 25.7 t -58.46 -37.56 64.89 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.13 0 CA-C-N 114.928 -1.033 . . . . 0.0 109.835 -178.468 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -79.18 1.81 73.62 Favored Glycine 0 CA--C 1.524 0.602 0 CA-C-N 115.55 -0.75 . . . . 0.0 113.608 -179.908 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 124.65 -28.8 5.14 Favored Glycine 0 N--CA 1.44 -1.053 0 C-N-CA 119.956 -1.116 . . . . 0.0 114.168 176.657 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 12.4 t -157.33 172.7 18.14 Favored 'General case' 0 N--CA 1.426 -1.636 0 CA-C-N 117.566 0.683 . . . . 0.0 109.324 -176.641 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 33.4 m -98.81 164.21 12.31 Favored 'General case' 0 C--N 1.276 -2.604 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 -178.581 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 14.6 m-80 -85.23 -42.01 15.07 Favored 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 107.261 -1.385 . . . . 0.0 107.261 178.909 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 14.3 m -77.9 114.74 44.36 Favored Pre-proline 0 N--CA 1.422 -1.868 0 CA-C-N 114.035 -1.439 . . . . 0.0 108.685 177.52 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -73.43 -0.67 9.56 Favored 'Trans proline' 0 N--CA 1.483 0.861 0 C-N-CA 123.662 2.908 . . . . 0.0 113.536 -174.538 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -96.4 -11.83 52.98 Favored Glycine 0 C--N 1.261 -3.6 0 CA-C-N 113.985 -1.462 . . . . 0.0 111.15 177.843 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 76.2 m -103.91 127.96 51.41 Favored 'General case' 0 N--CA 1.419 -2.019 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 179.446 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 8.8 m -90.44 153.51 20.34 Favored 'General case' 0 C--N 1.288 -2.093 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 -176.229 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 52.8 t -89.84 116.48 27.96 Favored 'General case' 0 C--N 1.284 -2.241 0 CA-C-O 121.657 0.742 . . . . 0.0 111.247 -177.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 34.4 t -119.35 57.7 0.89 Allowed 'General case' 0 C--N 1.29 -1.984 0 N-CA-C 104.568 -2.382 . . . . 0.0 104.568 176.099 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . 0.442 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 42.5 t90 -29.62 131.86 0.22 Allowed Pre-proline 0 C--N 1.346 0.454 0 C-N-CA 127.261 2.224 . . . . 0.0 113.966 -170.564 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.442 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 2.4 Cg_endo -90.16 6.24 68.11 Favored 'Cis proline' 0 C--N 1.327 -0.56 0 C-N-CA 123.082 -1.632 . . . . 0.0 114.664 3.325 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 26.8 m -108.75 152.57 10.71 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 C-N-CA 120.181 -0.608 . . . . 0.0 112.175 -176.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 82.2 m -93.35 144.57 25.2 Favored 'General case' 0 N--CA 1.407 -2.622 0 CA-C-O 121.59 0.71 . . . . 0.0 112.188 178.246 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 3.1 p -116.17 179.14 4.08 Favored 'General case' 0 C--N 1.29 -2.016 0 C-N-CA 124.654 1.181 . . . . 0.0 110.049 178.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.427 ' O ' ' HD3' ' A' ' 27' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.386 -3.672 0 CA-C-O 121.863 0.84 . . . . 0.0 111.856 -176.662 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.47 ' SG ' ' HG3' ' A' ' 27' ' ' ARG . 94.6 m . . . . . 0 N--CA 1.439 -0.988 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -94.58 17.35 59.26 Favored Glycine 0 N--CA 1.446 -0.692 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 176.723 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 17.6 mm-40 -90.08 148.44 23.02 Favored 'General case' 0 N--CA 1.42 -1.946 0 CA-C-N 113.888 -1.156 . . . . 0.0 107.884 179.035 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 3.7 p -127.77 146.81 50.47 Favored 'General case' 0 C--N 1.268 -2.948 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.57 -179.755 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 21.7 p -127.18 35.99 4.49 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-O 121.07 0.462 . . . . 0.0 110.337 -176.579 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 25.2 t -57.25 -35.12 47.6 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 CA-C-N 115.06 -0.973 . . . . 0.0 109.828 -179.42 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -93.12 4.91 75.05 Favored Glycine 0 N--CA 1.437 -1.283 0 CA-C-N 115.526 -0.761 . . . . 0.0 113.171 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 151.43 -79.94 0.2 Allowed Glycine 0 N--CA 1.443 -0.841 0 C-N-CA 119.431 -1.366 . . . . 0.0 114.594 178.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 5.1 m -149.75 164.74 34.46 Favored 'General case' 0 N--CA 1.435 -1.187 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 -172.46 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 91.7 m -98.58 149.04 23.17 Favored 'General case' 0 C--N 1.285 -2.2 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 175.364 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -95.2 -0.37 53.23 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-O 121.437 0.637 . . . . 0.0 111.409 -179.002 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 56.2 m -85.73 111.19 35.79 Favored Pre-proline 0 N--CA 1.429 -1.509 0 N-CA-C 106.29 -1.744 . . . . 0.0 106.29 171.101 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -68.54 -12.29 34.33 Favored 'Trans proline' 0 C--N 1.36 1.181 0 C-N-CA 123.27 2.646 . . . . 0.0 115.664 -168.828 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -87.16 -15.74 62.02 Favored Glycine 1 C--N 1.251 -4.153 0 CA-C-N 114.65 -1.159 . . . . 0.0 110.571 178.813 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.589 ' HA ' ' O ' ' A' ' 26' ' ' THR . 58.1 m -105.63 125.48 51.03 Favored 'General case' 0 N--CA 1.414 -2.243 0 CA-C-N 115.098 -0.551 . . . . 0.0 110.076 -177.597 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 5.0 m -103.71 148.29 26.23 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 -179.021 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 46.7 t -78.91 125.57 29.54 Favored 'General case' 0 N--CA 1.413 -2.318 0 CA-C-O 122.113 0.958 . . . . 0.0 110.537 -178.262 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 37.5 m -130.66 59.26 1.67 Allowed 'General case' 0 N--CA 1.398 -3.06 0 N-CA-C 105.345 -2.094 . . . . 0.0 105.345 174.806 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . 0.48 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 31.6 t90 -28.08 132.97 0.17 Allowed Pre-proline 0 C--O 1.246 0.877 0 C-N-CA 127.381 2.272 . . . . 0.0 114.348 -171.052 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.48 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 5.1 Cg_exo -88.48 6.94 68.4 Favored 'Cis proline' 0 CA--C 1.54 0.8 0 C-N-CA 123.044 -1.648 . . . . 0.0 114.631 2.328 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.5 m -113.79 152.83 15.42 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.137 0 C-N-CA 120.329 -0.548 . . . . 0.0 112.464 -175.479 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 36.0 m -96.13 145.77 25.22 Favored 'General case' 0 N--CA 1.406 -2.631 0 CA-C-O 122.02 0.914 . . . . 0.0 112.716 176.035 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.589 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 19.6 p -121.51 -162.6 0.98 Allowed 'General case' 0 C--N 1.293 -1.883 0 CA-C-N 114.036 -1.438 . . . . 0.0 108.059 179.672 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.47 ' HG3' ' SG ' ' A' ' 4' ' ' CYS . 78.9 mtt180 . . . . . 0 N--CA 1.397 -3.083 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 177.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.431 ' O ' ' HB ' ' A' ' 32' ' ' VAL . . . . . . . . 0 N--CA 1.428 -1.884 0 N-CA-C 108.804 -1.719 . . . . 0.0 108.804 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -85.28 67.8 3.57 Favored Glycine 0 C--N 1.303 -1.27 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 178.501 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 80.67 -121.08 5.33 Favored Glycine 0 N--CA 1.439 -1.106 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 -176.209 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 77.7 m -141.86 108.11 5.25 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 174.081 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -82.61 8.48 62.0 Favored Glycine 0 C--N 1.308 -0.999 0 C-N-CA 121.432 -0.414 . . . . 0.0 113.168 -176.03 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.404 ' HG3' ' SG ' ' A' ' 25' ' ' CYS . 12.4 pt-20 -90.13 156.67 18.19 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 -179.393 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 5.8 p -107.55 161.7 14.61 Favored 'General case' 0 N--CA 1.409 -2.503 0 CA-C-O 120.739 0.305 . . . . 0.0 110.767 178.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.444 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 19.1 p -127.66 35.7 4.47 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -178.622 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 29.6 t -52.36 -37.31 23.03 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.987 0 CA-C-N 114.81 -1.086 . . . . 0.0 111.628 -177.559 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -68.95 -37.52 83.52 Favored Glycine 0 N--CA 1.443 -0.846 0 C-N-CA 121.068 -0.587 . . . . 0.0 111.94 177.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.477 ' C ' ' HG1' ' A' ' 12' ' ' THR . . . 157.05 -20.53 0.43 Allowed Glycine 0 N--CA 1.44 -1.035 0 C-N-CA 119.472 -1.347 . . . . 0.0 115.483 177.646 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.477 ' HG1' ' C ' ' A' ' 11' ' ' GLY . 27.6 m -155.89 164.86 37.97 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 -176.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 40.3 m -94.71 164.65 12.86 Favored 'General case' 0 C--N 1.283 -2.312 0 C-N-CA 123.688 0.795 . . . . 0.0 108.949 178.536 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 39.7 m-80 -93.5 -30.86 14.81 Favored 'General case' 0 C--N 1.302 -1.477 0 CA-C-O 121.163 0.506 . . . . 0.0 110.008 -177.595 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.487 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 20.6 m -90.13 120.28 69.22 Favored Pre-proline 0 C--N 1.304 -1.395 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 176.836 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -71.05 -3.56 13.11 Favored 'Trans proline' 0 N--CA 1.485 1.022 0 C-N-CA 123.258 2.639 . . . . 0.0 114.285 -175.626 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -89.0 -11.94 64.41 Favored Glycine 0 C--N 1.269 -3.19 0 CA-C-N 114.176 -1.375 . . . . 0.0 110.117 176.453 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.487 ' SG ' ' HB ' ' A' ' 15' ' ' THR . 34.5 m -103.68 144.67 31.15 Favored 'General case' 0 N--CA 1.423 -1.817 0 CA-C-N 114.761 -0.719 . . . . 0.0 109.25 -179.372 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 14.7 m -112.7 151.33 30.34 Favored 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 179.5 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 52.0 t -89.14 118.69 29.03 Favored 'General case' 0 C--N 1.277 -2.549 0 CA-C-O 121.531 0.682 . . . . 0.0 110.318 -179.34 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 63.0 m -116.54 63.81 0.71 Allowed 'General case' 0 N--CA 1.407 -2.579 0 N-CA-C 104.54 -2.393 . . . . 0.0 104.54 171.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.428 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 40.6 t90 -36.27 132.43 0.61 Allowed Pre-proline 0 N--CA 1.437 -1.082 0 C-N-CA 126.404 1.882 . . . . 0.0 113.592 -170.144 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.428 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 2.8 Cg_endo -90.31 13.56 53.0 Favored 'Cis proline' 0 CA--C 1.547 1.139 0 C-N-CA 122.882 -1.716 . . . . 0.0 114.849 2.039 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.6 m -110.91 144.46 18.82 Favored 'Isoleucine or valine' 0 C--O 1.204 -1.316 0 N-CA-C 112.877 0.695 . . . . 0.0 112.877 -176.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.444 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 76.5 m -86.19 152.14 23.06 Favored 'General case' 0 N--CA 1.407 -2.578 0 O-C-N 121.164 -0.96 . . . . 0.0 110.693 176.287 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.438 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.6 p -130.83 -176.89 4.14 Favored 'General case' 0 C--N 1.291 -1.951 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 175.164 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 14.4 ttm180 -124.39 128.55 49.23 Favored 'General case' 0 N--CA 1.416 -2.172 0 N-CA-C 106.107 -1.812 . . . . 0.0 106.107 178.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -82.41 67.84 8.61 Favored 'General case' 0 C--N 1.27 -2.855 0 N-CA-C 114.335 1.235 . . . . 0.0 114.335 -172.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.12 5.2 52.65 Favored Glycine 0 CA--C 1.523 0.552 0 CA-C-N 115.833 -0.621 . . . . 0.0 114.285 175.08 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 54.2 mt -78.59 160.36 72.49 Favored Pre-proline 0 C--N 1.304 -1.37 0 C-N-CA 122.974 0.51 . . . . 0.0 110.793 -177.751 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.47 135.89 62.29 Favored 'Trans proline' 0 C--O 1.245 0.836 0 C-N-CA 122.3 2.0 . . . . 0.0 109.887 178.169 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.431 ' HB ' ' O ' ' A' ' 1' ' ' GLY . 5.4 m -95.89 107.06 19.12 Favored 'Isoleucine or valine' 0 N--CA 1.402 -2.867 0 CA-C-O 121.831 0.824 . . . . 0.0 112.992 -174.096 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 4.8 p . . . . . 0 C--N 1.306 -1.305 0 CA-C-O 122.079 0.942 . . . . 0.0 109.77 174.866 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.431 -1.688 0 N-CA-C 110.206 -1.158 . . . . 0.0 110.206 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -95.17 -42.41 3.75 Favored Glycine 0 N--CA 1.439 -1.119 0 C-N-CA 120.817 -0.706 . . . . 0.0 111.485 -179.25 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 144.85 -103.22 0.29 Allowed Glycine 0 N--CA 1.435 -1.401 0 N-CA-C 109.801 -1.32 . . . . 0.0 109.801 -178.229 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 81.4 m -127.58 108.39 10.74 Favored 'General case' 0 C--N 1.278 -2.529 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 175.856 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -76.13 7.12 31.35 Favored Glycine 0 C--N 1.31 -0.881 0 CA-C-N 115.877 -0.601 . . . . 0.0 112.853 -178.165 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -90.56 150.18 21.85 Favored 'General case' 0 N--CA 1.417 -2.122 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 178.823 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 6.6 p -109.7 154.17 23.25 Favored 'General case' 0 N--CA 1.392 -3.372 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.439 178.031 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.478 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 20.0 p -118.06 37.28 4.03 Favored 'General case' 0 CA--C 1.484 -1.575 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -177.807 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.8 t -55.71 -35.64 39.92 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.971 0 CA-C-N 115.002 -0.999 . . . . 0.0 109.912 -178.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -65.7 -26.26 71.99 Favored Glycine 0 N--CA 1.446 -0.693 0 CA-C-N 115.354 -0.839 . . . . 0.0 112.587 178.244 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 137.41 -22.01 3.23 Favored Glycine 0 N--CA 1.437 -1.249 0 C-N-CA 120.849 -0.691 . . . . 0.0 113.917 178.782 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 12.1 m -150.31 158.99 44.76 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 -175.624 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.478 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 61.0 m -95.23 155.94 16.52 Favored 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 176.467 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 40.1 m-80 -88.72 -18.61 27.47 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-O 121.178 0.513 . . . . 0.0 111.194 -178.613 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.543 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 34.0 m -101.14 124.77 40.31 Favored Pre-proline 0 C--N 1.297 -1.684 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 175.316 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -68.57 -13.68 37.85 Favored 'Trans proline' 0 N--CA 1.488 1.151 0 C-N-CA 122.974 2.449 . . . . 0.0 112.907 -178.2 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -84.55 -12.78 74.61 Favored Glycine 0 C--N 1.263 -3.525 0 CA-C-N 113.311 -1.768 . . . . 0.0 110.525 178.633 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.62 ' HA ' ' O ' ' A' ' 26' ' ' THR . 56.1 m -103.51 126.28 50.57 Favored 'General case' 0 N--CA 1.403 -2.792 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 -179.153 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.451 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 1.1 m -89.23 144.03 26.4 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 -177.77 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 53.7 t -88.14 103.26 15.59 Favored 'General case' 0 N--CA 1.421 -1.904 0 C-N-CA 119.602 -0.839 . . . . 0.0 109.887 177.764 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 14.7 m -104.82 58.36 0.69 Allowed 'General case' 0 C--N 1.285 -2.231 0 N-CA-C 104.473 -2.417 . . . . 0.0 104.473 174.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.437 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 42.1 t90 -33.98 132.9 0.38 Allowed Pre-proline 0 N--CA 1.441 -0.893 0 C-N-CA 127.133 2.173 . . . . 0.0 113.495 -169.808 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.437 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 4.5 Cg_exo -89.31 11.32 59.45 Favored 'Cis proline' 0 C--N 1.322 -0.859 0 C-N-CA 122.851 -1.729 . . . . 0.0 114.981 2.203 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 34.8 m -109.68 143.6 19.49 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.765 0 C-N-CA 120.166 -0.614 . . . . 0.0 112.538 -176.458 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.47 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 77.5 m -89.36 147.92 23.8 Favored 'General case' 0 N--CA 1.414 -2.273 0 O-C-N 121.7 -0.625 . . . . 0.0 110.984 177.21 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.62 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.9 p -132.74 -167.31 1.88 Allowed 'General case' 0 C--O 1.195 -1.796 0 C-N-CA 123.923 0.889 . . . . 0.0 109.206 178.069 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 98.8 mtt180 -121.96 136.85 54.95 Favored 'General case' 0 N--CA 1.399 -2.996 0 CA-C-N 119.048 0.84 . . . . 0.0 109.51 179.083 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 6.5 p30 -123.05 133.57 54.32 Favored 'General case' 0 C--N 1.288 -2.088 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 177.115 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 61.83 22.66 62.44 Favored Glycine 0 N--CA 1.462 0.377 0 O-C-N 123.483 0.489 . . . . 0.0 112.354 179.246 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 71.9 mt -129.59 157.43 76.5 Favored Pre-proline 0 N--CA 1.429 -1.508 0 CA-C-O 120.8 0.333 . . . . 0.0 111.693 -176.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -73.43 137.7 25.97 Favored 'Trans proline' 0 N--CA 1.438 -1.753 0 C-N-CA 122.523 2.148 . . . . 0.0 109.021 174.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 24.2 t -96.81 104.06 15.42 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.068 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 -179.712 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 22.0 p . . . . . 0 C--N 1.267 -3.019 0 CA-C-N 114.689 -1.141 . . . . 0.0 108.878 178.986 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.906 0 N-CA-C 110.231 -1.148 . . . . 0.0 110.231 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -102.57 4.05 50.38 Favored Glycine 0 N--CA 1.433 -1.512 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 177.157 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 82.87 -58.27 5.04 Favored Glycine 0 CA--C 1.498 -1.023 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 -177.118 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 4.0 m -150.74 134.1 16.28 Favored 'General case' 0 N--CA 1.413 -2.275 0 C-N-CA 125.318 1.447 . . . . 0.0 108.181 175.207 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -88.92 -5.75 73.25 Favored Glycine 0 N--CA 1.439 -1.165 0 N-CA-C 110.123 -1.191 . . . . 0.0 110.123 177.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -78.77 147.93 33.16 Favored 'General case' 0 N--CA 1.428 -1.558 0 CA-C-N 114.92 -0.64 . . . . 0.0 109.438 179.689 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 32.2 p -105.01 155.09 19.29 Favored 'General case' 0 N--CA 1.401 -2.907 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.271 -177.178 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.624 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 30.0 p -118.8 41.62 2.98 Favored 'General case' 0 N--CA 1.428 -1.537 0 CA-C-O 121.614 0.721 . . . . 0.0 109.228 -179.104 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 35.4 t -56.57 -36.47 48.23 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.919 0 CA-C-N 114.933 -1.03 . . . . 0.0 111.075 -178.366 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -91.7 3.93 78.66 Favored Glycine 0 CA--C 1.519 0.312 0 N-CA-C 112.025 -0.43 . . . . 0.0 112.025 178.338 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 83.17 42.51 7.98 Favored Glycine 0 N--CA 1.44 -1.066 0 C-N-CA 121.753 -0.26 . . . . 0.0 112.847 179.231 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.3 t -155.09 151.03 27.84 Favored 'General case' 0 N--CA 1.431 -1.377 0 CA-C-O 121.286 0.565 . . . . 0.0 111.227 179.219 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.442 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 82.9 m -138.2 145.85 41.94 Favored 'General case' 0 C--N 1.286 -2.166 0 CA-C-N 113.812 -1.54 . . . . 0.0 108.105 178.696 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 31.6 m-80 -87.18 -39.25 15.66 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-O 121.61 0.719 . . . . 0.0 110.162 -178.505 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 16.0 m -78.52 120.85 82.55 Favored Pre-proline 0 C--N 1.305 -1.366 0 N-CA-C 108.785 -0.821 . . . . 0.0 108.785 178.208 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -72.98 -8.42 22.22 Favored 'Trans proline' 0 C--N 1.365 1.425 0 C-N-CA 122.802 2.335 . . . . 0.0 113.127 -175.501 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -92.97 -6.66 63.21 Favored Glycine 0 C--N 1.265 -3.369 0 CA-C-N 113.45 -1.705 . . . . 0.0 109.881 177.725 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.479 ' HA ' ' O ' ' A' ' 26' ' ' THR . 98.7 m -109.57 125.93 53.05 Favored 'General case' 0 N--CA 1.401 -2.898 0 CA-C-O 122.532 1.158 . . . . 0.0 111.106 179.202 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 3.5 m -100.09 153.23 19.39 Favored 'General case' 0 N--CA 1.401 -2.916 0 C-N-CA 127.153 2.181 . . . . 0.0 107.688 -175.283 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 53.9 t -85.27 117.59 24.3 Favored 'General case' 0 C--N 1.285 -2.198 0 CA-C-O 121.466 0.65 . . . . 0.0 110.364 179.001 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 21.3 t -124.55 74.88 1.36 Allowed 'General case' 0 C--N 1.282 -2.364 0 N-CA-C 103.197 -2.89 . . . . 0.0 103.197 172.47 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.472 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 42.9 t90 -39.56 133.88 1.28 Allowed Pre-proline 0 N--CA 1.431 -1.411 0 CA-C-N 113.858 -1.519 . . . . 0.0 113.096 -171.063 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.472 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 1.4 Cg_endo -92.38 15.27 46.72 Favored 'Cis proline' 0 CA--C 1.541 0.868 0 C-N-CA 122.874 -1.719 . . . . 0.0 114.695 1.958 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 30.9 m -115.63 146.62 19.82 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 N-CA-C 113.986 1.106 . . . . 0.0 113.986 -175.696 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.624 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 70.0 m -83.8 132.93 34.79 Favored 'General case' 0 N--CA 1.402 -2.846 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 173.309 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.479 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 2.5 p -135.55 -176.57 4.33 Favored 'General case' 0 C--O 1.182 -2.485 0 C-N-CA 124.057 0.943 . . . . 0.0 108.654 -179.779 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 57.2 mtp180 -114.72 107.06 14.96 Favored 'General case' 0 N--CA 1.407 -2.585 0 CA-C-N 119.515 1.052 . . . . 0.0 110.009 -177.407 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -68.67 127.75 34.18 Favored 'General case' 0 C--N 1.313 -0.993 0 N-CA-C 111.627 0.232 . . . . 0.0 111.627 179.218 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 60.7 25.94 64.23 Favored Glycine 0 N--CA 1.46 0.287 0 CA-C-N 116.008 -0.542 . . . . 0.0 113.551 175.61 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 32.8 mt -125.56 145.66 52.02 Favored Pre-proline 0 C--N 1.301 -1.52 0 N-CA-C 111.923 0.342 . . . . 0.0 111.923 -175.674 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_exo -49.99 138.24 35.41 Favored 'Trans proline' 0 C--O 1.246 0.912 0 C-N-CA 124.149 3.233 . . . . 0.0 113.335 178.719 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.3 p -70.03 120.74 18.3 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.665 0 CA-C-O 122.231 1.015 . . . . 0.0 112.461 -177.613 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 5.0 t . . . . . 0 C--N 1.281 -2.383 0 CA-C-N 114.101 -1.409 . . . . 0.0 109.828 175.457 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.493 -1.308 0 N-CA-C 110.424 -1.071 . . . . 0.0 110.424 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 147.34 127.97 1.8 Allowed Glycine 0 N--CA 1.42 -2.419 0 N-CA-C 108.889 -1.684 . . . . 0.0 108.889 -177.211 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -76.16 -94.07 0.18 Allowed Glycine 0 N--CA 1.436 -1.308 0 C-N-CA 120.483 -0.865 . . . . 0.0 111.984 -179.53 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 73.2 m -131.02 134.96 47.17 Favored 'General case' 0 C--N 1.29 -2.002 0 N-CA-C 109.665 -0.495 . . . . 0.0 109.665 -179.017 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -88.41 16.9 51.51 Favored Glycine 0 C--N 1.315 -0.612 0 N-CA-C 110.741 -0.944 . . . . 0.0 110.741 177.65 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 -90.35 150.63 21.81 Favored 'General case' 0 N--CA 1.432 -1.354 0 C-N-CA 124.018 0.927 . . . . 0.0 109.881 -178.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 7.1 p -124.58 151.94 44.15 Favored 'General case' 0 N--CA 1.411 -2.384 0 CA-C-N 116.186 -0.461 . . . . 0.0 109.869 176.025 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.491 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 27.0 p -130.9 41.12 3.4 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-O 121.446 0.641 . . . . 0.0 109.989 -176.507 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 19.4 t -61.87 -32.94 55.64 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 114.965 -1.016 . . . . 0.0 109.533 -179.317 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -85.79 -1.61 87.08 Favored Glycine 0 N--CA 1.442 -0.943 0 CA-C-N 115.452 -0.795 . . . . 0.0 111.78 178.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 109.4 -10.14 33.18 Favored Glycine 0 N--CA 1.433 -1.516 0 N-CA-C 114.81 0.684 . . . . 0.0 114.81 176.059 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 1.1 m -137.55 152.57 49.59 Favored 'General case' 0 N--CA 1.43 -1.471 0 CA-C-N 118.773 1.286 . . . . 0.0 110.198 -174.708 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.463 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 82.8 m -106.92 136.39 46.84 Favored 'General case' 0 C--N 1.277 -2.546 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 174.469 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 33.9 m-80 -65.54 -44.44 86.85 Favored 'General case' 0 N--CA 1.475 0.778 0 CA-C-O 121.236 0.541 . . . . 0.0 109.816 176.884 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 55.0 m -83.33 112.48 39.35 Favored Pre-proline 0 N--CA 1.43 -1.447 0 N-CA-C 108.852 -0.796 . . . . 0.0 108.852 175.197 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -75.87 -1.39 11.34 Favored 'Trans proline' 0 C--N 1.359 1.096 0 C-N-CA 123.337 2.691 . . . . 0.0 113.781 -174.716 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -86.69 -10.64 72.57 Favored Glycine 0 C--N 1.27 -3.084 0 CA-C-N 113.971 -1.468 . . . . 0.0 110.356 177.14 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.456 ' HA ' ' O ' ' A' ' 26' ' ' THR . 49.9 m -105.92 133.5 50.54 Favored 'General case' 0 N--CA 1.419 -2.006 0 CA-C-N 114.552 -0.824 . . . . 0.0 109.537 -179.053 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.419 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 5.8 m -89.86 151.88 21.54 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 108.299 -1.001 . . . . 0.0 108.299 -177.693 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 50.5 t -88.52 104.71 17.07 Favored 'General case' 0 C--N 1.292 -1.93 0 CA-C-O 122.021 0.915 . . . . 0.0 111.331 179.604 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 42.6 t -107.51 65.59 0.65 Allowed 'General case' 0 C--N 1.285 -2.201 0 N-CA-C 104.22 -2.511 . . . . 0.0 104.22 173.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.444 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 56.7 t90 -36.24 132.63 0.61 Allowed Pre-proline 0 N--CA 1.439 -1.018 0 C-N-CA 125.884 1.673 . . . . 0.0 112.668 -172.171 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.444 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 2.2 Cg_endo -90.23 10.76 60.48 Favored 'Cis proline' 0 CA--C 1.546 1.117 0 C-N-CA 123.017 -1.66 . . . . 0.0 115.294 3.09 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 30.6 m -111.34 153.78 13.03 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.0 0 O-C-N 121.561 -0.712 . . . . 0.0 112.466 -176.611 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.491 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 68.3 m -92.89 135.37 34.2 Favored 'General case' 0 N--CA 1.397 -3.078 0 O-C-N 121.835 -0.541 . . . . 0.0 109.617 175.044 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.456 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 11.8 p -116.45 -174.21 2.52 Favored 'General case' 0 C--N 1.285 -2.23 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.836 -179.558 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.69 149.59 32.68 Favored 'General case' 0 N--CA 1.383 -3.784 0 CA-C-O 121.523 0.677 . . . . 0.0 110.901 -176.79 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . 0.419 ' C ' ' H ' ' A' ' 30' ' ' LEU . 8.0 p30 -136.14 129.69 32.15 Favored 'General case' 0 C--N 1.266 -3.053 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 174.667 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.13 -33.58 1.09 Allowed Glycine 0 CA--C 1.533 1.205 0 N-CA-C 113.894 0.318 . . . . 0.0 113.894 179.285 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.419 ' H ' ' C ' ' A' ' 28' ' ' ASN . 55.9 mt -57.76 142.26 78.63 Favored Pre-proline 0 C--N 1.321 -0.648 0 C-N-CA 124.701 1.2 . . . . 0.0 113.465 -177.703 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_endo -69.27 148.27 67.88 Favored 'Trans proline' 0 N--CA 1.445 -1.374 0 C-N-CA 122.797 2.331 . . . . 0.0 111.931 -176.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 25.7 t -69.51 113.31 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.49 0 N-CA-C 108.269 -1.011 . . . . 0.0 108.269 -179.497 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 14.9 m . . . . . 0 C--N 1.273 -2.737 0 CA-C-N 115.078 -0.965 . . . . 0.0 109.914 -175.789 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.425 -2.042 0 N-CA-C 108.384 -1.887 . . . . 0.0 108.384 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -89.94 -19.62 46.45 Favored Glycine 0 C--N 1.306 -1.086 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.277 -178.103 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -173.27 -139.48 2.9 Favored Glycine 0 CA--C 1.486 -1.729 0 N-CA-C 110.721 -0.952 . . . . 0.0 110.721 -179.025 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 71.9 m -142.02 135.24 29.05 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 178.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -94.93 -2.76 62.45 Favored Glycine 0 C--N 1.308 -1.005 0 C-N-CA 121.227 -0.511 . . . . 0.0 111.869 -176.521 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.434 ' O ' ' HB2' ' A' ' 25' ' ' CYS . 1.6 pm0 -83.82 141.74 31.13 Favored 'General case' 0 N--CA 1.426 -1.673 0 CA-C-O 121.488 0.661 . . . . 0.0 110.87 177.001 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 22.8 p -106.83 153.57 22.29 Favored 'General case' 0 N--CA 1.404 -2.732 0 CA-C-N 115.279 -0.873 . . . . 0.0 109.765 -179.603 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.447 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 19.5 p -122.01 37.59 4.33 Favored 'General case' 0 CA--C 1.492 -1.277 0 CA-C-O 121.389 0.614 . . . . 0.0 110.268 -177.876 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 16.0 t -60.06 -33.99 55.04 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.204 0 CA-C-N 114.734 -1.121 . . . . 0.0 109.636 -178.646 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -87.73 6.62 83.17 Favored Glycine 0 N--CA 1.439 -1.107 0 CA-C-N 115.258 -0.883 . . . . 0.0 113.087 179.647 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.452 ' C ' ' HG1' ' A' ' 12' ' ' THR . . . 142.18 -69.01 0.44 Allowed Glycine 0 N--CA 1.438 -1.189 0 C-N-CA 120.131 -1.033 . . . . 0.0 114.502 177.384 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.452 ' HG1' ' C ' ' A' ' 11' ' ' GLY . 20.5 m -157.04 163.24 39.27 Favored 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 106.748 -1.575 . . . . 0.0 106.748 -174.851 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 98.3 m -94.76 158.49 15.48 Favored 'General case' 0 C--N 1.281 -2.384 0 CA-C-O 120.808 0.337 . . . . 0.0 110.493 178.58 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 16.1 m120 -84.39 -26.73 28.15 Favored 'General case' 0 C--N 1.31 -1.144 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.845 -178.64 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 9.1 m -71.22 112.87 15.14 Favored Pre-proline 0 CA--C 1.556 1.175 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 177.243 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -70.8 -10.21 27.28 Favored 'Trans proline' 0 C--N 1.362 1.274 0 C-N-CA 123.293 2.662 . . . . 0.0 115.257 -172.101 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -93.3 -6.06 63.18 Favored Glycine 0 C--N 1.258 -3.753 0 CA-C-N 114.309 -1.314 . . . . 0.0 111.124 179.121 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.501 ' HA ' ' O ' ' A' ' 26' ' ' THR . 60.3 m -108.49 126.01 52.43 Favored 'General case' 0 N--CA 1.422 -1.834 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 1.4 m -95.16 143.9 26.22 Favored 'General case' 0 C--N 1.284 -2.268 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 -178.203 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 41.1 t -87.65 125.94 34.67 Favored 'General case' 0 C--N 1.285 -2.225 0 CA-C-O 121.593 0.711 . . . . 0.0 109.879 -179.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 6.4 t -132.22 71.41 1.47 Allowed 'General case' 0 N--CA 1.4 -2.973 0 N-CA-C 103.426 -2.805 . . . . 0.0 103.426 174.53 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.491 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 55.5 t90 -35.69 132.87 0.53 Allowed Pre-proline 0 N--CA 1.433 -1.297 0 C-N-CA 126.319 1.848 . . . . 0.0 112.95 -171.281 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.491 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 1.6 Cg_endo -91.95 10.59 58.15 Favored 'Cis proline' 0 CA--C 1.539 0.729 0 C-N-CA 123.081 -1.633 . . . . 0.0 115.381 4.053 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 34.1 m -118.56 150.03 20.88 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 C-N-CA 119.511 -0.875 . . . . 0.0 112.438 -175.177 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.447 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 64.5 m -95.66 148.56 22.41 Favored 'General case' 0 N--CA 1.398 -3.047 0 CA-C-O 121.704 0.764 . . . . 0.0 111.331 175.933 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.501 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 0.6 OUTLIER -135.47 -165.23 1.66 Allowed 'General case' 0 C--N 1.284 -2.242 0 CA-C-N 114.518 -1.219 . . . . 0.0 109.975 177.851 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 3.8 ptm180 -108.62 153.48 23.35 Favored 'General case' 0 N--CA 1.389 -3.491 0 CA-C-O 121.746 0.784 . . . . 0.0 110.554 -174.476 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 43.3 m-80 -78.32 -23.4 47.09 Favored 'General case' 0 C--N 1.28 -2.45 0 CA-C-N 114.564 -1.198 . . . . 0.0 108.738 174.634 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 106.37 43.4 1.48 Allowed Glycine 0 N--CA 1.429 -1.814 0 CA-C-N 114.111 -1.404 . . . . 0.0 111.213 -178.152 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 4.4 mp -76.43 166.02 48.26 Favored Pre-proline 0 C--O 1.249 1.04 0 N-CA-C 106.44 -1.689 . . . . 0.0 106.44 178.58 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_exo -46.23 136.37 14.72 Favored 'Trans proline' 0 C--N 1.376 1.999 0 C-N-CA 122.363 2.042 . . . . 0.0 109.707 178.846 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 26.8 t -68.34 112.25 3.19 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 CA-C-O 122.397 1.094 . . . . 0.0 113.374 -168.107 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 12.8 m . . . . . 0 C--N 1.282 -2.357 0 CA-C-N 113.428 -1.714 . . . . 0.0 107.162 174.371 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.497 -1.033 0 N-CA-C 109.946 -1.262 . . . . 0.0 109.946 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 84.5 -73.85 2.59 Favored Glycine 0 C--N 1.298 -1.533 0 N-CA-C 109.989 -1.244 . . . . 0.0 109.989 -175.121 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 153.14 -100.8 0.2 Allowed Glycine 0 N--CA 1.422 -2.258 0 C-N-CA 121.157 -0.544 . . . . 0.0 111.774 179.397 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 65.2 m -118.92 135.92 54.34 Favored 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 -179.231 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -96.25 14.72 64.06 Favored Glycine 0 C--N 1.314 -0.678 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 176.534 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.423 ' HB2' ' HB2' ' A' ' 25' ' ' CYS . 6.7 mm-40 -81.21 149.76 28.92 Favored 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 179.132 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 18.3 p -123.49 150.75 43.54 Favored 'General case' 0 N--CA 1.401 -2.914 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 177.198 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.481 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 30.1 p -127.22 44.85 2.83 Favored 'General case' 0 N--CA 1.427 -1.578 0 CA-C-O 121.231 0.539 . . . . 0.0 109.588 -177.103 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 38.8 t -57.62 -33.82 45.75 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.059 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.894 -178.37 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -81.09 -31.49 34.71 Favored Glycine 0 N--CA 1.444 -0.83 0 N-CA-C 110.803 -0.919 . . . . 0.0 110.803 175.474 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 124.84 14.89 3.31 Favored Glycine 0 N--CA 1.441 -1.006 0 C-N-CA 121.507 -0.378 . . . . 0.0 113.613 178.41 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 12.7 m -139.62 153.77 47.42 Favored 'General case' 0 N--CA 1.424 -1.727 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 -178.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.463 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 41.5 m -122.59 137.93 54.74 Favored 'General case' 0 C--N 1.274 -2.709 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 175.194 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -66.01 -52.44 49.24 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.043 178.188 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 32.8 m -73.39 112.53 16.32 Favored Pre-proline 0 CA--C 1.554 1.122 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 176.57 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -72.86 -4.64 15.74 Favored 'Trans proline' 0 C--N 1.36 1.178 0 C-N-CA 123.438 2.759 . . . . 0.0 114.868 -172.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -86.0 -14.77 66.37 Favored Glycine 0 C--N 1.257 -3.822 0 CA-C-N 114.388 -1.278 . . . . 0.0 110.358 177.416 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.534 ' HA ' ' O ' ' A' ' 26' ' ' THR . 22.0 m -103.95 129.94 51.54 Favored 'General case' 0 N--CA 1.419 -1.999 0 CA-C-N 114.952 -0.624 . . . . 0.0 109.658 -179.163 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 4.3 m -95.85 156.48 16.31 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 124.346 1.058 . . . . 0.0 108.151 -178.806 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 42.0 t -83.04 123.76 29.78 Favored 'General case' 0 N--CA 1.423 -1.809 0 CA-C-O 121.61 0.719 . . . . 0.0 110.987 -179.299 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 32.7 t -133.76 69.93 1.46 Allowed 'General case' 0 C--N 1.283 -2.306 0 N-CA-C 104.526 -2.398 . . . . 0.0 104.526 173.831 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.491 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 41.7 t90 -36.53 134.59 0.6 Allowed Pre-proline 0 N--CA 1.443 -0.821 0 C-N-CA 126.258 1.823 . . . . 0.0 113.93 -170.702 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.491 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 1.9 Cg_endo -90.12 8.83 65.17 Favored 'Cis proline' 0 N--CA 1.456 -0.705 0 C-N-CA 122.679 -1.8 . . . . 0.0 114.261 1.277 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 35.9 m -108.88 158.66 8.62 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.928 0 CA-C-O 121.415 0.626 . . . . 0.0 112.548 -175.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.481 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 84.1 m -95.41 135.52 36.94 Favored 'General case' 0 N--CA 1.405 -2.7 0 O-C-N 121.733 -0.604 . . . . 0.0 109.829 174.453 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.534 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 10.5 p -119.35 -169.46 1.76 Allowed 'General case' 0 C--N 1.286 -2.168 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.83 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 10.5 mtp-105 -110.77 165.04 12.16 Favored 'General case' 0 N--CA 1.392 -3.326 0 CA-C-O 121.878 0.847 . . . . 0.0 110.442 -177.447 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -143.82 105.2 4.27 Favored 'General case' 0 C--N 1.272 -2.794 0 CA-C-N 113.705 -1.589 . . . . 0.0 109.56 177.435 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.08 33.84 69.92 Favored Glycine 0 C--N 1.316 -0.557 0 CA-C-N 115.752 -0.658 . . . . 0.0 112.458 179.429 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 45.7 mt -127.69 147.28 62.01 Favored Pre-proline 0 C--N 1.314 -0.975 0 N-CA-C 112.849 0.685 . . . . 0.0 112.849 -176.274 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_exo -60.78 148.08 93.11 Favored 'Trans proline' 0 C--O 1.247 0.929 0 C-N-CA 123.386 2.724 . . . . 0.0 110.881 176.264 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.4 p -81.81 115.81 25.01 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.737 0 CA-C-O 122.415 1.102 . . . . 0.0 111.467 -179.418 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 18.1 p . . . . . 0 C--N 1.277 -2.586 0 CA-C-N 113.738 -1.574 . . . . 0.0 111.387 -179.442 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.429 -1.81 0 N-CA-C 109.206 -1.557 . . . . 0.0 109.206 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -85.12 69.38 3.31 Favored Glycine 0 CA--C 1.495 -1.17 0 N-CA-C 110.145 -1.182 . . . . 0.0 110.145 177.362 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 84.27 -107.84 3.04 Favored Glycine 0 N--CA 1.413 -2.848 0 N-CA-C 109.409 -1.476 . . . . 0.0 109.409 -175.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.711 ' SG ' ' HG3' ' A' ' 27' ' ' ARG . 78.0 m -133.16 146.73 51.82 Favored 'General case' 0 C--N 1.298 -1.653 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 176.812 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -81.57 -3.47 90.61 Favored Glycine 0 C--N 1.308 -1.007 0 C-N-CA 120.99 -0.624 . . . . 0.0 111.944 -179.501 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -89.62 160.06 16.84 Favored 'General case' 0 N--CA 1.437 -1.096 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 179.602 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' THR . . . . . 0.412 ' HB ' HG23 ' A' ' 9' ' ' VAL . 38.0 p -113.88 164.07 14.25 Favored 'General case' 0 N--CA 1.406 -2.647 0 CA-C-O 121.109 0.481 . . . . 0.0 112.271 -174.83 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.498 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 26.1 p -131.41 33.8 4.03 Favored 'General case' 0 N--CA 1.426 -1.663 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 178.034 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.412 HG23 ' HB ' ' A' ' 7' ' ' THR . 21.9 t -57.7 -35.52 51.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 114.74 -1.118 . . . . 0.0 110.01 -178.766 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -82.27 -4.77 90.08 Favored Glycine 0 N--CA 1.444 -0.782 0 CA-C-N 115.684 -0.689 . . . . 0.0 113.063 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 128.46 -24.98 4.87 Favored Glycine 0 N--CA 1.444 -0.771 0 C-N-CA 120.231 -0.985 . . . . 0.0 114.344 177.497 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 15.3 t -156.89 173.03 17.61 Favored 'General case' 0 N--CA 1.431 -1.402 0 CA-C-N 118.277 1.039 . . . . 0.0 110.446 -175.689 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 57.5 m -101.77 175.88 5.41 Favored 'General case' 0 C--N 1.276 -2.612 0 CA-C-N 114.527 -1.215 . . . . 0.0 109.977 -175.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 51.0 m-80 -97.88 -38.32 9.48 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.046 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 33.9 m -90.03 126.12 58.28 Favored Pre-proline 0 N--CA 1.429 -1.524 0 CA-C-N 115.505 -0.77 . . . . 0.0 108.979 178.33 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -72.33 -2.34 11.55 Favored 'Trans proline' 0 C--N 1.358 1.043 0 C-N-CA 122.693 2.262 . . . . 0.0 113.416 -177.383 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -93.07 -10.09 60.08 Favored Glycine 0 C--N 1.271 -3.054 0 CA-C-N 113.836 -1.529 . . . . 0.0 110.311 177.176 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.522 ' HA ' ' O ' ' A' ' 26' ' ' THR . 80.3 m -104.09 132.37 50.4 Favored 'General case' 0 N--CA 1.42 -1.926 0 CA-C-N 114.96 -0.62 . . . . 0.0 109.472 179.478 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 7.5 m -101.49 156.43 17.47 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 -179.736 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 44.4 t -88.16 123.97 33.35 Favored 'General case' 0 N--CA 1.418 -2.066 0 CA-C-O 121.409 0.623 . . . . 0.0 109.961 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 8.8 t -130.82 62.83 1.6 Allowed 'General case' 0 C--N 1.282 -2.34 0 N-CA-C 103.463 -2.792 . . . . 0.0 103.463 175.121 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.537 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 35.5 t90 -33.28 135.78 0.29 Allowed Pre-proline 0 C--O 1.243 0.732 0 C-N-CA 127.827 2.451 . . . . 0.0 113.821 -170.335 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.537 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 4.4 Cg_exo -88.4 4.98 69.71 Favored 'Cis proline' 0 CA--C 1.534 0.507 0 C-N-CA 123.004 -1.665 . . . . 0.0 114.812 2.183 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 34.1 m -107.82 157.66 7.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 C-N-CA 120.26 -0.576 . . . . 0.0 111.913 -176.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.506 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 93.1 m -91.28 150.33 21.37 Favored 'General case' 0 N--CA 1.404 -2.77 0 CA-C-O 121.305 0.574 . . . . 0.0 111.086 177.063 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.522 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 16.7 p -130.9 -178.65 4.9 Favored 'General case' 0 N--CA 1.421 -1.895 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.624 179.765 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.711 ' HG3' ' SG ' ' A' ' 4' ' ' CYS . 34.4 mtt85 -120.71 120.12 34.78 Favored 'General case' 0 N--CA 1.414 -2.241 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 -177.798 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -79.72 97.44 6.58 Favored 'General case' 0 C--N 1.287 -2.135 0 CA-C-N 115.448 -0.796 . . . . 0.0 112.284 -177.238 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 60.81 44.21 98.29 Favored Glycine 0 C--N 1.331 0.25 0 CA-C-N 115.733 -0.667 . . . . 0.0 112.933 176.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.496 ' HB2' ' HB3' ' A' ' 27' ' ' ARG . 55.0 mt -119.35 157.81 50.38 Favored Pre-proline 0 C--N 1.298 -1.668 0 O-C-N 122.885 -0.185 . . . . 0.0 110.625 -177.529 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 77.1 Cg_exo -50.24 139.47 35.67 Favored 'Trans proline' 0 C--O 1.252 1.21 0 C-N-CA 123.963 3.108 . . . . 0.0 112.033 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.6 p -64.64 112.74 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.186 0 CA-C-O 122.576 1.179 . . . . 0.0 111.597 -177.781 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 6.5 m . . . . . 0 C--N 1.293 -1.848 0 CA-C-N 113.288 -1.778 . . . . 0.0 107.979 -179.201 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.667 0 N-CA-C 112.502 -0.239 . . . . 0.0 112.502 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 117.72 -34.73 4.38 Favored Glycine 0 N--CA 1.432 -1.626 0 N-CA-C 110.909 -0.876 . . . . 0.0 110.909 179.401 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 87.35 -79.71 1.76 Allowed Glycine 0 N--CA 1.435 -1.407 0 N-CA-C 111.381 -0.687 . . . . 0.0 111.381 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 73.7 m -137.33 138.43 39.96 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 178.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -77.78 -6.24 86.94 Favored Glycine 0 C--N 1.312 -0.778 0 C-N-CA 121.212 -0.518 . . . . 0.0 113.163 -177.262 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -86.14 146.94 26.37 Favored 'General case' 0 C--N 1.308 -1.222 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 -179.398 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 24.9 p -104.39 161.43 14.08 Favored 'General case' 0 N--CA 1.414 -2.255 0 CA-C-O 121.013 0.435 . . . . 0.0 111.891 -179.401 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.47 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 9.2 p -126.63 34.72 4.75 Favored 'General case' 0 CA--C 1.492 -1.255 0 CA-C-O 121.271 0.558 . . . . 0.0 110.27 -178.858 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.446 ' HA ' ' NE1' ' A' ' 22' ' ' TRP . 5.7 t -65.43 -28.79 45.27 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-N 115.273 -0.876 . . . . 0.0 109.46 -178.698 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -79.76 -15.83 78.58 Favored Glycine 0 C--O 1.241 0.564 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.512 177.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 125.98 -18.39 6.63 Favored Glycine 0 N--CA 1.436 -1.361 0 C-N-CA 120.519 -0.848 . . . . 0.0 115.217 175.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.5 m -145.67 158.14 43.88 Favored 'General case' 0 N--CA 1.437 -1.092 0 CA-C-N 118.764 1.282 . . . . 0.0 108.172 -175.341 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 62.7 m -99.51 170.85 8.32 Favored 'General case' 0 C--N 1.281 -2.372 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 175.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 26.9 m-80 -101.37 -18.82 15.87 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.468 0.651 . . . . 0.0 110.621 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.565 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 29.2 m -105.58 124.83 35.0 Favored Pre-proline 0 C--N 1.293 -1.888 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 175.561 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -73.29 -3.26 13.38 Favored 'Trans proline' 0 N--CA 1.486 1.078 0 C-N-CA 122.744 2.296 . . . . 0.0 113.098 -177.735 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -94.89 -8.03 59.47 Favored Glycine 0 C--N 1.27 -3.134 0 CA-C-N 113.38 -1.736 . . . . 0.0 109.839 176.419 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.613 ' HA ' ' O ' ' A' ' 26' ' ' THR . 85.0 m -106.12 125.75 51.37 Favored 'General case' 0 N--CA 1.419 -1.998 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.168 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 7.4 m -101.55 160.42 14.46 Favored 'General case' 0 C--N 1.286 -2.168 0 N-CA-C 107.483 -1.302 . . . . 0.0 107.483 -178.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 42.1 t -93.11 122.58 35.63 Favored 'General case' 0 N--CA 1.419 -2.013 0 CA-C-O 121.305 0.574 . . . . 0.0 110.911 -177.352 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 49.3 m -123.99 67.69 1.04 Allowed 'General case' 0 N--CA 1.409 -2.483 0 N-CA-C 105.03 -2.211 . . . . 0.0 105.03 171.644 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.526 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 50.4 t90 -37.27 133.69 0.73 Allowed Pre-proline 0 N--CA 1.435 -1.177 0 C-N-CA 126.091 1.757 . . . . 0.0 113.23 -170.157 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.526 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 1.9 Cg_endo -89.52 7.07 68.27 Favored 'Cis proline' 0 CA--C 1.55 1.299 0 C-N-CA 122.924 -1.698 . . . . 0.0 115.905 3.32 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.3 m -109.52 151.47 11.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 O-C-N 121.581 -0.7 . . . . 0.0 112.421 -175.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.47 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 71.1 m -86.52 147.34 26.0 Favored 'General case' 0 N--CA 1.405 -2.68 0 CA-C-O 121.297 0.57 . . . . 0.0 109.954 175.395 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.613 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 31.0 p -132.6 -169.99 2.35 Favored 'General case' 0 C--N 1.294 -1.829 0 C-N-CA 122.758 0.423 . . . . 0.0 110.257 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 95.9 mtt180 -113.61 148.7 35.73 Favored 'General case' 0 N--CA 1.391 -3.396 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 -178.266 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -125.67 135.98 52.72 Favored 'General case' 0 C--N 1.276 -2.612 0 CA-C-N 114.47 -1.241 . . . . 0.0 109.144 179.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 60.57 27.41 66.06 Favored Glycine 0 N--CA 1.462 0.4 0 O-C-N 123.369 0.418 . . . . 0.0 112.446 177.024 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 55.7 mt -129.45 164.38 40.09 Favored Pre-proline 0 C--N 1.299 -1.607 0 CA-C-N 115.566 -0.317 . . . . 0.0 110.807 -175.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_exo -54.47 136.62 70.39 Favored 'Trans proline' 0 C--O 1.25 1.121 0 C-N-CA 122.976 2.45 . . . . 0.0 109.76 175.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 35.7 t -73.14 115.77 14.47 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.274 0 CA-C-O 122.371 1.081 . . . . 0.0 110.633 -173.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 9.7 m . . . . . 0 C--N 1.268 -2.95 0 CA-C-N 113.184 -1.826 . . . . 0.0 107.187 -179.519 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.426 -1.98 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -97.72 -17.65 30.04 Favored Glycine 0 C--N 1.306 -1.132 0 N-CA-C 111.028 -0.829 . . . . 0.0 111.028 179.125 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -150.6 -172.88 20.2 Favored Glycine 0 N--CA 1.423 -2.198 0 N-CA-C 108.857 -1.697 . . . . 0.0 108.857 179.598 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 88.2 m -103.66 124.21 48.42 Favored 'General case' 0 C--N 1.292 -1.904 0 C-N-CA 119.613 -0.835 . . . . 0.0 112.323 -179.349 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -89.88 23.41 20.43 Favored Glycine 0 C--N 1.316 -0.554 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 175.555 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.422 ' HB2' ' HB2' ' A' ' 25' ' ' CYS . 8.3 mm-40 -90.38 156.76 18.01 Favored 'General case' 0 N--CA 1.437 -1.109 0 C-N-CA 124.181 0.992 . . . . 0.0 110.005 -177.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 21.8 p -126.16 153.54 44.45 Favored 'General case' 0 N--CA 1.41 -2.443 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 174.23 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.432 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 21.6 p -124.79 33.75 5.15 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.781 -0.574 . . . . 0.0 111.005 -178.442 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.434 ' HA ' ' NE1' ' A' ' 22' ' ' TRP . 22.3 t -62.03 -35.98 71.57 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.867 0 CA-C-N 114.786 -1.097 . . . . 0.0 109.193 -179.835 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -71.33 -16.06 75.23 Favored Glycine 0 C--O 1.22 -0.733 0 CA-C-N 115.094 -0.957 . . . . 0.0 112.336 178.747 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 132.66 -23.65 3.97 Favored Glycine 0 N--CA 1.435 -1.428 0 C-N-CA 120.242 -0.98 . . . . 0.0 113.696 177.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 20.4 m -157.08 162.27 39.47 Favored 'General case' 0 C--N 1.31 -1.116 0 N-CA-C 107.114 -1.439 . . . . 0.0 107.114 -176.483 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 52.5 m -86.45 140.15 30.24 Favored 'General case' 0 C--N 1.283 -2.301 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 177.163 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 44.8 m-80 -72.0 -44.21 63.83 Favored 'General case' 0 C--N 1.315 -0.93 0 C-N-CA 120.746 -0.382 . . . . 0.0 110.892 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.406 HG21 HG22 ' A' ' 32' ' ' VAL . 27.2 m -76.34 121.08 84.27 Favored Pre-proline 0 CA--C 1.556 1.195 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 172.928 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_endo -71.24 -1.48 9.69 Favored 'Trans proline' 0 C--N 1.36 1.169 0 C-N-CA 123.551 2.834 . . . . 0.0 114.683 -173.45 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -95.06 2.32 65.9 Favored Glycine 0 C--N 1.261 -3.619 0 CA-C-N 114.506 -1.225 . . . . 0.0 112.003 -179.122 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 32.5 m -112.03 140.77 46.43 Favored 'General case' 0 N--CA 1.426 -1.674 0 CA-C-O 120.908 0.385 . . . . 0.0 111.674 -175.253 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 3.2 m -89.91 145.19 25.31 Favored 'General case' 0 C--N 1.315 -0.909 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 179.324 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 43.2 t -93.09 105.43 17.53 Favored 'General case' 0 C--N 1.29 -1.991 0 C-N-CA 120.073 -0.651 . . . . 0.0 110.369 177.547 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 2.3 p -113.97 65.69 0.66 Allowed 'General case' 0 C--N 1.278 -2.538 0 N-CA-C 106.274 -1.751 . . . . 0.0 106.274 173.444 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.517 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 49.2 t90 -34.83 135.34 0.41 Allowed Pre-proline 0 N--CA 1.446 -0.628 0 C-N-CA 126.985 2.114 . . . . 0.0 113.512 -169.933 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.517 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 1.8 Cg_endo -89.93 2.42 68.04 Favored 'Cis proline' 0 C--N 1.329 -0.499 0 C-N-CA 122.929 -1.696 . . . . 0.0 114.725 2.875 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.1 m -108.1 146.35 14.13 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 C-N-CA 120.259 -0.576 . . . . 0.0 111.95 -175.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.432 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 72.3 m -93.27 141.59 28.27 Favored 'General case' 0 N--CA 1.396 -3.162 0 CA-C-O 121.4 0.619 . . . . 0.0 111.5 179.341 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 1.4 p -109.14 -169.61 1.51 Allowed 'General case' 0 C--N 1.283 -2.313 0 CA-C-N 114.736 -1.12 . . . . 0.0 108.683 176.079 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.456 ' HG2' ' H ' ' A' ' 29' ' ' GLY . 39.7 ttp180 -117.45 137.11 52.73 Favored 'General case' 0 N--CA 1.404 -2.73 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 -178.478 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . 0.537 ' HB2' ' CD2' ' A' ' 30' ' ' LEU . 25.1 m-80 -76.61 -14.99 59.94 Favored 'General case' 0 C--N 1.291 -1.955 0 CA-C-O 121.568 0.699 . . . . 0.0 110.537 -178.477 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.456 ' H ' ' HG2' ' A' ' 27' ' ' ARG . . . 118.89 -21.16 9.69 Favored Glycine 0 C--N 1.294 -1.787 0 CA-C-N 115.195 -0.911 . . . . 0.0 111.234 -175.664 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.537 ' CD2' ' HB2' ' A' ' 28' ' ' ASN . 2.6 pt? -75.42 150.33 84.76 Favored Pre-proline 0 C--N 1.323 -0.547 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 174.223 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_exo -66.17 137.13 46.8 Favored 'Trans proline' 0 CA--C 1.481 -2.137 0 C-N-CA 123.168 2.578 . . . . 0.0 115.034 -172.797 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.406 HG22 HG21 ' A' ' 15' ' ' THR . 14.6 p -133.36 160.4 42.37 Favored 'Isoleucine or valine' 0 N--CA 1.388 -3.543 0 CA-C-N 112.102 -2.317 . . . . 0.0 104.747 175.702 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 22.7 m . . . . . 0 C--N 1.265 -3.104 0 CA-C-O 121.351 0.596 . . . . 0.0 110.296 175.895 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.401 ' O ' HG22 ' A' ' 32' ' ' VAL . . . . . . . . 0 N--CA 1.415 -2.757 0 N-CA-C 107.033 -2.427 . . . . 0.0 107.033 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -63.06 -39.09 97.61 Favored Glycine 0 C--N 1.314 -0.646 0 N-CA-C 111.254 -0.738 . . . . 0.0 111.254 -178.726 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -172.83 -168.2 33.81 Favored Glycine 0 N--CA 1.419 -2.49 0 N-CA-C 108.202 -1.959 . . . . 0.0 108.202 178.216 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 61.2 m -103.41 119.65 39.29 Favored 'General case' 0 C--N 1.29 -2.02 0 CA-C-N 117.929 0.864 . . . . 0.0 110.049 179.412 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -84.98 -4.45 87.01 Favored Glycine 0 N--CA 1.443 -0.882 0 CA-C-N 115.699 -0.682 . . . . 0.0 113.978 -175.219 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -86.5 169.45 12.81 Favored 'General case' 0 C--N 1.309 -1.185 0 C-N-CA 119.836 -0.746 . . . . 0.0 111.064 -179.637 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 7.0 p -120.36 155.52 33.22 Favored 'General case' 0 N--CA 1.401 -2.911 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 178.402 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.484 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 13.4 p -119.06 37.2 4.2 Favored 'General case' 0 CA--C 1.484 -1.587 0 CA-C-O 121.043 0.449 . . . . 0.0 110.571 -176.648 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.7 t -57.69 -34.2 47.02 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 CA-C-N 114.926 -1.034 . . . . 0.0 109.353 -179.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -70.62 -8.51 63.4 Favored Glycine 0 N--CA 1.436 -1.321 0 CA-C-N 114.964 -1.017 . . . . 0.0 113.557 179.172 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 144.21 -54.07 0.58 Allowed Glycine 0 N--CA 1.441 -0.979 0 C-N-CA 120.67 -0.776 . . . . 0.0 113.962 176.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 14.7 t -157.61 173.33 17.02 Favored 'General case' 0 N--CA 1.425 -1.72 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -176.226 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.484 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 35.6 m -96.21 137.29 35.49 Favored 'General case' 0 C--N 1.27 -2.867 0 CA-C-N 115.342 -0.844 . . . . 0.0 108.759 -178.158 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 40.8 m-80 -70.47 -47.74 59.13 Favored 'General case' 0 C--N 1.319 -0.755 0 O-C-N 123.199 0.312 . . . . 0.0 111.43 -179.168 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 42.3 m -69.91 119.56 72.2 Favored Pre-proline 0 N--CA 1.437 -1.079 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 178.774 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_exo -66.87 -9.82 26.14 Favored 'Trans proline' 0 C--N 1.36 1.134 0 C-N-CA 123.458 2.772 . . . . 0.0 113.927 -175.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -83.3 -17.27 67.12 Favored Glycine 0 C--N 1.265 -3.392 0 CA-C-N 113.787 -1.551 . . . . 0.0 110.412 177.252 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.495 ' HA ' ' O ' ' A' ' 26' ' ' THR . 47.8 m -108.55 126.68 53.2 Favored 'General case' 0 N--CA 1.416 -2.173 0 N-CA-C 108.096 -1.076 . . . . 0.0 108.096 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 6.8 m -101.22 148.04 25.57 Favored 'General case' 0 C--N 1.274 -2.701 0 N-CA-C 107.459 -1.311 . . . . 0.0 107.459 -175.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 50.3 t -90.78 106.27 18.4 Favored 'General case' 0 C--N 1.275 -2.653 0 CA-C-O 121.702 0.763 . . . . 0.0 110.662 -178.156 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 31.3 t -107.67 67.09 0.68 Allowed 'General case' 0 C--N 1.28 -2.426 0 N-CA-C 102.9 -3.0 . . . . 0.0 102.9 172.81 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.51 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 57.4 t90 -39.39 133.59 1.23 Allowed Pre-proline 0 N--CA 1.433 -1.286 0 CA-C-N 113.405 -1.725 . . . . 0.0 112.326 -171.356 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.51 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 1.9 Cg_endo -90.75 12.17 56.75 Favored 'Cis proline' 0 CA--C 1.543 0.967 0 C-N-CA 122.723 -1.782 . . . . 0.0 115.812 3.721 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.0 m -110.66 146.86 15.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 119.071 0.851 . . . . 0.0 113.007 -176.419 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 90.9 m -86.53 140.64 29.71 Favored 'General case' 0 N--CA 1.401 -2.898 0 O-C-N 121.679 -0.638 . . . . 0.0 109.327 174.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.495 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 2.6 p -135.6 -177.3 4.61 Favored 'General case' 0 C--N 1.269 -2.92 0 CA-C-N 115.206 -0.907 . . . . 0.0 109.084 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 12.9 ttm180 -124.79 118.81 27.2 Favored 'General case' 0 N--CA 1.421 -1.89 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 176.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 34.8 p30 -69.8 7.04 0.97 Allowed 'General case' 0 C--N 1.285 -2.205 0 N-CA-C 114.865 1.431 . . . . 0.0 114.865 -172.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 116.92 -4.16 18.96 Favored Glycine 0 C--N 1.3 -1.428 0 C-N-CA 119.659 -1.258 . . . . 0.0 111.429 -177.533 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 28.2 mt -62.36 158.71 46.0 Favored Pre-proline 0 C--O 1.243 0.717 0 CA-C-O 119.35 -0.357 . . . . 0.0 111.034 174.703 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_exo -37.46 137.63 0.34 Allowed 'Trans proline' 0 C--N 1.362 1.278 0 C-N-CA 124.879 3.719 . . . . 0.0 115.472 -175.53 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.401 HG22 ' O ' ' A' ' 1' ' ' GLY . 3.4 p -80.91 99.49 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.782 0 CA-C-O 122.971 1.367 . . . . 0.0 111.172 -178.203 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 18.7 m . . . . . 0 C--N 1.271 -2.834 0 CA-C-N 113.28 -1.782 . . . . 0.0 107.263 179.091 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.441 -0.988 0 N-CA-C 110.597 -1.001 . . . . 0.0 110.597 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -142.32 -140.46 3.75 Favored Glycine 0 N--CA 1.415 -2.736 0 N-CA-C 109.959 -1.256 . . . . 0.0 109.959 177.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 107.68 -154.71 16.52 Favored Glycine 0 C--N 1.281 -2.477 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 -176.629 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 3.5 m -150.85 139.32 20.48 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 113.55 0.945 . . . . 0.0 113.55 -176.815 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -103.93 18.39 46.62 Favored Glycine 0 C--N 1.313 -0.739 0 N-CA-C 107.724 -2.15 . . . . 0.0 107.724 169.806 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 23.2 mm-40 -80.99 170.85 15.73 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 113.605 -1.298 . . . . 0.0 109.552 -178.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 16.8 p -122.57 156.5 34.1 Favored 'General case' 0 N--CA 1.402 -2.827 0 CA-C-O 120.791 0.329 . . . . 0.0 111.062 178.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 20.5 p -128.22 38.24 4.03 Favored 'General case' 0 CA--C 1.491 -1.294 0 CA-C-O 121.41 0.624 . . . . 0.0 109.601 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 11.1 t -58.62 -29.89 40.37 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.007 0 CA-C-N 114.426 -1.261 . . . . 0.0 110.709 -177.16 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -74.1 -22.11 78.24 Favored Glycine 0 N--CA 1.437 -1.256 0 CA-C-N 115.849 -0.614 . . . . 0.0 112.544 179.028 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 149.63 -36.55 0.99 Allowed Glycine 0 N--CA 1.438 -1.226 0 C-N-CA 120.207 -0.997 . . . . 0.0 113.863 179.672 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 8.8 t -158.3 173.65 16.36 Favored 'General case' 0 N--CA 1.423 -1.793 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 -178.429 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 63.2 m -89.75 150.54 22.25 Favored 'General case' 0 C--N 1.268 -2.937 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.134 -177.277 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 13.9 m120 -90.43 -12.23 38.06 Favored 'General case' 0 C--N 1.308 -1.203 0 CA-C-O 121.177 0.513 . . . . 0.0 110.158 177.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 10.4 m -100.37 122.96 48.13 Favored Pre-proline 0 C--N 1.305 -1.335 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 176.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 96.6 Cg_endo -78.39 -1.85 11.97 Favored 'Trans proline' 0 N--CA 1.484 0.949 0 C-N-CA 123.232 2.621 . . . . 0.0 115.926 -169.186 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -102.5 0.02 49.84 Favored Glycine 0 C--N 1.261 -3.634 0 N-CA-C 110.001 -1.24 . . . . 0.0 110.001 178.221 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.424 ' HA ' ' O ' ' A' ' 26' ' ' THR . 56.1 m -118.65 134.15 55.32 Favored 'General case' 0 N--CA 1.402 -2.854 0 CA-C-N 113.75 -1.225 . . . . 0.0 109.041 -175.429 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 10.5 t -109.89 163.86 13.13 Favored 'General case' 0 N--CA 1.426 -1.651 0 C-N-CA 119.584 -0.846 . . . . 0.0 109.639 -178.74 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 48.9 t -92.96 125.06 37.37 Favored 'General case' 0 N--CA 1.387 -3.605 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.117 -174.495 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 46.0 m -128.75 59.85 1.54 Allowed 'General case' 0 N--CA 1.397 -3.121 0 N-CA-C 104.557 -2.386 . . . . 0.0 104.557 173.211 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.41 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 47.7 t90 -31.8 131.49 0.29 Allowed Pre-proline 0 C--O 1.247 0.931 0 C-N-CA 126.851 2.06 . . . . 0.0 113.149 -172.452 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.41 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 2.8 Cg_endo -89.04 6.62 69.08 Favored 'Cis proline' 0 CA--C 1.537 0.644 0 C-N-CA 122.872 -1.72 . . . . 0.0 115.242 2.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 28.9 m -107.76 152.24 9.54 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.004 0 N-CA-C 112.855 0.687 . . . . 0.0 112.855 -176.223 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 94.5 m -88.56 149.4 23.61 Favored 'General case' 0 N--CA 1.402 -2.836 0 CA-C-O 121.452 0.644 . . . . 0.0 110.986 175.71 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.424 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.8 p -125.37 -146.72 0.35 Allowed 'General case' 0 C--N 1.285 -2.236 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 173.761 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 6.6 ptp180 -124.14 147.83 47.65 Favored 'General case' 1 N--CA 1.377 -4.077 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 -176.5 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 26.4 p30 -82.58 67.7 8.74 Favored 'General case' 0 C--N 1.272 -2.801 0 N-CA-C 113.696 0.999 . . . . 0.0 113.696 -177.733 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 66.72 22.7 71.99 Favored Glycine 0 C--N 1.316 -0.575 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.627 179.646 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 44.8 mt -76.8 155.29 83.15 Favored Pre-proline 0 C--N 1.313 -1.012 0 CA-C-N 115.819 -0.191 . . . . 0.0 110.706 179.387 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 75.9 Cg_exo -50.24 137.74 37.94 Favored 'Trans proline' 0 C--O 1.247 0.946 0 C-N-CA 123.602 2.868 . . . . 0.0 112.615 179.855 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 41.9 t -65.62 121.31 14.45 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.622 0 CA-C-N 115.078 -0.965 . . . . 0.0 109.133 -179.402 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 27.5 m . . . . . 0 C--N 1.294 -1.825 0 O-C-N 124.847 1.342 . . . . 0.0 111.659 179.239 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.411 -2.999 0 N-CA-C 105.22 -3.152 . . . . 0.0 105.22 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -73.03 -53.32 7.98 Favored Glycine 0 C--N 1.299 -1.48 0 N-CA-C 110.215 -1.154 . . . . 0.0 110.215 178.414 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -172.53 -173.87 39.41 Favored Glycine 0 N--CA 1.418 -2.553 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 178.669 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 58.5 m -126.42 138.37 53.53 Favored 'General case' 0 C--N 1.286 -2.175 0 CA-C-O 120.764 0.316 . . . . 0.0 110.999 179.634 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -107.94 -6.69 32.1 Favored Glycine 0 N--CA 1.431 -1.661 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 174.853 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -69.59 151.35 46.06 Favored 'General case' 0 C--O 1.25 1.086 0 CA-C-N 115.169 -0.515 . . . . 0.0 110.948 179.389 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 39.9 p -102.62 163.38 12.25 Favored 'General case' 0 N--CA 1.408 -2.571 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.072 -178.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.709 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 29.3 p -129.38 43.42 3.14 Favored 'General case' 0 N--CA 1.425 -1.677 0 CA-C-O 121.465 0.65 . . . . 0.0 109.485 -178.839 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 58.3 t -58.42 -33.14 47.07 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.862 -177.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -90.03 -0.95 76.89 Favored Glycine 0 C--O 1.224 -0.528 0 CA-C-N 116.211 -0.45 . . . . 0.0 112.109 178.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 86.72 29.18 24.53 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 121.823 -0.227 . . . . 0.0 113.217 177.752 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 7.0 m -148.52 155.08 40.67 Favored 'General case' 0 N--CA 1.436 -1.131 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 179.196 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 61.1 m -133.04 156.87 46.58 Favored 'General case' 0 C--N 1.279 -2.464 0 N-CA-C 107.572 -1.269 . . . . 0.0 107.572 176.862 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 33.3 m-80 -84.1 -39.42 19.53 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 -179.787 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 16.2 m -84.79 116.62 66.09 Favored Pre-proline 0 N--CA 1.429 -1.507 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 175.415 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -74.72 -7.67 19.61 Favored 'Trans proline' 0 C--N 1.358 1.07 0 C-N-CA 122.433 2.089 . . . . 0.0 112.758 -175.444 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -90.44 -6.84 67.88 Favored Glycine 0 C--N 1.268 -3.239 0 CA-C-N 113.233 -1.803 . . . . 0.0 110.143 178.368 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.427 ' HA ' ' O ' ' A' ' 26' ' ' THR . 86.8 m -105.28 125.91 51.51 Favored 'General case' 0 N--CA 1.412 -2.361 0 CA-C-O 122.407 1.098 . . . . 0.0 109.679 177.269 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.435 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 6.8 m -93.59 150.72 20.2 Favored 'General case' 0 C--N 1.276 -2.595 0 CA-C-N 113.125 -1.852 . . . . 0.0 108.603 -173.641 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 52.2 t -93.1 105.77 17.82 Favored 'General case' 0 N--CA 1.409 -2.493 0 CA-C-O 121.866 0.841 . . . . 0.0 110.904 -178.374 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 31.1 m -108.68 79.61 1.25 Allowed 'General case' 0 N--CA 1.391 -3.405 0 N-CA-C 103.569 -2.752 . . . . 0.0 103.569 171.074 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.505 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 54.5 t90 -44.31 134.51 4.37 Favored Pre-proline 0 N--CA 1.429 -1.517 0 CA-C-N 113.322 -1.763 . . . . 0.0 112.919 -167.976 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.505 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 4.0 Cg_endo -95.64 22.96 26.79 Favored 'Cis proline' 0 N--CA 1.458 -0.561 0 C-N-CA 122.969 -1.68 . . . . 0.0 114.597 3.15 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 29.9 m -120.68 144.22 30.25 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.968 0 N-CA-C 114.057 1.132 . . . . 0.0 114.057 -175.712 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.709 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 56.1 m -86.05 129.87 34.71 Favored 'General case' 0 N--CA 1.414 -2.268 0 O-C-N 121.791 -0.568 . . . . 0.0 109.616 176.212 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.427 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 1.3 p -135.78 -170.82 2.71 Favored 'General case' 0 C--N 1.287 -2.119 0 C-N-CA 123.541 0.737 . . . . 0.0 109.828 178.439 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 70.8 mtp180 -112.69 129.14 56.51 Favored 'General case' 0 N--CA 1.396 -3.145 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 177.729 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 11.0 p30 -79.37 21.22 0.49 Allowed 'General case' 0 C--N 1.281 -2.378 0 N-CA-C 112.89 0.7 . . . . 0.0 112.89 -177.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.31 33.08 32.99 Favored Glycine 0 C--N 1.315 -0.627 0 C-N-CA 119.727 -1.225 . . . . 0.0 111.679 -177.308 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.422 ' H ' HD22 ' A' ' 30' ' ' LEU . 2.5 pt? -101.18 169.82 7.3 Favored Pre-proline 0 C--N 1.298 -1.636 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.56 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 81.1 Cg_exo -49.01 162.43 0.41 Allowed 'Trans proline' 0 C--N 1.369 1.613 0 C-N-CA 123.428 2.752 . . . . 0.0 113.961 178.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 34.7 t -67.98 107.75 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 CA-C-O 122.23 1.014 . . . . 0.0 110.973 -175.387 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 8.9 t . . . . . 0 C--N 1.275 -2.658 0 CA-C-N 113.96 -1.473 . . . . 0.0 107.275 177.549 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.429 -1.8 0 N-CA-C 108.152 -1.979 . . . . 0.0 108.152 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -70.71 -38.57 66.98 Favored Glycine 0 CA--C 1.498 -0.978 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 177.696 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -142.0 -148.88 5.09 Favored Glycine 0 N--CA 1.415 -2.746 0 N-CA-C 107.703 -2.159 . . . . 0.0 107.703 175.474 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 96.4 m -129.83 143.44 50.81 Favored 'General case' 0 C--N 1.285 -2.225 0 CA-C-N 117.31 0.555 . . . . 0.0 110.209 178.293 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -85.65 4.01 86.36 Favored Glycine 0 N--CA 1.447 -0.581 0 N-CA-C 110.788 -0.925 . . . . 0.0 110.788 179.677 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 74.6 mm-40 -89.6 146.82 24.3 Favored 'General case' 0 N--CA 1.421 -1.909 0 CA-C-N 114.79 -0.705 . . . . 0.0 110.816 -179.511 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 32.6 p -123.71 150.81 43.87 Favored 'General case' 0 N--CA 1.392 -3.335 0 N-CA-C 106.185 -1.783 . . . . 0.0 106.185 174.4 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.438 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 24.4 p -123.99 38.35 4.21 Favored 'General case' 0 C--N 1.289 -2.022 0 CA-C-N 118.63 0.65 . . . . 0.0 110.254 -177.521 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 13.6 t -61.76 -40.48 87.04 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 CA-C-N 114.494 -1.23 . . . . 0.0 108.306 178.791 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -73.78 -22.24 78.42 Favored Glycine 0 N--CA 1.441 -1.032 0 CA-C-N 114.902 -1.045 . . . . 0.0 111.022 177.127 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 120.4 -6.94 11.57 Favored Glycine 0 N--CA 1.436 -1.302 0 C-N-CA 121.255 -0.498 . . . . 0.0 113.876 177.211 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 6.1 m -136.51 155.25 50.23 Favored 'General case' 0 N--CA 1.429 -1.492 0 CA-C-N 118.047 0.924 . . . . 0.0 108.936 -176.336 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 57.6 m -113.99 143.33 44.92 Favored 'General case' 0 C--N 1.279 -2.463 0 N-CA-C 106.154 -1.795 . . . . 0.0 106.154 175.676 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 33.4 m-80 -68.09 -39.36 82.88 Favored 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 119.053 0.842 . . . . 0.0 110.656 177.395 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 9.9 m -94.1 113.19 60.04 Favored Pre-proline 0 N--CA 1.426 -1.671 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 176.358 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -76.33 -1.89 12.0 Favored 'Trans proline' 0 C--N 1.354 0.828 0 C-N-CA 122.668 2.245 . . . . 0.0 112.534 -178.727 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -79.59 -14.41 81.26 Favored Glycine 0 C--N 1.284 -2.33 0 CA-C-N 113.105 -1.861 . . . . 0.0 108.936 175.166 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.543 ' HA ' ' O ' ' A' ' 26' ' ' THR . 63.7 m -103.14 127.33 50.47 Favored 'General case' 0 N--CA 1.406 -2.653 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.115 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.407 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 10.3 m -89.9 148.86 22.9 Favored 'General case' 0 C--N 1.279 -2.493 0 CA-C-N 114.876 -1.056 . . . . 0.0 108.633 -177.129 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 50.5 t -84.64 115.15 22.49 Favored 'General case' 0 C--N 1.269 -2.897 0 CA-C-O 121.461 0.648 . . . . 0.0 110.453 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 16.6 t -120.26 68.24 0.84 Allowed 'General case' 0 C--N 1.287 -2.152 0 N-CA-C 103.728 -2.693 . . . . 0.0 103.728 172.85 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.45 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 51.3 t90 -35.92 133.08 0.56 Allowed Pre-proline 0 N--CA 1.441 -0.904 0 CA-C-N 113.108 -1.86 . . . . 0.0 112.969 -170.417 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.45 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 1.6 Cg_endo -91.63 14.46 49.62 Favored 'Cis proline' 0 CA--C 1.541 0.855 0 C-N-CA 123.145 -1.606 . . . . 0.0 115.343 2.517 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 28.9 m -115.65 152.6 17.3 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.019 0 O-C-N 121.182 -0.949 . . . . 0.0 112.36 -177.629 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.438 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 59.6 m -95.73 139.32 32.14 Favored 'General case' 0 N--CA 1.403 -2.81 0 O-C-N 121.77 -0.581 . . . . 0.0 109.543 177.123 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.543 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 20.1 p -125.49 -173.29 2.79 Favored 'General case' 0 C--N 1.29 -1.989 0 C-N-CA 123.119 0.568 . . . . 0.0 111.345 -179.157 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 53.8 ttt180 -118.2 123.0 44.41 Favored 'General case' 0 N--CA 1.417 -2.095 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 -177.619 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 10.2 p30 -89.94 25.25 2.16 Favored 'General case' 0 C--N 1.279 -2.496 0 CA-C-N 115.028 -0.987 . . . . 0.0 113.052 -173.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 92.59 4.8 65.46 Favored Glycine 0 C--N 1.305 -1.161 0 C-N-CA 118.837 -1.649 . . . . 0.0 112.131 -178.42 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.409 ' HB3' ' HD2' ' A' ' 31' ' ' PRO . 17.6 mt -69.88 171.26 7.66 Favored Pre-proline 0 C--N 1.315 -0.928 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 174.016 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.409 ' HD2' ' HB3' ' A' ' 30' ' ' LEU . 61.8 Cg_exo -47.49 161.49 0.28 Allowed 'Trans proline' 0 C--N 1.36 1.161 0 C-N-CA 123.703 2.935 . . . . 0.0 112.188 176.689 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 24.6 m -60.33 115.18 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.415 -2.208 0 N-CA-C 114.262 1.208 . . . . 0.0 114.262 -170.244 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.444 HG23 ' SG ' ' A' ' 18' ' ' CYS . 1.3 m . . . . . 0 C--N 1.305 -1.336 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 173.454 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.427 -1.929 0 N-CA-C 109.278 -1.529 . . . . 0.0 109.278 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -80.2 58.45 4.61 Favored Glycine 0 C--N 1.31 -0.904 0 CA-C-N 116.976 0.388 . . . . 0.0 113.061 -177.317 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 93.34 -106.05 3.37 Favored Glycine 0 N--CA 1.43 -1.746 0 N-CA-C 111.825 -0.51 . . . . 0.0 111.825 179.294 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 98.1 m -152.82 154.65 35.57 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 179.246 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -107.19 5.64 36.16 Favored Glycine 0 C--N 1.31 -0.892 0 C-N-CA 120.465 -0.874 . . . . 0.0 112.443 -178.295 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -88.73 166.43 14.06 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.779 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 24.4 p -112.49 163.25 14.68 Favored 'General case' 0 N--CA 1.415 -2.194 0 N-CA-C 112.15 0.426 . . . . 0.0 112.15 -175.79 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.443 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 21.4 p -137.13 36.01 2.55 Favored 'General case' 0 CA--C 1.497 -1.073 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 179.58 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 15.4 t -60.8 -35.4 64.15 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.084 0 CA-C-N 114.719 -1.128 . . . . 0.0 109.4 -177.867 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -74.27 -17.27 79.63 Favored Glycine 0 N--CA 1.44 -1.044 0 CA-C-N 115.132 -0.94 . . . . 0.0 112.935 178.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 141.49 -33.43 1.98 Allowed Glycine 0 N--CA 1.435 -1.402 0 C-N-CA 119.992 -1.099 . . . . 0.0 113.795 179.848 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 9.0 t -153.58 172.8 16.64 Favored 'General case' 0 N--CA 1.424 -1.745 0 CA-C-N 117.771 0.785 . . . . 0.0 109.845 -174.726 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 58.1 m -94.75 176.35 6.31 Favored 'General case' 0 C--N 1.274 -2.687 0 CA-C-N 114.475 -1.239 . . . . 0.0 110.042 -177.391 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 26.8 m-80 -100.55 -36.43 9.18 Favored 'General case' 0 C--N 1.307 -1.243 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 178.588 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.495 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 25.8 m -90.69 121.86 67.69 Favored Pre-proline 0 N--CA 1.427 -1.607 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 177.179 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 15' ' ' THR . 13.6 Cg_exo -69.66 -3.58 12.22 Favored 'Trans proline' 0 N--CA 1.488 1.157 0 C-N-CA 123.132 2.555 . . . . 0.0 113.458 -177.506 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -90.3 -14.22 59.08 Favored Glycine 0 C--N 1.255 -3.949 0 CA-C-N 113.719 -1.582 . . . . 0.0 110.283 176.458 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.562 ' HA ' ' O ' ' A' ' 26' ' ' THR . 57.8 m -103.55 129.97 50.86 Favored 'General case' 0 N--CA 1.396 -3.128 0 N-CA-C 107.575 -1.269 . . . . 0.0 107.575 179.254 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.545 ' OG1' ' HB3' ' A' ' 28' ' ' ASN . 25.1 m -114.78 155.5 26.61 Favored 'General case' 0 C--N 1.281 -2.389 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 -179.13 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 38.2 t -83.48 128.15 34.28 Favored 'General case' 0 N--CA 1.409 -2.521 0 CA-C-O 122.251 1.024 . . . . 0.0 113.065 -171.477 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.8 m -128.26 65.32 1.39 Allowed 'General case' 0 N--CA 1.402 -2.833 0 N-CA-C 104.401 -2.444 . . . . 0.0 104.401 170.149 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.479 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 37.9 t90 -33.67 134.87 0.33 Allowed Pre-proline 0 N--CA 1.442 -0.849 0 C-N-CA 127.433 2.293 . . . . 0.0 113.918 -170.92 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.479 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 4.6 Cg_exo -88.96 12.01 57.51 Favored 'Cis proline' 0 CA--C 1.544 0.98 0 C-N-CA 122.894 -1.711 . . . . 0.0 114.403 0.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.7 m -114.38 150.49 16.36 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.889 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -175.254 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.443 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 95.5 m -86.14 151.6 23.53 Favored 'General case' 0 N--CA 1.41 -2.435 0 CA-C-O 121.74 0.781 . . . . 0.0 112.206 178.39 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.562 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.0 p -129.27 -164.44 1.4 Allowed 'General case' 0 C--N 1.298 -1.642 0 C-N-CA 124.609 1.164 . . . . 0.0 108.331 175.559 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 17.3 ttm180 -122.62 135.27 54.56 Favored 'General case' 0 N--CA 1.407 -2.603 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 -178.277 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . 0.545 ' HB3' ' OG1' ' A' ' 19' ' ' THR . 1.1 t30 -131.88 129.6 40.57 Favored 'General case' 0 C--N 1.26 -3.29 0 N-CA-C 113.72 1.008 . . . . 0.0 113.72 -177.042 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 65.44 22.47 69.52 Favored Glycine 0 CA--C 1.499 -0.962 0 CA-C-N 114.956 -1.02 . . . . 0.0 112.884 173.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 68.4 mt -129.96 161.41 59.92 Favored Pre-proline 0 C--N 1.298 -1.654 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 -175.596 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -56.84 137.71 82.69 Favored 'Trans proline' 0 C--O 1.242 0.721 0 C-N-CA 123.35 2.7 . . . . 0.0 111.15 176.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 32.4 t -85.28 117.66 30.76 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.018 0 CA-C-O 121.914 0.864 . . . . 0.0 109.639 -177.263 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 24.6 m . . . . . 0 C--N 1.27 -2.861 0 N-CA-C 105.912 -1.885 . . . . 0.0 105.912 176.294 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.782 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 78.41 -53.25 3.89 Favored Glycine 0 CA--C 1.519 0.297 0 N-CA-C 111.883 -0.487 . . . . 0.0 111.883 -176.271 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -154.94 -138.59 2.62 Favored Glycine 0 N--CA 1.422 -2.239 0 N-CA-C 108.61 -1.796 . . . . 0.0 108.61 177.806 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 85.3 m -111.55 107.97 17.32 Favored 'General case' 0 C--N 1.29 -2.02 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 175.427 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -80.06 13.9 23.53 Favored Glycine 0 C--N 1.314 -0.675 0 CA-C-N 116.117 -0.492 . . . . 0.0 112.927 -176.382 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -91.56 162.13 14.66 Favored 'General case' 0 C--N 1.306 -1.288 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 178.762 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 25.3 p -114.74 163.48 15.42 Favored 'General case' 0 N--CA 1.411 -2.385 0 N-CA-C 110.374 -0.232 . . . . 0.0 110.374 -179.739 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 16.9 p -134.2 41.2 2.98 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-O 121.229 0.538 . . . . 0.0 110.185 -179.036 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 23.2 t -59.94 -29.89 44.26 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.042 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.619 -176.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -83.09 -8.14 86.02 Favored Glycine 0 N--CA 1.441 -0.995 0 CA-C-N 115.769 -0.65 . . . . 0.0 112.903 -179.786 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 139.82 -39.61 1.49 Allowed Glycine 0 N--CA 1.443 -0.885 0 C-N-CA 120.214 -0.993 . . . . 0.0 113.777 178.2 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 13.5 t -155.6 173.23 17.01 Favored 'General case' 0 N--CA 1.423 -1.802 0 CA-C-N 117.354 0.577 . . . . 0.0 109.649 -176.807 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 32.2 m -91.87 173.11 8.03 Favored 'General case' 0 C--N 1.274 -2.713 0 CA-C-N 114.815 -1.084 . . . . 0.0 109.578 -175.048 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 36.3 m-80 -93.27 -36.63 12.47 Favored 'General case' 0 CA--C 1.496 -1.097 0 N-CA-C 110.059 -0.348 . . . . 0.0 110.059 177.017 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.463 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 17.6 m -84.63 124.26 73.38 Favored Pre-proline 0 C--N 1.297 -1.675 0 N-CA-C 108.131 -1.062 . . . . 0.0 108.131 176.304 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_endo -72.86 -1.53 10.58 Favored 'Trans proline' 0 C--N 1.359 1.098 0 C-N-CA 123.05 2.5 . . . . 0.0 113.425 -176.194 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -97.63 -4.05 58.2 Favored Glycine 0 C--N 1.265 -3.407 0 CA-C-N 113.964 -1.471 . . . . 0.0 110.152 177.782 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.463 ' SG ' ' HB ' ' A' ' 15' ' ' THR . 60.3 m -108.66 125.84 52.32 Favored 'General case' 0 N--CA 1.409 -2.518 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 178.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 8.6 m -91.45 151.39 20.82 Favored 'General case' 0 C--N 1.291 -1.959 0 N-CA-C 107.74 -1.208 . . . . 0.0 107.74 -177.213 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 46.6 t -90.17 127.73 36.18 Favored 'General case' 0 N--CA 1.411 -2.415 0 CA-C-O 121.388 0.613 . . . . 0.0 109.565 179.501 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 22.6 t -128.71 56.8 1.63 Allowed 'General case' 0 C--N 1.28 -2.448 0 N-CA-C 103.688 -2.708 . . . . 0.0 103.688 176.001 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.446 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 56.6 t90 -31.2 131.91 0.25 Allowed Pre-proline 0 N--CA 1.446 -0.644 0 C-N-CA 127.009 2.124 . . . . 0.0 113.347 -171.314 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.446 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 1.8 Cg_endo -90.37 9.68 63.07 Favored 'Cis proline' 0 C--N 1.323 -0.811 0 C-N-CA 122.883 -1.715 . . . . 0.0 115.074 4.091 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 29.8 m -112.32 153.01 14.04 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 O-C-N 122.043 -0.41 . . . . 0.0 111.927 -176.2 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 73.4 m -93.39 158.78 15.56 Favored 'General case' 0 N--CA 1.416 -2.15 0 CA-C-O 121.487 0.661 . . . . 0.0 112.42 178.05 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.427 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.1 p -129.81 -175.04 3.48 Favored 'General case' 0 C--N 1.31 -1.145 0 C-N-CA 124.519 1.128 . . . . 0.0 108.562 175.679 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 20.0 ptt180 -119.29 139.78 51.36 Favored 'General case' 0 N--CA 1.384 -3.725 0 CA-C-N 119.407 1.003 . . . . 0.0 112.138 -178.027 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 8.7 p30 -122.42 109.61 14.6 Favored 'General case' 0 C--N 1.277 -2.546 0 CA-C-N 114.705 -1.134 . . . . 0.0 109.244 173.224 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 67.0 31.99 79.58 Favored Glycine 0 C--O 1.244 0.744 0 CA-C-N 115.893 -0.594 . . . . 0.0 113.538 177.89 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.415 ' HA ' ' HD3' ' A' ' 31' ' ' PRO . 35.2 mt -107.93 147.42 35.43 Favored Pre-proline 0 C--N 1.31 -1.148 0 O-C-N 122.388 -0.478 . . . . 0.0 112.199 -179.506 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.415 ' HD3' ' HA ' ' A' ' 30' ' ' LEU . 2.9 Cg_exo -69.12 148.6 69.54 Favored 'Trans proline' 0 N--CA 1.449 -1.092 0 C-N-CA 122.616 2.211 . . . . 0.0 109.668 175.001 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 13.1 t -74.38 100.05 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 CA-C-O 121.769 0.795 . . . . 0.0 109.201 -177.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 3.8 m . . . . . 0 C--N 1.272 -2.767 0 CA-C-N 114.105 -1.407 . . . . 0.0 109.788 -177.286 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.791 0 N-CA-C 110.346 -1.102 . . . . 0.0 110.346 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.91 -75.02 1.92 Allowed Glycine 0 N--CA 1.445 -0.75 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 -177.234 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.419 ' HA2' ' HE ' ' A' ' 27' ' ' ARG . . . -141.86 -92.43 0.19 Allowed Glycine 0 N--CA 1.419 -2.44 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 178.219 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 72.4 m -143.51 141.43 30.74 Favored 'General case' 0 C--N 1.291 -1.966 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 173.652 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -88.03 12.98 62.52 Favored Glycine 0 C--N 1.304 -1.201 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.025 -178.057 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -90.23 154.67 19.56 Favored 'General case' 0 N--CA 1.431 -1.401 0 CA-C-O 121.096 0.474 . . . . 0.0 110.013 -179.289 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 35.9 p -111.65 158.53 19.16 Favored 'General case' 0 N--CA 1.395 -3.225 0 N-CA-C 106.32 -1.734 . . . . 0.0 106.32 170.449 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.604 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 28.1 p -135.85 50.86 2.07 Favored 'General case' 0 C--N 1.283 -2.304 0 CA-C-O 121.502 0.668 . . . . 0.0 110.056 -177.66 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 40.3 t -62.43 -31.0 50.35 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.36 -178.568 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -74.45 -26.36 68.08 Favored Glycine 0 N--CA 1.446 -0.638 0 N-CA-C 111.338 -0.705 . . . . 0.0 111.338 176.701 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 122.27 0.18 10.46 Favored Glycine 0 N--CA 1.443 -0.875 0 C-N-CA 120.657 -0.782 . . . . 0.0 114.219 177.021 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 15.7 m -148.81 162.59 39.51 Favored 'General case' 0 N--CA 1.432 -1.372 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 -179.664 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 35.9 m -111.82 166.78 10.9 Favored 'General case' 0 C--N 1.281 -2.407 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 177.841 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 36.0 m-80 -83.43 -38.89 21.31 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-O 120.923 0.392 . . . . 0.0 110.022 179.223 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.575 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 13.4 m -79.88 123.85 83.54 Favored Pre-proline 0 N--CA 1.429 -1.509 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 178.979 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_exo -69.81 -2.92 11.03 Favored 'Trans proline' 0 C--N 1.353 0.809 0 C-N-CA 123.009 2.472 . . . . 0.0 112.898 179.504 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -96.47 -12.19 51.83 Favored Glycine 0 C--N 1.27 -3.134 0 CA-C-N 113.752 -1.567 . . . . 0.0 110.449 177.17 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.575 ' SG ' ' HB ' ' A' ' 15' ' ' THR . 62.3 m -103.7 130.63 51.22 Favored 'General case' 0 N--CA 1.415 -2.198 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 179.659 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 9.6 m -109.26 147.7 32.2 Favored 'General case' 0 C--N 1.282 -2.329 0 N-CA-C 107.928 -1.138 . . . . 0.0 107.928 -177.625 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 46.2 t -83.45 121.15 26.8 Favored 'General case' 0 N--CA 1.403 -2.777 0 CA-C-O 121.629 0.728 . . . . 0.0 111.073 -177.434 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 25.2 t -123.58 72.36 1.13 Allowed 'General case' 0 C--N 1.279 -2.472 0 N-CA-C 103.417 -2.809 . . . . 0.0 103.417 173.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.48 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 36.9 t90 -41.24 133.71 1.95 Allowed Pre-proline 0 N--CA 1.444 -0.729 0 C-N-CA 125.893 1.677 . . . . 0.0 113.411 -168.343 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.48 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 1.6 Cg_endo -92.23 16.81 43.42 Favored 'Cis proline' 0 CA--C 1.538 0.705 0 C-N-CA 122.826 -1.739 . . . . 0.0 114.655 2.113 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 26.8 m -117.38 151.13 19.3 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.863 0 N-CA-C 113.95 1.093 . . . . 0.0 113.95 -176.11 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.604 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 82.8 m -86.21 148.95 25.42 Favored 'General case' 0 N--CA 1.409 -2.506 0 O-C-N 121.536 -0.727 . . . . 0.0 110.928 176.459 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.497 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.2 p -132.72 -174.51 3.48 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 175.959 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.419 ' HE ' ' HA2' ' A' ' 3' ' ' GLY . 3.5 ppt_? -123.82 160.26 27.76 Favored 'General case' 0 N--CA 1.379 -3.975 0 CA-C-N 119.524 1.056 . . . . 0.0 110.43 179.368 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 7.8 p30 -132.8 134.46 44.71 Favored 'General case' 0 C--N 1.265 -3.069 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 -179.144 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 60.77 22.78 60.22 Favored Glycine 0 C--O 1.227 -0.3 0 O-C-N 123.573 0.546 . . . . 0.0 112.861 178.799 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.42 ' HA ' ' HD3' ' A' ' 31' ' ' PRO . 46.0 mt -118.2 145.88 38.05 Favored Pre-proline 0 N--CA 1.424 -1.738 0 O-C-N 122.602 -0.352 . . . . 0.0 111.881 -176.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 30' ' ' LEU . 6.4 Cg_exo -66.73 162.06 39.05 Favored 'Trans proline' 0 N--CA 1.451 -0.986 0 C-N-CA 122.777 2.318 . . . . 0.0 110.296 176.096 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 16.7 t -75.68 112.22 13.04 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 -179.031 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 9.1 t . . . . . 0 C--N 1.278 -2.515 0 CA-C-N 114.614 -1.175 . . . . 0.0 108.214 179.015 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.433 -1.523 0 N-CA-C 109.821 -1.311 . . . . 0.0 109.821 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -67.89 -39.36 89.54 Favored Glycine 0 C--N 1.314 -0.669 0 CA-C-N 116.976 0.388 . . . . 0.0 112.207 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -170.9 -130.81 1.26 Allowed Glycine 0 N--CA 1.437 -1.274 0 N-CA-C 109.261 -1.536 . . . . 0.0 109.261 179.287 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.627 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 88.7 m -104.7 162.94 12.86 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 174.708 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -92.42 -16.75 48.55 Favored Glycine 0 N--CA 1.44 -1.096 0 C-N-CA 120.454 -0.879 . . . . 0.0 112.866 -174.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.627 ' OE1' ' HB3' ' A' ' 4' ' ' CYS . 1.0 OUTLIER -90.15 145.94 24.66 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 122.447 -0.443 . . . . 0.0 111.056 -178.786 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 21.7 p -109.83 157.04 19.6 Favored 'General case' 0 N--CA 1.417 -2.114 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.485 -179.209 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.48 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 19.5 p -126.23 38.85 4.06 Favored 'General case' 0 C--N 1.303 -1.422 0 CA-C-O 121.169 0.509 . . . . 0.0 110.589 -177.05 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 35.5 t -56.12 -35.48 41.97 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 CA-C-N 115.106 -0.952 . . . . 0.0 110.722 -178.427 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -95.4 7.85 68.97 Favored Glycine 0 N--CA 1.441 -1.027 0 C-N-CA 121.089 -0.577 . . . . 0.0 113.053 -179.483 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 152.1 -82.06 0.18 Allowed Glycine 0 N--CA 1.434 -1.477 0 C-N-CA 119.186 -1.483 . . . . 0.0 114.425 178.369 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 7.5 m -153.44 163.89 39.15 Favored 'General case' 0 N--CA 1.428 -1.57 0 N-CA-C 106.867 -1.531 . . . . 0.0 106.867 -171.153 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 76.7 m -99.13 161.56 13.55 Favored 'General case' 0 C--N 1.291 -1.95 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 176.188 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 41.7 m-80 -92.82 -16.51 25.24 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-O 120.99 0.424 . . . . 0.0 110.837 -177.839 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 10.7 m -72.49 114.89 33.98 Favored Pre-proline 0 N--CA 1.438 -1.07 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 178.814 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -70.17 -9.02 25.01 Favored 'Trans proline' 0 C--N 1.351 0.709 0 C-N-CA 122.806 2.337 . . . . 0.0 114.213 -174.204 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -91.74 -15.34 54.94 Favored Glycine 0 C--N 1.261 -3.623 0 CA-C-N 113.988 -1.46 . . . . 0.0 111.234 178.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.552 ' HA ' ' O ' ' A' ' 26' ' ' THR . 82.9 m -118.7 125.29 49.35 Favored 'General case' 0 N--CA 1.415 -2.195 0 CA-C-O 121.639 0.733 . . . . 0.0 110.795 -177.687 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 8.1 m -101.88 156.61 17.42 Favored 'General case' 0 C--N 1.293 -1.871 0 C-N-CA 124.666 1.187 . . . . 0.0 108.521 -176.734 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 51.8 t -88.64 119.64 29.3 Favored 'General case' 0 C--N 1.297 -1.707 0 CA-C-O 121.503 0.668 . . . . 0.0 111.851 -176.696 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 21.1 t -124.76 75.69 1.45 Allowed 'General case' 0 N--CA 1.417 -2.097 0 N-CA-C 103.541 -2.763 . . . . 0.0 103.541 171.11 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.539 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 57.2 t90 -38.0 135.79 0.81 Allowed Pre-proline 0 N--CA 1.436 -1.125 0 C-N-CA 126.063 1.745 . . . . 0.0 113.058 -170.809 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.539 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 1.2 Cg_endo -91.47 9.54 61.59 Favored 'Cis proline' 0 CA--C 1.536 0.618 0 C-N-CA 122.862 -1.724 . . . . 0.0 114.958 3.426 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 25.3 m -113.86 158.09 14.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 C-N-CA 120.102 -0.639 . . . . 0.0 111.725 -175.442 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.48 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 53.4 m -96.86 143.06 28.12 Favored 'General case' 0 N--CA 1.388 -3.528 0 CA-C-O 121.838 0.828 . . . . 0.0 110.442 173.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.552 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 7.9 p -128.19 -170.13 2.19 Favored 'General case' 0 C--N 1.273 -2.742 0 CA-C-N 114.466 -1.243 . . . . 0.0 110.994 -177.558 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 19.1 mtm180 -99.84 151.58 21.12 Favored 'General case' 0 N--CA 1.381 -3.914 0 CA-C-O 121.459 0.647 . . . . 0.0 110.77 -169.179 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 7.1 p30 -133.62 112.75 11.71 Favored 'General case' 0 C--N 1.266 -3.055 0 CA-C-N 113.652 -1.613 . . . . 0.0 106.773 169.563 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.0 -33.45 2.65 Favored Glycine 0 CA--C 1.533 1.163 0 CA-C-N 116.337 -0.392 . . . . 0.0 112.929 179.902 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 62.9 mt -60.91 149.75 79.88 Favored Pre-proline 0 C--O 1.243 0.742 0 N-CA-C 113.792 1.034 . . . . 0.0 113.792 -178.481 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -76.61 162.73 32.68 Favored 'Trans proline' 0 N--CA 1.444 -1.414 0 C-N-CA 123.377 2.718 . . . . 0.0 111.578 -179.183 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.5 t -84.26 98.8 6.04 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.69 0 CA-C-O 121.736 0.779 . . . . 0.0 109.774 -177.436 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 8.2 m . . . . . 0 C--N 1.274 -2.694 0 CA-C-N 115.031 -0.986 . . . . 0.0 109.486 179.017 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.733 0 N-CA-C 111.904 -0.479 . . . . 0.0 111.904 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 89.39 -81.88 1.46 Allowed Glycine 0 N--CA 1.43 -1.728 0 N-CA-C 108.939 -1.664 . . . . 0.0 108.939 -176.042 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.436 ' HA2' ' HG3' ' A' ' 27' ' ' ARG . . . -115.79 -102.76 2.36 Favored Glycine 0 N--CA 1.426 -1.979 0 N-CA-C 109.305 -1.518 . . . . 0.0 109.305 176.651 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 99.1 m -140.82 152.52 45.22 Favored 'General case' 0 C--N 1.295 -1.768 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 176.334 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -87.64 9.83 72.24 Favored Glycine 0 C--N 1.314 -0.671 0 N-CA-C 110.581 -1.008 . . . . 0.0 110.581 178.459 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.409 ' HB2' ' HB2' ' A' ' 25' ' ' CYS . 6.2 mm-40 -86.38 154.16 21.39 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 124.14 0.976 . . . . 0.0 108.735 -179.64 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 9.2 p -126.82 153.94 44.97 Favored 'General case' 0 N--CA 1.41 -2.452 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 174.062 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.438 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 25.1 p -133.94 40.38 3.08 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-O 120.92 0.391 . . . . 0.0 110.862 -175.825 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 18.7 t -56.48 -29.17 28.29 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.182 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.345 -179.075 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -79.66 -17.19 76.0 Favored Glycine 0 N--CA 1.445 -0.7 0 CA-C-N 115.612 -0.722 . . . . 0.0 113.392 179.562 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 138.03 -32.07 2.39 Favored Glycine 0 N--CA 1.444 -0.828 0 C-N-CA 119.775 -1.202 . . . . 0.0 114.543 178.874 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 15.7 m -152.32 159.13 43.52 Favored 'General case' 0 C--N 1.31 -1.123 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 -176.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.438 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 32.6 m -89.95 165.66 13.94 Favored 'General case' 0 C--N 1.285 -2.221 0 O-C-N 123.767 0.667 . . . . 0.0 109.599 -179.295 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 14.0 m120 -85.16 -48.98 8.61 Favored 'General case' 0 CA--C 1.503 -0.842 0 CA-C-O 120.884 0.373 . . . . 0.0 110.142 178.079 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 29.1 m -70.52 118.93 69.14 Favored Pre-proline 0 C--N 1.311 -1.077 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 175.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -72.35 -5.1 16.49 Favored 'Trans proline' 0 C--N 1.365 1.421 0 C-N-CA 123.134 2.556 . . . . 0.0 114.164 -173.534 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -90.42 -8.43 66.1 Favored Glycine 0 C--N 1.261 -3.606 0 CA-C-N 114.008 -1.451 . . . . 0.0 110.35 178.703 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.432 ' HA ' ' O ' ' A' ' 26' ' ' THR . 67.9 m -107.98 127.39 53.72 Favored 'General case' 0 N--CA 1.409 -2.512 0 CA-C-O 121.41 0.624 . . . . 0.0 110.663 -178.464 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 6.3 m -90.16 148.63 22.85 Favored 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 107.969 -1.122 . . . . 0.0 107.969 -178.241 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 51.5 t -88.97 102.81 15.45 Favored 'General case' 0 N--CA 1.412 -2.332 0 CA-C-O 121.501 0.667 . . . . 0.0 111.183 -178.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.1 p -105.65 64.89 0.7 Allowed 'General case' 0 C--N 1.288 -2.097 0 N-CA-C 106.225 -1.768 . . . . 0.0 106.225 172.244 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.431 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 56.1 t90 -35.74 134.31 0.52 Allowed Pre-proline 0 N--CA 1.443 -0.821 0 C-N-CA 127.358 2.263 . . . . 0.0 113.586 -169.652 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.431 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 1.5 Cg_endo -91.28 10.01 61.09 Favored 'Cis proline' 0 C--N 1.323 -0.777 0 C-N-CA 122.823 -1.741 . . . . 0.0 114.188 2.474 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.9 m -110.81 150.0 13.44 Favored 'Isoleucine or valine' 0 C--O 1.21 -1.019 0 C-N-CA 120.212 -0.595 . . . . 0.0 111.846 -176.426 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.424 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 69.0 m -92.93 141.29 28.58 Favored 'General case' 0 N--CA 1.408 -2.539 0 CA-C-O 121.44 0.638 . . . . 0.0 112.45 178.808 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.432 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 1.7 p -117.83 -177.18 3.19 Favored 'General case' 0 C--N 1.292 -1.903 0 CA-C-N 115.016 -0.993 . . . . 0.0 108.526 175.534 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.436 ' HG3' ' HA2' ' A' ' 3' ' ' GLY . 4.9 ppt_? -119.17 154.96 32.48 Favored 'General case' 0 N--CA 1.387 -3.602 0 CA-C-N 119.669 1.122 . . . . 0.0 112.298 -176.521 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -140.66 127.68 20.75 Favored 'General case' 0 C--N 1.274 -2.69 0 CA-C-N 114.426 -1.261 . . . . 0.0 109.957 177.414 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 65.66 34.19 88.23 Favored Glycine 0 N--CA 1.449 -0.489 0 N-CA-C 111.35 -0.7 . . . . 0.0 111.35 -178.616 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 47.5 mt -129.46 160.32 64.94 Favored Pre-proline 0 C--N 1.309 -1.184 0 N-CA-C 112.443 0.535 . . . . 0.0 112.443 -177.719 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -61.19 148.58 92.48 Favored 'Trans proline' 0 C--O 1.251 1.147 0 C-N-CA 123.3 2.666 . . . . 0.0 111.55 176.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 5.7 m -81.91 98.61 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.399 -3.022 0 CA-C-O 122.088 0.947 . . . . 0.0 110.952 179.171 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 10.0 t . . . . . 0 N--CA 1.42 -1.96 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 178.63 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.796 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -125.56 25.94 5.54 Favored Glycine 0 N--CA 1.436 -1.302 0 N-CA-C 110.624 -0.991 . . . . 0.0 110.624 178.85 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 145.35 -94.63 0.17 Allowed Glycine 0 N--CA 1.437 -1.247 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 178.745 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 63.4 m -131.56 151.48 51.56 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 173.842 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -89.21 16.62 55.33 Favored Glycine 0 C--N 1.315 -0.608 0 N-CA-C 110.201 -1.16 . . . . 0.0 110.201 178.408 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 7.8 mm-40 -91.53 151.44 20.75 Favored 'General case' 0 N--CA 1.425 -1.699 0 C-N-CA 124.433 1.093 . . . . 0.0 110.153 -179.403 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 17.2 p -126.4 152.27 46.57 Favored 'General case' 0 N--CA 1.405 -2.675 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 174.746 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 24.7 p -130.37 37.67 3.84 Favored 'General case' 0 C--N 1.301 -1.513 0 CA-C-O 121.153 0.501 . . . . 0.0 110.934 -175.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 25.7 t -58.46 -37.56 64.89 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.13 0 CA-C-N 114.928 -1.033 . . . . 0.0 109.835 -178.468 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -79.18 1.81 73.62 Favored Glycine 0 CA--C 1.524 0.602 0 CA-C-N 115.55 -0.75 . . . . 0.0 113.608 -179.908 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 124.65 -28.8 5.14 Favored Glycine 0 N--CA 1.44 -1.053 0 C-N-CA 119.956 -1.116 . . . . 0.0 114.168 176.657 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 12.4 t -157.33 172.7 18.14 Favored 'General case' 0 N--CA 1.426 -1.636 0 CA-C-N 117.566 0.683 . . . . 0.0 109.324 -176.641 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 33.4 m -98.81 164.21 12.31 Favored 'General case' 0 C--N 1.276 -2.604 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 -178.581 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 14.6 m-80 -85.23 -42.01 15.07 Favored 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 107.261 -1.385 . . . . 0.0 107.261 178.909 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 14.3 m -77.9 114.74 44.36 Favored Pre-proline 0 N--CA 1.422 -1.868 0 CA-C-N 114.035 -1.439 . . . . 0.0 108.685 177.52 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -73.43 -0.67 9.56 Favored 'Trans proline' 0 N--CA 1.483 0.861 0 C-N-CA 123.662 2.908 . . . . 0.0 113.536 -174.538 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -96.4 -11.83 52.98 Favored Glycine 0 C--N 1.261 -3.6 0 CA-C-N 113.985 -1.462 . . . . 0.0 111.15 177.843 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 76.2 m -103.91 127.96 51.41 Favored 'General case' 0 N--CA 1.419 -2.019 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 179.446 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 8.8 m -90.44 153.51 20.34 Favored 'General case' 0 C--N 1.288 -2.093 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 -176.229 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 52.8 t -89.84 116.48 27.96 Favored 'General case' 0 C--N 1.284 -2.241 0 CA-C-O 121.657 0.742 . . . . 0.0 111.247 -177.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 34.4 t -119.35 57.7 0.89 Allowed 'General case' 0 C--N 1.29 -1.984 0 N-CA-C 104.568 -2.382 . . . . 0.0 104.568 176.099 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.442 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 42.5 t90 -29.62 131.86 0.22 Allowed Pre-proline 0 C--N 1.346 0.454 0 C-N-CA 127.261 2.224 . . . . 0.0 113.966 -170.564 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.442 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 2.4 Cg_endo -90.16 6.24 68.11 Favored 'Cis proline' 0 C--N 1.327 -0.56 0 C-N-CA 123.082 -1.632 . . . . 0.0 114.664 3.325 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 26.8 m -108.75 152.57 10.71 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 C-N-CA 120.181 -0.608 . . . . 0.0 112.175 -176.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 82.2 m -93.35 144.57 25.2 Favored 'General case' 0 N--CA 1.407 -2.622 0 CA-C-O 121.59 0.71 . . . . 0.0 112.188 178.246 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 3.1 p -116.17 179.14 4.08 Favored 'General case' 0 C--N 1.29 -2.016 0 C-N-CA 124.654 1.181 . . . . 0.0 110.049 178.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.427 ' O ' ' HD3' ' A' ' 27' ' ' ARG . 0.0 OUTLIER -120.4 149.58 42.13 Favored 'General case' 0 N--CA 1.386 -3.672 0 CA-C-O 121.863 0.84 . . . . 0.0 111.856 -176.662 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 6.9 p30 -132.57 118.43 19.2 Favored 'General case' 0 C--N 1.266 -3.046 0 N-CA-C 106.521 -1.659 . . . . 0.0 106.521 172.899 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.43 -33.57 1.36 Allowed Glycine 0 CA--C 1.535 1.285 0 CA-C-N 116.187 -0.461 . . . . 0.0 113.474 -178.235 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 53.0 mt -68.15 154.61 93.71 Favored Pre-proline 0 C--N 1.318 -0.787 0 N-CA-C 113.55 0.944 . . . . 0.0 113.55 -178.47 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_exo -61.55 137.05 66.85 Favored 'Trans proline' 0 C--O 1.25 1.103 0 C-N-CA 122.921 2.414 . . . . 0.0 110.398 176.038 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.4 p -64.94 114.14 2.33 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.277 0 CA-C-O 122.286 1.041 . . . . 0.0 111.087 -178.505 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 28.6 m . . . . . 0 C--N 1.27 -2.888 0 CA-C-N 114.141 -1.39 . . . . 0.0 108.206 178.95 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.9 0 N-CA-C 110.09 -1.204 . . . . 0.0 110.09 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -107.1 25.48 22.02 Favored Glycine 0 C--N 1.304 -1.198 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 178.103 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 108.46 -83.79 0.35 Allowed Glycine 0 N--CA 1.429 -1.814 0 N-CA-C 110.097 -1.201 . . . . 0.0 110.097 179.757 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.47 ' SG ' ' HG3' ' A' ' 27' ' ' ARG . 94.6 m -135.95 154.16 51.19 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.361 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -94.58 17.35 59.26 Favored Glycine 0 N--CA 1.446 -0.692 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 176.723 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 17.6 mm-40 -90.08 148.44 23.02 Favored 'General case' 0 N--CA 1.42 -1.946 0 CA-C-N 113.888 -1.156 . . . . 0.0 107.884 179.035 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 3.7 p -127.77 146.81 50.47 Favored 'General case' 0 C--N 1.268 -2.948 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.57 -179.755 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 21.7 p -127.18 35.99 4.49 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-O 121.07 0.462 . . . . 0.0 110.337 -176.579 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 25.2 t -57.25 -35.12 47.6 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 CA-C-N 115.06 -0.973 . . . . 0.0 109.828 -179.42 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -93.12 4.91 75.05 Favored Glycine 0 N--CA 1.437 -1.283 0 CA-C-N 115.526 -0.761 . . . . 0.0 113.171 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 151.43 -79.94 0.2 Allowed Glycine 0 N--CA 1.443 -0.841 0 C-N-CA 119.431 -1.366 . . . . 0.0 114.594 178.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 5.1 m -149.75 164.74 34.46 Favored 'General case' 0 N--CA 1.435 -1.187 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 -172.46 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 91.7 m -98.58 149.04 23.17 Favored 'General case' 0 C--N 1.285 -2.2 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 175.364 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -95.2 -0.37 53.23 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-O 121.437 0.637 . . . . 0.0 111.409 -179.002 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 56.2 m -85.73 111.19 35.79 Favored Pre-proline 0 N--CA 1.429 -1.509 0 N-CA-C 106.29 -1.744 . . . . 0.0 106.29 171.101 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -68.54 -12.29 34.33 Favored 'Trans proline' 0 C--N 1.36 1.181 0 C-N-CA 123.27 2.646 . . . . 0.0 115.664 -168.828 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -87.16 -15.74 62.02 Favored Glycine 1 C--N 1.251 -4.153 0 CA-C-N 114.65 -1.159 . . . . 0.0 110.571 178.813 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.589 ' HA ' ' O ' ' A' ' 26' ' ' THR . 58.1 m -105.63 125.48 51.03 Favored 'General case' 0 N--CA 1.414 -2.243 0 CA-C-N 115.098 -0.551 . . . . 0.0 110.076 -177.597 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 5.0 m -103.71 148.29 26.23 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 -179.021 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 46.7 t -78.91 125.57 29.54 Favored 'General case' 0 N--CA 1.413 -2.318 0 CA-C-O 122.113 0.958 . . . . 0.0 110.537 -178.262 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 37.5 m -130.66 59.26 1.67 Allowed 'General case' 0 N--CA 1.398 -3.06 0 N-CA-C 105.345 -2.094 . . . . 0.0 105.345 174.806 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.48 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 31.6 t90 -28.08 132.97 0.17 Allowed Pre-proline 0 C--O 1.246 0.877 0 C-N-CA 127.381 2.272 . . . . 0.0 114.348 -171.052 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.48 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 5.1 Cg_exo -88.48 6.94 68.4 Favored 'Cis proline' 0 CA--C 1.54 0.8 0 C-N-CA 123.044 -1.648 . . . . 0.0 114.631 2.328 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.5 m -113.79 152.83 15.42 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.137 0 C-N-CA 120.329 -0.548 . . . . 0.0 112.464 -175.479 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 36.0 m -96.13 145.77 25.22 Favored 'General case' 0 N--CA 1.406 -2.631 0 CA-C-O 122.02 0.914 . . . . 0.0 112.716 176.035 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.589 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 19.6 p -121.51 -162.6 0.98 Allowed 'General case' 0 C--N 1.293 -1.883 0 CA-C-N 114.036 -1.438 . . . . 0.0 108.059 179.672 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.47 ' HG3' ' SG ' ' A' ' 4' ' ' CYS . 78.9 mtt180 -123.36 162.24 23.13 Favored 'General case' 0 N--CA 1.397 -3.083 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 177.927 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -139.25 135.36 33.81 Favored 'General case' 0 C--N 1.273 -2.718 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 178.157 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 60.96 16.7 48.67 Favored Glycine 0 N--CA 1.464 0.556 0 O-C-N 123.306 0.379 . . . . 0.0 113.078 179.555 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 57.7 mt -129.21 157.61 75.53 Favored Pre-proline 0 C--N 1.298 -1.67 0 C-N-CA 122.314 0.246 . . . . 0.0 111.007 -174.784 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 22.7 Cg_exo -62.07 137.2 65.31 Favored 'Trans proline' 0 C--O 1.254 1.278 0 C-N-CA 122.261 1.974 . . . . 0.0 109.735 175.154 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 28.2 t -87.58 114.29 26.22 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.565 0 CA-C-O 121.567 0.699 . . . . 0.0 109.407 -176.683 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 11.0 t . . . . . 0 C--N 1.262 -3.234 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 176.27 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 77.7 m . . . . . 0 N--CA 1.442 -0.854 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -82.61 8.48 62.0 Favored Glycine 0 C--N 1.308 -0.999 0 C-N-CA 121.432 -0.414 . . . . 0.0 113.168 -176.03 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.416 ' HG3' ' SG ' ' A' ' 25' ' ' CYS . 12.4 pt-20 -90.13 156.67 18.19 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 -179.393 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' THR . . . . . 0.415 ' HB ' HG23 ' A' ' 9' ' ' VAL . 5.8 p -107.55 161.7 14.61 Favored 'General case' 0 N--CA 1.409 -2.503 0 CA-C-O 120.739 0.305 . . . . 0.0 110.767 178.715 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.441 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 19.1 p -127.66 35.7 4.47 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -178.622 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.415 HG23 ' HB ' ' A' ' 7' ' ' THR . 29.6 t -52.36 -37.31 23.03 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.987 0 CA-C-N 114.81 -1.086 . . . . 0.0 111.628 -177.559 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -68.95 -37.52 83.52 Favored Glycine 0 N--CA 1.443 -0.846 0 C-N-CA 121.068 -0.587 . . . . 0.0 111.94 177.871 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 157.05 -20.53 0.43 Allowed Glycine 0 N--CA 1.44 -1.035 0 C-N-CA 119.472 -1.347 . . . . 0.0 115.483 177.646 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 27.6 m -155.89 164.86 37.97 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 -176.987 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 40.3 m -94.71 164.65 12.86 Favored 'General case' 0 C--N 1.283 -2.312 0 C-N-CA 123.688 0.795 . . . . 0.0 108.949 178.536 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 39.7 m-80 -93.5 -30.86 14.81 Favored 'General case' 0 C--N 1.302 -1.477 0 CA-C-O 121.163 0.506 . . . . 0.0 110.008 -177.595 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.503 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 20.6 m -90.13 120.28 69.22 Favored Pre-proline 0 C--N 1.304 -1.395 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 176.836 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -71.05 -3.56 13.11 Favored 'Trans proline' 0 N--CA 1.485 1.022 0 C-N-CA 123.258 2.639 . . . . 0.0 114.285 -175.626 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -89.0 -11.94 64.41 Favored Glycine 0 C--N 1.269 -3.19 0 CA-C-N 114.176 -1.375 . . . . 0.0 110.117 176.453 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.503 ' SG ' ' HB ' ' A' ' 15' ' ' THR . 34.5 m -103.68 144.67 31.15 Favored 'General case' 0 N--CA 1.423 -1.817 0 CA-C-N 114.761 -0.719 . . . . 0.0 109.25 -179.372 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 14.7 m -112.7 151.33 30.34 Favored 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 179.5 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 52.0 t -89.14 118.69 29.03 Favored 'General case' 0 C--N 1.277 -2.549 0 CA-C-O 121.531 0.682 . . . . 0.0 110.318 -179.34 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 63.0 m -116.54 63.81 0.71 Allowed 'General case' 0 N--CA 1.407 -2.579 0 N-CA-C 104.54 -2.393 . . . . 0.0 104.54 171.826 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.459 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 40.6 t90 -36.27 132.43 0.61 Allowed Pre-proline 0 N--CA 1.437 -1.082 0 C-N-CA 126.404 1.882 . . . . 0.0 113.592 -170.144 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.459 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 2.8 Cg_endo -90.31 13.56 53.0 Favored 'Cis proline' 0 CA--C 1.547 1.139 0 C-N-CA 122.882 -1.716 . . . . 0.0 114.849 2.039 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.404 HG12 HG22 ' A' ' 7' ' ' THR . 27.6 m -110.91 144.46 18.82 Favored 'Isoleucine or valine' 0 C--O 1.204 -1.316 0 N-CA-C 112.877 0.695 . . . . 0.0 112.877 -176.936 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.441 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 76.5 m -86.19 152.14 23.06 Favored 'General case' 0 N--CA 1.407 -2.578 0 O-C-N 121.164 -0.96 . . . . 0.0 110.693 176.287 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.429 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.6 p -130.83 -176.89 4.14 Favored 'General case' 0 C--N 1.291 -1.951 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 175.164 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 14.4 ttm180 . . . . . 0 N--CA 1.416 -2.172 0 N-CA-C 106.107 -1.812 . . . . 0.0 106.107 178.844 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 81.4 m . . . . . 0 N--CA 1.429 -1.489 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -76.13 7.12 31.35 Favored Glycine 0 C--N 1.31 -0.881 0 CA-C-N 115.877 -0.601 . . . . 0.0 112.853 -178.165 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -90.56 150.18 21.85 Favored 'General case' 0 N--CA 1.417 -2.122 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 178.823 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 6.6 p -109.7 154.17 23.25 Favored 'General case' 0 N--CA 1.392 -3.372 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.439 178.031 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.509 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 20.0 p -118.06 37.28 4.03 Favored 'General case' 0 CA--C 1.484 -1.575 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -177.807 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.8 t -55.71 -35.64 39.92 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.971 0 CA-C-N 115.002 -0.999 . . . . 0.0 109.912 -178.713 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -65.7 -26.26 71.99 Favored Glycine 0 N--CA 1.446 -0.693 0 CA-C-N 115.354 -0.839 . . . . 0.0 112.587 178.244 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 137.41 -22.01 3.23 Favored Glycine 0 N--CA 1.437 -1.249 0 C-N-CA 120.849 -0.691 . . . . 0.0 113.917 178.782 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 12.1 m -150.31 158.99 44.76 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 -175.624 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.509 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 61.0 m -95.23 155.94 16.52 Favored 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 176.467 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 40.1 m-80 -88.72 -18.61 27.47 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-O 121.178 0.513 . . . . 0.0 111.194 -178.613 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.554 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 34.0 m -101.14 124.77 40.31 Favored Pre-proline 0 C--N 1.297 -1.684 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 175.316 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -68.57 -13.68 37.85 Favored 'Trans proline' 0 N--CA 1.488 1.151 0 C-N-CA 122.974 2.449 . . . . 0.0 112.907 -178.2 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.429 ' H ' HG22 ' A' ' 15' ' ' THR . . . -84.55 -12.78 74.61 Favored Glycine 0 C--N 1.263 -3.525 0 CA-C-N 113.311 -1.768 . . . . 0.0 110.525 178.633 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.644 ' HA ' ' O ' ' A' ' 26' ' ' THR . 56.1 m -103.51 126.28 50.57 Favored 'General case' 0 N--CA 1.403 -2.792 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 -179.153 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.464 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 1.1 m -89.23 144.03 26.4 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 -177.77 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 53.7 t -88.14 103.26 15.59 Favored 'General case' 0 N--CA 1.421 -1.904 0 C-N-CA 119.602 -0.839 . . . . 0.0 109.887 177.764 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 14.7 m -104.82 58.36 0.69 Allowed 'General case' 0 C--N 1.285 -2.231 0 N-CA-C 104.473 -2.417 . . . . 0.0 104.473 174.933 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.444 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 42.1 t90 -33.98 132.9 0.38 Allowed Pre-proline 0 N--CA 1.441 -0.893 0 C-N-CA 127.133 2.173 . . . . 0.0 113.495 -169.808 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.444 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 4.5 Cg_exo -89.31 11.32 59.45 Favored 'Cis proline' 0 C--N 1.322 -0.859 0 C-N-CA 122.851 -1.729 . . . . 0.0 114.981 2.203 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 34.8 m -109.68 143.6 19.49 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.765 0 C-N-CA 120.166 -0.614 . . . . 0.0 112.538 -176.458 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.513 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 77.5 m -89.36 147.92 23.8 Favored 'General case' 0 N--CA 1.414 -2.273 0 O-C-N 121.7 -0.625 . . . . 0.0 110.984 177.21 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.644 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.9 p -132.74 -167.31 1.88 Allowed 'General case' 0 C--O 1.195 -1.796 0 C-N-CA 123.923 0.889 . . . . 0.0 109.206 178.069 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 98.8 mtt180 . . . . . 0 N--CA 1.399 -2.996 0 CA-C-N 119.048 0.84 . . . . 0.0 109.51 179.083 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.444 ' HB3' ' HG2' ' A' ' 6' ' ' GLU . 4.0 m . . . . . 0 N--CA 1.413 -2.275 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -88.92 -5.75 73.25 Favored Glycine 0 N--CA 1.439 -1.165 0 N-CA-C 110.123 -1.191 . . . . 0.0 110.123 177.83 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.444 ' HG2' ' HB3' ' A' ' 4' ' ' CYS . 13.0 pt-20 -78.77 147.93 33.16 Favored 'General case' 0 N--CA 1.428 -1.558 0 CA-C-N 114.92 -0.64 . . . . 0.0 109.438 179.689 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 32.2 p -105.01 155.09 19.29 Favored 'General case' 0 N--CA 1.401 -2.907 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.271 -177.178 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.624 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 30.0 p -118.8 41.62 2.98 Favored 'General case' 0 N--CA 1.428 -1.537 0 CA-C-O 121.614 0.721 . . . . 0.0 109.228 -179.104 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 35.4 t -56.57 -36.47 48.23 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.919 0 CA-C-N 114.933 -1.03 . . . . 0.0 111.075 -178.366 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -91.7 3.93 78.66 Favored Glycine 0 CA--C 1.519 0.312 0 N-CA-C 112.025 -0.43 . . . . 0.0 112.025 178.338 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 83.17 42.51 7.98 Favored Glycine 0 N--CA 1.44 -1.066 0 C-N-CA 121.753 -0.26 . . . . 0.0 112.847 179.231 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.3 t -155.09 151.03 27.84 Favored 'General case' 0 N--CA 1.431 -1.377 0 CA-C-O 121.286 0.565 . . . . 0.0 111.227 179.219 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.491 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 82.9 m -138.2 145.85 41.94 Favored 'General case' 0 C--N 1.286 -2.166 0 CA-C-N 113.812 -1.54 . . . . 0.0 108.105 178.696 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 31.6 m-80 -87.18 -39.25 15.66 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-O 121.61 0.719 . . . . 0.0 110.162 -178.505 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 16.0 m -78.52 120.85 82.55 Favored Pre-proline 0 C--N 1.305 -1.366 0 N-CA-C 108.785 -0.821 . . . . 0.0 108.785 178.208 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -72.98 -8.42 22.22 Favored 'Trans proline' 0 C--N 1.365 1.425 0 C-N-CA 122.802 2.335 . . . . 0.0 113.127 -175.501 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -92.97 -6.66 63.21 Favored Glycine 0 C--N 1.265 -3.369 0 CA-C-N 113.45 -1.705 . . . . 0.0 109.881 177.725 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.512 ' HA ' ' O ' ' A' ' 26' ' ' THR . 98.7 m -109.57 125.93 53.05 Favored 'General case' 0 N--CA 1.401 -2.898 0 CA-C-O 122.532 1.158 . . . . 0.0 111.106 179.202 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 3.5 m -100.09 153.23 19.39 Favored 'General case' 0 N--CA 1.401 -2.916 0 C-N-CA 127.153 2.181 . . . . 0.0 107.688 -175.283 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 53.9 t -85.27 117.59 24.3 Favored 'General case' 0 C--N 1.285 -2.198 0 CA-C-O 121.466 0.65 . . . . 0.0 110.364 179.001 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 21.3 t -124.55 74.88 1.36 Allowed 'General case' 0 C--N 1.282 -2.364 0 N-CA-C 103.197 -2.89 . . . . 0.0 103.197 172.47 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.497 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 42.9 t90 -39.56 133.88 1.28 Allowed Pre-proline 0 N--CA 1.431 -1.411 0 CA-C-N 113.858 -1.519 . . . . 0.0 113.096 -171.063 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.497 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 1.4 Cg_endo -92.38 15.27 46.72 Favored 'Cis proline' 0 CA--C 1.541 0.868 0 C-N-CA 122.874 -1.719 . . . . 0.0 114.695 1.958 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 30.9 m -115.63 146.62 19.82 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 N-CA-C 113.986 1.106 . . . . 0.0 113.986 -175.696 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.624 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 70.0 m -83.8 132.93 34.79 Favored 'General case' 0 N--CA 1.402 -2.846 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 173.309 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.512 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 2.5 p -135.55 -176.57 4.33 Favored 'General case' 0 C--O 1.182 -2.485 0 C-N-CA 124.057 0.943 . . . . 0.0 108.654 -179.779 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 57.2 mtp180 . . . . . 0 N--CA 1.407 -2.585 0 CA-C-N 119.515 1.052 . . . . 0.0 110.009 -177.407 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 73.2 m . . . . . 0 N--CA 1.431 -1.4 0 N-CA-C 109.665 -0.495 . . . . 0.0 109.665 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -88.41 16.9 51.51 Favored Glycine 0 C--N 1.315 -0.612 0 N-CA-C 110.741 -0.944 . . . . 0.0 110.741 177.65 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.437 ' HB2' ' HB2' ' A' ' 25' ' ' CYS . 6.0 mm-40 -90.35 150.63 21.81 Favored 'General case' 0 N--CA 1.432 -1.354 0 C-N-CA 124.018 0.927 . . . . 0.0 109.881 -178.817 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 7.1 p -124.58 151.94 44.15 Favored 'General case' 0 N--CA 1.411 -2.384 0 CA-C-N 116.186 -0.461 . . . . 0.0 109.869 176.025 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.497 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 27.0 p -130.9 41.12 3.4 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-O 121.446 0.641 . . . . 0.0 109.989 -176.507 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 19.4 t -61.87 -32.94 55.64 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 114.965 -1.016 . . . . 0.0 109.533 -179.317 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -85.79 -1.61 87.08 Favored Glycine 0 N--CA 1.442 -0.943 0 CA-C-N 115.452 -0.795 . . . . 0.0 111.78 178.834 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 109.4 -10.14 33.18 Favored Glycine 0 N--CA 1.433 -1.516 0 N-CA-C 114.81 0.684 . . . . 0.0 114.81 176.059 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 1.1 m -137.55 152.57 49.59 Favored 'General case' 0 N--CA 1.43 -1.471 0 CA-C-N 118.773 1.286 . . . . 0.0 110.198 -174.708 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.497 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 82.8 m -106.92 136.39 46.84 Favored 'General case' 0 C--N 1.277 -2.546 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 174.469 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' ASN . . . . . 0.41 ' HB2' ' OE2' ' A' ' 6' ' ' GLU . 33.9 m-80 -65.54 -44.44 86.85 Favored 'General case' 0 N--CA 1.475 0.778 0 CA-C-O 121.236 0.541 . . . . 0.0 109.816 176.884 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 55.0 m -83.33 112.48 39.35 Favored Pre-proline 0 N--CA 1.43 -1.447 0 N-CA-C 108.852 -0.796 . . . . 0.0 108.852 175.197 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -75.87 -1.39 11.34 Favored 'Trans proline' 0 C--N 1.359 1.096 0 C-N-CA 123.337 2.691 . . . . 0.0 113.781 -174.716 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -86.69 -10.64 72.57 Favored Glycine 0 C--N 1.27 -3.084 0 CA-C-N 113.971 -1.468 . . . . 0.0 110.356 177.14 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.445 ' HA ' ' O ' ' A' ' 26' ' ' THR . 49.9 m -105.92 133.5 50.54 Favored 'General case' 0 N--CA 1.419 -2.006 0 CA-C-N 114.552 -0.824 . . . . 0.0 109.537 -179.053 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.433 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 5.8 m -89.86 151.88 21.54 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 108.299 -1.001 . . . . 0.0 108.299 -177.693 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 50.5 t -88.52 104.71 17.07 Favored 'General case' 0 C--N 1.292 -1.93 0 CA-C-O 122.021 0.915 . . . . 0.0 111.331 179.604 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 42.6 t -107.51 65.59 0.65 Allowed 'General case' 0 C--N 1.285 -2.201 0 N-CA-C 104.22 -2.511 . . . . 0.0 104.22 173.95 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.444 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 56.7 t90 -36.24 132.63 0.61 Allowed Pre-proline 0 N--CA 1.439 -1.018 0 C-N-CA 125.884 1.673 . . . . 0.0 112.668 -172.171 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.444 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 2.2 Cg_endo -90.23 10.76 60.48 Favored 'Cis proline' 0 CA--C 1.546 1.117 0 C-N-CA 123.017 -1.66 . . . . 0.0 115.294 3.09 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 30.6 m -111.34 153.78 13.03 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.0 0 O-C-N 121.561 -0.712 . . . . 0.0 112.466 -176.611 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.476 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 68.3 m -92.89 135.37 34.2 Favored 'General case' 0 N--CA 1.397 -3.078 0 O-C-N 121.835 -0.541 . . . . 0.0 109.617 175.044 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.445 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 11.8 p -116.45 -174.21 2.52 Favored 'General case' 0 C--N 1.285 -2.23 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.836 -179.558 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.383 -3.784 0 CA-C-O 121.523 0.677 . . . . 0.0 110.901 -176.79 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 71.9 m . . . . . 0 N--CA 1.439 -0.996 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -94.93 -2.76 62.45 Favored Glycine 0 C--N 1.308 -1.005 0 C-N-CA 121.227 -0.511 . . . . 0.0 111.869 -176.521 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.443 ' O ' ' HB2' ' A' ' 25' ' ' CYS . 1.6 pm0 -83.82 141.74 31.13 Favored 'General case' 0 N--CA 1.426 -1.673 0 CA-C-O 121.488 0.661 . . . . 0.0 110.87 177.001 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' THR . . . . . 0.414 HG22 HG12 ' A' ' 24' ' ' VAL . 22.8 p -106.83 153.57 22.29 Favored 'General case' 0 N--CA 1.404 -2.732 0 CA-C-N 115.279 -0.873 . . . . 0.0 109.765 -179.603 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.467 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 19.5 p -122.01 37.59 4.33 Favored 'General case' 0 CA--C 1.492 -1.277 0 CA-C-O 121.389 0.614 . . . . 0.0 110.268 -177.876 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 16.0 t -60.06 -33.99 55.04 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.204 0 CA-C-N 114.734 -1.121 . . . . 0.0 109.636 -178.646 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -87.73 6.62 83.17 Favored Glycine 0 N--CA 1.439 -1.107 0 CA-C-N 115.258 -0.883 . . . . 0.0 113.087 179.647 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 142.18 -69.01 0.44 Allowed Glycine 0 N--CA 1.438 -1.189 0 C-N-CA 120.131 -1.033 . . . . 0.0 114.502 177.384 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 20.5 m -157.04 163.24 39.27 Favored 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 106.748 -1.575 . . . . 0.0 106.748 -174.851 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 98.3 m -94.76 158.49 15.48 Favored 'General case' 0 C--N 1.281 -2.384 0 CA-C-O 120.808 0.337 . . . . 0.0 110.493 178.58 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 87.2 m-20 -84.39 -26.73 28.15 Favored 'General case' 0 C--N 1.31 -1.144 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.845 -178.64 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 9.1 m -71.22 112.87 15.14 Favored Pre-proline 0 CA--C 1.556 1.175 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 177.243 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -70.8 -10.21 27.28 Favored 'Trans proline' 0 C--N 1.362 1.274 0 C-N-CA 123.293 2.662 . . . . 0.0 115.257 -172.101 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -93.3 -6.06 63.18 Favored Glycine 0 C--N 1.258 -3.753 0 CA-C-N 114.309 -1.314 . . . . 0.0 111.124 179.121 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.506 ' HA ' ' O ' ' A' ' 26' ' ' THR . 60.3 m -108.49 126.01 52.43 Favored 'General case' 0 N--CA 1.422 -1.834 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 1.4 m -95.16 143.9 26.22 Favored 'General case' 0 C--N 1.284 -2.268 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 -178.203 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 41.1 t -87.65 125.94 34.67 Favored 'General case' 0 C--N 1.285 -2.225 0 CA-C-O 121.593 0.711 . . . . 0.0 109.879 -179.873 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 6.4 t -132.22 71.41 1.47 Allowed 'General case' 0 N--CA 1.4 -2.973 0 N-CA-C 103.426 -2.805 . . . . 0.0 103.426 174.53 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.485 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 55.5 t90 -35.69 132.87 0.53 Allowed Pre-proline 0 N--CA 1.433 -1.297 0 C-N-CA 126.319 1.848 . . . . 0.0 112.95 -171.281 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.485 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 1.6 Cg_endo -91.95 10.59 58.15 Favored 'Cis proline' 0 CA--C 1.539 0.729 0 C-N-CA 123.081 -1.633 . . . . 0.0 115.381 4.053 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.414 HG12 HG22 ' A' ' 7' ' ' THR . 34.1 m -118.56 150.03 20.88 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 C-N-CA 119.511 -0.875 . . . . 0.0 112.438 -175.177 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.467 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 64.5 m -95.66 148.56 22.41 Favored 'General case' 0 N--CA 1.398 -3.047 0 CA-C-O 121.704 0.764 . . . . 0.0 111.331 175.933 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.506 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 0.6 OUTLIER -135.47 -165.23 1.66 Allowed 'General case' 0 C--N 1.284 -2.242 0 CA-C-N 114.518 -1.219 . . . . 0.0 109.975 177.851 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.405 HH11 ' HD3' ' A' ' 27' ' ' ARG . 3.8 ptm180 . . . . . 0 N--CA 1.389 -3.491 0 CA-C-O 121.746 0.784 . . . . 0.0 110.554 -174.476 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 65.2 m . . . . . 0 N--CA 1.438 -1.029 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -96.25 14.72 64.06 Favored Glycine 0 C--N 1.314 -0.678 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 176.534 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.501 ' HB2' ' HB2' ' A' ' 25' ' ' CYS . 6.7 mm-40 -81.21 149.76 28.92 Favored 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 179.132 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 18.3 p -123.49 150.75 43.54 Favored 'General case' 0 N--CA 1.401 -2.914 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 177.198 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.499 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 30.1 p -127.22 44.85 2.83 Favored 'General case' 0 N--CA 1.427 -1.578 0 CA-C-O 121.231 0.539 . . . . 0.0 109.588 -177.103 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 38.8 t -57.62 -33.82 45.75 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.059 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.894 -178.37 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -81.09 -31.49 34.71 Favored Glycine 0 N--CA 1.444 -0.83 0 N-CA-C 110.803 -0.919 . . . . 0.0 110.803 175.474 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 124.84 14.89 3.31 Favored Glycine 0 N--CA 1.441 -1.006 0 C-N-CA 121.507 -0.378 . . . . 0.0 113.613 178.41 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 12.7 m -139.62 153.77 47.42 Favored 'General case' 0 N--CA 1.424 -1.727 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 -178.872 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.499 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 41.5 m -122.59 137.93 54.74 Favored 'General case' 0 C--N 1.274 -2.709 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 175.194 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -66.01 -52.44 49.24 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.043 178.188 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 32.8 m -73.39 112.53 16.32 Favored Pre-proline 0 CA--C 1.554 1.122 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 176.57 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -72.86 -4.64 15.74 Favored 'Trans proline' 0 C--N 1.36 1.178 0 C-N-CA 123.438 2.759 . . . . 0.0 114.868 -172.85 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -86.0 -14.77 66.37 Favored Glycine 0 C--N 1.257 -3.822 0 CA-C-N 114.388 -1.278 . . . . 0.0 110.358 177.416 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.541 ' HA ' ' O ' ' A' ' 26' ' ' THR . 22.0 m -103.95 129.94 51.54 Favored 'General case' 0 N--CA 1.419 -1.999 0 CA-C-N 114.952 -0.624 . . . . 0.0 109.658 -179.163 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 4.3 m -95.85 156.48 16.31 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 124.346 1.058 . . . . 0.0 108.151 -178.806 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 42.0 t -83.04 123.76 29.78 Favored 'General case' 0 N--CA 1.423 -1.809 0 CA-C-O 121.61 0.719 . . . . 0.0 110.987 -179.299 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 32.7 t -133.76 69.93 1.46 Allowed 'General case' 0 C--N 1.283 -2.306 0 N-CA-C 104.526 -2.398 . . . . 0.0 104.526 173.831 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.437 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 41.7 t90 -36.53 134.59 0.6 Allowed Pre-proline 0 N--CA 1.443 -0.821 0 C-N-CA 126.258 1.823 . . . . 0.0 113.93 -170.702 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.437 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 1.9 Cg_endo -90.12 8.83 65.17 Favored 'Cis proline' 0 N--CA 1.456 -0.705 0 C-N-CA 122.679 -1.8 . . . . 0.0 114.261 1.277 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 35.9 m -108.88 158.66 8.62 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.928 0 CA-C-O 121.415 0.626 . . . . 0.0 112.548 -175.876 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.501 ' HB2' ' HB2' ' A' ' 6' ' ' GLU . 84.1 m -95.41 135.52 36.94 Favored 'General case' 0 N--CA 1.405 -2.7 0 O-C-N 121.733 -0.604 . . . . 0.0 109.829 174.453 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.541 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 10.5 p -119.35 -169.46 1.76 Allowed 'General case' 0 C--N 1.286 -2.168 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.83 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 10.5 mtp-105 . . . . . 0 N--CA 1.392 -3.326 0 CA-C-O 121.878 0.847 . . . . 0.0 110.442 -177.447 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.722 ' SG ' ' HG3' ' A' ' 27' ' ' ARG . 78.0 m . . . . . 0 N--CA 1.439 -0.978 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -81.57 -3.47 90.61 Favored Glycine 0 C--N 1.308 -1.007 0 C-N-CA 120.99 -0.624 . . . . 0.0 111.944 -179.501 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -89.62 160.06 16.84 Favored 'General case' 0 N--CA 1.437 -1.096 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 179.602 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' THR . . . . . 0.526 ' HB ' HG23 ' A' ' 9' ' ' VAL . 38.0 p -113.88 164.07 14.25 Favored 'General case' 0 N--CA 1.406 -2.647 0 CA-C-O 121.109 0.481 . . . . 0.0 112.271 -174.83 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.495 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 26.1 p -131.41 33.8 4.03 Favored 'General case' 0 N--CA 1.426 -1.663 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 178.034 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.526 HG23 ' HB ' ' A' ' 7' ' ' THR . 21.9 t -57.7 -35.52 51.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 114.74 -1.118 . . . . 0.0 110.01 -178.766 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -82.27 -4.77 90.08 Favored Glycine 0 N--CA 1.444 -0.782 0 CA-C-N 115.684 -0.689 . . . . 0.0 113.063 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 128.46 -24.98 4.87 Favored Glycine 0 N--CA 1.444 -0.771 0 C-N-CA 120.231 -0.985 . . . . 0.0 114.344 177.497 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 15.3 t -156.89 173.03 17.61 Favored 'General case' 0 N--CA 1.431 -1.402 0 CA-C-N 118.277 1.039 . . . . 0.0 110.446 -175.689 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 57.5 m -101.77 175.88 5.41 Favored 'General case' 0 C--N 1.276 -2.612 0 CA-C-N 114.527 -1.215 . . . . 0.0 109.977 -175.82 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 51.0 m-80 -97.88 -38.32 9.48 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.046 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.422 HG22 ' H ' ' A' ' 17' ' ' GLY . 33.9 m -90.03 126.12 58.28 Favored Pre-proline 0 N--CA 1.429 -1.524 0 CA-C-N 115.505 -0.77 . . . . 0.0 108.979 178.33 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -72.33 -2.34 11.55 Favored 'Trans proline' 0 C--N 1.358 1.043 0 C-N-CA 122.693 2.262 . . . . 0.0 113.416 -177.383 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.422 ' H ' HG22 ' A' ' 15' ' ' THR . . . -93.07 -10.09 60.08 Favored Glycine 0 C--N 1.271 -3.054 0 CA-C-N 113.836 -1.529 . . . . 0.0 110.311 177.176 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.577 ' HB3' ' HB3' ' A' ' 25' ' ' CYS . 80.3 m -104.09 132.37 50.4 Favored 'General case' 0 N--CA 1.42 -1.926 0 CA-C-N 114.96 -0.62 . . . . 0.0 109.472 179.478 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 7.5 m -101.49 156.43 17.47 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 -179.736 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 44.4 t -88.16 123.97 33.35 Favored 'General case' 0 N--CA 1.418 -2.066 0 CA-C-O 121.409 0.623 . . . . 0.0 109.961 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 8.8 t -130.82 62.83 1.6 Allowed 'General case' 0 C--N 1.282 -2.34 0 N-CA-C 103.463 -2.792 . . . . 0.0 103.463 175.121 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.489 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 35.5 t90 -33.28 135.78 0.29 Allowed Pre-proline 0 C--O 1.243 0.732 0 C-N-CA 127.827 2.451 . . . . 0.0 113.821 -170.335 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.489 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 4.4 Cg_exo -88.4 4.98 69.71 Favored 'Cis proline' 0 CA--C 1.534 0.507 0 C-N-CA 123.004 -1.665 . . . . 0.0 114.812 2.183 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 34.1 m -107.82 157.66 7.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 C-N-CA 120.26 -0.576 . . . . 0.0 111.913 -176.892 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.577 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 93.1 m -91.28 150.33 21.37 Favored 'General case' 0 N--CA 1.404 -2.77 0 CA-C-O 121.305 0.574 . . . . 0.0 111.086 177.063 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.518 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 16.7 p -130.9 -178.65 4.9 Favored 'General case' 0 N--CA 1.421 -1.895 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.624 179.765 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.722 ' HG3' ' SG ' ' A' ' 4' ' ' CYS . 34.4 mtt85 . . . . . 0 N--CA 1.414 -2.241 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 -177.798 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 73.7 m . . . . . 0 N--CA 1.446 -0.66 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -77.78 -6.24 86.94 Favored Glycine 0 C--N 1.312 -0.778 0 C-N-CA 121.212 -0.518 . . . . 0.0 113.163 -177.262 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -86.14 146.94 26.37 Favored 'General case' 0 C--N 1.308 -1.222 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 -179.398 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' THR . . . . . 0.458 HG22 HG12 ' A' ' 24' ' ' VAL . 24.9 p -104.39 161.43 14.08 Favored 'General case' 0 N--CA 1.414 -2.255 0 CA-C-O 121.013 0.435 . . . . 0.0 111.891 -179.401 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.471 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 9.2 p -126.63 34.72 4.75 Favored 'General case' 0 CA--C 1.492 -1.255 0 CA-C-O 121.271 0.558 . . . . 0.0 110.27 -178.858 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.459 ' HA ' ' NE1' ' A' ' 22' ' ' TRP . 5.7 t -65.43 -28.79 45.27 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-N 115.273 -0.876 . . . . 0.0 109.46 -178.698 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -79.76 -15.83 78.58 Favored Glycine 0 C--O 1.241 0.564 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.512 177.814 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 125.98 -18.39 6.63 Favored Glycine 0 N--CA 1.436 -1.361 0 C-N-CA 120.519 -0.848 . . . . 0.0 115.217 175.695 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.5 m -145.67 158.14 43.88 Favored 'General case' 0 N--CA 1.437 -1.092 0 CA-C-N 118.764 1.282 . . . . 0.0 108.172 -175.341 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 62.7 m -99.51 170.85 8.32 Favored 'General case' 0 C--N 1.281 -2.372 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 175.884 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 26.9 m-80 -101.37 -18.82 15.87 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.468 0.651 . . . . 0.0 110.621 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.576 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 29.2 m -105.58 124.83 35.0 Favored Pre-proline 0 C--N 1.293 -1.888 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 175.561 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -73.29 -3.26 13.38 Favored 'Trans proline' 0 N--CA 1.486 1.078 0 C-N-CA 122.744 2.296 . . . . 0.0 113.098 -177.735 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.409 ' H ' HG22 ' A' ' 15' ' ' THR . . . -94.89 -8.03 59.47 Favored Glycine 0 C--N 1.27 -3.134 0 CA-C-N 113.38 -1.736 . . . . 0.0 109.839 176.419 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.621 ' HA ' ' O ' ' A' ' 26' ' ' THR . 85.0 m -106.12 125.75 51.37 Favored 'General case' 0 N--CA 1.419 -1.998 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.168 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 7.4 m -101.55 160.42 14.46 Favored 'General case' 0 C--N 1.286 -2.168 0 N-CA-C 107.483 -1.302 . . . . 0.0 107.483 -178.839 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 42.1 t -93.11 122.58 35.63 Favored 'General case' 0 N--CA 1.419 -2.013 0 CA-C-O 121.305 0.574 . . . . 0.0 110.911 -177.352 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 49.3 m -123.99 67.69 1.04 Allowed 'General case' 0 N--CA 1.409 -2.483 0 N-CA-C 105.03 -2.211 . . . . 0.0 105.03 171.644 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.465 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 50.4 t90 -37.27 133.69 0.73 Allowed Pre-proline 0 N--CA 1.435 -1.177 0 C-N-CA 126.091 1.757 . . . . 0.0 113.23 -170.157 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 1.9 Cg_endo -89.52 7.07 68.27 Favored 'Cis proline' 0 CA--C 1.55 1.299 0 C-N-CA 122.924 -1.698 . . . . 0.0 115.905 3.32 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.458 HG12 HG22 ' A' ' 7' ' ' THR . 33.3 m -109.52 151.47 11.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 O-C-N 121.581 -0.7 . . . . 0.0 112.421 -175.982 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.507 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 71.1 m -86.52 147.34 26.0 Favored 'General case' 0 N--CA 1.405 -2.68 0 CA-C-O 121.297 0.57 . . . . 0.0 109.954 175.395 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.621 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 31.0 p -132.6 -169.99 2.35 Favored 'General case' 0 C--N 1.294 -1.829 0 C-N-CA 122.758 0.423 . . . . 0.0 110.257 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 95.9 mtt180 . . . . . 0 N--CA 1.391 -3.396 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 -178.266 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 88.2 m . . . . . 0 N--CA 1.427 -1.596 0 N-CA-C 112.323 0.49 . . . . 0.0 112.323 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -89.88 23.41 20.43 Favored Glycine 0 C--N 1.316 -0.554 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 175.555 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.491 ' HB2' ' HB2' ' A' ' 25' ' ' CYS . 8.3 mm-40 -90.38 156.76 18.01 Favored 'General case' 0 N--CA 1.437 -1.109 0 C-N-CA 124.181 0.992 . . . . 0.0 110.005 -177.983 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 21.8 p -126.16 153.54 44.45 Favored 'General case' 0 N--CA 1.41 -2.443 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 174.23 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.428 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 21.6 p -124.79 33.75 5.15 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.781 -0.574 . . . . 0.0 111.005 -178.442 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.431 ' HA ' ' NE1' ' A' ' 22' ' ' TRP . 22.3 t -62.03 -35.98 71.57 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.867 0 CA-C-N 114.786 -1.097 . . . . 0.0 109.193 -179.835 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -71.33 -16.06 75.23 Favored Glycine 0 C--O 1.22 -0.733 0 CA-C-N 115.094 -0.957 . . . . 0.0 112.336 178.747 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 132.66 -23.65 3.97 Favored Glycine 0 N--CA 1.435 -1.428 0 C-N-CA 120.242 -0.98 . . . . 0.0 113.696 177.874 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 20.4 m -157.08 162.27 39.47 Favored 'General case' 0 C--N 1.31 -1.116 0 N-CA-C 107.114 -1.439 . . . . 0.0 107.114 -176.483 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 52.5 m -86.45 140.15 30.24 Favored 'General case' 0 C--N 1.283 -2.301 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 177.163 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 44.8 m-80 -72.0 -44.21 63.83 Favored 'General case' 0 C--N 1.315 -0.93 0 C-N-CA 120.746 -0.382 . . . . 0.0 110.892 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 27.2 m -76.34 121.08 84.27 Favored Pre-proline 0 CA--C 1.556 1.195 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 172.928 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_endo -71.24 -1.48 9.69 Favored 'Trans proline' 0 C--N 1.36 1.169 0 C-N-CA 123.551 2.834 . . . . 0.0 114.683 -173.45 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -95.06 2.32 65.9 Favored Glycine 0 C--N 1.261 -3.619 0 CA-C-N 114.506 -1.225 . . . . 0.0 112.003 -179.122 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 32.5 m -112.03 140.77 46.43 Favored 'General case' 0 N--CA 1.426 -1.674 0 CA-C-O 120.908 0.385 . . . . 0.0 111.674 -175.253 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 3.2 m -89.91 145.19 25.31 Favored 'General case' 0 C--N 1.315 -0.909 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 179.324 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 43.2 t -93.09 105.43 17.53 Favored 'General case' 0 C--N 1.29 -1.991 0 C-N-CA 120.073 -0.651 . . . . 0.0 110.369 177.547 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 2.3 p -113.97 65.69 0.66 Allowed 'General case' 0 C--N 1.278 -2.538 0 N-CA-C 106.274 -1.751 . . . . 0.0 106.274 173.444 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.47 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 49.2 t90 -34.83 135.34 0.41 Allowed Pre-proline 0 N--CA 1.446 -0.628 0 C-N-CA 126.985 2.114 . . . . 0.0 113.512 -169.933 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.47 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 1.8 Cg_endo -89.93 2.42 68.04 Favored 'Cis proline' 0 C--N 1.329 -0.499 0 C-N-CA 122.929 -1.696 . . . . 0.0 114.725 2.875 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.1 m -108.1 146.35 14.13 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 C-N-CA 120.259 -0.576 . . . . 0.0 111.95 -175.655 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.491 ' HB2' ' HB2' ' A' ' 6' ' ' GLU . 72.3 m -93.27 141.59 28.27 Favored 'General case' 0 N--CA 1.396 -3.162 0 CA-C-O 121.4 0.619 . . . . 0.0 111.5 179.341 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 1.4 p -109.14 -169.61 1.51 Allowed 'General case' 0 C--N 1.283 -2.313 0 CA-C-N 114.736 -1.12 . . . . 0.0 108.683 176.079 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 39.7 ttp180 . . . . . 0 N--CA 1.404 -2.73 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 -178.478 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 61.2 m . . . . . 0 N--CA 1.437 -1.092 0 CA-C-O 121.136 0.493 . . . . 0.0 110.049 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -84.98 -4.45 87.01 Favored Glycine 0 N--CA 1.443 -0.882 0 CA-C-N 115.699 -0.682 . . . . 0.0 113.978 -175.219 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -86.5 169.45 12.81 Favored 'General case' 0 C--N 1.309 -1.185 0 C-N-CA 119.836 -0.746 . . . . 0.0 111.064 -179.637 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' THR . . . . . 0.42 HG22 HG12 ' A' ' 24' ' ' VAL . 7.0 p -120.36 155.52 33.22 Favored 'General case' 0 N--CA 1.401 -2.911 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 178.402 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.513 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 13.4 p -119.06 37.2 4.2 Favored 'General case' 0 CA--C 1.484 -1.587 0 CA-C-O 121.043 0.449 . . . . 0.0 110.571 -176.648 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.7 t -57.69 -34.2 47.02 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 CA-C-N 114.926 -1.034 . . . . 0.0 109.353 -179.612 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -70.62 -8.51 63.4 Favored Glycine 0 N--CA 1.436 -1.321 0 CA-C-N 114.964 -1.017 . . . . 0.0 113.557 179.172 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 144.21 -54.07 0.58 Allowed Glycine 0 N--CA 1.441 -0.979 0 C-N-CA 120.67 -0.776 . . . . 0.0 113.962 176.672 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 14.7 t -157.61 173.33 17.02 Favored 'General case' 0 N--CA 1.425 -1.72 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -176.226 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.513 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 35.6 m -96.21 137.29 35.49 Favored 'General case' 0 C--N 1.27 -2.867 0 CA-C-N 115.342 -0.844 . . . . 0.0 108.759 -178.158 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 40.8 m-80 -70.47 -47.74 59.13 Favored 'General case' 0 C--N 1.319 -0.755 0 O-C-N 123.199 0.312 . . . . 0.0 111.43 -179.168 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.405 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 42.3 m -69.91 119.56 72.2 Favored Pre-proline 0 N--CA 1.437 -1.079 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 178.774 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 15' ' ' THR . 22.0 Cg_exo -66.87 -9.82 26.14 Favored 'Trans proline' 0 C--N 1.36 1.134 0 C-N-CA 123.458 2.772 . . . . 0.0 113.927 -175.672 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -83.3 -17.27 67.12 Favored Glycine 0 C--N 1.265 -3.392 0 CA-C-N 113.787 -1.551 . . . . 0.0 110.412 177.252 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.493 ' HA ' ' O ' ' A' ' 26' ' ' THR . 47.8 m -108.55 126.68 53.2 Favored 'General case' 0 N--CA 1.416 -2.173 0 N-CA-C 108.096 -1.076 . . . . 0.0 108.096 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 6.8 m -101.22 148.04 25.57 Favored 'General case' 0 C--N 1.274 -2.701 0 N-CA-C 107.459 -1.311 . . . . 0.0 107.459 -175.914 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 50.3 t -90.78 106.27 18.4 Favored 'General case' 0 C--N 1.275 -2.653 0 CA-C-O 121.702 0.763 . . . . 0.0 110.662 -178.156 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 31.3 t -107.67 67.09 0.68 Allowed 'General case' 0 C--N 1.28 -2.426 0 N-CA-C 102.9 -3.0 . . . . 0.0 102.9 172.81 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.44 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 57.4 t90 -39.39 133.59 1.23 Allowed Pre-proline 0 N--CA 1.433 -1.286 0 CA-C-N 113.405 -1.725 . . . . 0.0 112.326 -171.356 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.44 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 1.9 Cg_endo -90.75 12.17 56.75 Favored 'Cis proline' 0 CA--C 1.543 0.967 0 C-N-CA 122.723 -1.782 . . . . 0.0 115.812 3.721 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.42 HG12 HG22 ' A' ' 7' ' ' THR . 21.0 m -110.66 146.86 15.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 119.071 0.851 . . . . 0.0 113.007 -176.419 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 90.9 m -86.53 140.64 29.71 Favored 'General case' 0 N--CA 1.401 -2.898 0 O-C-N 121.679 -0.638 . . . . 0.0 109.327 174.996 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.493 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 2.6 p -135.6 -177.3 4.61 Favored 'General case' 0 C--N 1.269 -2.92 0 CA-C-N 115.206 -0.907 . . . . 0.0 109.084 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 12.9 ttm180 . . . . . 0 N--CA 1.421 -1.89 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 176.883 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 3.5 m . . . . . 0 N--CA 1.44 -0.937 0 N-CA-C 113.55 0.945 . . . . 0.0 113.55 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -103.93 18.39 46.62 Favored Glycine 0 C--N 1.313 -0.739 0 N-CA-C 107.724 -2.15 . . . . 0.0 107.724 169.806 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 23.2 mm-40 -80.99 170.85 15.73 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 113.605 -1.298 . . . . 0.0 109.552 -178.962 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' THR . . . . . 0.457 ' HB ' HG23 ' A' ' 9' ' ' VAL . 16.8 p -122.57 156.5 34.1 Favored 'General case' 0 N--CA 1.402 -2.827 0 CA-C-O 120.791 0.329 . . . . 0.0 111.062 178.825 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 20.5 p -128.22 38.24 4.03 Favored 'General case' 0 CA--C 1.491 -1.294 0 CA-C-O 121.41 0.624 . . . . 0.0 109.601 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.457 HG23 ' HB ' ' A' ' 7' ' ' THR . 11.1 t -58.62 -29.89 40.37 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.007 0 CA-C-N 114.426 -1.261 . . . . 0.0 110.709 -177.16 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -74.1 -22.11 78.24 Favored Glycine 0 N--CA 1.437 -1.256 0 CA-C-N 115.849 -0.614 . . . . 0.0 112.544 179.028 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 149.63 -36.55 0.99 Allowed Glycine 0 N--CA 1.438 -1.226 0 C-N-CA 120.207 -0.997 . . . . 0.0 113.863 179.672 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 8.8 t -158.3 173.65 16.36 Favored 'General case' 0 N--CA 1.423 -1.793 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 -178.429 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 63.2 m -89.75 150.54 22.25 Favored 'General case' 0 C--N 1.268 -2.937 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.134 -177.277 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 83.8 m-20 -90.43 -12.23 38.06 Favored 'General case' 0 C--N 1.308 -1.203 0 CA-C-O 121.177 0.513 . . . . 0.0 110.158 177.901 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 10.4 m -100.37 122.96 48.13 Favored Pre-proline 0 C--N 1.305 -1.335 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 176.945 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 96.6 Cg_endo -78.39 -1.85 11.97 Favored 'Trans proline' 0 N--CA 1.484 0.949 0 C-N-CA 123.232 2.621 . . . . 0.0 115.926 -169.186 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -102.5 0.02 49.84 Favored Glycine 0 C--N 1.261 -3.634 0 N-CA-C 110.001 -1.24 . . . . 0.0 110.001 178.221 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.44 ' HA ' ' O ' ' A' ' 26' ' ' THR . 56.1 m -118.65 134.15 55.32 Favored 'General case' 0 N--CA 1.402 -2.854 0 CA-C-N 113.75 -1.225 . . . . 0.0 109.041 -175.429 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 10.5 t -109.89 163.86 13.13 Favored 'General case' 0 N--CA 1.426 -1.651 0 C-N-CA 119.584 -0.846 . . . . 0.0 109.639 -178.74 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 48.9 t -92.96 125.06 37.37 Favored 'General case' 0 N--CA 1.387 -3.605 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.117 -174.495 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 46.0 m -128.75 59.85 1.54 Allowed 'General case' 0 N--CA 1.397 -3.121 0 N-CA-C 104.557 -2.386 . . . . 0.0 104.557 173.211 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.435 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 47.7 t90 -31.8 131.49 0.29 Allowed Pre-proline 0 C--O 1.247 0.931 0 C-N-CA 126.851 2.06 . . . . 0.0 113.149 -172.452 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.435 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 2.8 Cg_endo -89.04 6.62 69.08 Favored 'Cis proline' 0 CA--C 1.537 0.644 0 C-N-CA 122.872 -1.72 . . . . 0.0 115.242 2.955 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 28.9 m -107.76 152.24 9.54 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.004 0 N-CA-C 112.855 0.687 . . . . 0.0 112.855 -176.223 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 94.5 m -88.56 149.4 23.61 Favored 'General case' 0 N--CA 1.402 -2.836 0 CA-C-O 121.452 0.644 . . . . 0.0 110.986 175.71 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.44 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.8 p -125.37 -146.72 0.35 Allowed 'General case' 0 C--N 1.285 -2.236 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 173.761 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 6.6 ptp180 . . . . . 1 N--CA 1.377 -4.077 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 -176.5 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 58.5 m . . . . . 0 N--CA 1.43 -1.471 0 CA-C-O 120.764 0.316 . . . . 0.0 110.999 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -107.94 -6.69 32.1 Favored Glycine 0 N--CA 1.431 -1.661 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 174.853 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -69.59 151.35 46.06 Favored 'General case' 0 C--O 1.25 1.086 0 CA-C-N 115.169 -0.515 . . . . 0.0 110.948 179.389 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 39.9 p -102.62 163.38 12.25 Favored 'General case' 0 N--CA 1.408 -2.571 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.072 -178.984 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.712 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 29.3 p -129.38 43.42 3.14 Favored 'General case' 0 N--CA 1.425 -1.677 0 CA-C-O 121.465 0.65 . . . . 0.0 109.485 -178.839 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 58.3 t -58.42 -33.14 47.07 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.862 -177.977 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -90.03 -0.95 76.89 Favored Glycine 0 C--O 1.224 -0.528 0 CA-C-N 116.211 -0.45 . . . . 0.0 112.109 178.762 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 86.72 29.18 24.53 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 121.823 -0.227 . . . . 0.0 113.217 177.752 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 7.0 m -148.52 155.08 40.67 Favored 'General case' 0 N--CA 1.436 -1.131 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 179.196 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.433 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 61.1 m -133.04 156.87 46.58 Favored 'General case' 0 C--N 1.279 -2.464 0 N-CA-C 107.572 -1.269 . . . . 0.0 107.572 176.862 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 33.3 m-80 -84.1 -39.42 19.53 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 -179.787 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 16.2 m -84.79 116.62 66.09 Favored Pre-proline 0 N--CA 1.429 -1.507 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 175.415 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -74.72 -7.67 19.61 Favored 'Trans proline' 0 C--N 1.358 1.07 0 C-N-CA 122.433 2.089 . . . . 0.0 112.758 -175.444 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -90.44 -6.84 67.88 Favored Glycine 0 C--N 1.268 -3.239 0 CA-C-N 113.233 -1.803 . . . . 0.0 110.143 178.368 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.447 ' HA ' ' O ' ' A' ' 26' ' ' THR . 86.8 m -105.28 125.91 51.51 Favored 'General case' 0 N--CA 1.412 -2.361 0 CA-C-O 122.407 1.098 . . . . 0.0 109.679 177.269 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.435 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 6.8 m -93.59 150.72 20.2 Favored 'General case' 0 C--N 1.276 -2.595 0 CA-C-N 113.125 -1.852 . . . . 0.0 108.603 -173.641 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 52.2 t -93.1 105.77 17.82 Favored 'General case' 0 N--CA 1.409 -2.493 0 CA-C-O 121.866 0.841 . . . . 0.0 110.904 -178.374 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 31.1 m -108.68 79.61 1.25 Allowed 'General case' 0 N--CA 1.391 -3.405 0 N-CA-C 103.569 -2.752 . . . . 0.0 103.569 171.074 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.436 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 54.5 t90 -44.31 134.51 4.37 Favored Pre-proline 0 N--CA 1.429 -1.517 0 CA-C-N 113.322 -1.763 . . . . 0.0 112.919 -167.976 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.436 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 4.0 Cg_endo -95.64 22.96 26.79 Favored 'Cis proline' 0 N--CA 1.458 -0.561 0 C-N-CA 122.969 -1.68 . . . . 0.0 114.597 3.15 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 29.9 m -120.68 144.22 30.25 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.968 0 N-CA-C 114.057 1.132 . . . . 0.0 114.057 -175.712 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.712 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 56.1 m -86.05 129.87 34.71 Favored 'General case' 0 N--CA 1.414 -2.268 0 O-C-N 121.791 -0.568 . . . . 0.0 109.616 176.212 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.447 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 1.3 p -135.78 -170.82 2.71 Favored 'General case' 0 C--N 1.287 -2.119 0 C-N-CA 123.541 0.737 . . . . 0.0 109.828 178.439 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 70.8 mtp180 . . . . . 0 N--CA 1.396 -3.145 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 177.729 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 96.4 m . . . . . 0 N--CA 1.431 -1.394 0 N-CA-C 110.209 -0.293 . . . . 0.0 110.209 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -85.65 4.01 86.36 Favored Glycine 0 N--CA 1.447 -0.581 0 N-CA-C 110.788 -0.925 . . . . 0.0 110.788 179.677 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 74.6 mm-40 -89.6 146.82 24.3 Favored 'General case' 0 N--CA 1.421 -1.909 0 CA-C-N 114.79 -0.705 . . . . 0.0 110.816 -179.511 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 32.6 p -123.71 150.81 43.87 Favored 'General case' 0 N--CA 1.392 -3.335 0 N-CA-C 106.185 -1.783 . . . . 0.0 106.185 174.4 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.43 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 24.4 p -123.99 38.35 4.21 Favored 'General case' 0 C--N 1.289 -2.022 0 CA-C-N 118.63 0.65 . . . . 0.0 110.254 -177.521 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 13.6 t -61.76 -40.48 87.04 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 CA-C-N 114.494 -1.23 . . . . 0.0 108.306 178.791 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -73.78 -22.24 78.42 Favored Glycine 0 N--CA 1.441 -1.032 0 CA-C-N 114.902 -1.045 . . . . 0.0 111.022 177.127 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 120.4 -6.94 11.57 Favored Glycine 0 N--CA 1.436 -1.302 0 C-N-CA 121.255 -0.498 . . . . 0.0 113.876 177.211 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 6.1 m -136.51 155.25 50.23 Favored 'General case' 0 N--CA 1.429 -1.492 0 CA-C-N 118.047 0.924 . . . . 0.0 108.936 -176.336 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 57.6 m -113.99 143.33 44.92 Favored 'General case' 0 C--N 1.279 -2.463 0 N-CA-C 106.154 -1.795 . . . . 0.0 106.154 175.676 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 33.4 m-80 -68.09 -39.36 82.88 Favored 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 119.053 0.842 . . . . 0.0 110.656 177.395 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 9.9 m -94.1 113.19 60.04 Favored Pre-proline 0 N--CA 1.426 -1.671 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 176.358 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -76.33 -1.89 12.0 Favored 'Trans proline' 0 C--N 1.354 0.828 0 C-N-CA 122.668 2.245 . . . . 0.0 112.534 -178.727 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -79.59 -14.41 81.26 Favored Glycine 0 C--N 1.284 -2.33 0 CA-C-N 113.105 -1.861 . . . . 0.0 108.936 175.166 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.536 ' HA ' ' O ' ' A' ' 26' ' ' THR . 63.7 m -103.14 127.33 50.47 Favored 'General case' 0 N--CA 1.406 -2.653 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.115 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.43 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 10.3 m -89.9 148.86 22.9 Favored 'General case' 0 C--N 1.279 -2.493 0 CA-C-N 114.876 -1.056 . . . . 0.0 108.633 -177.129 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 50.5 t -84.64 115.15 22.49 Favored 'General case' 0 C--N 1.269 -2.897 0 CA-C-O 121.461 0.648 . . . . 0.0 110.453 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 16.6 t -120.26 68.24 0.84 Allowed 'General case' 0 C--N 1.287 -2.152 0 N-CA-C 103.728 -2.693 . . . . 0.0 103.728 172.85 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.448 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 51.3 t90 -35.92 133.08 0.56 Allowed Pre-proline 0 N--CA 1.441 -0.904 0 CA-C-N 113.108 -1.86 . . . . 0.0 112.969 -170.417 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.448 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 1.6 Cg_endo -91.63 14.46 49.62 Favored 'Cis proline' 0 CA--C 1.541 0.855 0 C-N-CA 123.145 -1.606 . . . . 0.0 115.343 2.517 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 28.9 m -115.65 152.6 17.3 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.019 0 O-C-N 121.182 -0.949 . . . . 0.0 112.36 -177.629 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.43 ' HA ' ' O ' ' A' ' 19' ' ' THR . 59.6 m -95.73 139.32 32.14 Favored 'General case' 0 N--CA 1.403 -2.81 0 O-C-N 121.77 -0.581 . . . . 0.0 109.543 177.123 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.536 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 20.1 p -125.49 -173.29 2.79 Favored 'General case' 0 C--N 1.29 -1.989 0 C-N-CA 123.119 0.568 . . . . 0.0 111.345 -179.157 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 53.8 ttt180 . . . . . 0 N--CA 1.417 -2.095 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 -177.619 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 98.1 m . . . . . 0 CA--C 1.515 -0.39 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -107.19 5.64 36.16 Favored Glycine 0 C--N 1.31 -0.892 0 C-N-CA 120.465 -0.874 . . . . 0.0 112.443 -178.295 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -88.73 166.43 14.06 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.779 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' THR . . . . . 0.43 ' HB ' HG23 ' A' ' 9' ' ' VAL . 24.4 p -112.49 163.25 14.68 Favored 'General case' 0 N--CA 1.415 -2.194 0 N-CA-C 112.15 0.426 . . . . 0.0 112.15 -175.79 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.462 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 21.4 p -137.13 36.01 2.55 Favored 'General case' 0 CA--C 1.497 -1.073 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 179.58 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.43 HG23 ' HB ' ' A' ' 7' ' ' THR . 15.4 t -60.8 -35.4 64.15 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.084 0 CA-C-N 114.719 -1.128 . . . . 0.0 109.4 -177.867 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -74.27 -17.27 79.63 Favored Glycine 0 N--CA 1.44 -1.044 0 CA-C-N 115.132 -0.94 . . . . 0.0 112.935 178.97 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 141.49 -33.43 1.98 Allowed Glycine 0 N--CA 1.435 -1.402 0 C-N-CA 119.992 -1.099 . . . . 0.0 113.795 179.848 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 9.0 t -153.58 172.8 16.64 Favored 'General case' 0 N--CA 1.424 -1.745 0 CA-C-N 117.771 0.785 . . . . 0.0 109.845 -174.726 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 58.1 m -94.75 176.35 6.31 Favored 'General case' 0 C--N 1.274 -2.687 0 CA-C-N 114.475 -1.239 . . . . 0.0 110.042 -177.391 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 26.8 m-80 -100.55 -36.43 9.18 Favored 'General case' 0 C--N 1.307 -1.243 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 178.588 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.507 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 25.8 m -90.69 121.86 67.69 Favored Pre-proline 0 N--CA 1.427 -1.607 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 177.179 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.443 ' HD3' ' HA ' ' A' ' 15' ' ' THR . 13.6 Cg_exo -69.66 -3.58 12.22 Favored 'Trans proline' 0 N--CA 1.488 1.157 0 C-N-CA 123.132 2.555 . . . . 0.0 113.458 -177.506 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -90.3 -14.22 59.08 Favored Glycine 0 C--N 1.255 -3.949 0 CA-C-N 113.719 -1.582 . . . . 0.0 110.283 176.458 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.589 ' HA ' ' O ' ' A' ' 26' ' ' THR . 57.8 m -103.55 129.97 50.86 Favored 'General case' 0 N--CA 1.396 -3.128 0 N-CA-C 107.575 -1.269 . . . . 0.0 107.575 179.254 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 25.1 m -114.78 155.5 26.61 Favored 'General case' 0 C--N 1.281 -2.389 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 -179.13 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 38.2 t -83.48 128.15 34.28 Favored 'General case' 0 N--CA 1.409 -2.521 0 CA-C-O 122.251 1.024 . . . . 0.0 113.065 -171.477 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.8 m -128.26 65.32 1.39 Allowed 'General case' 0 N--CA 1.402 -2.833 0 N-CA-C 104.401 -2.444 . . . . 0.0 104.401 170.149 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.426 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 37.9 t90 -33.67 134.87 0.33 Allowed Pre-proline 0 N--CA 1.442 -0.849 0 C-N-CA 127.433 2.293 . . . . 0.0 113.918 -170.92 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.426 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 4.6 Cg_exo -88.96 12.01 57.51 Favored 'Cis proline' 0 CA--C 1.544 0.98 0 C-N-CA 122.894 -1.711 . . . . 0.0 114.403 0.993 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.7 m -114.38 150.49 16.36 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.889 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -175.254 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.463 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 95.5 m -86.14 151.6 23.53 Favored 'General case' 0 N--CA 1.41 -2.435 0 CA-C-O 121.74 0.781 . . . . 0.0 112.206 178.39 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.589 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.0 p -129.27 -164.44 1.4 Allowed 'General case' 0 C--N 1.298 -1.642 0 C-N-CA 124.609 1.164 . . . . 0.0 108.331 175.559 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 17.3 ttm180 . . . . . 0 N--CA 1.407 -2.603 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 -178.277 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 85.3 m . . . . . 0 N--CA 1.433 -1.312 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -80.06 13.9 23.53 Favored Glycine 0 C--N 1.314 -0.675 0 CA-C-N 116.117 -0.492 . . . . 0.0 112.927 -176.382 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -91.56 162.13 14.66 Favored 'General case' 0 C--N 1.306 -1.288 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 178.762 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 25.3 p -114.74 163.48 15.42 Favored 'General case' 0 N--CA 1.411 -2.385 0 N-CA-C 110.374 -0.232 . . . . 0.0 110.374 -179.739 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 16.9 p -134.2 41.2 2.98 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-O 121.229 0.538 . . . . 0.0 110.185 -179.036 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 23.2 t -59.94 -29.89 44.26 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.042 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.619 -176.945 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -83.09 -8.14 86.02 Favored Glycine 0 N--CA 1.441 -0.995 0 CA-C-N 115.769 -0.65 . . . . 0.0 112.903 -179.786 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 139.82 -39.61 1.49 Allowed Glycine 0 N--CA 1.443 -0.885 0 C-N-CA 120.214 -0.993 . . . . 0.0 113.777 178.2 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 13.5 t -155.6 173.23 17.01 Favored 'General case' 0 N--CA 1.423 -1.802 0 CA-C-N 117.354 0.577 . . . . 0.0 109.649 -176.807 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 32.2 m -91.87 173.11 8.03 Favored 'General case' 0 C--N 1.274 -2.713 0 CA-C-N 114.815 -1.084 . . . . 0.0 109.578 -175.048 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 36.3 m-80 -93.27 -36.63 12.47 Favored 'General case' 0 CA--C 1.496 -1.097 0 N-CA-C 110.059 -0.348 . . . . 0.0 110.059 177.017 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.48 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 17.6 m -84.63 124.26 73.38 Favored Pre-proline 0 C--N 1.297 -1.675 0 N-CA-C 108.131 -1.062 . . . . 0.0 108.131 176.304 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_endo -72.86 -1.53 10.58 Favored 'Trans proline' 0 C--N 1.359 1.098 0 C-N-CA 123.05 2.5 . . . . 0.0 113.425 -176.194 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -97.63 -4.05 58.2 Favored Glycine 0 C--N 1.265 -3.407 0 CA-C-N 113.964 -1.471 . . . . 0.0 110.152 177.782 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.48 ' SG ' ' HB ' ' A' ' 15' ' ' THR . 60.3 m -108.66 125.84 52.32 Favored 'General case' 0 N--CA 1.409 -2.518 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 178.992 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 8.6 m -91.45 151.39 20.82 Favored 'General case' 0 C--N 1.291 -1.959 0 N-CA-C 107.74 -1.208 . . . . 0.0 107.74 -177.213 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 46.6 t -90.17 127.73 36.18 Favored 'General case' 0 N--CA 1.411 -2.415 0 CA-C-O 121.388 0.613 . . . . 0.0 109.565 179.501 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 22.6 t -128.71 56.8 1.63 Allowed 'General case' 0 C--N 1.28 -2.448 0 N-CA-C 103.688 -2.708 . . . . 0.0 103.688 176.001 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.429 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 56.6 t90 -31.2 131.91 0.25 Allowed Pre-proline 0 N--CA 1.446 -0.644 0 C-N-CA 127.009 2.124 . . . . 0.0 113.347 -171.314 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 1.8 Cg_endo -90.37 9.68 63.07 Favored 'Cis proline' 0 C--N 1.323 -0.811 0 C-N-CA 122.883 -1.715 . . . . 0.0 115.074 4.091 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 29.8 m -112.32 153.01 14.04 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 O-C-N 122.043 -0.41 . . . . 0.0 111.927 -176.2 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 73.4 m -93.39 158.78 15.56 Favored 'General case' 0 N--CA 1.416 -2.15 0 CA-C-O 121.487 0.661 . . . . 0.0 112.42 178.05 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.461 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.1 p -129.81 -175.04 3.48 Favored 'General case' 0 C--N 1.31 -1.145 0 C-N-CA 124.519 1.128 . . . . 0.0 108.562 175.679 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 20.0 ptt180 . . . . . 0 N--CA 1.384 -3.725 0 CA-C-N 119.407 1.003 . . . . 0.0 112.138 -178.027 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 72.4 m . . . . . 0 N--CA 1.441 -0.924 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -88.03 12.98 62.52 Favored Glycine 0 C--N 1.304 -1.201 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.025 -178.057 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -90.23 154.67 19.56 Favored 'General case' 0 N--CA 1.431 -1.401 0 CA-C-O 121.096 0.474 . . . . 0.0 110.013 -179.289 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' THR . . . . . 0.401 ' HA ' ' HA ' ' A' ' 24' ' ' VAL . 35.9 p -111.65 158.53 19.16 Favored 'General case' 0 N--CA 1.395 -3.225 0 N-CA-C 106.32 -1.734 . . . . 0.0 106.32 170.449 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.604 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 28.1 p -135.85 50.86 2.07 Favored 'General case' 0 C--N 1.283 -2.304 0 CA-C-O 121.502 0.668 . . . . 0.0 110.056 -177.66 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 40.3 t -62.43 -31.0 50.35 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.36 -178.568 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -74.45 -26.36 68.08 Favored Glycine 0 N--CA 1.446 -0.638 0 N-CA-C 111.338 -0.705 . . . . 0.0 111.338 176.701 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 122.27 0.18 10.46 Favored Glycine 0 N--CA 1.443 -0.875 0 C-N-CA 120.657 -0.782 . . . . 0.0 114.219 177.021 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 15.7 m -148.81 162.59 39.51 Favored 'General case' 0 N--CA 1.432 -1.372 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 -179.664 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 35.9 m -111.82 166.78 10.9 Favored 'General case' 0 C--N 1.281 -2.407 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 177.841 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 36.0 m-80 -83.43 -38.89 21.31 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-O 120.923 0.392 . . . . 0.0 110.022 179.223 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.582 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 13.4 m -79.88 123.85 83.54 Favored Pre-proline 0 N--CA 1.429 -1.509 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 178.979 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_exo -69.81 -2.92 11.03 Favored 'Trans proline' 0 C--N 1.353 0.809 0 C-N-CA 123.009 2.472 . . . . 0.0 112.898 179.504 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.445 ' H ' HG22 ' A' ' 15' ' ' THR . . . -96.47 -12.19 51.83 Favored Glycine 0 C--N 1.27 -3.134 0 CA-C-N 113.752 -1.567 . . . . 0.0 110.449 177.17 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.582 ' SG ' ' HB ' ' A' ' 15' ' ' THR . 62.3 m -103.7 130.63 51.22 Favored 'General case' 0 N--CA 1.415 -2.198 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 179.659 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 9.6 m -109.26 147.7 32.2 Favored 'General case' 0 C--N 1.282 -2.329 0 N-CA-C 107.928 -1.138 . . . . 0.0 107.928 -177.625 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 46.2 t -83.45 121.15 26.8 Favored 'General case' 0 N--CA 1.403 -2.777 0 CA-C-O 121.629 0.728 . . . . 0.0 111.073 -177.434 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 25.2 t -123.58 72.36 1.13 Allowed 'General case' 0 C--N 1.279 -2.472 0 N-CA-C 103.417 -2.809 . . . . 0.0 103.417 173.88 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.464 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 36.9 t90 -41.24 133.71 1.95 Allowed Pre-proline 0 N--CA 1.444 -0.729 0 C-N-CA 125.893 1.677 . . . . 0.0 113.411 -168.343 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.464 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 1.6 Cg_endo -92.23 16.81 43.42 Favored 'Cis proline' 0 CA--C 1.538 0.705 0 C-N-CA 122.826 -1.739 . . . . 0.0 114.655 2.113 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.401 ' HA ' ' HA ' ' A' ' 7' ' ' THR . 26.8 m -117.38 151.13 19.3 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.863 0 N-CA-C 113.95 1.093 . . . . 0.0 113.95 -176.11 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.604 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 82.8 m -86.21 148.95 25.42 Favored 'General case' 0 N--CA 1.409 -2.506 0 O-C-N 121.536 -0.727 . . . . 0.0 110.928 176.459 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.494 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.2 p -132.72 -174.51 3.48 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 175.959 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 3.5 ppt_? . . . . . 0 N--CA 1.379 -3.975 0 CA-C-N 119.524 1.056 . . . . 0.0 110.43 179.368 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.638 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 88.7 m . . . . . 0 N--CA 1.442 -0.852 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -92.42 -16.75 48.55 Favored Glycine 0 N--CA 1.44 -1.096 0 C-N-CA 120.454 -0.879 . . . . 0.0 112.866 -174.966 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.638 ' OE1' ' HB3' ' A' ' 4' ' ' CYS . 1.0 OUTLIER -90.15 145.94 24.66 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 122.447 -0.443 . . . . 0.0 111.056 -178.786 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 7' ' ' THR . . . . . 0.442 HG22 HG12 ' A' ' 24' ' ' VAL . 21.7 p -109.83 157.04 19.6 Favored 'General case' 0 N--CA 1.417 -2.114 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.485 -179.209 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.5 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 19.5 p -126.23 38.85 4.06 Favored 'General case' 0 C--N 1.303 -1.422 0 CA-C-O 121.169 0.509 . . . . 0.0 110.589 -177.05 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 35.5 t -56.12 -35.48 41.97 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 CA-C-N 115.106 -0.952 . . . . 0.0 110.722 -178.427 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -95.4 7.85 68.97 Favored Glycine 0 N--CA 1.441 -1.027 0 C-N-CA 121.089 -0.577 . . . . 0.0 113.053 -179.483 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 152.1 -82.06 0.18 Allowed Glycine 0 N--CA 1.434 -1.477 0 C-N-CA 119.186 -1.483 . . . . 0.0 114.425 178.369 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 7.5 m -153.44 163.89 39.15 Favored 'General case' 0 N--CA 1.428 -1.57 0 N-CA-C 106.867 -1.531 . . . . 0.0 106.867 -171.153 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 76.7 m -99.13 161.56 13.55 Favored 'General case' 0 C--N 1.291 -1.95 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 176.188 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 41.7 m-80 -92.82 -16.51 25.24 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-O 120.99 0.424 . . . . 0.0 110.837 -177.839 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 10.7 m -72.49 114.89 33.98 Favored Pre-proline 0 N--CA 1.438 -1.07 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 178.814 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -70.17 -9.02 25.01 Favored 'Trans proline' 0 C--N 1.351 0.709 0 C-N-CA 122.806 2.337 . . . . 0.0 114.213 -174.204 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -91.74 -15.34 54.94 Favored Glycine 0 C--N 1.261 -3.623 0 CA-C-N 113.988 -1.46 . . . . 0.0 111.234 178.901 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.568 ' HA ' ' O ' ' A' ' 26' ' ' THR . 82.9 m -118.7 125.29 49.35 Favored 'General case' 0 N--CA 1.415 -2.195 0 CA-C-O 121.639 0.733 . . . . 0.0 110.795 -177.687 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 8.1 m -101.88 156.61 17.42 Favored 'General case' 0 C--N 1.293 -1.871 0 C-N-CA 124.666 1.187 . . . . 0.0 108.521 -176.734 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 51.8 t -88.64 119.64 29.3 Favored 'General case' 0 C--N 1.297 -1.707 0 CA-C-O 121.503 0.668 . . . . 0.0 111.851 -176.696 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 21.1 t -124.76 75.69 1.45 Allowed 'General case' 0 N--CA 1.417 -2.097 0 N-CA-C 103.541 -2.763 . . . . 0.0 103.541 171.11 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.485 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 57.2 t90 -38.0 135.79 0.81 Allowed Pre-proline 0 N--CA 1.436 -1.125 0 C-N-CA 126.063 1.745 . . . . 0.0 113.058 -170.809 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.485 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 1.2 Cg_endo -91.47 9.54 61.59 Favored 'Cis proline' 0 CA--C 1.536 0.618 0 C-N-CA 122.862 -1.724 . . . . 0.0 114.958 3.426 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.442 HG12 HG22 ' A' ' 7' ' ' THR . 25.3 m -113.86 158.09 14.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 C-N-CA 120.102 -0.639 . . . . 0.0 111.725 -175.442 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.5 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 53.4 m -96.86 143.06 28.12 Favored 'General case' 0 N--CA 1.388 -3.528 0 CA-C-O 121.838 0.828 . . . . 0.0 110.442 173.954 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.568 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 7.9 p -128.19 -170.13 2.19 Favored 'General case' 0 C--N 1.273 -2.742 0 CA-C-N 114.466 -1.243 . . . . 0.0 110.994 -177.558 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 19.1 mtm180 . . . . . 0 N--CA 1.381 -3.914 0 CA-C-O 121.459 0.647 . . . . 0.0 110.77 -169.179 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 99.1 m . . . . . 0 N--CA 1.444 -0.737 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -87.64 9.83 72.24 Favored Glycine 0 C--N 1.314 -0.671 0 N-CA-C 110.581 -1.008 . . . . 0.0 110.581 178.459 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.47 ' HB2' ' HB2' ' A' ' 25' ' ' CYS . 6.2 mm-40 -86.38 154.16 21.39 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 124.14 0.976 . . . . 0.0 108.735 -179.64 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 9.2 p -126.82 153.94 44.97 Favored 'General case' 0 N--CA 1.41 -2.452 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 174.062 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.467 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 25.1 p -133.94 40.38 3.08 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-O 120.92 0.391 . . . . 0.0 110.862 -175.825 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 18.7 t -56.48 -29.17 28.29 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.182 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.345 -179.075 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -79.66 -17.19 76.0 Favored Glycine 0 N--CA 1.445 -0.7 0 CA-C-N 115.612 -0.722 . . . . 0.0 113.392 179.562 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 138.03 -32.07 2.39 Favored Glycine 0 N--CA 1.444 -0.828 0 C-N-CA 119.775 -1.202 . . . . 0.0 114.543 178.874 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 15.7 m -152.32 159.13 43.52 Favored 'General case' 0 C--N 1.31 -1.123 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 -176.925 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.467 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 32.6 m -89.95 165.66 13.94 Favored 'General case' 0 C--N 1.285 -2.221 0 O-C-N 123.767 0.667 . . . . 0.0 109.599 -179.295 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -85.16 -48.98 8.61 Favored 'General case' 0 CA--C 1.503 -0.842 0 CA-C-O 120.884 0.373 . . . . 0.0 110.142 178.079 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 29.1 m -70.52 118.93 69.14 Favored Pre-proline 0 C--N 1.311 -1.077 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 175.914 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -72.35 -5.1 16.49 Favored 'Trans proline' 0 C--N 1.365 1.421 0 C-N-CA 123.134 2.556 . . . . 0.0 114.164 -173.534 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -90.42 -8.43 66.1 Favored Glycine 0 C--N 1.261 -3.606 0 CA-C-N 114.008 -1.451 . . . . 0.0 110.35 178.703 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.498 ' HB3' ' HB3' ' A' ' 25' ' ' CYS . 67.9 m -107.98 127.39 53.72 Favored 'General case' 0 N--CA 1.409 -2.512 0 CA-C-O 121.41 0.624 . . . . 0.0 110.663 -178.464 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 6.3 m -90.16 148.63 22.85 Favored 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 107.969 -1.122 . . . . 0.0 107.969 -178.241 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 51.5 t -88.97 102.81 15.45 Favored 'General case' 0 N--CA 1.412 -2.332 0 CA-C-O 121.501 0.667 . . . . 0.0 111.183 -178.977 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.1 p -105.65 64.89 0.7 Allowed 'General case' 0 C--N 1.288 -2.097 0 N-CA-C 106.225 -1.768 . . . . 0.0 106.225 172.244 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.44 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 56.1 t90 -35.74 134.31 0.52 Allowed Pre-proline 0 N--CA 1.443 -0.821 0 C-N-CA 127.358 2.263 . . . . 0.0 113.586 -169.652 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.44 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 1.5 Cg_endo -91.28 10.01 61.09 Favored 'Cis proline' 0 C--N 1.323 -0.777 0 C-N-CA 122.823 -1.741 . . . . 0.0 114.188 2.474 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.9 m -110.81 150.0 13.44 Favored 'Isoleucine or valine' 0 C--O 1.21 -1.019 0 C-N-CA 120.212 -0.595 . . . . 0.0 111.846 -176.426 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.498 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 69.0 m -92.93 141.29 28.58 Favored 'General case' 0 N--CA 1.408 -2.539 0 CA-C-O 121.44 0.638 . . . . 0.0 112.45 178.808 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.455 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 1.7 p -117.83 -177.18 3.19 Favored 'General case' 0 C--N 1.292 -1.903 0 CA-C-N 115.016 -0.993 . . . . 0.0 108.526 175.534 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 4.9 ppt_? . . . . . 0 N--CA 1.387 -3.602 0 CA-C-N 119.669 1.122 . . . . 0.0 112.298 -176.521 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.422 ' SG ' ' HB3' ' A' ' 27' ' ' ARG . 63.4 m . . . . . 0 N--CA 1.443 -0.794 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -89.21 16.62 55.33 Favored Glycine 0 C--N 1.315 -0.608 0 N-CA-C 110.201 -1.16 . . . . 0.0 110.201 178.408 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.466 ' HB2' ' HB2' ' A' ' 25' ' ' CYS . 7.8 mm-40 -91.53 151.44 20.75 Favored 'General case' 0 N--CA 1.425 -1.699 0 C-N-CA 124.433 1.093 . . . . 0.0 110.153 -179.403 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 17.2 p -126.4 152.27 46.57 Favored 'General case' 0 N--CA 1.405 -2.675 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 174.746 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 24.7 p -130.37 37.67 3.84 Favored 'General case' 0 C--N 1.301 -1.513 0 CA-C-O 121.153 0.501 . . . . 0.0 110.934 -175.986 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 25.7 t -58.46 -37.56 64.89 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.13 0 CA-C-N 114.928 -1.033 . . . . 0.0 109.835 -178.468 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -79.18 1.81 73.62 Favored Glycine 0 CA--C 1.524 0.602 0 CA-C-N 115.55 -0.75 . . . . 0.0 113.608 -179.908 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 124.65 -28.8 5.14 Favored Glycine 0 N--CA 1.44 -1.053 0 C-N-CA 119.956 -1.116 . . . . 0.0 114.168 176.657 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 12.4 t -157.33 172.7 18.14 Favored 'General case' 0 N--CA 1.426 -1.636 0 CA-C-N 117.566 0.683 . . . . 0.0 109.324 -176.641 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 33.4 m -98.81 164.21 12.31 Favored 'General case' 0 C--N 1.276 -2.604 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 -178.581 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 14.6 m-80 -85.23 -42.01 15.07 Favored 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 107.261 -1.385 . . . . 0.0 107.261 178.909 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 14.3 m -77.9 114.74 44.36 Favored Pre-proline 0 N--CA 1.422 -1.868 0 CA-C-N 114.035 -1.439 . . . . 0.0 108.685 177.52 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -73.43 -0.67 9.56 Favored 'Trans proline' 0 N--CA 1.483 0.861 0 C-N-CA 123.662 2.908 . . . . 0.0 113.536 -174.538 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -96.4 -11.83 52.98 Favored Glycine 0 C--N 1.261 -3.6 0 CA-C-N 113.985 -1.462 . . . . 0.0 111.15 177.843 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.404 ' HB3' ' HB3' ' A' ' 25' ' ' CYS . 76.2 m -103.91 127.96 51.41 Favored 'General case' 0 N--CA 1.419 -2.019 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 179.446 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 8.8 m -90.44 153.51 20.34 Favored 'General case' 0 C--N 1.288 -2.093 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 -176.229 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 52.8 t -89.84 116.48 27.96 Favored 'General case' 0 C--N 1.284 -2.241 0 CA-C-O 121.657 0.742 . . . . 0.0 111.247 -177.959 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 34.4 t -119.35 57.7 0.89 Allowed 'General case' 0 C--N 1.29 -1.984 0 N-CA-C 104.568 -2.382 . . . . 0.0 104.568 176.099 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.412 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 42.5 t90 -29.62 131.86 0.22 Allowed Pre-proline 0 C--N 1.346 0.454 0 C-N-CA 127.261 2.224 . . . . 0.0 113.966 -170.564 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.412 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 2.4 Cg_endo -90.16 6.24 68.11 Favored 'Cis proline' 0 C--N 1.327 -0.56 0 C-N-CA 123.082 -1.632 . . . . 0.0 114.664 3.325 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 26.8 m -108.75 152.57 10.71 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 C-N-CA 120.181 -0.608 . . . . 0.0 112.175 -176.946 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.466 ' HB2' ' HB2' ' A' ' 6' ' ' GLU . 82.2 m -93.35 144.57 25.2 Favored 'General case' 0 N--CA 1.407 -2.622 0 CA-C-O 121.59 0.71 . . . . 0.0 112.188 178.246 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 3.1 p -116.17 179.14 4.08 Favored 'General case' 0 C--N 1.29 -2.016 0 C-N-CA 124.654 1.181 . . . . 0.0 110.049 178.985 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.422 ' HB3' ' SG ' ' A' ' 4' ' ' CYS . 0.0 OUTLIER . . . . . 0 N--CA 1.386 -3.672 0 CA-C-O 121.863 0.84 . . . . 0.0 111.856 -176.662 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.493 ' SG ' ' HG3' ' A' ' 27' ' ' ARG . 94.6 m . . . . . 0 N--CA 1.439 -0.988 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -94.58 17.35 59.26 Favored Glycine 0 N--CA 1.446 -0.692 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 176.723 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.415 ' HB2' ' HB2' ' A' ' 25' ' ' CYS . 17.6 mm-40 -90.08 148.44 23.02 Favored 'General case' 0 N--CA 1.42 -1.946 0 CA-C-N 113.888 -1.156 . . . . 0.0 107.884 179.035 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' THR . . . . . 0.41 HG22 HG12 ' A' ' 24' ' ' VAL . 3.7 p -127.77 146.81 50.47 Favored 'General case' 0 C--N 1.268 -2.948 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.57 -179.755 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 21.7 p -127.18 35.99 4.49 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-O 121.07 0.462 . . . . 0.0 110.337 -176.579 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 25.2 t -57.25 -35.12 47.6 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 CA-C-N 115.06 -0.973 . . . . 0.0 109.828 -179.42 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -93.12 4.91 75.05 Favored Glycine 0 N--CA 1.437 -1.283 0 CA-C-N 115.526 -0.761 . . . . 0.0 113.171 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 151.43 -79.94 0.2 Allowed Glycine 0 N--CA 1.443 -0.841 0 C-N-CA 119.431 -1.366 . . . . 0.0 114.594 178.942 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 5.1 m -149.75 164.74 34.46 Favored 'General case' 0 N--CA 1.435 -1.187 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 -172.46 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.406 ' SG ' ' HB3' ' A' ' 6' ' ' GLU . 91.7 m -98.58 149.04 23.17 Favored 'General case' 0 C--N 1.285 -2.2 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 175.364 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 89.1 m-20 -95.2 -0.37 53.23 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-O 121.437 0.637 . . . . 0.0 111.409 -179.002 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 56.2 m -85.73 111.19 35.79 Favored Pre-proline 0 N--CA 1.429 -1.509 0 N-CA-C 106.29 -1.744 . . . . 0.0 106.29 171.101 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -68.54 -12.29 34.33 Favored 'Trans proline' 0 C--N 1.36 1.181 0 C-N-CA 123.27 2.646 . . . . 0.0 115.664 -168.828 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -87.16 -15.74 62.02 Favored Glycine 1 C--N 1.251 -4.153 0 CA-C-N 114.65 -1.159 . . . . 0.0 110.571 178.813 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.601 ' HA ' ' O ' ' A' ' 26' ' ' THR . 58.1 m -105.63 125.48 51.03 Favored 'General case' 0 N--CA 1.414 -2.243 0 CA-C-N 115.098 -0.551 . . . . 0.0 110.076 -177.597 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 5.0 m -103.71 148.29 26.23 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 -179.021 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 46.7 t -78.91 125.57 29.54 Favored 'General case' 0 N--CA 1.413 -2.318 0 CA-C-O 122.113 0.958 . . . . 0.0 110.537 -178.262 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 37.5 m -130.66 59.26 1.67 Allowed 'General case' 0 N--CA 1.398 -3.06 0 N-CA-C 105.345 -2.094 . . . . 0.0 105.345 174.806 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.45 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 31.6 t90 -28.08 132.97 0.17 Allowed Pre-proline 0 C--O 1.246 0.877 0 C-N-CA 127.381 2.272 . . . . 0.0 114.348 -171.052 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.45 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 5.1 Cg_exo -88.48 6.94 68.4 Favored 'Cis proline' 0 CA--C 1.54 0.8 0 C-N-CA 123.044 -1.648 . . . . 0.0 114.631 2.328 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.41 HG12 HG22 ' A' ' 7' ' ' THR . 27.5 m -113.79 152.83 15.42 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.137 0 C-N-CA 120.329 -0.548 . . . . 0.0 112.464 -175.479 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.419 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 36.0 m -96.13 145.77 25.22 Favored 'General case' 0 N--CA 1.406 -2.631 0 CA-C-O 122.02 0.914 . . . . 0.0 112.716 176.035 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.601 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 19.6 p -121.51 -162.6 0.98 Allowed 'General case' 0 C--N 1.293 -1.883 0 CA-C-N 114.036 -1.438 . . . . 0.0 108.059 179.672 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.493 ' HG3' ' SG ' ' A' ' 4' ' ' CYS . 78.9 mtt180 . . . . . 0 N--CA 1.397 -3.083 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 177.927 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.447 ' O ' ' HB ' ' A' ' 32' ' ' VAL . . . . . . . . 0 N--CA 1.428 -1.884 0 N-CA-C 108.804 -1.719 . . . . 0.0 108.804 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -85.28 67.8 3.57 Favored Glycine 0 C--N 1.303 -1.27 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 178.501 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 80.67 -121.08 5.33 Favored Glycine 0 N--CA 1.439 -1.106 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 -176.209 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 77.7 m -141.86 108.11 5.25 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 174.081 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -82.61 8.48 62.0 Favored Glycine 0 C--N 1.308 -0.999 0 C-N-CA 121.432 -0.414 . . . . 0.0 113.168 -176.03 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.416 ' HG3' ' SG ' ' A' ' 25' ' ' CYS . 12.4 pt-20 -90.13 156.67 18.19 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 -179.393 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' THR . . . . . 0.415 ' HB ' HG23 ' A' ' 9' ' ' VAL . 5.8 p -107.55 161.7 14.61 Favored 'General case' 0 N--CA 1.409 -2.503 0 CA-C-O 120.739 0.305 . . . . 0.0 110.767 178.715 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.441 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 19.1 p -127.66 35.7 4.47 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -178.622 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.415 HG23 ' HB ' ' A' ' 7' ' ' THR . 29.6 t -52.36 -37.31 23.03 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.987 0 CA-C-N 114.81 -1.086 . . . . 0.0 111.628 -177.559 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -68.95 -37.52 83.52 Favored Glycine 0 N--CA 1.443 -0.846 0 C-N-CA 121.068 -0.587 . . . . 0.0 111.94 177.871 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 157.05 -20.53 0.43 Allowed Glycine 0 N--CA 1.44 -1.035 0 C-N-CA 119.472 -1.347 . . . . 0.0 115.483 177.646 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 27.6 m -155.89 164.86 37.97 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 -176.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 40.3 m -94.71 164.65 12.86 Favored 'General case' 0 C--N 1.283 -2.312 0 C-N-CA 123.688 0.795 . . . . 0.0 108.949 178.536 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 39.7 m-80 -93.5 -30.86 14.81 Favored 'General case' 0 C--N 1.302 -1.477 0 CA-C-O 121.163 0.506 . . . . 0.0 110.008 -177.595 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.503 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 20.6 m -90.13 120.28 69.22 Favored Pre-proline 0 C--N 1.304 -1.395 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 176.836 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -71.05 -3.56 13.11 Favored 'Trans proline' 0 N--CA 1.485 1.022 0 C-N-CA 123.258 2.639 . . . . 0.0 114.285 -175.626 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -89.0 -11.94 64.41 Favored Glycine 0 C--N 1.269 -3.19 0 CA-C-N 114.176 -1.375 . . . . 0.0 110.117 176.453 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.503 ' SG ' ' HB ' ' A' ' 15' ' ' THR . 34.5 m -103.68 144.67 31.15 Favored 'General case' 0 N--CA 1.423 -1.817 0 CA-C-N 114.761 -0.719 . . . . 0.0 109.25 -179.372 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 14.7 m -112.7 151.33 30.34 Favored 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 179.5 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 52.0 t -89.14 118.69 29.03 Favored 'General case' 0 C--N 1.277 -2.549 0 CA-C-O 121.531 0.682 . . . . 0.0 110.318 -179.34 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 63.0 m -116.54 63.81 0.71 Allowed 'General case' 0 N--CA 1.407 -2.579 0 N-CA-C 104.54 -2.393 . . . . 0.0 104.54 171.826 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.459 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 40.6 t90 -36.27 132.43 0.61 Allowed Pre-proline 0 N--CA 1.437 -1.082 0 C-N-CA 126.404 1.882 . . . . 0.0 113.592 -170.144 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.459 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 2.8 Cg_endo -90.31 13.56 53.0 Favored 'Cis proline' 0 CA--C 1.547 1.139 0 C-N-CA 122.882 -1.716 . . . . 0.0 114.849 2.039 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.404 HG12 HG22 ' A' ' 7' ' ' THR . 27.6 m -110.91 144.46 18.82 Favored 'Isoleucine or valine' 0 C--O 1.204 -1.316 0 N-CA-C 112.877 0.695 . . . . 0.0 112.877 -176.936 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.441 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 76.5 m -86.19 152.14 23.06 Favored 'General case' 0 N--CA 1.407 -2.578 0 O-C-N 121.164 -0.96 . . . . 0.0 110.693 176.287 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.429 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.6 p -130.83 -176.89 4.14 Favored 'General case' 0 C--N 1.291 -1.951 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 175.164 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 14.4 ttm180 -124.39 128.55 49.23 Favored 'General case' 0 N--CA 1.416 -2.172 0 N-CA-C 106.107 -1.812 . . . . 0.0 106.107 178.844 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -82.41 67.84 8.61 Favored 'General case' 0 C--N 1.27 -2.855 0 N-CA-C 114.335 1.235 . . . . 0.0 114.335 -172.73 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.12 5.2 52.65 Favored Glycine 0 CA--C 1.523 0.552 0 CA-C-N 115.833 -0.621 . . . . 0.0 114.285 175.08 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 54.2 mt -78.59 160.36 72.49 Favored Pre-proline 0 C--N 1.304 -1.37 0 C-N-CA 122.974 0.51 . . . . 0.0 110.793 -177.751 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.47 135.89 62.29 Favored 'Trans proline' 0 C--O 1.245 0.836 0 C-N-CA 122.3 2.0 . . . . 0.0 109.887 178.169 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.447 ' HB ' ' O ' ' A' ' 1' ' ' GLY . 5.4 m -95.89 107.06 19.12 Favored 'Isoleucine or valine' 0 N--CA 1.402 -2.867 0 CA-C-O 121.831 0.824 . . . . 0.0 112.992 -174.096 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 4.8 p . . . . . 0 C--N 1.306 -1.305 0 CA-C-O 122.079 0.942 . . . . 0.0 109.77 174.866 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.431 -1.688 0 N-CA-C 110.206 -1.158 . . . . 0.0 110.206 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -95.17 -42.41 3.75 Favored Glycine 0 N--CA 1.439 -1.119 0 C-N-CA 120.817 -0.706 . . . . 0.0 111.485 -179.25 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 144.85 -103.22 0.29 Allowed Glycine 0 N--CA 1.435 -1.401 0 N-CA-C 109.801 -1.32 . . . . 0.0 109.801 -178.229 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 81.4 m -127.58 108.39 10.74 Favored 'General case' 0 C--N 1.278 -2.529 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 175.856 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -76.13 7.12 31.35 Favored Glycine 0 C--N 1.31 -0.881 0 CA-C-N 115.877 -0.601 . . . . 0.0 112.853 -178.165 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -90.56 150.18 21.85 Favored 'General case' 0 N--CA 1.417 -2.122 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 178.823 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 6.6 p -109.7 154.17 23.25 Favored 'General case' 0 N--CA 1.392 -3.372 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.439 178.031 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.509 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 20.0 p -118.06 37.28 4.03 Favored 'General case' 0 CA--C 1.484 -1.575 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -177.807 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.8 t -55.71 -35.64 39.92 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.971 0 CA-C-N 115.002 -0.999 . . . . 0.0 109.912 -178.713 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -65.7 -26.26 71.99 Favored Glycine 0 N--CA 1.446 -0.693 0 CA-C-N 115.354 -0.839 . . . . 0.0 112.587 178.244 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 137.41 -22.01 3.23 Favored Glycine 0 N--CA 1.437 -1.249 0 C-N-CA 120.849 -0.691 . . . . 0.0 113.917 178.782 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 12.1 m -150.31 158.99 44.76 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 -175.624 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.509 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 61.0 m -95.23 155.94 16.52 Favored 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 176.467 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 40.1 m-80 -88.72 -18.61 27.47 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-O 121.178 0.513 . . . . 0.0 111.194 -178.613 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.554 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 34.0 m -101.14 124.77 40.31 Favored Pre-proline 0 C--N 1.297 -1.684 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 175.316 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -68.57 -13.68 37.85 Favored 'Trans proline' 0 N--CA 1.488 1.151 0 C-N-CA 122.974 2.449 . . . . 0.0 112.907 -178.2 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.429 ' H ' HG22 ' A' ' 15' ' ' THR . . . -84.55 -12.78 74.61 Favored Glycine 0 C--N 1.263 -3.525 0 CA-C-N 113.311 -1.768 . . . . 0.0 110.525 178.633 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.644 ' HA ' ' O ' ' A' ' 26' ' ' THR . 56.1 m -103.51 126.28 50.57 Favored 'General case' 0 N--CA 1.403 -2.792 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 -179.153 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.464 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 1.1 m -89.23 144.03 26.4 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 -177.77 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 53.7 t -88.14 103.26 15.59 Favored 'General case' 0 N--CA 1.421 -1.904 0 C-N-CA 119.602 -0.839 . . . . 0.0 109.887 177.764 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 14.7 m -104.82 58.36 0.69 Allowed 'General case' 0 C--N 1.285 -2.231 0 N-CA-C 104.473 -2.417 . . . . 0.0 104.473 174.933 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.444 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 42.1 t90 -33.98 132.9 0.38 Allowed Pre-proline 0 N--CA 1.441 -0.893 0 C-N-CA 127.133 2.173 . . . . 0.0 113.495 -169.808 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.444 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 4.5 Cg_exo -89.31 11.32 59.45 Favored 'Cis proline' 0 C--N 1.322 -0.859 0 C-N-CA 122.851 -1.729 . . . . 0.0 114.981 2.203 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 34.8 m -109.68 143.6 19.49 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.765 0 C-N-CA 120.166 -0.614 . . . . 0.0 112.538 -176.458 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.513 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 77.5 m -89.36 147.92 23.8 Favored 'General case' 0 N--CA 1.414 -2.273 0 O-C-N 121.7 -0.625 . . . . 0.0 110.984 177.21 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.644 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.9 p -132.74 -167.31 1.88 Allowed 'General case' 0 C--O 1.195 -1.796 0 C-N-CA 123.923 0.889 . . . . 0.0 109.206 178.069 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.411 ' HB3' ' HB2' ' A' ' 30' ' ' LEU . 98.8 mtt180 -121.96 136.85 54.95 Favored 'General case' 0 N--CA 1.399 -2.996 0 CA-C-N 119.048 0.84 . . . . 0.0 109.51 179.083 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 6.5 p30 -123.05 133.57 54.32 Favored 'General case' 0 C--N 1.288 -2.088 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 177.115 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 61.83 22.66 62.44 Favored Glycine 0 N--CA 1.462 0.377 0 O-C-N 123.483 0.489 . . . . 0.0 112.354 179.246 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.413 ' HA ' ' HD3' ' A' ' 31' ' ' PRO . 71.9 mt -129.59 157.43 76.5 Favored Pre-proline 0 N--CA 1.429 -1.508 0 CA-C-O 120.8 0.333 . . . . 0.0 111.693 -176.717 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.413 ' HD3' ' HA ' ' A' ' 30' ' ' LEU . 1.8 Cg_endo -73.43 137.7 25.97 Favored 'Trans proline' 0 N--CA 1.438 -1.753 0 C-N-CA 122.523 2.148 . . . . 0.0 109.021 174.409 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 24.2 t -96.81 104.06 15.42 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.068 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 -179.712 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 22.0 p . . . . . 0 C--N 1.267 -3.019 0 CA-C-N 114.689 -1.141 . . . . 0.0 108.878 178.986 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.906 0 N-CA-C 110.231 -1.148 . . . . 0.0 110.231 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -102.57 4.05 50.38 Favored Glycine 0 N--CA 1.433 -1.512 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 177.157 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 82.87 -58.27 5.04 Favored Glycine 0 CA--C 1.498 -1.023 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 -177.118 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.444 ' HB3' ' HG2' ' A' ' 6' ' ' GLU . 4.0 m -150.74 134.1 16.28 Favored 'General case' 0 N--CA 1.413 -2.275 0 C-N-CA 125.318 1.447 . . . . 0.0 108.181 175.207 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -88.92 -5.75 73.25 Favored Glycine 0 N--CA 1.439 -1.165 0 N-CA-C 110.123 -1.191 . . . . 0.0 110.123 177.83 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.444 ' HG2' ' HB3' ' A' ' 4' ' ' CYS . 13.0 pt-20 -78.77 147.93 33.16 Favored 'General case' 0 N--CA 1.428 -1.558 0 CA-C-N 114.92 -0.64 . . . . 0.0 109.438 179.689 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 32.2 p -105.01 155.09 19.29 Favored 'General case' 0 N--CA 1.401 -2.907 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.271 -177.178 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.624 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 30.0 p -118.8 41.62 2.98 Favored 'General case' 0 N--CA 1.428 -1.537 0 CA-C-O 121.614 0.721 . . . . 0.0 109.228 -179.104 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 35.4 t -56.57 -36.47 48.23 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.919 0 CA-C-N 114.933 -1.03 . . . . 0.0 111.075 -178.366 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -91.7 3.93 78.66 Favored Glycine 0 CA--C 1.519 0.312 0 N-CA-C 112.025 -0.43 . . . . 0.0 112.025 178.338 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 83.17 42.51 7.98 Favored Glycine 0 N--CA 1.44 -1.066 0 C-N-CA 121.753 -0.26 . . . . 0.0 112.847 179.231 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.3 t -155.09 151.03 27.84 Favored 'General case' 0 N--CA 1.431 -1.377 0 CA-C-O 121.286 0.565 . . . . 0.0 111.227 179.219 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.491 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 82.9 m -138.2 145.85 41.94 Favored 'General case' 0 C--N 1.286 -2.166 0 CA-C-N 113.812 -1.54 . . . . 0.0 108.105 178.696 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 31.6 m-80 -87.18 -39.25 15.66 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-O 121.61 0.719 . . . . 0.0 110.162 -178.505 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 16.0 m -78.52 120.85 82.55 Favored Pre-proline 0 C--N 1.305 -1.366 0 N-CA-C 108.785 -0.821 . . . . 0.0 108.785 178.208 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -72.98 -8.42 22.22 Favored 'Trans proline' 0 C--N 1.365 1.425 0 C-N-CA 122.802 2.335 . . . . 0.0 113.127 -175.501 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -92.97 -6.66 63.21 Favored Glycine 0 C--N 1.265 -3.369 0 CA-C-N 113.45 -1.705 . . . . 0.0 109.881 177.725 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.512 ' HA ' ' O ' ' A' ' 26' ' ' THR . 98.7 m -109.57 125.93 53.05 Favored 'General case' 0 N--CA 1.401 -2.898 0 CA-C-O 122.532 1.158 . . . . 0.0 111.106 179.202 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 3.5 m -100.09 153.23 19.39 Favored 'General case' 0 N--CA 1.401 -2.916 0 C-N-CA 127.153 2.181 . . . . 0.0 107.688 -175.283 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 53.9 t -85.27 117.59 24.3 Favored 'General case' 0 C--N 1.285 -2.198 0 CA-C-O 121.466 0.65 . . . . 0.0 110.364 179.001 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 21.3 t -124.55 74.88 1.36 Allowed 'General case' 0 C--N 1.282 -2.364 0 N-CA-C 103.197 -2.89 . . . . 0.0 103.197 172.47 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.497 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 42.9 t90 -39.56 133.88 1.28 Allowed Pre-proline 0 N--CA 1.431 -1.411 0 CA-C-N 113.858 -1.519 . . . . 0.0 113.096 -171.063 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.497 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 1.4 Cg_endo -92.38 15.27 46.72 Favored 'Cis proline' 0 CA--C 1.541 0.868 0 C-N-CA 122.874 -1.719 . . . . 0.0 114.695 1.958 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 30.9 m -115.63 146.62 19.82 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 N-CA-C 113.986 1.106 . . . . 0.0 113.986 -175.696 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.624 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 70.0 m -83.8 132.93 34.79 Favored 'General case' 0 N--CA 1.402 -2.846 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 173.309 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.512 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 2.5 p -135.55 -176.57 4.33 Favored 'General case' 0 C--O 1.182 -2.485 0 C-N-CA 124.057 0.943 . . . . 0.0 108.654 -179.779 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.432 ' HB3' ' HB2' ' A' ' 30' ' ' LEU . 57.2 mtp180 -114.72 107.06 14.96 Favored 'General case' 0 N--CA 1.407 -2.585 0 CA-C-N 119.515 1.052 . . . . 0.0 110.009 -177.407 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 20.4 p-10 -68.67 127.75 34.18 Favored 'General case' 0 C--N 1.313 -0.993 0 N-CA-C 111.627 0.232 . . . . 0.0 111.627 179.218 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 60.7 25.94 64.23 Favored Glycine 0 N--CA 1.46 0.287 0 CA-C-N 116.008 -0.542 . . . . 0.0 113.551 175.61 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.432 ' HB2' ' HB3' ' A' ' 27' ' ' ARG . 32.8 mt -125.56 145.66 52.02 Favored Pre-proline 0 C--N 1.301 -1.52 0 N-CA-C 111.923 0.342 . . . . 0.0 111.923 -175.674 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 30' ' ' LEU . 73.9 Cg_exo -49.99 138.24 35.41 Favored 'Trans proline' 0 C--O 1.246 0.912 0 C-N-CA 124.149 3.233 . . . . 0.0 113.335 178.719 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.3 p -70.03 120.74 18.3 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.665 0 CA-C-O 122.231 1.015 . . . . 0.0 112.461 -177.613 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 5.0 t . . . . . 0 C--N 1.281 -2.383 0 CA-C-N 114.101 -1.409 . . . . 0.0 109.828 175.457 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.493 -1.308 0 N-CA-C 110.424 -1.071 . . . . 0.0 110.424 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 147.34 127.97 1.8 Allowed Glycine 0 N--CA 1.42 -2.419 0 N-CA-C 108.889 -1.684 . . . . 0.0 108.889 -177.211 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -76.16 -94.07 0.18 Allowed Glycine 0 N--CA 1.436 -1.308 0 C-N-CA 120.483 -0.865 . . . . 0.0 111.984 -179.53 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 73.2 m -131.02 134.96 47.17 Favored 'General case' 0 C--N 1.29 -2.002 0 N-CA-C 109.665 -0.495 . . . . 0.0 109.665 -179.017 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -88.41 16.9 51.51 Favored Glycine 0 C--N 1.315 -0.612 0 N-CA-C 110.741 -0.944 . . . . 0.0 110.741 177.65 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.437 ' HB2' ' HB2' ' A' ' 25' ' ' CYS . 6.0 mm-40 -90.35 150.63 21.81 Favored 'General case' 0 N--CA 1.432 -1.354 0 C-N-CA 124.018 0.927 . . . . 0.0 109.881 -178.817 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 7.1 p -124.58 151.94 44.15 Favored 'General case' 0 N--CA 1.411 -2.384 0 CA-C-N 116.186 -0.461 . . . . 0.0 109.869 176.025 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.497 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 27.0 p -130.9 41.12 3.4 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-O 121.446 0.641 . . . . 0.0 109.989 -176.507 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 19.4 t -61.87 -32.94 55.64 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 114.965 -1.016 . . . . 0.0 109.533 -179.317 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -85.79 -1.61 87.08 Favored Glycine 0 N--CA 1.442 -0.943 0 CA-C-N 115.452 -0.795 . . . . 0.0 111.78 178.834 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 109.4 -10.14 33.18 Favored Glycine 0 N--CA 1.433 -1.516 0 N-CA-C 114.81 0.684 . . . . 0.0 114.81 176.059 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 1.1 m -137.55 152.57 49.59 Favored 'General case' 0 N--CA 1.43 -1.471 0 CA-C-N 118.773 1.286 . . . . 0.0 110.198 -174.708 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.497 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 82.8 m -106.92 136.39 46.84 Favored 'General case' 0 C--N 1.277 -2.546 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 174.469 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ASN . . . . . 0.41 ' HB2' ' OE2' ' A' ' 6' ' ' GLU . 33.9 m-80 -65.54 -44.44 86.85 Favored 'General case' 0 N--CA 1.475 0.778 0 CA-C-O 121.236 0.541 . . . . 0.0 109.816 176.884 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 55.0 m -83.33 112.48 39.35 Favored Pre-proline 0 N--CA 1.43 -1.447 0 N-CA-C 108.852 -0.796 . . . . 0.0 108.852 175.197 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -75.87 -1.39 11.34 Favored 'Trans proline' 0 C--N 1.359 1.096 0 C-N-CA 123.337 2.691 . . . . 0.0 113.781 -174.716 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -86.69 -10.64 72.57 Favored Glycine 0 C--N 1.27 -3.084 0 CA-C-N 113.971 -1.468 . . . . 0.0 110.356 177.14 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.445 ' HA ' ' O ' ' A' ' 26' ' ' THR . 49.9 m -105.92 133.5 50.54 Favored 'General case' 0 N--CA 1.419 -2.006 0 CA-C-N 114.552 -0.824 . . . . 0.0 109.537 -179.053 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.433 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 5.8 m -89.86 151.88 21.54 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 108.299 -1.001 . . . . 0.0 108.299 -177.693 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 50.5 t -88.52 104.71 17.07 Favored 'General case' 0 C--N 1.292 -1.93 0 CA-C-O 122.021 0.915 . . . . 0.0 111.331 179.604 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 42.6 t -107.51 65.59 0.65 Allowed 'General case' 0 C--N 1.285 -2.201 0 N-CA-C 104.22 -2.511 . . . . 0.0 104.22 173.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.444 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 56.7 t90 -36.24 132.63 0.61 Allowed Pre-proline 0 N--CA 1.439 -1.018 0 C-N-CA 125.884 1.673 . . . . 0.0 112.668 -172.171 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.444 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 2.2 Cg_endo -90.23 10.76 60.48 Favored 'Cis proline' 0 CA--C 1.546 1.117 0 C-N-CA 123.017 -1.66 . . . . 0.0 115.294 3.09 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 30.6 m -111.34 153.78 13.03 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.0 0 O-C-N 121.561 -0.712 . . . . 0.0 112.466 -176.611 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.476 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 68.3 m -92.89 135.37 34.2 Favored 'General case' 0 N--CA 1.397 -3.078 0 O-C-N 121.835 -0.541 . . . . 0.0 109.617 175.044 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.445 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 11.8 p -116.45 -174.21 2.52 Favored 'General case' 0 C--N 1.285 -2.23 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.836 -179.558 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.437 ' HB2' ' HB2' ' A' ' 30' ' ' LEU . 0.0 OUTLIER -112.69 149.59 32.68 Favored 'General case' 0 N--CA 1.383 -3.784 0 CA-C-O 121.523 0.677 . . . . 0.0 110.901 -176.79 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -136.14 129.69 32.15 Favored 'General case' 0 C--N 1.266 -3.053 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 174.667 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.13 -33.58 1.09 Allowed Glycine 0 CA--C 1.533 1.205 0 N-CA-C 113.894 0.318 . . . . 0.0 113.894 179.285 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.437 ' HB2' ' HB2' ' A' ' 27' ' ' ARG . 55.9 mt -57.76 142.26 78.63 Favored Pre-proline 0 C--N 1.321 -0.648 0 C-N-CA 124.701 1.2 . . . . 0.0 113.465 -177.703 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_endo -69.27 148.27 67.88 Favored 'Trans proline' 0 N--CA 1.445 -1.374 0 C-N-CA 122.797 2.331 . . . . 0.0 111.931 -176.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 25.7 t -69.51 113.31 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.49 0 N-CA-C 108.269 -1.011 . . . . 0.0 108.269 -179.497 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 14.9 m . . . . . 0 C--N 1.273 -2.737 0 CA-C-N 115.078 -0.965 . . . . 0.0 109.914 -175.789 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.425 -2.042 0 N-CA-C 108.384 -1.887 . . . . 0.0 108.384 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -89.94 -19.62 46.45 Favored Glycine 0 C--N 1.306 -1.086 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.277 -178.103 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -173.27 -139.48 2.9 Favored Glycine 0 CA--C 1.486 -1.729 0 N-CA-C 110.721 -0.952 . . . . 0.0 110.721 -179.025 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 71.9 m -142.02 135.24 29.05 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 178.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -94.93 -2.76 62.45 Favored Glycine 0 C--N 1.308 -1.005 0 C-N-CA 121.227 -0.511 . . . . 0.0 111.869 -176.521 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.443 ' O ' ' HB2' ' A' ' 25' ' ' CYS . 1.6 pm0 -83.82 141.74 31.13 Favored 'General case' 0 N--CA 1.426 -1.673 0 CA-C-O 121.488 0.661 . . . . 0.0 110.87 177.001 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' THR . . . . . 0.414 HG22 HG12 ' A' ' 24' ' ' VAL . 22.8 p -106.83 153.57 22.29 Favored 'General case' 0 N--CA 1.404 -2.732 0 CA-C-N 115.279 -0.873 . . . . 0.0 109.765 -179.603 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.467 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 19.5 p -122.01 37.59 4.33 Favored 'General case' 0 CA--C 1.492 -1.277 0 CA-C-O 121.389 0.614 . . . . 0.0 110.268 -177.876 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 16.0 t -60.06 -33.99 55.04 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.204 0 CA-C-N 114.734 -1.121 . . . . 0.0 109.636 -178.646 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -87.73 6.62 83.17 Favored Glycine 0 N--CA 1.439 -1.107 0 CA-C-N 115.258 -0.883 . . . . 0.0 113.087 179.647 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 142.18 -69.01 0.44 Allowed Glycine 0 N--CA 1.438 -1.189 0 C-N-CA 120.131 -1.033 . . . . 0.0 114.502 177.384 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 20.5 m -157.04 163.24 39.27 Favored 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 106.748 -1.575 . . . . 0.0 106.748 -174.851 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 98.3 m -94.76 158.49 15.48 Favored 'General case' 0 C--N 1.281 -2.384 0 CA-C-O 120.808 0.337 . . . . 0.0 110.493 178.58 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 87.2 m-20 -84.39 -26.73 28.15 Favored 'General case' 0 C--N 1.31 -1.144 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.845 -178.64 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 9.1 m -71.22 112.87 15.14 Favored Pre-proline 0 CA--C 1.556 1.175 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 177.243 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -70.8 -10.21 27.28 Favored 'Trans proline' 0 C--N 1.362 1.274 0 C-N-CA 123.293 2.662 . . . . 0.0 115.257 -172.101 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -93.3 -6.06 63.18 Favored Glycine 0 C--N 1.258 -3.753 0 CA-C-N 114.309 -1.314 . . . . 0.0 111.124 179.121 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.506 ' HA ' ' O ' ' A' ' 26' ' ' THR . 60.3 m -108.49 126.01 52.43 Favored 'General case' 0 N--CA 1.422 -1.834 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 1.4 m -95.16 143.9 26.22 Favored 'General case' 0 C--N 1.284 -2.268 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 -178.203 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 41.1 t -87.65 125.94 34.67 Favored 'General case' 0 C--N 1.285 -2.225 0 CA-C-O 121.593 0.711 . . . . 0.0 109.879 -179.873 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 6.4 t -132.22 71.41 1.47 Allowed 'General case' 0 N--CA 1.4 -2.973 0 N-CA-C 103.426 -2.805 . . . . 0.0 103.426 174.53 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.485 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 55.5 t90 -35.69 132.87 0.53 Allowed Pre-proline 0 N--CA 1.433 -1.297 0 C-N-CA 126.319 1.848 . . . . 0.0 112.95 -171.281 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.485 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 1.6 Cg_endo -91.95 10.59 58.15 Favored 'Cis proline' 0 CA--C 1.539 0.729 0 C-N-CA 123.081 -1.633 . . . . 0.0 115.381 4.053 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.414 HG12 HG22 ' A' ' 7' ' ' THR . 34.1 m -118.56 150.03 20.88 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 C-N-CA 119.511 -0.875 . . . . 0.0 112.438 -175.177 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.467 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 64.5 m -95.66 148.56 22.41 Favored 'General case' 0 N--CA 1.398 -3.047 0 CA-C-O 121.704 0.764 . . . . 0.0 111.331 175.933 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.506 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 0.6 OUTLIER -135.47 -165.23 1.66 Allowed 'General case' 0 C--N 1.284 -2.242 0 CA-C-N 114.518 -1.219 . . . . 0.0 109.975 177.851 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.405 HH11 ' HD3' ' A' ' 27' ' ' ARG . 3.8 ptm180 -108.62 153.48 23.35 Favored 'General case' 0 N--CA 1.389 -3.491 0 CA-C-O 121.746 0.784 . . . . 0.0 110.554 -174.476 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 43.3 m-80 -78.32 -23.4 47.09 Favored 'General case' 0 C--N 1.28 -2.45 0 CA-C-N 114.564 -1.198 . . . . 0.0 108.738 174.634 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 106.37 43.4 1.48 Allowed Glycine 0 N--CA 1.429 -1.814 0 CA-C-N 114.111 -1.404 . . . . 0.0 111.213 -178.152 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 4.4 mp -76.43 166.02 48.26 Favored Pre-proline 0 C--O 1.249 1.04 0 N-CA-C 106.44 -1.689 . . . . 0.0 106.44 178.58 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_exo -46.23 136.37 14.72 Favored 'Trans proline' 0 C--N 1.376 1.999 0 C-N-CA 122.363 2.042 . . . . 0.0 109.707 178.846 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 26.8 t -68.34 112.25 3.19 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 CA-C-O 122.397 1.094 . . . . 0.0 113.374 -168.107 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 12.8 m . . . . . 0 C--N 1.282 -2.357 0 CA-C-N 113.428 -1.714 . . . . 0.0 107.162 174.371 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.497 -1.033 0 N-CA-C 109.946 -1.262 . . . . 0.0 109.946 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 84.5 -73.85 2.59 Favored Glycine 0 C--N 1.298 -1.533 0 N-CA-C 109.989 -1.244 . . . . 0.0 109.989 -175.121 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 153.14 -100.8 0.2 Allowed Glycine 0 N--CA 1.422 -2.258 0 C-N-CA 121.157 -0.544 . . . . 0.0 111.774 179.397 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 65.2 m -118.92 135.92 54.34 Favored 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 -179.231 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -96.25 14.72 64.06 Favored Glycine 0 C--N 1.314 -0.678 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 176.534 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.501 ' HB2' ' HB2' ' A' ' 25' ' ' CYS . 6.7 mm-40 -81.21 149.76 28.92 Favored 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 179.132 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 18.3 p -123.49 150.75 43.54 Favored 'General case' 0 N--CA 1.401 -2.914 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 177.198 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.499 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 30.1 p -127.22 44.85 2.83 Favored 'General case' 0 N--CA 1.427 -1.578 0 CA-C-O 121.231 0.539 . . . . 0.0 109.588 -177.103 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 38.8 t -57.62 -33.82 45.75 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.059 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.894 -178.37 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -81.09 -31.49 34.71 Favored Glycine 0 N--CA 1.444 -0.83 0 N-CA-C 110.803 -0.919 . . . . 0.0 110.803 175.474 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 124.84 14.89 3.31 Favored Glycine 0 N--CA 1.441 -1.006 0 C-N-CA 121.507 -0.378 . . . . 0.0 113.613 178.41 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 12.7 m -139.62 153.77 47.42 Favored 'General case' 0 N--CA 1.424 -1.727 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 -178.872 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.499 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 41.5 m -122.59 137.93 54.74 Favored 'General case' 0 C--N 1.274 -2.709 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 175.194 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -66.01 -52.44 49.24 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.043 178.188 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 32.8 m -73.39 112.53 16.32 Favored Pre-proline 0 CA--C 1.554 1.122 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 176.57 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -72.86 -4.64 15.74 Favored 'Trans proline' 0 C--N 1.36 1.178 0 C-N-CA 123.438 2.759 . . . . 0.0 114.868 -172.85 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -86.0 -14.77 66.37 Favored Glycine 0 C--N 1.257 -3.822 0 CA-C-N 114.388 -1.278 . . . . 0.0 110.358 177.416 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.541 ' HA ' ' O ' ' A' ' 26' ' ' THR . 22.0 m -103.95 129.94 51.54 Favored 'General case' 0 N--CA 1.419 -1.999 0 CA-C-N 114.952 -0.624 . . . . 0.0 109.658 -179.163 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 4.3 m -95.85 156.48 16.31 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 124.346 1.058 . . . . 0.0 108.151 -178.806 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 42.0 t -83.04 123.76 29.78 Favored 'General case' 0 N--CA 1.423 -1.809 0 CA-C-O 121.61 0.719 . . . . 0.0 110.987 -179.299 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 32.7 t -133.76 69.93 1.46 Allowed 'General case' 0 C--N 1.283 -2.306 0 N-CA-C 104.526 -2.398 . . . . 0.0 104.526 173.831 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.437 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 41.7 t90 -36.53 134.59 0.6 Allowed Pre-proline 0 N--CA 1.443 -0.821 0 C-N-CA 126.258 1.823 . . . . 0.0 113.93 -170.702 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.437 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 1.9 Cg_endo -90.12 8.83 65.17 Favored 'Cis proline' 0 N--CA 1.456 -0.705 0 C-N-CA 122.679 -1.8 . . . . 0.0 114.261 1.277 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 35.9 m -108.88 158.66 8.62 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.928 0 CA-C-O 121.415 0.626 . . . . 0.0 112.548 -175.876 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.501 ' HB2' ' HB2' ' A' ' 6' ' ' GLU . 84.1 m -95.41 135.52 36.94 Favored 'General case' 0 N--CA 1.405 -2.7 0 O-C-N 121.733 -0.604 . . . . 0.0 109.829 174.453 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.541 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 10.5 p -119.35 -169.46 1.76 Allowed 'General case' 0 C--N 1.286 -2.168 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.83 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 10.5 mtp-105 -110.77 165.04 12.16 Favored 'General case' 0 N--CA 1.392 -3.326 0 CA-C-O 121.878 0.847 . . . . 0.0 110.442 -177.447 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 22.7 p-10 -143.82 105.2 4.27 Favored 'General case' 0 C--N 1.272 -2.794 0 CA-C-N 113.705 -1.589 . . . . 0.0 109.56 177.435 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.08 33.84 69.92 Favored Glycine 0 C--N 1.316 -0.557 0 CA-C-N 115.752 -0.658 . . . . 0.0 112.458 179.429 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 45.7 mt -127.69 147.28 62.01 Favored Pre-proline 0 C--N 1.314 -0.975 0 N-CA-C 112.849 0.685 . . . . 0.0 112.849 -176.274 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_exo -60.78 148.08 93.11 Favored 'Trans proline' 0 C--O 1.247 0.929 0 C-N-CA 123.386 2.724 . . . . 0.0 110.881 176.264 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.4 p -81.81 115.81 25.01 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.737 0 CA-C-O 122.415 1.102 . . . . 0.0 111.467 -179.418 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 18.1 p . . . . . 0 C--N 1.277 -2.586 0 CA-C-N 113.738 -1.574 . . . . 0.0 111.387 -179.442 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.429 -1.81 0 N-CA-C 109.206 -1.557 . . . . 0.0 109.206 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -85.12 69.38 3.31 Favored Glycine 0 CA--C 1.495 -1.17 0 N-CA-C 110.145 -1.182 . . . . 0.0 110.145 177.362 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.417 ' HA3' ' HA ' ' A' ' 26' ' ' THR . . . 84.27 -107.84 3.04 Favored Glycine 0 N--CA 1.413 -2.848 0 N-CA-C 109.409 -1.476 . . . . 0.0 109.409 -175.947 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.722 ' SG ' ' HG3' ' A' ' 27' ' ' ARG . 78.0 m -133.16 146.73 51.82 Favored 'General case' 0 C--N 1.298 -1.653 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 176.812 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -81.57 -3.47 90.61 Favored Glycine 0 C--N 1.308 -1.007 0 C-N-CA 120.99 -0.624 . . . . 0.0 111.944 -179.501 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -89.62 160.06 16.84 Favored 'General case' 0 N--CA 1.437 -1.096 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 179.602 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' THR . . . . . 0.526 ' HB ' HG23 ' A' ' 9' ' ' VAL . 38.0 p -113.88 164.07 14.25 Favored 'General case' 0 N--CA 1.406 -2.647 0 CA-C-O 121.109 0.481 . . . . 0.0 112.271 -174.83 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.495 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 26.1 p -131.41 33.8 4.03 Favored 'General case' 0 N--CA 1.426 -1.663 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 178.034 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.526 HG23 ' HB ' ' A' ' 7' ' ' THR . 21.9 t -57.7 -35.52 51.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 114.74 -1.118 . . . . 0.0 110.01 -178.766 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -82.27 -4.77 90.08 Favored Glycine 0 N--CA 1.444 -0.782 0 CA-C-N 115.684 -0.689 . . . . 0.0 113.063 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 128.46 -24.98 4.87 Favored Glycine 0 N--CA 1.444 -0.771 0 C-N-CA 120.231 -0.985 . . . . 0.0 114.344 177.497 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 15.3 t -156.89 173.03 17.61 Favored 'General case' 0 N--CA 1.431 -1.402 0 CA-C-N 118.277 1.039 . . . . 0.0 110.446 -175.689 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 57.5 m -101.77 175.88 5.41 Favored 'General case' 0 C--N 1.276 -2.612 0 CA-C-N 114.527 -1.215 . . . . 0.0 109.977 -175.82 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 51.0 m-80 -97.88 -38.32 9.48 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.046 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.422 HG22 ' H ' ' A' ' 17' ' ' GLY . 33.9 m -90.03 126.12 58.28 Favored Pre-proline 0 N--CA 1.429 -1.524 0 CA-C-N 115.505 -0.77 . . . . 0.0 108.979 178.33 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -72.33 -2.34 11.55 Favored 'Trans proline' 0 C--N 1.358 1.043 0 C-N-CA 122.693 2.262 . . . . 0.0 113.416 -177.383 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.422 ' H ' HG22 ' A' ' 15' ' ' THR . . . -93.07 -10.09 60.08 Favored Glycine 0 C--N 1.271 -3.054 0 CA-C-N 113.836 -1.529 . . . . 0.0 110.311 177.176 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.577 ' HB3' ' HB3' ' A' ' 25' ' ' CYS . 80.3 m -104.09 132.37 50.4 Favored 'General case' 0 N--CA 1.42 -1.926 0 CA-C-N 114.96 -0.62 . . . . 0.0 109.472 179.478 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 7.5 m -101.49 156.43 17.47 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 -179.736 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 44.4 t -88.16 123.97 33.35 Favored 'General case' 0 N--CA 1.418 -2.066 0 CA-C-O 121.409 0.623 . . . . 0.0 109.961 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 8.8 t -130.82 62.83 1.6 Allowed 'General case' 0 C--N 1.282 -2.34 0 N-CA-C 103.463 -2.792 . . . . 0.0 103.463 175.121 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.489 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 35.5 t90 -33.28 135.78 0.29 Allowed Pre-proline 0 C--O 1.243 0.732 0 C-N-CA 127.827 2.451 . . . . 0.0 113.821 -170.335 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.489 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 4.4 Cg_exo -88.4 4.98 69.71 Favored 'Cis proline' 0 CA--C 1.534 0.507 0 C-N-CA 123.004 -1.665 . . . . 0.0 114.812 2.183 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 34.1 m -107.82 157.66 7.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 C-N-CA 120.26 -0.576 . . . . 0.0 111.913 -176.892 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.577 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 93.1 m -91.28 150.33 21.37 Favored 'General case' 0 N--CA 1.404 -2.77 0 CA-C-O 121.305 0.574 . . . . 0.0 111.086 177.063 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.518 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 16.7 p -130.9 -178.65 4.9 Favored 'General case' 0 N--CA 1.421 -1.895 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.624 179.765 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.722 ' HG3' ' SG ' ' A' ' 4' ' ' CYS . 34.4 mtt85 -120.71 120.12 34.78 Favored 'General case' 0 N--CA 1.414 -2.241 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 -177.798 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -79.72 97.44 6.58 Favored 'General case' 0 C--N 1.287 -2.135 0 CA-C-N 115.448 -0.796 . . . . 0.0 112.284 -177.238 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 60.81 44.21 98.29 Favored Glycine 0 C--N 1.331 0.25 0 CA-C-N 115.733 -0.667 . . . . 0.0 112.933 176.94 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.539 ' HB2' ' HB3' ' A' ' 27' ' ' ARG . 55.0 mt -119.35 157.81 50.38 Favored Pre-proline 0 C--N 1.298 -1.668 0 O-C-N 122.885 -0.185 . . . . 0.0 110.625 -177.529 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 77.1 Cg_exo -50.24 139.47 35.67 Favored 'Trans proline' 0 C--O 1.252 1.21 0 C-N-CA 123.963 3.108 . . . . 0.0 112.033 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.6 p -64.64 112.74 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.186 0 CA-C-O 122.576 1.179 . . . . 0.0 111.597 -177.781 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 6.5 m . . . . . 0 C--N 1.293 -1.848 0 CA-C-N 113.288 -1.778 . . . . 0.0 107.979 -179.201 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.667 0 N-CA-C 112.502 -0.239 . . . . 0.0 112.502 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 117.72 -34.73 4.38 Favored Glycine 0 N--CA 1.432 -1.626 0 N-CA-C 110.909 -0.876 . . . . 0.0 110.909 179.401 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 87.35 -79.71 1.76 Allowed Glycine 0 N--CA 1.435 -1.407 0 N-CA-C 111.381 -0.687 . . . . 0.0 111.381 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 73.7 m -137.33 138.43 39.96 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 178.941 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -77.78 -6.24 86.94 Favored Glycine 0 C--N 1.312 -0.778 0 C-N-CA 121.212 -0.518 . . . . 0.0 113.163 -177.262 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -86.14 146.94 26.37 Favored 'General case' 0 C--N 1.308 -1.222 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 -179.398 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' THR . . . . . 0.458 HG22 HG12 ' A' ' 24' ' ' VAL . 24.9 p -104.39 161.43 14.08 Favored 'General case' 0 N--CA 1.414 -2.255 0 CA-C-O 121.013 0.435 . . . . 0.0 111.891 -179.401 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.471 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 9.2 p -126.63 34.72 4.75 Favored 'General case' 0 CA--C 1.492 -1.255 0 CA-C-O 121.271 0.558 . . . . 0.0 110.27 -178.858 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.459 ' HA ' ' NE1' ' A' ' 22' ' ' TRP . 5.7 t -65.43 -28.79 45.27 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-N 115.273 -0.876 . . . . 0.0 109.46 -178.698 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -79.76 -15.83 78.58 Favored Glycine 0 C--O 1.241 0.564 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.512 177.814 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 125.98 -18.39 6.63 Favored Glycine 0 N--CA 1.436 -1.361 0 C-N-CA 120.519 -0.848 . . . . 0.0 115.217 175.695 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.5 m -145.67 158.14 43.88 Favored 'General case' 0 N--CA 1.437 -1.092 0 CA-C-N 118.764 1.282 . . . . 0.0 108.172 -175.341 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 62.7 m -99.51 170.85 8.32 Favored 'General case' 0 C--N 1.281 -2.372 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 175.884 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 26.9 m-80 -101.37 -18.82 15.87 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.468 0.651 . . . . 0.0 110.621 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.576 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 29.2 m -105.58 124.83 35.0 Favored Pre-proline 0 C--N 1.293 -1.888 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 175.561 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -73.29 -3.26 13.38 Favored 'Trans proline' 0 N--CA 1.486 1.078 0 C-N-CA 122.744 2.296 . . . . 0.0 113.098 -177.735 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.409 ' H ' HG22 ' A' ' 15' ' ' THR . . . -94.89 -8.03 59.47 Favored Glycine 0 C--N 1.27 -3.134 0 CA-C-N 113.38 -1.736 . . . . 0.0 109.839 176.419 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.621 ' HA ' ' O ' ' A' ' 26' ' ' THR . 85.0 m -106.12 125.75 51.37 Favored 'General case' 0 N--CA 1.419 -1.998 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.168 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 7.4 m -101.55 160.42 14.46 Favored 'General case' 0 C--N 1.286 -2.168 0 N-CA-C 107.483 -1.302 . . . . 0.0 107.483 -178.839 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 42.1 t -93.11 122.58 35.63 Favored 'General case' 0 N--CA 1.419 -2.013 0 CA-C-O 121.305 0.574 . . . . 0.0 110.911 -177.352 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 49.3 m -123.99 67.69 1.04 Allowed 'General case' 0 N--CA 1.409 -2.483 0 N-CA-C 105.03 -2.211 . . . . 0.0 105.03 171.644 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.465 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 50.4 t90 -37.27 133.69 0.73 Allowed Pre-proline 0 N--CA 1.435 -1.177 0 C-N-CA 126.091 1.757 . . . . 0.0 113.23 -170.157 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 1.9 Cg_endo -89.52 7.07 68.27 Favored 'Cis proline' 0 CA--C 1.55 1.299 0 C-N-CA 122.924 -1.698 . . . . 0.0 115.905 3.32 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.458 HG12 HG22 ' A' ' 7' ' ' THR . 33.3 m -109.52 151.47 11.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 O-C-N 121.581 -0.7 . . . . 0.0 112.421 -175.982 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.507 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 71.1 m -86.52 147.34 26.0 Favored 'General case' 0 N--CA 1.405 -2.68 0 CA-C-O 121.297 0.57 . . . . 0.0 109.954 175.395 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.621 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 31.0 p -132.6 -169.99 2.35 Favored 'General case' 0 C--N 1.294 -1.829 0 C-N-CA 122.758 0.423 . . . . 0.0 110.257 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 95.9 mtt180 -113.61 148.7 35.73 Favored 'General case' 0 N--CA 1.391 -3.396 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 -178.266 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -125.67 135.98 52.72 Favored 'General case' 0 C--N 1.276 -2.612 0 CA-C-N 114.47 -1.241 . . . . 0.0 109.144 179.804 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 60.57 27.41 66.06 Favored Glycine 0 N--CA 1.462 0.4 0 O-C-N 123.369 0.418 . . . . 0.0 112.446 177.024 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 55.7 mt -129.45 164.38 40.09 Favored Pre-proline 0 C--N 1.299 -1.607 0 CA-C-N 115.566 -0.317 . . . . 0.0 110.807 -175.629 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_exo -54.47 136.62 70.39 Favored 'Trans proline' 0 C--O 1.25 1.121 0 C-N-CA 122.976 2.45 . . . . 0.0 109.76 175.574 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 35.7 t -73.14 115.77 14.47 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.274 0 CA-C-O 122.371 1.081 . . . . 0.0 110.633 -173.831 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 9.7 m . . . . . 0 C--N 1.268 -2.95 0 CA-C-N 113.184 -1.826 . . . . 0.0 107.187 -179.519 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.426 -1.98 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -97.72 -17.65 30.04 Favored Glycine 0 C--N 1.306 -1.132 0 N-CA-C 111.028 -0.829 . . . . 0.0 111.028 179.125 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -150.6 -172.88 20.2 Favored Glycine 0 N--CA 1.423 -2.198 0 N-CA-C 108.857 -1.697 . . . . 0.0 108.857 179.598 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 88.2 m -103.66 124.21 48.42 Favored 'General case' 0 C--N 1.292 -1.904 0 C-N-CA 119.613 -0.835 . . . . 0.0 112.323 -179.349 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -89.88 23.41 20.43 Favored Glycine 0 C--N 1.316 -0.554 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 175.555 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.491 ' HB2' ' HB2' ' A' ' 25' ' ' CYS . 8.3 mm-40 -90.38 156.76 18.01 Favored 'General case' 0 N--CA 1.437 -1.109 0 C-N-CA 124.181 0.992 . . . . 0.0 110.005 -177.983 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 21.8 p -126.16 153.54 44.45 Favored 'General case' 0 N--CA 1.41 -2.443 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 174.23 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.428 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 21.6 p -124.79 33.75 5.15 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.781 -0.574 . . . . 0.0 111.005 -178.442 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.431 ' HA ' ' NE1' ' A' ' 22' ' ' TRP . 22.3 t -62.03 -35.98 71.57 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.867 0 CA-C-N 114.786 -1.097 . . . . 0.0 109.193 -179.835 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -71.33 -16.06 75.23 Favored Glycine 0 C--O 1.22 -0.733 0 CA-C-N 115.094 -0.957 . . . . 0.0 112.336 178.747 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 132.66 -23.65 3.97 Favored Glycine 0 N--CA 1.435 -1.428 0 C-N-CA 120.242 -0.98 . . . . 0.0 113.696 177.874 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 20.4 m -157.08 162.27 39.47 Favored 'General case' 0 C--N 1.31 -1.116 0 N-CA-C 107.114 -1.439 . . . . 0.0 107.114 -176.483 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 52.5 m -86.45 140.15 30.24 Favored 'General case' 0 C--N 1.283 -2.301 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 177.163 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 44.8 m-80 -72.0 -44.21 63.83 Favored 'General case' 0 C--N 1.315 -0.93 0 C-N-CA 120.746 -0.382 . . . . 0.0 110.892 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.483 HG21 HG23 ' A' ' 32' ' ' VAL . 27.2 m -76.34 121.08 84.27 Favored Pre-proline 0 CA--C 1.556 1.195 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 172.928 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_endo -71.24 -1.48 9.69 Favored 'Trans proline' 0 C--N 1.36 1.169 0 C-N-CA 123.551 2.834 . . . . 0.0 114.683 -173.45 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -95.06 2.32 65.9 Favored Glycine 0 C--N 1.261 -3.619 0 CA-C-N 114.506 -1.225 . . . . 0.0 112.003 -179.122 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 32.5 m -112.03 140.77 46.43 Favored 'General case' 0 N--CA 1.426 -1.674 0 CA-C-O 120.908 0.385 . . . . 0.0 111.674 -175.253 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 3.2 m -89.91 145.19 25.31 Favored 'General case' 0 C--N 1.315 -0.909 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 179.324 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 43.2 t -93.09 105.43 17.53 Favored 'General case' 0 C--N 1.29 -1.991 0 C-N-CA 120.073 -0.651 . . . . 0.0 110.369 177.547 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 2.3 p -113.97 65.69 0.66 Allowed 'General case' 0 C--N 1.278 -2.538 0 N-CA-C 106.274 -1.751 . . . . 0.0 106.274 173.444 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.47 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 49.2 t90 -34.83 135.34 0.41 Allowed Pre-proline 0 N--CA 1.446 -0.628 0 C-N-CA 126.985 2.114 . . . . 0.0 113.512 -169.933 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.47 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 1.8 Cg_endo -89.93 2.42 68.04 Favored 'Cis proline' 0 C--N 1.329 -0.499 0 C-N-CA 122.929 -1.696 . . . . 0.0 114.725 2.875 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.1 m -108.1 146.35 14.13 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 C-N-CA 120.259 -0.576 . . . . 0.0 111.95 -175.655 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.491 ' HB2' ' HB2' ' A' ' 6' ' ' GLU . 72.3 m -93.27 141.59 28.27 Favored 'General case' 0 N--CA 1.396 -3.162 0 CA-C-O 121.4 0.619 . . . . 0.0 111.5 179.341 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 1.4 p -109.14 -169.61 1.51 Allowed 'General case' 0 C--N 1.283 -2.313 0 CA-C-N 114.736 -1.12 . . . . 0.0 108.683 176.079 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.547 ' HG2' ' H ' ' A' ' 29' ' ' GLY . 39.7 ttp180 -117.45 137.11 52.73 Favored 'General case' 0 N--CA 1.404 -2.73 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 -178.478 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ASN . . . . . 0.545 ' HB2' ' CD2' ' A' ' 30' ' ' LEU . 25.1 m-80 -76.61 -14.99 59.94 Favored 'General case' 0 C--N 1.291 -1.955 0 CA-C-O 121.568 0.699 . . . . 0.0 110.537 -178.477 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.547 ' H ' ' HG2' ' A' ' 27' ' ' ARG . . . 118.89 -21.16 9.69 Favored Glycine 0 C--N 1.294 -1.787 0 CA-C-N 115.195 -0.911 . . . . 0.0 111.234 -175.664 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.561 ' H ' HD23 ' A' ' 30' ' ' LEU . 2.6 pt? -75.42 150.33 84.76 Favored Pre-proline 0 C--N 1.323 -0.547 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 174.223 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_exo -66.17 137.13 46.8 Favored 'Trans proline' 0 CA--C 1.481 -2.137 0 C-N-CA 123.168 2.578 . . . . 0.0 115.034 -172.797 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.483 HG23 HG21 ' A' ' 15' ' ' THR . 14.6 p -133.36 160.4 42.37 Favored 'Isoleucine or valine' 0 N--CA 1.388 -3.543 0 CA-C-N 112.102 -2.317 . . . . 0.0 104.747 175.702 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 22.7 m . . . . . 0 C--N 1.265 -3.104 0 CA-C-O 121.351 0.596 . . . . 0.0 110.296 175.895 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.412 ' O ' HG23 ' A' ' 32' ' ' VAL . . . . . . . . 0 N--CA 1.415 -2.757 0 N-CA-C 107.033 -2.427 . . . . 0.0 107.033 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -63.06 -39.09 97.61 Favored Glycine 0 C--N 1.314 -0.646 0 N-CA-C 111.254 -0.738 . . . . 0.0 111.254 -178.726 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -172.83 -168.2 33.81 Favored Glycine 0 N--CA 1.419 -2.49 0 N-CA-C 108.202 -1.959 . . . . 0.0 108.202 178.216 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 61.2 m -103.41 119.65 39.29 Favored 'General case' 0 C--N 1.29 -2.02 0 CA-C-N 117.929 0.864 . . . . 0.0 110.049 179.412 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -84.98 -4.45 87.01 Favored Glycine 0 N--CA 1.443 -0.882 0 CA-C-N 115.699 -0.682 . . . . 0.0 113.978 -175.219 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -86.5 169.45 12.81 Favored 'General case' 0 C--N 1.309 -1.185 0 C-N-CA 119.836 -0.746 . . . . 0.0 111.064 -179.637 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' THR . . . . . 0.42 HG22 HG12 ' A' ' 24' ' ' VAL . 7.0 p -120.36 155.52 33.22 Favored 'General case' 0 N--CA 1.401 -2.911 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 178.402 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.513 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 13.4 p -119.06 37.2 4.2 Favored 'General case' 0 CA--C 1.484 -1.587 0 CA-C-O 121.043 0.449 . . . . 0.0 110.571 -176.648 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.7 t -57.69 -34.2 47.02 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 CA-C-N 114.926 -1.034 . . . . 0.0 109.353 -179.612 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -70.62 -8.51 63.4 Favored Glycine 0 N--CA 1.436 -1.321 0 CA-C-N 114.964 -1.017 . . . . 0.0 113.557 179.172 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 144.21 -54.07 0.58 Allowed Glycine 0 N--CA 1.441 -0.979 0 C-N-CA 120.67 -0.776 . . . . 0.0 113.962 176.672 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 14.7 t -157.61 173.33 17.02 Favored 'General case' 0 N--CA 1.425 -1.72 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -176.226 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.513 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 35.6 m -96.21 137.29 35.49 Favored 'General case' 0 C--N 1.27 -2.867 0 CA-C-N 115.342 -0.844 . . . . 0.0 108.759 -178.158 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 40.8 m-80 -70.47 -47.74 59.13 Favored 'General case' 0 C--N 1.319 -0.755 0 O-C-N 123.199 0.312 . . . . 0.0 111.43 -179.168 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.405 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 42.3 m -69.91 119.56 72.2 Favored Pre-proline 0 N--CA 1.437 -1.079 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 178.774 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 15' ' ' THR . 22.0 Cg_exo -66.87 -9.82 26.14 Favored 'Trans proline' 0 C--N 1.36 1.134 0 C-N-CA 123.458 2.772 . . . . 0.0 113.927 -175.672 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -83.3 -17.27 67.12 Favored Glycine 0 C--N 1.265 -3.392 0 CA-C-N 113.787 -1.551 . . . . 0.0 110.412 177.252 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.493 ' HA ' ' O ' ' A' ' 26' ' ' THR . 47.8 m -108.55 126.68 53.2 Favored 'General case' 0 N--CA 1.416 -2.173 0 N-CA-C 108.096 -1.076 . . . . 0.0 108.096 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 6.8 m -101.22 148.04 25.57 Favored 'General case' 0 C--N 1.274 -2.701 0 N-CA-C 107.459 -1.311 . . . . 0.0 107.459 -175.914 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 50.3 t -90.78 106.27 18.4 Favored 'General case' 0 C--N 1.275 -2.653 0 CA-C-O 121.702 0.763 . . . . 0.0 110.662 -178.156 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 31.3 t -107.67 67.09 0.68 Allowed 'General case' 0 C--N 1.28 -2.426 0 N-CA-C 102.9 -3.0 . . . . 0.0 102.9 172.81 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.44 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 57.4 t90 -39.39 133.59 1.23 Allowed Pre-proline 0 N--CA 1.433 -1.286 0 CA-C-N 113.405 -1.725 . . . . 0.0 112.326 -171.356 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.44 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 1.9 Cg_endo -90.75 12.17 56.75 Favored 'Cis proline' 0 CA--C 1.543 0.967 0 C-N-CA 122.723 -1.782 . . . . 0.0 115.812 3.721 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.42 HG12 HG22 ' A' ' 7' ' ' THR . 21.0 m -110.66 146.86 15.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 119.071 0.851 . . . . 0.0 113.007 -176.419 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 90.9 m -86.53 140.64 29.71 Favored 'General case' 0 N--CA 1.401 -2.898 0 O-C-N 121.679 -0.638 . . . . 0.0 109.327 174.996 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.493 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 2.6 p -135.6 -177.3 4.61 Favored 'General case' 0 C--N 1.269 -2.92 0 CA-C-N 115.206 -0.907 . . . . 0.0 109.084 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 12.9 ttm180 -124.79 118.81 27.2 Favored 'General case' 0 N--CA 1.421 -1.89 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 176.883 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 34.8 p30 -69.8 7.04 0.97 Allowed 'General case' 0 C--N 1.285 -2.205 0 N-CA-C 114.865 1.431 . . . . 0.0 114.865 -172.846 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 116.92 -4.16 18.96 Favored Glycine 0 C--N 1.3 -1.428 0 C-N-CA 119.659 -1.258 . . . . 0.0 111.429 -177.533 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 28.2 mt -62.36 158.71 46.0 Favored Pre-proline 0 C--O 1.243 0.717 0 CA-C-O 119.35 -0.357 . . . . 0.0 111.034 174.703 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_exo -37.46 137.63 0.34 Allowed 'Trans proline' 0 C--N 1.362 1.278 0 C-N-CA 124.879 3.719 . . . . 0.0 115.472 -175.53 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.412 HG23 ' O ' ' A' ' 1' ' ' GLY . 3.4 p -80.91 99.49 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.782 0 CA-C-O 122.971 1.367 . . . . 0.0 111.172 -178.203 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 18.7 m . . . . . 0 C--N 1.271 -2.834 0 CA-C-N 113.28 -1.782 . . . . 0.0 107.263 179.091 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.441 -0.988 0 N-CA-C 110.597 -1.001 . . . . 0.0 110.597 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -142.32 -140.46 3.75 Favored Glycine 0 N--CA 1.415 -2.736 0 N-CA-C 109.959 -1.256 . . . . 0.0 109.959 177.884 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 107.68 -154.71 16.52 Favored Glycine 0 C--N 1.281 -2.477 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 -176.629 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 3.5 m -150.85 139.32 20.48 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 113.55 0.945 . . . . 0.0 113.55 -176.815 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -103.93 18.39 46.62 Favored Glycine 0 C--N 1.313 -0.739 0 N-CA-C 107.724 -2.15 . . . . 0.0 107.724 169.806 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 23.2 mm-40 -80.99 170.85 15.73 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 113.605 -1.298 . . . . 0.0 109.552 -178.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' THR . . . . . 0.457 ' HB ' HG23 ' A' ' 9' ' ' VAL . 16.8 p -122.57 156.5 34.1 Favored 'General case' 0 N--CA 1.402 -2.827 0 CA-C-O 120.791 0.329 . . . . 0.0 111.062 178.825 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 20.5 p -128.22 38.24 4.03 Favored 'General case' 0 CA--C 1.491 -1.294 0 CA-C-O 121.41 0.624 . . . . 0.0 109.601 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.457 HG23 ' HB ' ' A' ' 7' ' ' THR . 11.1 t -58.62 -29.89 40.37 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.007 0 CA-C-N 114.426 -1.261 . . . . 0.0 110.709 -177.16 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -74.1 -22.11 78.24 Favored Glycine 0 N--CA 1.437 -1.256 0 CA-C-N 115.849 -0.614 . . . . 0.0 112.544 179.028 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 149.63 -36.55 0.99 Allowed Glycine 0 N--CA 1.438 -1.226 0 C-N-CA 120.207 -0.997 . . . . 0.0 113.863 179.672 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 8.8 t -158.3 173.65 16.36 Favored 'General case' 0 N--CA 1.423 -1.793 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 -178.429 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 63.2 m -89.75 150.54 22.25 Favored 'General case' 0 C--N 1.268 -2.937 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.134 -177.277 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 83.8 m-20 -90.43 -12.23 38.06 Favored 'General case' 0 C--N 1.308 -1.203 0 CA-C-O 121.177 0.513 . . . . 0.0 110.158 177.901 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 10.4 m -100.37 122.96 48.13 Favored Pre-proline 0 C--N 1.305 -1.335 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 176.945 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 96.6 Cg_endo -78.39 -1.85 11.97 Favored 'Trans proline' 0 N--CA 1.484 0.949 0 C-N-CA 123.232 2.621 . . . . 0.0 115.926 -169.186 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -102.5 0.02 49.84 Favored Glycine 0 C--N 1.261 -3.634 0 N-CA-C 110.001 -1.24 . . . . 0.0 110.001 178.221 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.44 ' HA ' ' O ' ' A' ' 26' ' ' THR . 56.1 m -118.65 134.15 55.32 Favored 'General case' 0 N--CA 1.402 -2.854 0 CA-C-N 113.75 -1.225 . . . . 0.0 109.041 -175.429 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 10.5 t -109.89 163.86 13.13 Favored 'General case' 0 N--CA 1.426 -1.651 0 C-N-CA 119.584 -0.846 . . . . 0.0 109.639 -178.74 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 48.9 t -92.96 125.06 37.37 Favored 'General case' 0 N--CA 1.387 -3.605 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.117 -174.495 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 46.0 m -128.75 59.85 1.54 Allowed 'General case' 0 N--CA 1.397 -3.121 0 N-CA-C 104.557 -2.386 . . . . 0.0 104.557 173.211 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.435 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 47.7 t90 -31.8 131.49 0.29 Allowed Pre-proline 0 C--O 1.247 0.931 0 C-N-CA 126.851 2.06 . . . . 0.0 113.149 -172.452 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.435 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 2.8 Cg_endo -89.04 6.62 69.08 Favored 'Cis proline' 0 CA--C 1.537 0.644 0 C-N-CA 122.872 -1.72 . . . . 0.0 115.242 2.955 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 28.9 m -107.76 152.24 9.54 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.004 0 N-CA-C 112.855 0.687 . . . . 0.0 112.855 -176.223 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 94.5 m -88.56 149.4 23.61 Favored 'General case' 0 N--CA 1.402 -2.836 0 CA-C-O 121.452 0.644 . . . . 0.0 110.986 175.71 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.44 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.8 p -125.37 -146.72 0.35 Allowed 'General case' 0 C--N 1.285 -2.236 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 173.761 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 6.6 ptp180 -124.14 147.83 47.65 Favored 'General case' 1 N--CA 1.377 -4.077 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 -176.5 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 26.4 p30 -82.58 67.7 8.74 Favored 'General case' 0 C--N 1.272 -2.801 0 N-CA-C 113.696 0.999 . . . . 0.0 113.696 -177.733 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 66.72 22.7 71.99 Favored Glycine 0 C--N 1.316 -0.575 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.627 179.646 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 44.8 mt -76.8 155.29 83.15 Favored Pre-proline 0 C--N 1.313 -1.012 0 CA-C-N 115.819 -0.191 . . . . 0.0 110.706 179.387 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 75.9 Cg_exo -50.24 137.74 37.94 Favored 'Trans proline' 0 C--O 1.247 0.946 0 C-N-CA 123.602 2.868 . . . . 0.0 112.615 179.855 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 41.9 t -65.62 121.31 14.45 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.622 0 CA-C-N 115.078 -0.965 . . . . 0.0 109.133 -179.402 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 27.5 m . . . . . 0 C--N 1.294 -1.825 0 O-C-N 124.847 1.342 . . . . 0.0 111.659 179.239 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.411 -2.999 0 N-CA-C 105.22 -3.152 . . . . 0.0 105.22 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -73.03 -53.32 7.98 Favored Glycine 0 C--N 1.299 -1.48 0 N-CA-C 110.215 -1.154 . . . . 0.0 110.215 178.414 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -172.53 -173.87 39.41 Favored Glycine 0 N--CA 1.418 -2.553 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 178.669 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 58.5 m -126.42 138.37 53.53 Favored 'General case' 0 C--N 1.286 -2.175 0 CA-C-O 120.764 0.316 . . . . 0.0 110.999 179.634 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -107.94 -6.69 32.1 Favored Glycine 0 N--CA 1.431 -1.661 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 174.853 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -69.59 151.35 46.06 Favored 'General case' 0 C--O 1.25 1.086 0 CA-C-N 115.169 -0.515 . . . . 0.0 110.948 179.389 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 39.9 p -102.62 163.38 12.25 Favored 'General case' 0 N--CA 1.408 -2.571 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.072 -178.984 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.712 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 29.3 p -129.38 43.42 3.14 Favored 'General case' 0 N--CA 1.425 -1.677 0 CA-C-O 121.465 0.65 . . . . 0.0 109.485 -178.839 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 58.3 t -58.42 -33.14 47.07 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.862 -177.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -90.03 -0.95 76.89 Favored Glycine 0 C--O 1.224 -0.528 0 CA-C-N 116.211 -0.45 . . . . 0.0 112.109 178.762 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 86.72 29.18 24.53 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 121.823 -0.227 . . . . 0.0 113.217 177.752 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 7.0 m -148.52 155.08 40.67 Favored 'General case' 0 N--CA 1.436 -1.131 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 179.196 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.433 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 61.1 m -133.04 156.87 46.58 Favored 'General case' 0 C--N 1.279 -2.464 0 N-CA-C 107.572 -1.269 . . . . 0.0 107.572 176.862 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 33.3 m-80 -84.1 -39.42 19.53 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 -179.787 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 16.2 m -84.79 116.62 66.09 Favored Pre-proline 0 N--CA 1.429 -1.507 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 175.415 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -74.72 -7.67 19.61 Favored 'Trans proline' 0 C--N 1.358 1.07 0 C-N-CA 122.433 2.089 . . . . 0.0 112.758 -175.444 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -90.44 -6.84 67.88 Favored Glycine 0 C--N 1.268 -3.239 0 CA-C-N 113.233 -1.803 . . . . 0.0 110.143 178.368 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.447 ' HA ' ' O ' ' A' ' 26' ' ' THR . 86.8 m -105.28 125.91 51.51 Favored 'General case' 0 N--CA 1.412 -2.361 0 CA-C-O 122.407 1.098 . . . . 0.0 109.679 177.269 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.435 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 6.8 m -93.59 150.72 20.2 Favored 'General case' 0 C--N 1.276 -2.595 0 CA-C-N 113.125 -1.852 . . . . 0.0 108.603 -173.641 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 52.2 t -93.1 105.77 17.82 Favored 'General case' 0 N--CA 1.409 -2.493 0 CA-C-O 121.866 0.841 . . . . 0.0 110.904 -178.374 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 31.1 m -108.68 79.61 1.25 Allowed 'General case' 0 N--CA 1.391 -3.405 0 N-CA-C 103.569 -2.752 . . . . 0.0 103.569 171.074 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.436 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 54.5 t90 -44.31 134.51 4.37 Favored Pre-proline 0 N--CA 1.429 -1.517 0 CA-C-N 113.322 -1.763 . . . . 0.0 112.919 -167.976 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.436 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 4.0 Cg_endo -95.64 22.96 26.79 Favored 'Cis proline' 0 N--CA 1.458 -0.561 0 C-N-CA 122.969 -1.68 . . . . 0.0 114.597 3.15 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 29.9 m -120.68 144.22 30.25 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.968 0 N-CA-C 114.057 1.132 . . . . 0.0 114.057 -175.712 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.712 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 56.1 m -86.05 129.87 34.71 Favored 'General case' 0 N--CA 1.414 -2.268 0 O-C-N 121.791 -0.568 . . . . 0.0 109.616 176.212 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.447 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 1.3 p -135.78 -170.82 2.71 Favored 'General case' 0 C--N 1.287 -2.119 0 C-N-CA 123.541 0.737 . . . . 0.0 109.828 178.439 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 70.8 mtp180 -112.69 129.14 56.51 Favored 'General case' 0 N--CA 1.396 -3.145 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 177.729 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 11.0 p30 -79.37 21.22 0.49 Allowed 'General case' 0 C--N 1.281 -2.378 0 N-CA-C 112.89 0.7 . . . . 0.0 112.89 -177.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.31 33.08 32.99 Favored Glycine 0 C--N 1.315 -0.627 0 C-N-CA 119.727 -1.225 . . . . 0.0 111.679 -177.308 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.577 ' H ' HD23 ' A' ' 30' ' ' LEU . 2.5 pt? -101.18 169.82 7.3 Favored Pre-proline 0 C--N 1.298 -1.636 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.56 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 81.1 Cg_exo -49.01 162.43 0.41 Allowed 'Trans proline' 0 C--N 1.369 1.613 0 C-N-CA 123.428 2.752 . . . . 0.0 113.961 178.814 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 34.7 t -67.98 107.75 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 CA-C-O 122.23 1.014 . . . . 0.0 110.973 -175.387 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 8.9 t . . . . . 0 C--N 1.275 -2.658 0 CA-C-N 113.96 -1.473 . . . . 0.0 107.275 177.549 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.429 -1.8 0 N-CA-C 108.152 -1.979 . . . . 0.0 108.152 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -70.71 -38.57 66.98 Favored Glycine 0 CA--C 1.498 -0.978 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 177.696 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -142.0 -148.88 5.09 Favored Glycine 0 N--CA 1.415 -2.746 0 N-CA-C 107.703 -2.159 . . . . 0.0 107.703 175.474 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 96.4 m -129.83 143.44 50.81 Favored 'General case' 0 C--N 1.285 -2.225 0 CA-C-N 117.31 0.555 . . . . 0.0 110.209 178.293 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -85.65 4.01 86.36 Favored Glycine 0 N--CA 1.447 -0.581 0 N-CA-C 110.788 -0.925 . . . . 0.0 110.788 179.677 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 74.6 mm-40 -89.6 146.82 24.3 Favored 'General case' 0 N--CA 1.421 -1.909 0 CA-C-N 114.79 -0.705 . . . . 0.0 110.816 -179.511 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 32.6 p -123.71 150.81 43.87 Favored 'General case' 0 N--CA 1.392 -3.335 0 N-CA-C 106.185 -1.783 . . . . 0.0 106.185 174.4 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.43 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 24.4 p -123.99 38.35 4.21 Favored 'General case' 0 C--N 1.289 -2.022 0 CA-C-N 118.63 0.65 . . . . 0.0 110.254 -177.521 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 13.6 t -61.76 -40.48 87.04 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 CA-C-N 114.494 -1.23 . . . . 0.0 108.306 178.791 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -73.78 -22.24 78.42 Favored Glycine 0 N--CA 1.441 -1.032 0 CA-C-N 114.902 -1.045 . . . . 0.0 111.022 177.127 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 120.4 -6.94 11.57 Favored Glycine 0 N--CA 1.436 -1.302 0 C-N-CA 121.255 -0.498 . . . . 0.0 113.876 177.211 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 6.1 m -136.51 155.25 50.23 Favored 'General case' 0 N--CA 1.429 -1.492 0 CA-C-N 118.047 0.924 . . . . 0.0 108.936 -176.336 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 57.6 m -113.99 143.33 44.92 Favored 'General case' 0 C--N 1.279 -2.463 0 N-CA-C 106.154 -1.795 . . . . 0.0 106.154 175.676 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 33.4 m-80 -68.09 -39.36 82.88 Favored 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 119.053 0.842 . . . . 0.0 110.656 177.395 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 9.9 m -94.1 113.19 60.04 Favored Pre-proline 0 N--CA 1.426 -1.671 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 176.358 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -76.33 -1.89 12.0 Favored 'Trans proline' 0 C--N 1.354 0.828 0 C-N-CA 122.668 2.245 . . . . 0.0 112.534 -178.727 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -79.59 -14.41 81.26 Favored Glycine 0 C--N 1.284 -2.33 0 CA-C-N 113.105 -1.861 . . . . 0.0 108.936 175.166 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.536 ' HA ' ' O ' ' A' ' 26' ' ' THR . 63.7 m -103.14 127.33 50.47 Favored 'General case' 0 N--CA 1.406 -2.653 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.115 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.43 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 10.3 m -89.9 148.86 22.9 Favored 'General case' 0 C--N 1.279 -2.493 0 CA-C-N 114.876 -1.056 . . . . 0.0 108.633 -177.129 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 50.5 t -84.64 115.15 22.49 Favored 'General case' 0 C--N 1.269 -2.897 0 CA-C-O 121.461 0.648 . . . . 0.0 110.453 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 16.6 t -120.26 68.24 0.84 Allowed 'General case' 0 C--N 1.287 -2.152 0 N-CA-C 103.728 -2.693 . . . . 0.0 103.728 172.85 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.448 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 51.3 t90 -35.92 133.08 0.56 Allowed Pre-proline 0 N--CA 1.441 -0.904 0 CA-C-N 113.108 -1.86 . . . . 0.0 112.969 -170.417 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.448 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 1.6 Cg_endo -91.63 14.46 49.62 Favored 'Cis proline' 0 CA--C 1.541 0.855 0 C-N-CA 123.145 -1.606 . . . . 0.0 115.343 2.517 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 28.9 m -115.65 152.6 17.3 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.019 0 O-C-N 121.182 -0.949 . . . . 0.0 112.36 -177.629 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.43 ' HA ' ' O ' ' A' ' 19' ' ' THR . 59.6 m -95.73 139.32 32.14 Favored 'General case' 0 N--CA 1.403 -2.81 0 O-C-N 121.77 -0.581 . . . . 0.0 109.543 177.123 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.536 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 20.1 p -125.49 -173.29 2.79 Favored 'General case' 0 C--N 1.29 -1.989 0 C-N-CA 123.119 0.568 . . . . 0.0 111.345 -179.157 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 53.8 ttt180 -118.2 123.0 44.41 Favored 'General case' 0 N--CA 1.417 -2.095 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 -177.619 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 10.2 p30 -89.94 25.25 2.16 Favored 'General case' 0 C--N 1.279 -2.496 0 CA-C-N 115.028 -0.987 . . . . 0.0 113.052 -173.948 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 92.59 4.8 65.46 Favored Glycine 0 C--N 1.305 -1.161 0 C-N-CA 118.837 -1.649 . . . . 0.0 112.131 -178.42 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.438 ' HB3' ' HD2' ' A' ' 31' ' ' PRO . 17.6 mt -69.88 171.26 7.66 Favored Pre-proline 0 C--N 1.315 -0.928 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 174.016 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.438 ' HD2' ' HB3' ' A' ' 30' ' ' LEU . 61.8 Cg_exo -47.49 161.49 0.28 Allowed 'Trans proline' 0 C--N 1.36 1.161 0 C-N-CA 123.703 2.935 . . . . 0.0 112.188 176.689 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 24.6 m -60.33 115.18 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.415 -2.208 0 N-CA-C 114.262 1.208 . . . . 0.0 114.262 -170.244 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.452 HG21 ' SG ' ' A' ' 18' ' ' CYS . 1.3 m . . . . . 0 C--N 1.305 -1.336 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 173.454 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.427 -1.929 0 N-CA-C 109.278 -1.529 . . . . 0.0 109.278 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -80.2 58.45 4.61 Favored Glycine 0 C--N 1.31 -0.904 0 CA-C-N 116.976 0.388 . . . . 0.0 113.061 -177.317 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 93.34 -106.05 3.37 Favored Glycine 0 N--CA 1.43 -1.746 0 N-CA-C 111.825 -0.51 . . . . 0.0 111.825 179.294 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 98.1 m -152.82 154.65 35.57 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 179.246 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -107.19 5.64 36.16 Favored Glycine 0 C--N 1.31 -0.892 0 C-N-CA 120.465 -0.874 . . . . 0.0 112.443 -178.295 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -88.73 166.43 14.06 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.779 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' THR . . . . . 0.43 ' HB ' HG23 ' A' ' 9' ' ' VAL . 24.4 p -112.49 163.25 14.68 Favored 'General case' 0 N--CA 1.415 -2.194 0 N-CA-C 112.15 0.426 . . . . 0.0 112.15 -175.79 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.462 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 21.4 p -137.13 36.01 2.55 Favored 'General case' 0 CA--C 1.497 -1.073 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 179.58 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.43 HG23 ' HB ' ' A' ' 7' ' ' THR . 15.4 t -60.8 -35.4 64.15 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.084 0 CA-C-N 114.719 -1.128 . . . . 0.0 109.4 -177.867 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -74.27 -17.27 79.63 Favored Glycine 0 N--CA 1.44 -1.044 0 CA-C-N 115.132 -0.94 . . . . 0.0 112.935 178.97 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 141.49 -33.43 1.98 Allowed Glycine 0 N--CA 1.435 -1.402 0 C-N-CA 119.992 -1.099 . . . . 0.0 113.795 179.848 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 9.0 t -153.58 172.8 16.64 Favored 'General case' 0 N--CA 1.424 -1.745 0 CA-C-N 117.771 0.785 . . . . 0.0 109.845 -174.726 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 58.1 m -94.75 176.35 6.31 Favored 'General case' 0 C--N 1.274 -2.687 0 CA-C-N 114.475 -1.239 . . . . 0.0 110.042 -177.391 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 26.8 m-80 -100.55 -36.43 9.18 Favored 'General case' 0 C--N 1.307 -1.243 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 178.588 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.507 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 25.8 m -90.69 121.86 67.69 Favored Pre-proline 0 N--CA 1.427 -1.607 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 177.179 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.443 ' HD3' ' HA ' ' A' ' 15' ' ' THR . 13.6 Cg_exo -69.66 -3.58 12.22 Favored 'Trans proline' 0 N--CA 1.488 1.157 0 C-N-CA 123.132 2.555 . . . . 0.0 113.458 -177.506 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -90.3 -14.22 59.08 Favored Glycine 0 C--N 1.255 -3.949 0 CA-C-N 113.719 -1.582 . . . . 0.0 110.283 176.458 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.589 ' HA ' ' O ' ' A' ' 26' ' ' THR . 57.8 m -103.55 129.97 50.86 Favored 'General case' 0 N--CA 1.396 -3.128 0 N-CA-C 107.575 -1.269 . . . . 0.0 107.575 179.254 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.556 ' OG1' ' HB3' ' A' ' 28' ' ' ASN . 25.1 m -114.78 155.5 26.61 Favored 'General case' 0 C--N 1.281 -2.389 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 -179.13 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 38.2 t -83.48 128.15 34.28 Favored 'General case' 0 N--CA 1.409 -2.521 0 CA-C-O 122.251 1.024 . . . . 0.0 113.065 -171.477 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.8 m -128.26 65.32 1.39 Allowed 'General case' 0 N--CA 1.402 -2.833 0 N-CA-C 104.401 -2.444 . . . . 0.0 104.401 170.149 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.426 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 37.9 t90 -33.67 134.87 0.33 Allowed Pre-proline 0 N--CA 1.442 -0.849 0 C-N-CA 127.433 2.293 . . . . 0.0 113.918 -170.92 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.426 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 4.6 Cg_exo -88.96 12.01 57.51 Favored 'Cis proline' 0 CA--C 1.544 0.98 0 C-N-CA 122.894 -1.711 . . . . 0.0 114.403 0.993 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.7 m -114.38 150.49 16.36 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.889 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -175.254 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.463 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 95.5 m -86.14 151.6 23.53 Favored 'General case' 0 N--CA 1.41 -2.435 0 CA-C-O 121.74 0.781 . . . . 0.0 112.206 178.39 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.589 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.0 p -129.27 -164.44 1.4 Allowed 'General case' 0 C--N 1.298 -1.642 0 C-N-CA 124.609 1.164 . . . . 0.0 108.331 175.559 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 17.3 ttm180 -122.62 135.27 54.56 Favored 'General case' 0 N--CA 1.407 -2.603 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 -178.277 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ASN . . . . . 0.556 ' HB3' ' OG1' ' A' ' 19' ' ' THR . 1.1 t30 -131.88 129.6 40.57 Favored 'General case' 0 C--N 1.26 -3.29 0 N-CA-C 113.72 1.008 . . . . 0.0 113.72 -177.042 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 65.44 22.47 69.52 Favored Glycine 0 CA--C 1.499 -0.962 0 CA-C-N 114.956 -1.02 . . . . 0.0 112.884 173.94 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 68.4 mt -129.96 161.41 59.92 Favored Pre-proline 0 C--N 1.298 -1.654 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 -175.596 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -56.84 137.71 82.69 Favored 'Trans proline' 0 C--O 1.242 0.721 0 C-N-CA 123.35 2.7 . . . . 0.0 111.15 176.935 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 32.4 t -85.28 117.66 30.76 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.018 0 CA-C-O 121.914 0.864 . . . . 0.0 109.639 -177.263 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 24.6 m . . . . . 0 C--N 1.27 -2.861 0 N-CA-C 105.912 -1.885 . . . . 0.0 105.912 176.294 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.782 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 78.41 -53.25 3.89 Favored Glycine 0 CA--C 1.519 0.297 0 N-CA-C 111.883 -0.487 . . . . 0.0 111.883 -176.271 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -154.94 -138.59 2.62 Favored Glycine 0 N--CA 1.422 -2.239 0 N-CA-C 108.61 -1.796 . . . . 0.0 108.61 177.806 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 85.3 m -111.55 107.97 17.32 Favored 'General case' 0 C--N 1.29 -2.02 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 175.427 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -80.06 13.9 23.53 Favored Glycine 0 C--N 1.314 -0.675 0 CA-C-N 116.117 -0.492 . . . . 0.0 112.927 -176.382 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -91.56 162.13 14.66 Favored 'General case' 0 C--N 1.306 -1.288 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 178.762 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 25.3 p -114.74 163.48 15.42 Favored 'General case' 0 N--CA 1.411 -2.385 0 N-CA-C 110.374 -0.232 . . . . 0.0 110.374 -179.739 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 16.9 p -134.2 41.2 2.98 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-O 121.229 0.538 . . . . 0.0 110.185 -179.036 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 23.2 t -59.94 -29.89 44.26 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.042 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.619 -176.945 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -83.09 -8.14 86.02 Favored Glycine 0 N--CA 1.441 -0.995 0 CA-C-N 115.769 -0.65 . . . . 0.0 112.903 -179.786 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 139.82 -39.61 1.49 Allowed Glycine 0 N--CA 1.443 -0.885 0 C-N-CA 120.214 -0.993 . . . . 0.0 113.777 178.2 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 13.5 t -155.6 173.23 17.01 Favored 'General case' 0 N--CA 1.423 -1.802 0 CA-C-N 117.354 0.577 . . . . 0.0 109.649 -176.807 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 32.2 m -91.87 173.11 8.03 Favored 'General case' 0 C--N 1.274 -2.713 0 CA-C-N 114.815 -1.084 . . . . 0.0 109.578 -175.048 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 36.3 m-80 -93.27 -36.63 12.47 Favored 'General case' 0 CA--C 1.496 -1.097 0 N-CA-C 110.059 -0.348 . . . . 0.0 110.059 177.017 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.48 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 17.6 m -84.63 124.26 73.38 Favored Pre-proline 0 C--N 1.297 -1.675 0 N-CA-C 108.131 -1.062 . . . . 0.0 108.131 176.304 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_endo -72.86 -1.53 10.58 Favored 'Trans proline' 0 C--N 1.359 1.098 0 C-N-CA 123.05 2.5 . . . . 0.0 113.425 -176.194 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -97.63 -4.05 58.2 Favored Glycine 0 C--N 1.265 -3.407 0 CA-C-N 113.964 -1.471 . . . . 0.0 110.152 177.782 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.48 ' SG ' ' HB ' ' A' ' 15' ' ' THR . 60.3 m -108.66 125.84 52.32 Favored 'General case' 0 N--CA 1.409 -2.518 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 178.992 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 8.6 m -91.45 151.39 20.82 Favored 'General case' 0 C--N 1.291 -1.959 0 N-CA-C 107.74 -1.208 . . . . 0.0 107.74 -177.213 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 46.6 t -90.17 127.73 36.18 Favored 'General case' 0 N--CA 1.411 -2.415 0 CA-C-O 121.388 0.613 . . . . 0.0 109.565 179.501 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 22.6 t -128.71 56.8 1.63 Allowed 'General case' 0 C--N 1.28 -2.448 0 N-CA-C 103.688 -2.708 . . . . 0.0 103.688 176.001 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.429 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 56.6 t90 -31.2 131.91 0.25 Allowed Pre-proline 0 N--CA 1.446 -0.644 0 C-N-CA 127.009 2.124 . . . . 0.0 113.347 -171.314 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 1.8 Cg_endo -90.37 9.68 63.07 Favored 'Cis proline' 0 C--N 1.323 -0.811 0 C-N-CA 122.883 -1.715 . . . . 0.0 115.074 4.091 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 29.8 m -112.32 153.01 14.04 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 O-C-N 122.043 -0.41 . . . . 0.0 111.927 -176.2 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 73.4 m -93.39 158.78 15.56 Favored 'General case' 0 N--CA 1.416 -2.15 0 CA-C-O 121.487 0.661 . . . . 0.0 112.42 178.05 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.461 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.1 p -129.81 -175.04 3.48 Favored 'General case' 0 C--N 1.31 -1.145 0 C-N-CA 124.519 1.128 . . . . 0.0 108.562 175.679 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.504 ' HB2' ' HB2' ' A' ' 30' ' ' LEU . 20.0 ptt180 -119.29 139.78 51.36 Favored 'General case' 0 N--CA 1.384 -3.725 0 CA-C-N 119.407 1.003 . . . . 0.0 112.138 -178.027 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 8.7 p30 -122.42 109.61 14.6 Favored 'General case' 0 C--N 1.277 -2.546 0 CA-C-N 114.705 -1.134 . . . . 0.0 109.244 173.224 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 67.0 31.99 79.58 Favored Glycine 0 C--O 1.244 0.744 0 CA-C-N 115.893 -0.594 . . . . 0.0 113.538 177.89 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.504 ' HB2' ' HB2' ' A' ' 27' ' ' ARG . 35.2 mt -107.93 147.42 35.43 Favored Pre-proline 0 C--N 1.31 -1.148 0 O-C-N 122.388 -0.478 . . . . 0.0 112.199 -179.506 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 30' ' ' LEU . 2.9 Cg_exo -69.12 148.6 69.54 Favored 'Trans proline' 0 N--CA 1.449 -1.092 0 C-N-CA 122.616 2.211 . . . . 0.0 109.668 175.001 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 13.1 t -74.38 100.05 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 CA-C-O 121.769 0.795 . . . . 0.0 109.201 -177.842 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 3.8 m . . . . . 0 C--N 1.272 -2.767 0 CA-C-N 114.105 -1.407 . . . . 0.0 109.788 -177.286 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.791 0 N-CA-C 110.346 -1.102 . . . . 0.0 110.346 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.91 -75.02 1.92 Allowed Glycine 0 N--CA 1.445 -0.75 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 -177.234 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.453 ' HA2' ' HE ' ' A' ' 27' ' ' ARG . . . -141.86 -92.43 0.19 Allowed Glycine 0 N--CA 1.419 -2.44 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 178.219 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 72.4 m -143.51 141.43 30.74 Favored 'General case' 0 C--N 1.291 -1.966 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 173.652 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -88.03 12.98 62.52 Favored Glycine 0 C--N 1.304 -1.201 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.025 -178.057 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -90.23 154.67 19.56 Favored 'General case' 0 N--CA 1.431 -1.401 0 CA-C-O 121.096 0.474 . . . . 0.0 110.013 -179.289 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' THR . . . . . 0.401 ' HA ' ' HA ' ' A' ' 24' ' ' VAL . 35.9 p -111.65 158.53 19.16 Favored 'General case' 0 N--CA 1.395 -3.225 0 N-CA-C 106.32 -1.734 . . . . 0.0 106.32 170.449 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.604 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 28.1 p -135.85 50.86 2.07 Favored 'General case' 0 C--N 1.283 -2.304 0 CA-C-O 121.502 0.668 . . . . 0.0 110.056 -177.66 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 40.3 t -62.43 -31.0 50.35 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.36 -178.568 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -74.45 -26.36 68.08 Favored Glycine 0 N--CA 1.446 -0.638 0 N-CA-C 111.338 -0.705 . . . . 0.0 111.338 176.701 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 122.27 0.18 10.46 Favored Glycine 0 N--CA 1.443 -0.875 0 C-N-CA 120.657 -0.782 . . . . 0.0 114.219 177.021 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 15.7 m -148.81 162.59 39.51 Favored 'General case' 0 N--CA 1.432 -1.372 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 -179.664 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 35.9 m -111.82 166.78 10.9 Favored 'General case' 0 C--N 1.281 -2.407 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 177.841 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 36.0 m-80 -83.43 -38.89 21.31 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-O 120.923 0.392 . . . . 0.0 110.022 179.223 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.582 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 13.4 m -79.88 123.85 83.54 Favored Pre-proline 0 N--CA 1.429 -1.509 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 178.979 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_exo -69.81 -2.92 11.03 Favored 'Trans proline' 0 C--N 1.353 0.809 0 C-N-CA 123.009 2.472 . . . . 0.0 112.898 179.504 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.445 ' H ' HG22 ' A' ' 15' ' ' THR . . . -96.47 -12.19 51.83 Favored Glycine 0 C--N 1.27 -3.134 0 CA-C-N 113.752 -1.567 . . . . 0.0 110.449 177.17 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.582 ' SG ' ' HB ' ' A' ' 15' ' ' THR . 62.3 m -103.7 130.63 51.22 Favored 'General case' 0 N--CA 1.415 -2.198 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 179.659 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 9.6 m -109.26 147.7 32.2 Favored 'General case' 0 C--N 1.282 -2.329 0 N-CA-C 107.928 -1.138 . . . . 0.0 107.928 -177.625 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 46.2 t -83.45 121.15 26.8 Favored 'General case' 0 N--CA 1.403 -2.777 0 CA-C-O 121.629 0.728 . . . . 0.0 111.073 -177.434 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 25.2 t -123.58 72.36 1.13 Allowed 'General case' 0 C--N 1.279 -2.472 0 N-CA-C 103.417 -2.809 . . . . 0.0 103.417 173.88 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.464 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 36.9 t90 -41.24 133.71 1.95 Allowed Pre-proline 0 N--CA 1.444 -0.729 0 C-N-CA 125.893 1.677 . . . . 0.0 113.411 -168.343 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.464 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 1.6 Cg_endo -92.23 16.81 43.42 Favored 'Cis proline' 0 CA--C 1.538 0.705 0 C-N-CA 122.826 -1.739 . . . . 0.0 114.655 2.113 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.401 ' HA ' ' HA ' ' A' ' 7' ' ' THR . 26.8 m -117.38 151.13 19.3 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.863 0 N-CA-C 113.95 1.093 . . . . 0.0 113.95 -176.11 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.604 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 82.8 m -86.21 148.95 25.42 Favored 'General case' 0 N--CA 1.409 -2.506 0 O-C-N 121.536 -0.727 . . . . 0.0 110.928 176.459 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.494 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.2 p -132.72 -174.51 3.48 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 175.959 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.453 ' HE ' ' HA2' ' A' ' 3' ' ' GLY . 3.5 ppt_? -123.82 160.26 27.76 Favored 'General case' 0 N--CA 1.379 -3.975 0 CA-C-N 119.524 1.056 . . . . 0.0 110.43 179.368 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 7.8 p30 -132.8 134.46 44.71 Favored 'General case' 0 C--N 1.265 -3.069 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 -179.144 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 60.77 22.78 60.22 Favored Glycine 0 C--O 1.227 -0.3 0 O-C-N 123.573 0.546 . . . . 0.0 112.861 178.799 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.442 ' HA ' ' HD3' ' A' ' 31' ' ' PRO . 46.0 mt -118.2 145.88 38.05 Favored Pre-proline 0 N--CA 1.424 -1.738 0 O-C-N 122.602 -0.352 . . . . 0.0 111.881 -176.954 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.442 ' HD3' ' HA ' ' A' ' 30' ' ' LEU . 6.4 Cg_exo -66.73 162.06 39.05 Favored 'Trans proline' 0 N--CA 1.451 -0.986 0 C-N-CA 122.777 2.318 . . . . 0.0 110.296 176.096 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 16.7 t -75.68 112.22 13.04 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 -179.031 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 9.1 t . . . . . 0 C--N 1.278 -2.515 0 CA-C-N 114.614 -1.175 . . . . 0.0 108.214 179.015 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.433 -1.523 0 N-CA-C 109.821 -1.311 . . . . 0.0 109.821 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -67.89 -39.36 89.54 Favored Glycine 0 C--N 1.314 -0.669 0 CA-C-N 116.976 0.388 . . . . 0.0 112.207 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -170.9 -130.81 1.26 Allowed Glycine 0 N--CA 1.437 -1.274 0 N-CA-C 109.261 -1.536 . . . . 0.0 109.261 179.287 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.638 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 88.7 m -104.7 162.94 12.86 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 174.708 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -92.42 -16.75 48.55 Favored Glycine 0 N--CA 1.44 -1.096 0 C-N-CA 120.454 -0.879 . . . . 0.0 112.866 -174.966 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.638 ' OE1' ' HB3' ' A' ' 4' ' ' CYS . 1.0 OUTLIER -90.15 145.94 24.66 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 122.447 -0.443 . . . . 0.0 111.056 -178.786 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 7' ' ' THR . . . . . 0.442 HG22 HG12 ' A' ' 24' ' ' VAL . 21.7 p -109.83 157.04 19.6 Favored 'General case' 0 N--CA 1.417 -2.114 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.485 -179.209 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.5 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 19.5 p -126.23 38.85 4.06 Favored 'General case' 0 C--N 1.303 -1.422 0 CA-C-O 121.169 0.509 . . . . 0.0 110.589 -177.05 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 35.5 t -56.12 -35.48 41.97 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 CA-C-N 115.106 -0.952 . . . . 0.0 110.722 -178.427 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -95.4 7.85 68.97 Favored Glycine 0 N--CA 1.441 -1.027 0 C-N-CA 121.089 -0.577 . . . . 0.0 113.053 -179.483 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 152.1 -82.06 0.18 Allowed Glycine 0 N--CA 1.434 -1.477 0 C-N-CA 119.186 -1.483 . . . . 0.0 114.425 178.369 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 7.5 m -153.44 163.89 39.15 Favored 'General case' 0 N--CA 1.428 -1.57 0 N-CA-C 106.867 -1.531 . . . . 0.0 106.867 -171.153 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 76.7 m -99.13 161.56 13.55 Favored 'General case' 0 C--N 1.291 -1.95 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 176.188 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 41.7 m-80 -92.82 -16.51 25.24 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-O 120.99 0.424 . . . . 0.0 110.837 -177.839 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 10.7 m -72.49 114.89 33.98 Favored Pre-proline 0 N--CA 1.438 -1.07 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 178.814 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -70.17 -9.02 25.01 Favored 'Trans proline' 0 C--N 1.351 0.709 0 C-N-CA 122.806 2.337 . . . . 0.0 114.213 -174.204 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -91.74 -15.34 54.94 Favored Glycine 0 C--N 1.261 -3.623 0 CA-C-N 113.988 -1.46 . . . . 0.0 111.234 178.901 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.568 ' HA ' ' O ' ' A' ' 26' ' ' THR . 82.9 m -118.7 125.29 49.35 Favored 'General case' 0 N--CA 1.415 -2.195 0 CA-C-O 121.639 0.733 . . . . 0.0 110.795 -177.687 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 8.1 m -101.88 156.61 17.42 Favored 'General case' 0 C--N 1.293 -1.871 0 C-N-CA 124.666 1.187 . . . . 0.0 108.521 -176.734 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 51.8 t -88.64 119.64 29.3 Favored 'General case' 0 C--N 1.297 -1.707 0 CA-C-O 121.503 0.668 . . . . 0.0 111.851 -176.696 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 21.1 t -124.76 75.69 1.45 Allowed 'General case' 0 N--CA 1.417 -2.097 0 N-CA-C 103.541 -2.763 . . . . 0.0 103.541 171.11 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.485 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 57.2 t90 -38.0 135.79 0.81 Allowed Pre-proline 0 N--CA 1.436 -1.125 0 C-N-CA 126.063 1.745 . . . . 0.0 113.058 -170.809 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.485 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 1.2 Cg_endo -91.47 9.54 61.59 Favored 'Cis proline' 0 CA--C 1.536 0.618 0 C-N-CA 122.862 -1.724 . . . . 0.0 114.958 3.426 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.442 HG12 HG22 ' A' ' 7' ' ' THR . 25.3 m -113.86 158.09 14.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 C-N-CA 120.102 -0.639 . . . . 0.0 111.725 -175.442 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.5 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 53.4 m -96.86 143.06 28.12 Favored 'General case' 0 N--CA 1.388 -3.528 0 CA-C-O 121.838 0.828 . . . . 0.0 110.442 173.954 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.568 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 7.9 p -128.19 -170.13 2.19 Favored 'General case' 0 C--N 1.273 -2.742 0 CA-C-N 114.466 -1.243 . . . . 0.0 110.994 -177.558 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.412 ' HB3' ' HB2' ' A' ' 30' ' ' LEU . 19.1 mtm180 -99.84 151.58 21.12 Favored 'General case' 0 N--CA 1.381 -3.914 0 CA-C-O 121.459 0.647 . . . . 0.0 110.77 -169.179 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 7.1 p30 -133.62 112.75 11.71 Favored 'General case' 0 C--N 1.266 -3.055 0 CA-C-N 113.652 -1.613 . . . . 0.0 106.773 169.563 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.0 -33.45 2.65 Favored Glycine 0 CA--C 1.533 1.163 0 CA-C-N 116.337 -0.392 . . . . 0.0 112.929 179.902 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.412 ' HB2' ' HB3' ' A' ' 27' ' ' ARG . 62.9 mt -60.91 149.75 79.88 Favored Pre-proline 0 C--O 1.243 0.742 0 N-CA-C 113.792 1.034 . . . . 0.0 113.792 -178.481 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -76.61 162.73 32.68 Favored 'Trans proline' 0 N--CA 1.444 -1.414 0 C-N-CA 123.377 2.718 . . . . 0.0 111.578 -179.183 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.5 t -84.26 98.8 6.04 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.69 0 CA-C-O 121.736 0.779 . . . . 0.0 109.774 -177.436 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 8.2 m . . . . . 0 C--N 1.274 -2.694 0 CA-C-N 115.031 -0.986 . . . . 0.0 109.486 179.017 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.733 0 N-CA-C 111.904 -0.479 . . . . 0.0 111.904 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 89.39 -81.88 1.46 Allowed Glycine 0 N--CA 1.43 -1.728 0 N-CA-C 108.939 -1.664 . . . . 0.0 108.939 -176.042 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.502 ' HA2' ' HG3' ' A' ' 27' ' ' ARG . . . -115.79 -102.76 2.36 Favored Glycine 0 N--CA 1.426 -1.979 0 N-CA-C 109.305 -1.518 . . . . 0.0 109.305 176.651 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 99.1 m -140.82 152.52 45.22 Favored 'General case' 0 C--N 1.295 -1.768 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 176.334 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -87.64 9.83 72.24 Favored Glycine 0 C--N 1.314 -0.671 0 N-CA-C 110.581 -1.008 . . . . 0.0 110.581 178.459 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.47 ' HB2' ' HB2' ' A' ' 25' ' ' CYS . 6.2 mm-40 -86.38 154.16 21.39 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 124.14 0.976 . . . . 0.0 108.735 -179.64 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 9.2 p -126.82 153.94 44.97 Favored 'General case' 0 N--CA 1.41 -2.452 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 174.062 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.467 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 25.1 p -133.94 40.38 3.08 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-O 120.92 0.391 . . . . 0.0 110.862 -175.825 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 18.7 t -56.48 -29.17 28.29 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.182 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.345 -179.075 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -79.66 -17.19 76.0 Favored Glycine 0 N--CA 1.445 -0.7 0 CA-C-N 115.612 -0.722 . . . . 0.0 113.392 179.562 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 138.03 -32.07 2.39 Favored Glycine 0 N--CA 1.444 -0.828 0 C-N-CA 119.775 -1.202 . . . . 0.0 114.543 178.874 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 15.7 m -152.32 159.13 43.52 Favored 'General case' 0 C--N 1.31 -1.123 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 -176.925 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.467 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 32.6 m -89.95 165.66 13.94 Favored 'General case' 0 C--N 1.285 -2.221 0 O-C-N 123.767 0.667 . . . . 0.0 109.599 -179.295 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -85.16 -48.98 8.61 Favored 'General case' 0 CA--C 1.503 -0.842 0 CA-C-O 120.884 0.373 . . . . 0.0 110.142 178.079 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 29.1 m -70.52 118.93 69.14 Favored Pre-proline 0 C--N 1.311 -1.077 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 175.914 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -72.35 -5.1 16.49 Favored 'Trans proline' 0 C--N 1.365 1.421 0 C-N-CA 123.134 2.556 . . . . 0.0 114.164 -173.534 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -90.42 -8.43 66.1 Favored Glycine 0 C--N 1.261 -3.606 0 CA-C-N 114.008 -1.451 . . . . 0.0 110.35 178.703 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.498 ' HB3' ' HB3' ' A' ' 25' ' ' CYS . 67.9 m -107.98 127.39 53.72 Favored 'General case' 0 N--CA 1.409 -2.512 0 CA-C-O 121.41 0.624 . . . . 0.0 110.663 -178.464 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 6.3 m -90.16 148.63 22.85 Favored 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 107.969 -1.122 . . . . 0.0 107.969 -178.241 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 51.5 t -88.97 102.81 15.45 Favored 'General case' 0 N--CA 1.412 -2.332 0 CA-C-O 121.501 0.667 . . . . 0.0 111.183 -178.977 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.1 p -105.65 64.89 0.7 Allowed 'General case' 0 C--N 1.288 -2.097 0 N-CA-C 106.225 -1.768 . . . . 0.0 106.225 172.244 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.44 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 56.1 t90 -35.74 134.31 0.52 Allowed Pre-proline 0 N--CA 1.443 -0.821 0 C-N-CA 127.358 2.263 . . . . 0.0 113.586 -169.652 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.44 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 1.5 Cg_endo -91.28 10.01 61.09 Favored 'Cis proline' 0 C--N 1.323 -0.777 0 C-N-CA 122.823 -1.741 . . . . 0.0 114.188 2.474 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.9 m -110.81 150.0 13.44 Favored 'Isoleucine or valine' 0 C--O 1.21 -1.019 0 C-N-CA 120.212 -0.595 . . . . 0.0 111.846 -176.426 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.498 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 69.0 m -92.93 141.29 28.58 Favored 'General case' 0 N--CA 1.408 -2.539 0 CA-C-O 121.44 0.638 . . . . 0.0 112.45 178.808 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.455 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 1.7 p -117.83 -177.18 3.19 Favored 'General case' 0 C--N 1.292 -1.903 0 CA-C-N 115.016 -0.993 . . . . 0.0 108.526 175.534 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.502 ' HG3' ' HA2' ' A' ' 3' ' ' GLY . 4.9 ppt_? -119.17 154.96 32.48 Favored 'General case' 0 N--CA 1.387 -3.602 0 CA-C-N 119.669 1.122 . . . . 0.0 112.298 -176.521 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 26.3 p-10 -140.66 127.68 20.75 Favored 'General case' 0 C--N 1.274 -2.69 0 CA-C-N 114.426 -1.261 . . . . 0.0 109.957 177.414 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 65.66 34.19 88.23 Favored Glycine 0 N--CA 1.449 -0.489 0 N-CA-C 111.35 -0.7 . . . . 0.0 111.35 -178.616 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 47.5 mt -129.46 160.32 64.94 Favored Pre-proline 0 C--N 1.309 -1.184 0 N-CA-C 112.443 0.535 . . . . 0.0 112.443 -177.719 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -61.19 148.58 92.48 Favored 'Trans proline' 0 C--O 1.251 1.147 0 C-N-CA 123.3 2.666 . . . . 0.0 111.55 176.959 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 5.7 m -81.91 98.61 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.399 -3.022 0 CA-C-O 122.088 0.947 . . . . 0.0 110.952 179.171 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 10.0 t . . . . . 0 N--CA 1.42 -1.96 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 178.63 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.796 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -125.56 25.94 5.54 Favored Glycine 0 N--CA 1.436 -1.302 0 N-CA-C 110.624 -0.991 . . . . 0.0 110.624 178.85 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 145.35 -94.63 0.17 Allowed Glycine 0 N--CA 1.437 -1.247 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 178.745 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.422 ' SG ' ' HB3' ' A' ' 27' ' ' ARG . 63.4 m -131.56 151.48 51.56 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 173.842 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -89.21 16.62 55.33 Favored Glycine 0 C--N 1.315 -0.608 0 N-CA-C 110.201 -1.16 . . . . 0.0 110.201 178.408 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.466 ' HB2' ' HB2' ' A' ' 25' ' ' CYS . 7.8 mm-40 -91.53 151.44 20.75 Favored 'General case' 0 N--CA 1.425 -1.699 0 C-N-CA 124.433 1.093 . . . . 0.0 110.153 -179.403 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 17.2 p -126.4 152.27 46.57 Favored 'General case' 0 N--CA 1.405 -2.675 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 174.746 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 24.7 p -130.37 37.67 3.84 Favored 'General case' 0 C--N 1.301 -1.513 0 CA-C-O 121.153 0.501 . . . . 0.0 110.934 -175.986 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 25.7 t -58.46 -37.56 64.89 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.13 0 CA-C-N 114.928 -1.033 . . . . 0.0 109.835 -178.468 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -79.18 1.81 73.62 Favored Glycine 0 CA--C 1.524 0.602 0 CA-C-N 115.55 -0.75 . . . . 0.0 113.608 -179.908 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 124.65 -28.8 5.14 Favored Glycine 0 N--CA 1.44 -1.053 0 C-N-CA 119.956 -1.116 . . . . 0.0 114.168 176.657 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 12.4 t -157.33 172.7 18.14 Favored 'General case' 0 N--CA 1.426 -1.636 0 CA-C-N 117.566 0.683 . . . . 0.0 109.324 -176.641 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 33.4 m -98.81 164.21 12.31 Favored 'General case' 0 C--N 1.276 -2.604 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 -178.581 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 14.6 m-80 -85.23 -42.01 15.07 Favored 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 107.261 -1.385 . . . . 0.0 107.261 178.909 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 14.3 m -77.9 114.74 44.36 Favored Pre-proline 0 N--CA 1.422 -1.868 0 CA-C-N 114.035 -1.439 . . . . 0.0 108.685 177.52 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -73.43 -0.67 9.56 Favored 'Trans proline' 0 N--CA 1.483 0.861 0 C-N-CA 123.662 2.908 . . . . 0.0 113.536 -174.538 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -96.4 -11.83 52.98 Favored Glycine 0 C--N 1.261 -3.6 0 CA-C-N 113.985 -1.462 . . . . 0.0 111.15 177.843 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.404 ' HB3' ' HB3' ' A' ' 25' ' ' CYS . 76.2 m -103.91 127.96 51.41 Favored 'General case' 0 N--CA 1.419 -2.019 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 179.446 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 8.8 m -90.44 153.51 20.34 Favored 'General case' 0 C--N 1.288 -2.093 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 -176.229 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 52.8 t -89.84 116.48 27.96 Favored 'General case' 0 C--N 1.284 -2.241 0 CA-C-O 121.657 0.742 . . . . 0.0 111.247 -177.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 34.4 t -119.35 57.7 0.89 Allowed 'General case' 0 C--N 1.29 -1.984 0 N-CA-C 104.568 -2.382 . . . . 0.0 104.568 176.099 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.412 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 42.5 t90 -29.62 131.86 0.22 Allowed Pre-proline 0 C--N 1.346 0.454 0 C-N-CA 127.261 2.224 . . . . 0.0 113.966 -170.564 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.412 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 2.4 Cg_endo -90.16 6.24 68.11 Favored 'Cis proline' 0 C--N 1.327 -0.56 0 C-N-CA 123.082 -1.632 . . . . 0.0 114.664 3.325 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 26.8 m -108.75 152.57 10.71 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 C-N-CA 120.181 -0.608 . . . . 0.0 112.175 -176.946 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.466 ' HB2' ' HB2' ' A' ' 6' ' ' GLU . 82.2 m -93.35 144.57 25.2 Favored 'General case' 0 N--CA 1.407 -2.622 0 CA-C-O 121.59 0.71 . . . . 0.0 112.188 178.246 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 3.1 p -116.17 179.14 4.08 Favored 'General case' 0 C--N 1.29 -2.016 0 C-N-CA 124.654 1.181 . . . . 0.0 110.049 178.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.422 ' HB3' ' SG ' ' A' ' 4' ' ' CYS . 0.0 OUTLIER -120.4 149.58 42.13 Favored 'General case' 0 N--CA 1.386 -3.672 0 CA-C-O 121.863 0.84 . . . . 0.0 111.856 -176.662 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 6.9 p30 -132.57 118.43 19.2 Favored 'General case' 0 C--N 1.266 -3.046 0 N-CA-C 106.521 -1.659 . . . . 0.0 106.521 172.899 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.43 -33.57 1.36 Allowed Glycine 0 CA--C 1.535 1.285 0 CA-C-N 116.187 -0.461 . . . . 0.0 113.474 -178.235 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 53.0 mt -68.15 154.61 93.71 Favored Pre-proline 0 C--N 1.318 -0.787 0 N-CA-C 113.55 0.944 . . . . 0.0 113.55 -178.47 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_exo -61.55 137.05 66.85 Favored 'Trans proline' 0 C--O 1.25 1.103 0 C-N-CA 122.921 2.414 . . . . 0.0 110.398 176.038 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.4 p -64.94 114.14 2.33 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.277 0 CA-C-O 122.286 1.041 . . . . 0.0 111.087 -178.505 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 28.6 m . . . . . 0 C--N 1.27 -2.888 0 CA-C-N 114.141 -1.39 . . . . 0.0 108.206 178.95 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.9 0 N-CA-C 110.09 -1.204 . . . . 0.0 110.09 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -107.1 25.48 22.02 Favored Glycine 0 C--N 1.304 -1.198 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 178.103 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 108.46 -83.79 0.35 Allowed Glycine 0 N--CA 1.429 -1.814 0 N-CA-C 110.097 -1.201 . . . . 0.0 110.097 179.757 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.493 ' SG ' ' HG3' ' A' ' 27' ' ' ARG . 94.6 m -135.95 154.16 51.19 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.361 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -94.58 17.35 59.26 Favored Glycine 0 N--CA 1.446 -0.692 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 176.723 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.415 ' HB2' ' HB2' ' A' ' 25' ' ' CYS . 17.6 mm-40 -90.08 148.44 23.02 Favored 'General case' 0 N--CA 1.42 -1.946 0 CA-C-N 113.888 -1.156 . . . . 0.0 107.884 179.035 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' THR . . . . . 0.41 HG22 HG12 ' A' ' 24' ' ' VAL . 3.7 p -127.77 146.81 50.47 Favored 'General case' 0 C--N 1.268 -2.948 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.57 -179.755 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 21.7 p -127.18 35.99 4.49 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-O 121.07 0.462 . . . . 0.0 110.337 -176.579 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 25.2 t -57.25 -35.12 47.6 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 CA-C-N 115.06 -0.973 . . . . 0.0 109.828 -179.42 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -93.12 4.91 75.05 Favored Glycine 0 N--CA 1.437 -1.283 0 CA-C-N 115.526 -0.761 . . . . 0.0 113.171 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 151.43 -79.94 0.2 Allowed Glycine 0 N--CA 1.443 -0.841 0 C-N-CA 119.431 -1.366 . . . . 0.0 114.594 178.942 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 5.1 m -149.75 164.74 34.46 Favored 'General case' 0 N--CA 1.435 -1.187 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 -172.46 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.406 ' SG ' ' HB3' ' A' ' 6' ' ' GLU . 91.7 m -98.58 149.04 23.17 Favored 'General case' 0 C--N 1.285 -2.2 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 175.364 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 89.1 m-20 -95.2 -0.37 53.23 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-O 121.437 0.637 . . . . 0.0 111.409 -179.002 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 56.2 m -85.73 111.19 35.79 Favored Pre-proline 0 N--CA 1.429 -1.509 0 N-CA-C 106.29 -1.744 . . . . 0.0 106.29 171.101 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -68.54 -12.29 34.33 Favored 'Trans proline' 0 C--N 1.36 1.181 0 C-N-CA 123.27 2.646 . . . . 0.0 115.664 -168.828 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -87.16 -15.74 62.02 Favored Glycine 1 C--N 1.251 -4.153 0 CA-C-N 114.65 -1.159 . . . . 0.0 110.571 178.813 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.601 ' HA ' ' O ' ' A' ' 26' ' ' THR . 58.1 m -105.63 125.48 51.03 Favored 'General case' 0 N--CA 1.414 -2.243 0 CA-C-N 115.098 -0.551 . . . . 0.0 110.076 -177.597 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 5.0 m -103.71 148.29 26.23 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 -179.021 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 46.7 t -78.91 125.57 29.54 Favored 'General case' 0 N--CA 1.413 -2.318 0 CA-C-O 122.113 0.958 . . . . 0.0 110.537 -178.262 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 37.5 m -130.66 59.26 1.67 Allowed 'General case' 0 N--CA 1.398 -3.06 0 N-CA-C 105.345 -2.094 . . . . 0.0 105.345 174.806 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.45 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 31.6 t90 -28.08 132.97 0.17 Allowed Pre-proline 0 C--O 1.246 0.877 0 C-N-CA 127.381 2.272 . . . . 0.0 114.348 -171.052 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.45 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 5.1 Cg_exo -88.48 6.94 68.4 Favored 'Cis proline' 0 CA--C 1.54 0.8 0 C-N-CA 123.044 -1.648 . . . . 0.0 114.631 2.328 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.41 HG12 HG22 ' A' ' 7' ' ' THR . 27.5 m -113.79 152.83 15.42 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.137 0 C-N-CA 120.329 -0.548 . . . . 0.0 112.464 -175.479 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.419 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 36.0 m -96.13 145.77 25.22 Favored 'General case' 0 N--CA 1.406 -2.631 0 CA-C-O 122.02 0.914 . . . . 0.0 112.716 176.035 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.601 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 19.6 p -121.51 -162.6 0.98 Allowed 'General case' 0 C--N 1.293 -1.883 0 CA-C-N 114.036 -1.438 . . . . 0.0 108.059 179.672 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.493 ' HG3' ' SG ' ' A' ' 4' ' ' CYS . 78.9 mtt180 -123.36 162.24 23.13 Favored 'General case' 0 N--CA 1.397 -3.083 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 177.927 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -139.25 135.36 33.81 Favored 'General case' 0 C--N 1.273 -2.718 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 178.157 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 60.96 16.7 48.67 Favored Glycine 0 N--CA 1.464 0.556 0 O-C-N 123.306 0.379 . . . . 0.0 113.078 179.555 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 57.7 mt -129.21 157.61 75.53 Favored Pre-proline 0 C--N 1.298 -1.67 0 C-N-CA 122.314 0.246 . . . . 0.0 111.007 -174.784 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 22.7 Cg_exo -62.07 137.2 65.31 Favored 'Trans proline' 0 C--O 1.254 1.278 0 C-N-CA 122.261 1.974 . . . . 0.0 109.735 175.154 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 28.2 t -87.58 114.29 26.22 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.565 0 CA-C-O 121.567 0.699 . . . . 0.0 109.407 -176.683 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 11.0 t . . . . . 0 C--N 1.262 -3.234 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 176.27 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 77.7 m . . . . . 0 N--CA 1.442 -0.854 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -82.61 8.48 62.0 Favored Glycine 0 C--N 1.308 -0.999 0 C-N-CA 121.432 -0.414 . . . . 0.0 113.168 -176.03 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.416 ' HG3' ' SG ' ' A' ' 25' ' ' CYS . 12.4 pt-20 -90.13 156.67 18.19 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 -179.393 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . 0.415 ' HB ' HG23 ' A' ' 9' ' ' VAL . 5.8 p -107.55 161.7 14.61 Favored 'General case' 0 N--CA 1.409 -2.503 0 CA-C-O 120.739 0.305 . . . . 0.0 110.767 178.715 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.441 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 19.1 p -127.66 35.7 4.47 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -178.622 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.415 HG23 ' HB ' ' A' ' 7' ' ' THR . 29.6 t -52.36 -37.31 23.03 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.987 0 CA-C-N 114.81 -1.086 . . . . 0.0 111.628 -177.559 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -68.95 -37.52 83.52 Favored Glycine 0 N--CA 1.443 -0.846 0 C-N-CA 121.068 -0.587 . . . . 0.0 111.94 177.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 157.05 -20.53 0.43 Allowed Glycine 0 N--CA 1.44 -1.035 0 C-N-CA 119.472 -1.347 . . . . 0.0 115.483 177.646 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 27.6 m -155.89 164.86 37.97 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 -176.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 40.3 m -94.71 164.65 12.86 Favored 'General case' 0 C--N 1.283 -2.312 0 C-N-CA 123.688 0.795 . . . . 0.0 108.949 178.536 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 39.7 m-80 -93.5 -30.86 14.81 Favored 'General case' 0 C--N 1.302 -1.477 0 CA-C-O 121.163 0.506 . . . . 0.0 110.008 -177.595 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.503 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 20.6 m -90.13 120.28 69.22 Favored Pre-proline 0 C--N 1.304 -1.395 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 176.836 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -71.05 -3.56 13.11 Favored 'Trans proline' 0 N--CA 1.485 1.022 0 C-N-CA 123.258 2.639 . . . . 0.0 114.285 -175.626 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -89.0 -11.94 64.41 Favored Glycine 0 C--N 1.269 -3.19 0 CA-C-N 114.176 -1.375 . . . . 0.0 110.117 176.453 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.503 ' SG ' ' HB ' ' A' ' 15' ' ' THR . 34.5 m -103.68 144.67 31.15 Favored 'General case' 0 N--CA 1.423 -1.817 0 CA-C-N 114.761 -0.719 . . . . 0.0 109.25 -179.372 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 14.7 m -112.7 151.33 30.34 Favored 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 179.5 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 52.0 t -89.14 118.69 29.03 Favored 'General case' 0 C--N 1.277 -2.549 0 CA-C-O 121.531 0.682 . . . . 0.0 110.318 -179.34 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 63.0 m -116.54 63.81 0.71 Allowed 'General case' 0 N--CA 1.407 -2.579 0 N-CA-C 104.54 -2.393 . . . . 0.0 104.54 171.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.459 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 40.6 t90 -36.27 132.43 0.61 Allowed Pre-proline 0 N--CA 1.437 -1.082 0 C-N-CA 126.404 1.882 . . . . 0.0 113.592 -170.144 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.459 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 2.8 Cg_endo -90.31 13.56 53.0 Favored 'Cis proline' 0 CA--C 1.547 1.139 0 C-N-CA 122.882 -1.716 . . . . 0.0 114.849 2.039 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.404 HG12 HG22 ' A' ' 7' ' ' THR . 27.6 m -110.91 144.46 18.82 Favored 'Isoleucine or valine' 0 C--O 1.204 -1.316 0 N-CA-C 112.877 0.695 . . . . 0.0 112.877 -176.936 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.441 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 76.5 m -86.19 152.14 23.06 Favored 'General case' 0 N--CA 1.407 -2.578 0 O-C-N 121.164 -0.96 . . . . 0.0 110.693 176.287 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.429 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.6 p -130.83 -176.89 4.14 Favored 'General case' 0 C--N 1.291 -1.951 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 175.164 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 14.4 ttm180 . . . . . 0 N--CA 1.416 -2.172 0 N-CA-C 106.107 -1.812 . . . . 0.0 106.107 178.844 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 81.4 m . . . . . 0 N--CA 1.429 -1.489 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -76.13 7.12 31.35 Favored Glycine 0 C--N 1.31 -0.881 0 CA-C-N 115.877 -0.601 . . . . 0.0 112.853 -178.165 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -90.56 150.18 21.85 Favored 'General case' 0 N--CA 1.417 -2.122 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 178.823 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 6.6 p -109.7 154.17 23.25 Favored 'General case' 0 N--CA 1.392 -3.372 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.439 178.031 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.509 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 20.0 p -118.06 37.28 4.03 Favored 'General case' 0 CA--C 1.484 -1.575 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -177.807 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.8 t -55.71 -35.64 39.92 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.971 0 CA-C-N 115.002 -0.999 . . . . 0.0 109.912 -178.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -65.7 -26.26 71.99 Favored Glycine 0 N--CA 1.446 -0.693 0 CA-C-N 115.354 -0.839 . . . . 0.0 112.587 178.244 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 137.41 -22.01 3.23 Favored Glycine 0 N--CA 1.437 -1.249 0 C-N-CA 120.849 -0.691 . . . . 0.0 113.917 178.782 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 12.1 m -150.31 158.99 44.76 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 -175.624 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.509 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 61.0 m -95.23 155.94 16.52 Favored 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 176.467 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 40.1 m-80 -88.72 -18.61 27.47 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-O 121.178 0.513 . . . . 0.0 111.194 -178.613 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.554 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 34.0 m -101.14 124.77 40.31 Favored Pre-proline 0 C--N 1.297 -1.684 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 175.316 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -68.57 -13.68 37.85 Favored 'Trans proline' 0 N--CA 1.488 1.151 0 C-N-CA 122.974 2.449 . . . . 0.0 112.907 -178.2 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.429 ' H ' HG22 ' A' ' 15' ' ' THR . . . -84.55 -12.78 74.61 Favored Glycine 0 C--N 1.263 -3.525 0 CA-C-N 113.311 -1.768 . . . . 0.0 110.525 178.633 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.644 ' HA ' ' O ' ' A' ' 26' ' ' THR . 56.1 m -103.51 126.28 50.57 Favored 'General case' 0 N--CA 1.403 -2.792 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 -179.153 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.464 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 1.1 m -89.23 144.03 26.4 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 -177.77 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 53.7 t -88.14 103.26 15.59 Favored 'General case' 0 N--CA 1.421 -1.904 0 C-N-CA 119.602 -0.839 . . . . 0.0 109.887 177.764 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 14.7 m -104.82 58.36 0.69 Allowed 'General case' 0 C--N 1.285 -2.231 0 N-CA-C 104.473 -2.417 . . . . 0.0 104.473 174.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.444 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 42.1 t90 -33.98 132.9 0.38 Allowed Pre-proline 0 N--CA 1.441 -0.893 0 C-N-CA 127.133 2.173 . . . . 0.0 113.495 -169.808 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.444 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 4.5 Cg_exo -89.31 11.32 59.45 Favored 'Cis proline' 0 C--N 1.322 -0.859 0 C-N-CA 122.851 -1.729 . . . . 0.0 114.981 2.203 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 34.8 m -109.68 143.6 19.49 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.765 0 C-N-CA 120.166 -0.614 . . . . 0.0 112.538 -176.458 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.513 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 77.5 m -89.36 147.92 23.8 Favored 'General case' 0 N--CA 1.414 -2.273 0 O-C-N 121.7 -0.625 . . . . 0.0 110.984 177.21 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.644 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.9 p -132.74 -167.31 1.88 Allowed 'General case' 0 C--O 1.195 -1.796 0 C-N-CA 123.923 0.889 . . . . 0.0 109.206 178.069 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 98.8 mtt180 . . . . . 0 N--CA 1.399 -2.996 0 CA-C-N 119.048 0.84 . . . . 0.0 109.51 179.083 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.444 ' HB3' ' HG2' ' A' ' 6' ' ' GLU . 4.0 m . . . . . 0 N--CA 1.413 -2.275 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -88.92 -5.75 73.25 Favored Glycine 0 N--CA 1.439 -1.165 0 N-CA-C 110.123 -1.191 . . . . 0.0 110.123 177.83 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.444 ' HG2' ' HB3' ' A' ' 4' ' ' CYS . 13.0 pt-20 -78.77 147.93 33.16 Favored 'General case' 0 N--CA 1.428 -1.558 0 CA-C-N 114.92 -0.64 . . . . 0.0 109.438 179.689 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 32.2 p -105.01 155.09 19.29 Favored 'General case' 0 N--CA 1.401 -2.907 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.271 -177.178 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.624 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 30.0 p -118.8 41.62 2.98 Favored 'General case' 0 N--CA 1.428 -1.537 0 CA-C-O 121.614 0.721 . . . . 0.0 109.228 -179.104 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 35.4 t -56.57 -36.47 48.23 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.919 0 CA-C-N 114.933 -1.03 . . . . 0.0 111.075 -178.366 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -91.7 3.93 78.66 Favored Glycine 0 CA--C 1.519 0.312 0 N-CA-C 112.025 -0.43 . . . . 0.0 112.025 178.338 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 83.17 42.51 7.98 Favored Glycine 0 N--CA 1.44 -1.066 0 C-N-CA 121.753 -0.26 . . . . 0.0 112.847 179.231 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.3 t -155.09 151.03 27.84 Favored 'General case' 0 N--CA 1.431 -1.377 0 CA-C-O 121.286 0.565 . . . . 0.0 111.227 179.219 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.491 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 82.9 m -138.2 145.85 41.94 Favored 'General case' 0 C--N 1.286 -2.166 0 CA-C-N 113.812 -1.54 . . . . 0.0 108.105 178.696 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 31.6 m-80 -87.18 -39.25 15.66 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-O 121.61 0.719 . . . . 0.0 110.162 -178.505 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 16.0 m -78.52 120.85 82.55 Favored Pre-proline 0 C--N 1.305 -1.366 0 N-CA-C 108.785 -0.821 . . . . 0.0 108.785 178.208 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -72.98 -8.42 22.22 Favored 'Trans proline' 0 C--N 1.365 1.425 0 C-N-CA 122.802 2.335 . . . . 0.0 113.127 -175.501 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -92.97 -6.66 63.21 Favored Glycine 0 C--N 1.265 -3.369 0 CA-C-N 113.45 -1.705 . . . . 0.0 109.881 177.725 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.512 ' HA ' ' O ' ' A' ' 26' ' ' THR . 98.7 m -109.57 125.93 53.05 Favored 'General case' 0 N--CA 1.401 -2.898 0 CA-C-O 122.532 1.158 . . . . 0.0 111.106 179.202 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 3.5 m -100.09 153.23 19.39 Favored 'General case' 0 N--CA 1.401 -2.916 0 C-N-CA 127.153 2.181 . . . . 0.0 107.688 -175.283 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 53.9 t -85.27 117.59 24.3 Favored 'General case' 0 C--N 1.285 -2.198 0 CA-C-O 121.466 0.65 . . . . 0.0 110.364 179.001 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 21.3 t -124.55 74.88 1.36 Allowed 'General case' 0 C--N 1.282 -2.364 0 N-CA-C 103.197 -2.89 . . . . 0.0 103.197 172.47 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.497 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 42.9 t90 -39.56 133.88 1.28 Allowed Pre-proline 0 N--CA 1.431 -1.411 0 CA-C-N 113.858 -1.519 . . . . 0.0 113.096 -171.063 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.497 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 1.4 Cg_endo -92.38 15.27 46.72 Favored 'Cis proline' 0 CA--C 1.541 0.868 0 C-N-CA 122.874 -1.719 . . . . 0.0 114.695 1.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 30.9 m -115.63 146.62 19.82 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 N-CA-C 113.986 1.106 . . . . 0.0 113.986 -175.696 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.624 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 70.0 m -83.8 132.93 34.79 Favored 'General case' 0 N--CA 1.402 -2.846 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 173.309 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.512 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 2.5 p -135.55 -176.57 4.33 Favored 'General case' 0 C--O 1.182 -2.485 0 C-N-CA 124.057 0.943 . . . . 0.0 108.654 -179.779 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 57.2 mtp180 . . . . . 0 N--CA 1.407 -2.585 0 CA-C-N 119.515 1.052 . . . . 0.0 110.009 -177.407 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 73.2 m . . . . . 0 N--CA 1.431 -1.4 0 N-CA-C 109.665 -0.495 . . . . 0.0 109.665 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -88.41 16.9 51.51 Favored Glycine 0 C--N 1.315 -0.612 0 N-CA-C 110.741 -0.944 . . . . 0.0 110.741 177.65 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.437 ' HB2' ' HB2' ' A' ' 25' ' ' CYS . 6.0 mm-40 -90.35 150.63 21.81 Favored 'General case' 0 N--CA 1.432 -1.354 0 C-N-CA 124.018 0.927 . . . . 0.0 109.881 -178.817 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 7.1 p -124.58 151.94 44.15 Favored 'General case' 0 N--CA 1.411 -2.384 0 CA-C-N 116.186 -0.461 . . . . 0.0 109.869 176.025 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.497 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 27.0 p -130.9 41.12 3.4 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-O 121.446 0.641 . . . . 0.0 109.989 -176.507 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 19.4 t -61.87 -32.94 55.64 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 114.965 -1.016 . . . . 0.0 109.533 -179.317 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -85.79 -1.61 87.08 Favored Glycine 0 N--CA 1.442 -0.943 0 CA-C-N 115.452 -0.795 . . . . 0.0 111.78 178.834 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 109.4 -10.14 33.18 Favored Glycine 0 N--CA 1.433 -1.516 0 N-CA-C 114.81 0.684 . . . . 0.0 114.81 176.059 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 1.1 m -137.55 152.57 49.59 Favored 'General case' 0 N--CA 1.43 -1.471 0 CA-C-N 118.773 1.286 . . . . 0.0 110.198 -174.708 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.497 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 82.8 m -106.92 136.39 46.84 Favored 'General case' 0 C--N 1.277 -2.546 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 174.469 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . 0.41 ' HB2' ' OE2' ' A' ' 6' ' ' GLU . 33.9 m-80 -65.54 -44.44 86.85 Favored 'General case' 0 N--CA 1.475 0.778 0 CA-C-O 121.236 0.541 . . . . 0.0 109.816 176.884 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 55.0 m -83.33 112.48 39.35 Favored Pre-proline 0 N--CA 1.43 -1.447 0 N-CA-C 108.852 -0.796 . . . . 0.0 108.852 175.197 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -75.87 -1.39 11.34 Favored 'Trans proline' 0 C--N 1.359 1.096 0 C-N-CA 123.337 2.691 . . . . 0.0 113.781 -174.716 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -86.69 -10.64 72.57 Favored Glycine 0 C--N 1.27 -3.084 0 CA-C-N 113.971 -1.468 . . . . 0.0 110.356 177.14 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.445 ' HA ' ' O ' ' A' ' 26' ' ' THR . 49.9 m -105.92 133.5 50.54 Favored 'General case' 0 N--CA 1.419 -2.006 0 CA-C-N 114.552 -0.824 . . . . 0.0 109.537 -179.053 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.433 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 5.8 m -89.86 151.88 21.54 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 108.299 -1.001 . . . . 0.0 108.299 -177.693 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 50.5 t -88.52 104.71 17.07 Favored 'General case' 0 C--N 1.292 -1.93 0 CA-C-O 122.021 0.915 . . . . 0.0 111.331 179.604 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 42.6 t -107.51 65.59 0.65 Allowed 'General case' 0 C--N 1.285 -2.201 0 N-CA-C 104.22 -2.511 . . . . 0.0 104.22 173.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.444 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 56.7 t90 -36.24 132.63 0.61 Allowed Pre-proline 0 N--CA 1.439 -1.018 0 C-N-CA 125.884 1.673 . . . . 0.0 112.668 -172.171 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.444 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 2.2 Cg_endo -90.23 10.76 60.48 Favored 'Cis proline' 0 CA--C 1.546 1.117 0 C-N-CA 123.017 -1.66 . . . . 0.0 115.294 3.09 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 30.6 m -111.34 153.78 13.03 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.0 0 O-C-N 121.561 -0.712 . . . . 0.0 112.466 -176.611 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.476 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 68.3 m -92.89 135.37 34.2 Favored 'General case' 0 N--CA 1.397 -3.078 0 O-C-N 121.835 -0.541 . . . . 0.0 109.617 175.044 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.445 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 11.8 p -116.45 -174.21 2.52 Favored 'General case' 0 C--N 1.285 -2.23 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.836 -179.558 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.383 -3.784 0 CA-C-O 121.523 0.677 . . . . 0.0 110.901 -176.79 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 71.9 m . . . . . 0 N--CA 1.439 -0.996 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -94.93 -2.76 62.45 Favored Glycine 0 C--N 1.308 -1.005 0 C-N-CA 121.227 -0.511 . . . . 0.0 111.869 -176.521 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.443 ' O ' ' HB2' ' A' ' 25' ' ' CYS . 1.6 pm0 -83.82 141.74 31.13 Favored 'General case' 0 N--CA 1.426 -1.673 0 CA-C-O 121.488 0.661 . . . . 0.0 110.87 177.001 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . 0.414 HG22 HG12 ' A' ' 24' ' ' VAL . 22.8 p -106.83 153.57 22.29 Favored 'General case' 0 N--CA 1.404 -2.732 0 CA-C-N 115.279 -0.873 . . . . 0.0 109.765 -179.603 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.467 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 19.5 p -122.01 37.59 4.33 Favored 'General case' 0 CA--C 1.492 -1.277 0 CA-C-O 121.389 0.614 . . . . 0.0 110.268 -177.876 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 16.0 t -60.06 -33.99 55.04 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.204 0 CA-C-N 114.734 -1.121 . . . . 0.0 109.636 -178.646 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -87.73 6.62 83.17 Favored Glycine 0 N--CA 1.439 -1.107 0 CA-C-N 115.258 -0.883 . . . . 0.0 113.087 179.647 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 142.18 -69.01 0.44 Allowed Glycine 0 N--CA 1.438 -1.189 0 C-N-CA 120.131 -1.033 . . . . 0.0 114.502 177.384 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 20.5 m -157.04 163.24 39.27 Favored 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 106.748 -1.575 . . . . 0.0 106.748 -174.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 98.3 m -94.76 158.49 15.48 Favored 'General case' 0 C--N 1.281 -2.384 0 CA-C-O 120.808 0.337 . . . . 0.0 110.493 178.58 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 16.1 m120 -84.39 -26.73 28.15 Favored 'General case' 0 C--N 1.31 -1.144 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.845 -178.64 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 9.1 m -71.22 112.87 15.14 Favored Pre-proline 0 CA--C 1.556 1.175 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 177.243 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -70.8 -10.21 27.28 Favored 'Trans proline' 0 C--N 1.362 1.274 0 C-N-CA 123.293 2.662 . . . . 0.0 115.257 -172.101 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -93.3 -6.06 63.18 Favored Glycine 0 C--N 1.258 -3.753 0 CA-C-N 114.309 -1.314 . . . . 0.0 111.124 179.121 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.506 ' HA ' ' O ' ' A' ' 26' ' ' THR . 60.3 m -108.49 126.01 52.43 Favored 'General case' 0 N--CA 1.422 -1.834 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 1.4 m -95.16 143.9 26.22 Favored 'General case' 0 C--N 1.284 -2.268 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 -178.203 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 41.1 t -87.65 125.94 34.67 Favored 'General case' 0 C--N 1.285 -2.225 0 CA-C-O 121.593 0.711 . . . . 0.0 109.879 -179.873 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 6.4 t -132.22 71.41 1.47 Allowed 'General case' 0 N--CA 1.4 -2.973 0 N-CA-C 103.426 -2.805 . . . . 0.0 103.426 174.53 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.485 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 55.5 t90 -35.69 132.87 0.53 Allowed Pre-proline 0 N--CA 1.433 -1.297 0 C-N-CA 126.319 1.848 . . . . 0.0 112.95 -171.281 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.485 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 1.6 Cg_endo -91.95 10.59 58.15 Favored 'Cis proline' 0 CA--C 1.539 0.729 0 C-N-CA 123.081 -1.633 . . . . 0.0 115.381 4.053 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.414 HG12 HG22 ' A' ' 7' ' ' THR . 34.1 m -118.56 150.03 20.88 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 C-N-CA 119.511 -0.875 . . . . 0.0 112.438 -175.177 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.467 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 64.5 m -95.66 148.56 22.41 Favored 'General case' 0 N--CA 1.398 -3.047 0 CA-C-O 121.704 0.764 . . . . 0.0 111.331 175.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.506 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 0.6 OUTLIER -135.47 -165.23 1.66 Allowed 'General case' 0 C--N 1.284 -2.242 0 CA-C-N 114.518 -1.219 . . . . 0.0 109.975 177.851 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.405 HH11 ' HD3' ' A' ' 27' ' ' ARG . 3.8 ptm180 . . . . . 0 N--CA 1.389 -3.491 0 CA-C-O 121.746 0.784 . . . . 0.0 110.554 -174.476 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 65.2 m . . . . . 0 N--CA 1.438 -1.029 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -96.25 14.72 64.06 Favored Glycine 0 C--N 1.314 -0.678 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 176.534 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.501 ' HB2' ' HB2' ' A' ' 25' ' ' CYS . 6.7 mm-40 -81.21 149.76 28.92 Favored 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 179.132 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 18.3 p -123.49 150.75 43.54 Favored 'General case' 0 N--CA 1.401 -2.914 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 177.198 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.499 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 30.1 p -127.22 44.85 2.83 Favored 'General case' 0 N--CA 1.427 -1.578 0 CA-C-O 121.231 0.539 . . . . 0.0 109.588 -177.103 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 38.8 t -57.62 -33.82 45.75 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.059 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.894 -178.37 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -81.09 -31.49 34.71 Favored Glycine 0 N--CA 1.444 -0.83 0 N-CA-C 110.803 -0.919 . . . . 0.0 110.803 175.474 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 124.84 14.89 3.31 Favored Glycine 0 N--CA 1.441 -1.006 0 C-N-CA 121.507 -0.378 . . . . 0.0 113.613 178.41 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 12.7 m -139.62 153.77 47.42 Favored 'General case' 0 N--CA 1.424 -1.727 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 -178.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.499 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 41.5 m -122.59 137.93 54.74 Favored 'General case' 0 C--N 1.274 -2.709 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 175.194 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -66.01 -52.44 49.24 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.043 178.188 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 32.8 m -73.39 112.53 16.32 Favored Pre-proline 0 CA--C 1.554 1.122 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 176.57 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -72.86 -4.64 15.74 Favored 'Trans proline' 0 C--N 1.36 1.178 0 C-N-CA 123.438 2.759 . . . . 0.0 114.868 -172.85 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -86.0 -14.77 66.37 Favored Glycine 0 C--N 1.257 -3.822 0 CA-C-N 114.388 -1.278 . . . . 0.0 110.358 177.416 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.541 ' HA ' ' O ' ' A' ' 26' ' ' THR . 22.0 m -103.95 129.94 51.54 Favored 'General case' 0 N--CA 1.419 -1.999 0 CA-C-N 114.952 -0.624 . . . . 0.0 109.658 -179.163 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 4.3 m -95.85 156.48 16.31 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 124.346 1.058 . . . . 0.0 108.151 -178.806 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 42.0 t -83.04 123.76 29.78 Favored 'General case' 0 N--CA 1.423 -1.809 0 CA-C-O 121.61 0.719 . . . . 0.0 110.987 -179.299 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 32.7 t -133.76 69.93 1.46 Allowed 'General case' 0 C--N 1.283 -2.306 0 N-CA-C 104.526 -2.398 . . . . 0.0 104.526 173.831 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.437 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 41.7 t90 -36.53 134.59 0.6 Allowed Pre-proline 0 N--CA 1.443 -0.821 0 C-N-CA 126.258 1.823 . . . . 0.0 113.93 -170.702 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.437 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 1.9 Cg_endo -90.12 8.83 65.17 Favored 'Cis proline' 0 N--CA 1.456 -0.705 0 C-N-CA 122.679 -1.8 . . . . 0.0 114.261 1.277 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 35.9 m -108.88 158.66 8.62 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.928 0 CA-C-O 121.415 0.626 . . . . 0.0 112.548 -175.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.501 ' HB2' ' HB2' ' A' ' 6' ' ' GLU . 84.1 m -95.41 135.52 36.94 Favored 'General case' 0 N--CA 1.405 -2.7 0 O-C-N 121.733 -0.604 . . . . 0.0 109.829 174.453 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.541 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 10.5 p -119.35 -169.46 1.76 Allowed 'General case' 0 C--N 1.286 -2.168 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.83 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 10.5 mtp-105 . . . . . 0 N--CA 1.392 -3.326 0 CA-C-O 121.878 0.847 . . . . 0.0 110.442 -177.447 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.722 ' SG ' ' HG3' ' A' ' 27' ' ' ARG . 78.0 m . . . . . 0 N--CA 1.439 -0.978 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -81.57 -3.47 90.61 Favored Glycine 0 C--N 1.308 -1.007 0 C-N-CA 120.99 -0.624 . . . . 0.0 111.944 -179.501 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -89.62 160.06 16.84 Favored 'General case' 0 N--CA 1.437 -1.096 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 179.602 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . 0.526 ' HB ' HG23 ' A' ' 9' ' ' VAL . 38.0 p -113.88 164.07 14.25 Favored 'General case' 0 N--CA 1.406 -2.647 0 CA-C-O 121.109 0.481 . . . . 0.0 112.271 -174.83 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.495 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 26.1 p -131.41 33.8 4.03 Favored 'General case' 0 N--CA 1.426 -1.663 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 178.034 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.526 HG23 ' HB ' ' A' ' 7' ' ' THR . 21.9 t -57.7 -35.52 51.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 114.74 -1.118 . . . . 0.0 110.01 -178.766 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -82.27 -4.77 90.08 Favored Glycine 0 N--CA 1.444 -0.782 0 CA-C-N 115.684 -0.689 . . . . 0.0 113.063 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 128.46 -24.98 4.87 Favored Glycine 0 N--CA 1.444 -0.771 0 C-N-CA 120.231 -0.985 . . . . 0.0 114.344 177.497 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 15.3 t -156.89 173.03 17.61 Favored 'General case' 0 N--CA 1.431 -1.402 0 CA-C-N 118.277 1.039 . . . . 0.0 110.446 -175.689 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 57.5 m -101.77 175.88 5.41 Favored 'General case' 0 C--N 1.276 -2.612 0 CA-C-N 114.527 -1.215 . . . . 0.0 109.977 -175.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 51.0 m-80 -97.88 -38.32 9.48 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.046 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.422 HG22 ' H ' ' A' ' 17' ' ' GLY . 33.9 m -90.03 126.12 58.28 Favored Pre-proline 0 N--CA 1.429 -1.524 0 CA-C-N 115.505 -0.77 . . . . 0.0 108.979 178.33 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -72.33 -2.34 11.55 Favored 'Trans proline' 0 C--N 1.358 1.043 0 C-N-CA 122.693 2.262 . . . . 0.0 113.416 -177.383 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.422 ' H ' HG22 ' A' ' 15' ' ' THR . . . -93.07 -10.09 60.08 Favored Glycine 0 C--N 1.271 -3.054 0 CA-C-N 113.836 -1.529 . . . . 0.0 110.311 177.176 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.577 ' HB3' ' HB3' ' A' ' 25' ' ' CYS . 80.3 m -104.09 132.37 50.4 Favored 'General case' 0 N--CA 1.42 -1.926 0 CA-C-N 114.96 -0.62 . . . . 0.0 109.472 179.478 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 7.5 m -101.49 156.43 17.47 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 -179.736 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 44.4 t -88.16 123.97 33.35 Favored 'General case' 0 N--CA 1.418 -2.066 0 CA-C-O 121.409 0.623 . . . . 0.0 109.961 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 8.8 t -130.82 62.83 1.6 Allowed 'General case' 0 C--N 1.282 -2.34 0 N-CA-C 103.463 -2.792 . . . . 0.0 103.463 175.121 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.489 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 35.5 t90 -33.28 135.78 0.29 Allowed Pre-proline 0 C--O 1.243 0.732 0 C-N-CA 127.827 2.451 . . . . 0.0 113.821 -170.335 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.489 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 4.4 Cg_exo -88.4 4.98 69.71 Favored 'Cis proline' 0 CA--C 1.534 0.507 0 C-N-CA 123.004 -1.665 . . . . 0.0 114.812 2.183 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 34.1 m -107.82 157.66 7.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 C-N-CA 120.26 -0.576 . . . . 0.0 111.913 -176.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.577 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 93.1 m -91.28 150.33 21.37 Favored 'General case' 0 N--CA 1.404 -2.77 0 CA-C-O 121.305 0.574 . . . . 0.0 111.086 177.063 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.518 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 16.7 p -130.9 -178.65 4.9 Favored 'General case' 0 N--CA 1.421 -1.895 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.624 179.765 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.722 ' HG3' ' SG ' ' A' ' 4' ' ' CYS . 34.4 mtt85 . . . . . 0 N--CA 1.414 -2.241 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 -177.798 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 73.7 m . . . . . 0 N--CA 1.446 -0.66 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -77.78 -6.24 86.94 Favored Glycine 0 C--N 1.312 -0.778 0 C-N-CA 121.212 -0.518 . . . . 0.0 113.163 -177.262 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -86.14 146.94 26.37 Favored 'General case' 0 C--N 1.308 -1.222 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 -179.398 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . 0.458 HG22 HG12 ' A' ' 24' ' ' VAL . 24.9 p -104.39 161.43 14.08 Favored 'General case' 0 N--CA 1.414 -2.255 0 CA-C-O 121.013 0.435 . . . . 0.0 111.891 -179.401 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.471 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 9.2 p -126.63 34.72 4.75 Favored 'General case' 0 CA--C 1.492 -1.255 0 CA-C-O 121.271 0.558 . . . . 0.0 110.27 -178.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.459 ' HA ' ' NE1' ' A' ' 22' ' ' TRP . 5.7 t -65.43 -28.79 45.27 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-N 115.273 -0.876 . . . . 0.0 109.46 -178.698 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -79.76 -15.83 78.58 Favored Glycine 0 C--O 1.241 0.564 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.512 177.814 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 125.98 -18.39 6.63 Favored Glycine 0 N--CA 1.436 -1.361 0 C-N-CA 120.519 -0.848 . . . . 0.0 115.217 175.695 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.5 m -145.67 158.14 43.88 Favored 'General case' 0 N--CA 1.437 -1.092 0 CA-C-N 118.764 1.282 . . . . 0.0 108.172 -175.341 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 62.7 m -99.51 170.85 8.32 Favored 'General case' 0 C--N 1.281 -2.372 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 175.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 26.9 m-80 -101.37 -18.82 15.87 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.468 0.651 . . . . 0.0 110.621 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.576 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 29.2 m -105.58 124.83 35.0 Favored Pre-proline 0 C--N 1.293 -1.888 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 175.561 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -73.29 -3.26 13.38 Favored 'Trans proline' 0 N--CA 1.486 1.078 0 C-N-CA 122.744 2.296 . . . . 0.0 113.098 -177.735 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.409 ' H ' HG22 ' A' ' 15' ' ' THR . . . -94.89 -8.03 59.47 Favored Glycine 0 C--N 1.27 -3.134 0 CA-C-N 113.38 -1.736 . . . . 0.0 109.839 176.419 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.621 ' HA ' ' O ' ' A' ' 26' ' ' THR . 85.0 m -106.12 125.75 51.37 Favored 'General case' 0 N--CA 1.419 -1.998 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.168 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 7.4 m -101.55 160.42 14.46 Favored 'General case' 0 C--N 1.286 -2.168 0 N-CA-C 107.483 -1.302 . . . . 0.0 107.483 -178.839 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 42.1 t -93.11 122.58 35.63 Favored 'General case' 0 N--CA 1.419 -2.013 0 CA-C-O 121.305 0.574 . . . . 0.0 110.911 -177.352 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 49.3 m -123.99 67.69 1.04 Allowed 'General case' 0 N--CA 1.409 -2.483 0 N-CA-C 105.03 -2.211 . . . . 0.0 105.03 171.644 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.465 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 50.4 t90 -37.27 133.69 0.73 Allowed Pre-proline 0 N--CA 1.435 -1.177 0 C-N-CA 126.091 1.757 . . . . 0.0 113.23 -170.157 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 1.9 Cg_endo -89.52 7.07 68.27 Favored 'Cis proline' 0 CA--C 1.55 1.299 0 C-N-CA 122.924 -1.698 . . . . 0.0 115.905 3.32 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.458 HG12 HG22 ' A' ' 7' ' ' THR . 33.3 m -109.52 151.47 11.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 O-C-N 121.581 -0.7 . . . . 0.0 112.421 -175.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.507 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 71.1 m -86.52 147.34 26.0 Favored 'General case' 0 N--CA 1.405 -2.68 0 CA-C-O 121.297 0.57 . . . . 0.0 109.954 175.395 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.621 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 31.0 p -132.6 -169.99 2.35 Favored 'General case' 0 C--N 1.294 -1.829 0 C-N-CA 122.758 0.423 . . . . 0.0 110.257 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 95.9 mtt180 . . . . . 0 N--CA 1.391 -3.396 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 -178.266 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 88.2 m . . . . . 0 N--CA 1.427 -1.596 0 N-CA-C 112.323 0.49 . . . . 0.0 112.323 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -89.88 23.41 20.43 Favored Glycine 0 C--N 1.316 -0.554 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 175.555 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.491 ' HB2' ' HB2' ' A' ' 25' ' ' CYS . 8.3 mm-40 -90.38 156.76 18.01 Favored 'General case' 0 N--CA 1.437 -1.109 0 C-N-CA 124.181 0.992 . . . . 0.0 110.005 -177.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 21.8 p -126.16 153.54 44.45 Favored 'General case' 0 N--CA 1.41 -2.443 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 174.23 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.428 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 21.6 p -124.79 33.75 5.15 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.781 -0.574 . . . . 0.0 111.005 -178.442 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.431 ' HA ' ' NE1' ' A' ' 22' ' ' TRP . 22.3 t -62.03 -35.98 71.57 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.867 0 CA-C-N 114.786 -1.097 . . . . 0.0 109.193 -179.835 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -71.33 -16.06 75.23 Favored Glycine 0 C--O 1.22 -0.733 0 CA-C-N 115.094 -0.957 . . . . 0.0 112.336 178.747 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 132.66 -23.65 3.97 Favored Glycine 0 N--CA 1.435 -1.428 0 C-N-CA 120.242 -0.98 . . . . 0.0 113.696 177.874 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 20.4 m -157.08 162.27 39.47 Favored 'General case' 0 C--N 1.31 -1.116 0 N-CA-C 107.114 -1.439 . . . . 0.0 107.114 -176.483 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 52.5 m -86.45 140.15 30.24 Favored 'General case' 0 C--N 1.283 -2.301 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 177.163 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 44.8 m-80 -72.0 -44.21 63.83 Favored 'General case' 0 C--N 1.315 -0.93 0 C-N-CA 120.746 -0.382 . . . . 0.0 110.892 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 27.2 m -76.34 121.08 84.27 Favored Pre-proline 0 CA--C 1.556 1.195 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 172.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_endo -71.24 -1.48 9.69 Favored 'Trans proline' 0 C--N 1.36 1.169 0 C-N-CA 123.551 2.834 . . . . 0.0 114.683 -173.45 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -95.06 2.32 65.9 Favored Glycine 0 C--N 1.261 -3.619 0 CA-C-N 114.506 -1.225 . . . . 0.0 112.003 -179.122 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 32.5 m -112.03 140.77 46.43 Favored 'General case' 0 N--CA 1.426 -1.674 0 CA-C-O 120.908 0.385 . . . . 0.0 111.674 -175.253 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 3.2 m -89.91 145.19 25.31 Favored 'General case' 0 C--N 1.315 -0.909 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 179.324 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 43.2 t -93.09 105.43 17.53 Favored 'General case' 0 C--N 1.29 -1.991 0 C-N-CA 120.073 -0.651 . . . . 0.0 110.369 177.547 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 2.3 p -113.97 65.69 0.66 Allowed 'General case' 0 C--N 1.278 -2.538 0 N-CA-C 106.274 -1.751 . . . . 0.0 106.274 173.444 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.47 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 49.2 t90 -34.83 135.34 0.41 Allowed Pre-proline 0 N--CA 1.446 -0.628 0 C-N-CA 126.985 2.114 . . . . 0.0 113.512 -169.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.47 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 1.8 Cg_endo -89.93 2.42 68.04 Favored 'Cis proline' 0 C--N 1.329 -0.499 0 C-N-CA 122.929 -1.696 . . . . 0.0 114.725 2.875 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.1 m -108.1 146.35 14.13 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 C-N-CA 120.259 -0.576 . . . . 0.0 111.95 -175.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.491 ' HB2' ' HB2' ' A' ' 6' ' ' GLU . 72.3 m -93.27 141.59 28.27 Favored 'General case' 0 N--CA 1.396 -3.162 0 CA-C-O 121.4 0.619 . . . . 0.0 111.5 179.341 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 1.4 p -109.14 -169.61 1.51 Allowed 'General case' 0 C--N 1.283 -2.313 0 CA-C-N 114.736 -1.12 . . . . 0.0 108.683 176.079 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 39.7 ttp180 . . . . . 0 N--CA 1.404 -2.73 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 -178.478 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 61.2 m . . . . . 0 N--CA 1.437 -1.092 0 CA-C-O 121.136 0.493 . . . . 0.0 110.049 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -84.98 -4.45 87.01 Favored Glycine 0 N--CA 1.443 -0.882 0 CA-C-N 115.699 -0.682 . . . . 0.0 113.978 -175.219 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -86.5 169.45 12.81 Favored 'General case' 0 C--N 1.309 -1.185 0 C-N-CA 119.836 -0.746 . . . . 0.0 111.064 -179.637 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . 0.42 HG22 HG12 ' A' ' 24' ' ' VAL . 7.0 p -120.36 155.52 33.22 Favored 'General case' 0 N--CA 1.401 -2.911 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 178.402 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.513 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 13.4 p -119.06 37.2 4.2 Favored 'General case' 0 CA--C 1.484 -1.587 0 CA-C-O 121.043 0.449 . . . . 0.0 110.571 -176.648 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.7 t -57.69 -34.2 47.02 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 CA-C-N 114.926 -1.034 . . . . 0.0 109.353 -179.612 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -70.62 -8.51 63.4 Favored Glycine 0 N--CA 1.436 -1.321 0 CA-C-N 114.964 -1.017 . . . . 0.0 113.557 179.172 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 144.21 -54.07 0.58 Allowed Glycine 0 N--CA 1.441 -0.979 0 C-N-CA 120.67 -0.776 . . . . 0.0 113.962 176.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 14.7 t -157.61 173.33 17.02 Favored 'General case' 0 N--CA 1.425 -1.72 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -176.226 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.513 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 35.6 m -96.21 137.29 35.49 Favored 'General case' 0 C--N 1.27 -2.867 0 CA-C-N 115.342 -0.844 . . . . 0.0 108.759 -178.158 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 40.8 m-80 -70.47 -47.74 59.13 Favored 'General case' 0 C--N 1.319 -0.755 0 O-C-N 123.199 0.312 . . . . 0.0 111.43 -179.168 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.405 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 42.3 m -69.91 119.56 72.2 Favored Pre-proline 0 N--CA 1.437 -1.079 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 178.774 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 15' ' ' THR . 22.0 Cg_exo -66.87 -9.82 26.14 Favored 'Trans proline' 0 C--N 1.36 1.134 0 C-N-CA 123.458 2.772 . . . . 0.0 113.927 -175.672 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -83.3 -17.27 67.12 Favored Glycine 0 C--N 1.265 -3.392 0 CA-C-N 113.787 -1.551 . . . . 0.0 110.412 177.252 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.493 ' HA ' ' O ' ' A' ' 26' ' ' THR . 47.8 m -108.55 126.68 53.2 Favored 'General case' 0 N--CA 1.416 -2.173 0 N-CA-C 108.096 -1.076 . . . . 0.0 108.096 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 6.8 m -101.22 148.04 25.57 Favored 'General case' 0 C--N 1.274 -2.701 0 N-CA-C 107.459 -1.311 . . . . 0.0 107.459 -175.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 50.3 t -90.78 106.27 18.4 Favored 'General case' 0 C--N 1.275 -2.653 0 CA-C-O 121.702 0.763 . . . . 0.0 110.662 -178.156 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 31.3 t -107.67 67.09 0.68 Allowed 'General case' 0 C--N 1.28 -2.426 0 N-CA-C 102.9 -3.0 . . . . 0.0 102.9 172.81 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.44 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 57.4 t90 -39.39 133.59 1.23 Allowed Pre-proline 0 N--CA 1.433 -1.286 0 CA-C-N 113.405 -1.725 . . . . 0.0 112.326 -171.356 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.44 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 1.9 Cg_endo -90.75 12.17 56.75 Favored 'Cis proline' 0 CA--C 1.543 0.967 0 C-N-CA 122.723 -1.782 . . . . 0.0 115.812 3.721 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.42 HG12 HG22 ' A' ' 7' ' ' THR . 21.0 m -110.66 146.86 15.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 119.071 0.851 . . . . 0.0 113.007 -176.419 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 90.9 m -86.53 140.64 29.71 Favored 'General case' 0 N--CA 1.401 -2.898 0 O-C-N 121.679 -0.638 . . . . 0.0 109.327 174.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.493 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 2.6 p -135.6 -177.3 4.61 Favored 'General case' 0 C--N 1.269 -2.92 0 CA-C-N 115.206 -0.907 . . . . 0.0 109.084 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 12.9 ttm180 . . . . . 0 N--CA 1.421 -1.89 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 176.883 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 3.5 m . . . . . 0 N--CA 1.44 -0.937 0 N-CA-C 113.55 0.945 . . . . 0.0 113.55 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -103.93 18.39 46.62 Favored Glycine 0 C--N 1.313 -0.739 0 N-CA-C 107.724 -2.15 . . . . 0.0 107.724 169.806 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 23.2 mm-40 -80.99 170.85 15.73 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 113.605 -1.298 . . . . 0.0 109.552 -178.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . 0.457 ' HB ' HG23 ' A' ' 9' ' ' VAL . 16.8 p -122.57 156.5 34.1 Favored 'General case' 0 N--CA 1.402 -2.827 0 CA-C-O 120.791 0.329 . . . . 0.0 111.062 178.825 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 20.5 p -128.22 38.24 4.03 Favored 'General case' 0 CA--C 1.491 -1.294 0 CA-C-O 121.41 0.624 . . . . 0.0 109.601 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.457 HG23 ' HB ' ' A' ' 7' ' ' THR . 11.1 t -58.62 -29.89 40.37 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.007 0 CA-C-N 114.426 -1.261 . . . . 0.0 110.709 -177.16 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -74.1 -22.11 78.24 Favored Glycine 0 N--CA 1.437 -1.256 0 CA-C-N 115.849 -0.614 . . . . 0.0 112.544 179.028 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 149.63 -36.55 0.99 Allowed Glycine 0 N--CA 1.438 -1.226 0 C-N-CA 120.207 -0.997 . . . . 0.0 113.863 179.672 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 8.8 t -158.3 173.65 16.36 Favored 'General case' 0 N--CA 1.423 -1.793 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 -178.429 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 63.2 m -89.75 150.54 22.25 Favored 'General case' 0 C--N 1.268 -2.937 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.134 -177.277 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 13.9 m120 -90.43 -12.23 38.06 Favored 'General case' 0 C--N 1.308 -1.203 0 CA-C-O 121.177 0.513 . . . . 0.0 110.158 177.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 10.4 m -100.37 122.96 48.13 Favored Pre-proline 0 C--N 1.305 -1.335 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 176.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 96.6 Cg_endo -78.39 -1.85 11.97 Favored 'Trans proline' 0 N--CA 1.484 0.949 0 C-N-CA 123.232 2.621 . . . . 0.0 115.926 -169.186 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -102.5 0.02 49.84 Favored Glycine 0 C--N 1.261 -3.634 0 N-CA-C 110.001 -1.24 . . . . 0.0 110.001 178.221 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.44 ' HA ' ' O ' ' A' ' 26' ' ' THR . 56.1 m -118.65 134.15 55.32 Favored 'General case' 0 N--CA 1.402 -2.854 0 CA-C-N 113.75 -1.225 . . . . 0.0 109.041 -175.429 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 10.5 t -109.89 163.86 13.13 Favored 'General case' 0 N--CA 1.426 -1.651 0 C-N-CA 119.584 -0.846 . . . . 0.0 109.639 -178.74 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 48.9 t -92.96 125.06 37.37 Favored 'General case' 0 N--CA 1.387 -3.605 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.117 -174.495 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 46.0 m -128.75 59.85 1.54 Allowed 'General case' 0 N--CA 1.397 -3.121 0 N-CA-C 104.557 -2.386 . . . . 0.0 104.557 173.211 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.435 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 47.7 t90 -31.8 131.49 0.29 Allowed Pre-proline 0 C--O 1.247 0.931 0 C-N-CA 126.851 2.06 . . . . 0.0 113.149 -172.452 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.435 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 2.8 Cg_endo -89.04 6.62 69.08 Favored 'Cis proline' 0 CA--C 1.537 0.644 0 C-N-CA 122.872 -1.72 . . . . 0.0 115.242 2.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 28.9 m -107.76 152.24 9.54 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.004 0 N-CA-C 112.855 0.687 . . . . 0.0 112.855 -176.223 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 94.5 m -88.56 149.4 23.61 Favored 'General case' 0 N--CA 1.402 -2.836 0 CA-C-O 121.452 0.644 . . . . 0.0 110.986 175.71 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.44 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.8 p -125.37 -146.72 0.35 Allowed 'General case' 0 C--N 1.285 -2.236 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 173.761 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 6.6 ptp180 . . . . . 1 N--CA 1.377 -4.077 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 -176.5 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 58.5 m . . . . . 0 N--CA 1.43 -1.471 0 CA-C-O 120.764 0.316 . . . . 0.0 110.999 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -107.94 -6.69 32.1 Favored Glycine 0 N--CA 1.431 -1.661 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 174.853 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -69.59 151.35 46.06 Favored 'General case' 0 C--O 1.25 1.086 0 CA-C-N 115.169 -0.515 . . . . 0.0 110.948 179.389 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 39.9 p -102.62 163.38 12.25 Favored 'General case' 0 N--CA 1.408 -2.571 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.072 -178.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.712 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 29.3 p -129.38 43.42 3.14 Favored 'General case' 0 N--CA 1.425 -1.677 0 CA-C-O 121.465 0.65 . . . . 0.0 109.485 -178.839 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 58.3 t -58.42 -33.14 47.07 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.862 -177.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -90.03 -0.95 76.89 Favored Glycine 0 C--O 1.224 -0.528 0 CA-C-N 116.211 -0.45 . . . . 0.0 112.109 178.762 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 86.72 29.18 24.53 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 121.823 -0.227 . . . . 0.0 113.217 177.752 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 7.0 m -148.52 155.08 40.67 Favored 'General case' 0 N--CA 1.436 -1.131 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 179.196 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.433 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 61.1 m -133.04 156.87 46.58 Favored 'General case' 0 C--N 1.279 -2.464 0 N-CA-C 107.572 -1.269 . . . . 0.0 107.572 176.862 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 33.3 m-80 -84.1 -39.42 19.53 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 -179.787 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 16.2 m -84.79 116.62 66.09 Favored Pre-proline 0 N--CA 1.429 -1.507 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 175.415 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -74.72 -7.67 19.61 Favored 'Trans proline' 0 C--N 1.358 1.07 0 C-N-CA 122.433 2.089 . . . . 0.0 112.758 -175.444 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -90.44 -6.84 67.88 Favored Glycine 0 C--N 1.268 -3.239 0 CA-C-N 113.233 -1.803 . . . . 0.0 110.143 178.368 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.447 ' HA ' ' O ' ' A' ' 26' ' ' THR . 86.8 m -105.28 125.91 51.51 Favored 'General case' 0 N--CA 1.412 -2.361 0 CA-C-O 122.407 1.098 . . . . 0.0 109.679 177.269 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.435 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 6.8 m -93.59 150.72 20.2 Favored 'General case' 0 C--N 1.276 -2.595 0 CA-C-N 113.125 -1.852 . . . . 0.0 108.603 -173.641 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 52.2 t -93.1 105.77 17.82 Favored 'General case' 0 N--CA 1.409 -2.493 0 CA-C-O 121.866 0.841 . . . . 0.0 110.904 -178.374 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 31.1 m -108.68 79.61 1.25 Allowed 'General case' 0 N--CA 1.391 -3.405 0 N-CA-C 103.569 -2.752 . . . . 0.0 103.569 171.074 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.436 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 54.5 t90 -44.31 134.51 4.37 Favored Pre-proline 0 N--CA 1.429 -1.517 0 CA-C-N 113.322 -1.763 . . . . 0.0 112.919 -167.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.436 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 4.0 Cg_endo -95.64 22.96 26.79 Favored 'Cis proline' 0 N--CA 1.458 -0.561 0 C-N-CA 122.969 -1.68 . . . . 0.0 114.597 3.15 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 29.9 m -120.68 144.22 30.25 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.968 0 N-CA-C 114.057 1.132 . . . . 0.0 114.057 -175.712 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.712 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 56.1 m -86.05 129.87 34.71 Favored 'General case' 0 N--CA 1.414 -2.268 0 O-C-N 121.791 -0.568 . . . . 0.0 109.616 176.212 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.447 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 1.3 p -135.78 -170.82 2.71 Favored 'General case' 0 C--N 1.287 -2.119 0 C-N-CA 123.541 0.737 . . . . 0.0 109.828 178.439 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 70.8 mtp180 . . . . . 0 N--CA 1.396 -3.145 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 177.729 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 96.4 m . . . . . 0 N--CA 1.431 -1.394 0 N-CA-C 110.209 -0.293 . . . . 0.0 110.209 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -85.65 4.01 86.36 Favored Glycine 0 N--CA 1.447 -0.581 0 N-CA-C 110.788 -0.925 . . . . 0.0 110.788 179.677 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 74.6 mm-40 -89.6 146.82 24.3 Favored 'General case' 0 N--CA 1.421 -1.909 0 CA-C-N 114.79 -0.705 . . . . 0.0 110.816 -179.511 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 32.6 p -123.71 150.81 43.87 Favored 'General case' 0 N--CA 1.392 -3.335 0 N-CA-C 106.185 -1.783 . . . . 0.0 106.185 174.4 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.43 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 24.4 p -123.99 38.35 4.21 Favored 'General case' 0 C--N 1.289 -2.022 0 CA-C-N 118.63 0.65 . . . . 0.0 110.254 -177.521 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 13.6 t -61.76 -40.48 87.04 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 CA-C-N 114.494 -1.23 . . . . 0.0 108.306 178.791 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -73.78 -22.24 78.42 Favored Glycine 0 N--CA 1.441 -1.032 0 CA-C-N 114.902 -1.045 . . . . 0.0 111.022 177.127 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 120.4 -6.94 11.57 Favored Glycine 0 N--CA 1.436 -1.302 0 C-N-CA 121.255 -0.498 . . . . 0.0 113.876 177.211 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 6.1 m -136.51 155.25 50.23 Favored 'General case' 0 N--CA 1.429 -1.492 0 CA-C-N 118.047 0.924 . . . . 0.0 108.936 -176.336 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 57.6 m -113.99 143.33 44.92 Favored 'General case' 0 C--N 1.279 -2.463 0 N-CA-C 106.154 -1.795 . . . . 0.0 106.154 175.676 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 33.4 m-80 -68.09 -39.36 82.88 Favored 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 119.053 0.842 . . . . 0.0 110.656 177.395 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 9.9 m -94.1 113.19 60.04 Favored Pre-proline 0 N--CA 1.426 -1.671 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 176.358 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -76.33 -1.89 12.0 Favored 'Trans proline' 0 C--N 1.354 0.828 0 C-N-CA 122.668 2.245 . . . . 0.0 112.534 -178.727 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -79.59 -14.41 81.26 Favored Glycine 0 C--N 1.284 -2.33 0 CA-C-N 113.105 -1.861 . . . . 0.0 108.936 175.166 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.536 ' HA ' ' O ' ' A' ' 26' ' ' THR . 63.7 m -103.14 127.33 50.47 Favored 'General case' 0 N--CA 1.406 -2.653 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.115 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.43 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 10.3 m -89.9 148.86 22.9 Favored 'General case' 0 C--N 1.279 -2.493 0 CA-C-N 114.876 -1.056 . . . . 0.0 108.633 -177.129 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 50.5 t -84.64 115.15 22.49 Favored 'General case' 0 C--N 1.269 -2.897 0 CA-C-O 121.461 0.648 . . . . 0.0 110.453 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 16.6 t -120.26 68.24 0.84 Allowed 'General case' 0 C--N 1.287 -2.152 0 N-CA-C 103.728 -2.693 . . . . 0.0 103.728 172.85 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.448 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 51.3 t90 -35.92 133.08 0.56 Allowed Pre-proline 0 N--CA 1.441 -0.904 0 CA-C-N 113.108 -1.86 . . . . 0.0 112.969 -170.417 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.448 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 1.6 Cg_endo -91.63 14.46 49.62 Favored 'Cis proline' 0 CA--C 1.541 0.855 0 C-N-CA 123.145 -1.606 . . . . 0.0 115.343 2.517 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 28.9 m -115.65 152.6 17.3 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.019 0 O-C-N 121.182 -0.949 . . . . 0.0 112.36 -177.629 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.43 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 59.6 m -95.73 139.32 32.14 Favored 'General case' 0 N--CA 1.403 -2.81 0 O-C-N 121.77 -0.581 . . . . 0.0 109.543 177.123 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.536 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 20.1 p -125.49 -173.29 2.79 Favored 'General case' 0 C--N 1.29 -1.989 0 C-N-CA 123.119 0.568 . . . . 0.0 111.345 -179.157 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 53.8 ttt180 . . . . . 0 N--CA 1.417 -2.095 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 -177.619 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 98.1 m . . . . . 0 CA--C 1.515 -0.39 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -107.19 5.64 36.16 Favored Glycine 0 C--N 1.31 -0.892 0 C-N-CA 120.465 -0.874 . . . . 0.0 112.443 -178.295 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -88.73 166.43 14.06 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.779 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . 0.43 ' HB ' HG23 ' A' ' 9' ' ' VAL . 24.4 p -112.49 163.25 14.68 Favored 'General case' 0 N--CA 1.415 -2.194 0 N-CA-C 112.15 0.426 . . . . 0.0 112.15 -175.79 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.462 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 21.4 p -137.13 36.01 2.55 Favored 'General case' 0 CA--C 1.497 -1.073 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 179.58 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.43 HG23 ' HB ' ' A' ' 7' ' ' THR . 15.4 t -60.8 -35.4 64.15 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.084 0 CA-C-N 114.719 -1.128 . . . . 0.0 109.4 -177.867 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -74.27 -17.27 79.63 Favored Glycine 0 N--CA 1.44 -1.044 0 CA-C-N 115.132 -0.94 . . . . 0.0 112.935 178.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 141.49 -33.43 1.98 Allowed Glycine 0 N--CA 1.435 -1.402 0 C-N-CA 119.992 -1.099 . . . . 0.0 113.795 179.848 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 9.0 t -153.58 172.8 16.64 Favored 'General case' 0 N--CA 1.424 -1.745 0 CA-C-N 117.771 0.785 . . . . 0.0 109.845 -174.726 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 58.1 m -94.75 176.35 6.31 Favored 'General case' 0 C--N 1.274 -2.687 0 CA-C-N 114.475 -1.239 . . . . 0.0 110.042 -177.391 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 26.8 m-80 -100.55 -36.43 9.18 Favored 'General case' 0 C--N 1.307 -1.243 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 178.588 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.507 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 25.8 m -90.69 121.86 67.69 Favored Pre-proline 0 N--CA 1.427 -1.607 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 177.179 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.443 ' HD3' ' HA ' ' A' ' 15' ' ' THR . 13.6 Cg_exo -69.66 -3.58 12.22 Favored 'Trans proline' 0 N--CA 1.488 1.157 0 C-N-CA 123.132 2.555 . . . . 0.0 113.458 -177.506 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -90.3 -14.22 59.08 Favored Glycine 0 C--N 1.255 -3.949 0 CA-C-N 113.719 -1.582 . . . . 0.0 110.283 176.458 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.589 ' HA ' ' O ' ' A' ' 26' ' ' THR . 57.8 m -103.55 129.97 50.86 Favored 'General case' 0 N--CA 1.396 -3.128 0 N-CA-C 107.575 -1.269 . . . . 0.0 107.575 179.254 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 25.1 m -114.78 155.5 26.61 Favored 'General case' 0 C--N 1.281 -2.389 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 -179.13 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 38.2 t -83.48 128.15 34.28 Favored 'General case' 0 N--CA 1.409 -2.521 0 CA-C-O 122.251 1.024 . . . . 0.0 113.065 -171.477 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.8 m -128.26 65.32 1.39 Allowed 'General case' 0 N--CA 1.402 -2.833 0 N-CA-C 104.401 -2.444 . . . . 0.0 104.401 170.149 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.426 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 37.9 t90 -33.67 134.87 0.33 Allowed Pre-proline 0 N--CA 1.442 -0.849 0 C-N-CA 127.433 2.293 . . . . 0.0 113.918 -170.92 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.426 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 4.6 Cg_exo -88.96 12.01 57.51 Favored 'Cis proline' 0 CA--C 1.544 0.98 0 C-N-CA 122.894 -1.711 . . . . 0.0 114.403 0.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.7 m -114.38 150.49 16.36 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.889 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -175.254 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.463 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 95.5 m -86.14 151.6 23.53 Favored 'General case' 0 N--CA 1.41 -2.435 0 CA-C-O 121.74 0.781 . . . . 0.0 112.206 178.39 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.589 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.0 p -129.27 -164.44 1.4 Allowed 'General case' 0 C--N 1.298 -1.642 0 C-N-CA 124.609 1.164 . . . . 0.0 108.331 175.559 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 17.3 ttm180 . . . . . 0 N--CA 1.407 -2.603 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 -178.277 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 85.3 m . . . . . 0 N--CA 1.433 -1.312 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -80.06 13.9 23.53 Favored Glycine 0 C--N 1.314 -0.675 0 CA-C-N 116.117 -0.492 . . . . 0.0 112.927 -176.382 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -91.56 162.13 14.66 Favored 'General case' 0 C--N 1.306 -1.288 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 178.762 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 25.3 p -114.74 163.48 15.42 Favored 'General case' 0 N--CA 1.411 -2.385 0 N-CA-C 110.374 -0.232 . . . . 0.0 110.374 -179.739 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 16.9 p -134.2 41.2 2.98 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-O 121.229 0.538 . . . . 0.0 110.185 -179.036 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 23.2 t -59.94 -29.89 44.26 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.042 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.619 -176.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -83.09 -8.14 86.02 Favored Glycine 0 N--CA 1.441 -0.995 0 CA-C-N 115.769 -0.65 . . . . 0.0 112.903 -179.786 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 139.82 -39.61 1.49 Allowed Glycine 0 N--CA 1.443 -0.885 0 C-N-CA 120.214 -0.993 . . . . 0.0 113.777 178.2 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 13.5 t -155.6 173.23 17.01 Favored 'General case' 0 N--CA 1.423 -1.802 0 CA-C-N 117.354 0.577 . . . . 0.0 109.649 -176.807 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 32.2 m -91.87 173.11 8.03 Favored 'General case' 0 C--N 1.274 -2.713 0 CA-C-N 114.815 -1.084 . . . . 0.0 109.578 -175.048 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 36.3 m-80 -93.27 -36.63 12.47 Favored 'General case' 0 CA--C 1.496 -1.097 0 N-CA-C 110.059 -0.348 . . . . 0.0 110.059 177.017 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.48 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 17.6 m -84.63 124.26 73.38 Favored Pre-proline 0 C--N 1.297 -1.675 0 N-CA-C 108.131 -1.062 . . . . 0.0 108.131 176.304 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_endo -72.86 -1.53 10.58 Favored 'Trans proline' 0 C--N 1.359 1.098 0 C-N-CA 123.05 2.5 . . . . 0.0 113.425 -176.194 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -97.63 -4.05 58.2 Favored Glycine 0 C--N 1.265 -3.407 0 CA-C-N 113.964 -1.471 . . . . 0.0 110.152 177.782 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.48 ' SG ' ' HB ' ' A' ' 15' ' ' THR . 60.3 m -108.66 125.84 52.32 Favored 'General case' 0 N--CA 1.409 -2.518 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 178.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 8.6 m -91.45 151.39 20.82 Favored 'General case' 0 C--N 1.291 -1.959 0 N-CA-C 107.74 -1.208 . . . . 0.0 107.74 -177.213 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 46.6 t -90.17 127.73 36.18 Favored 'General case' 0 N--CA 1.411 -2.415 0 CA-C-O 121.388 0.613 . . . . 0.0 109.565 179.501 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 22.6 t -128.71 56.8 1.63 Allowed 'General case' 0 C--N 1.28 -2.448 0 N-CA-C 103.688 -2.708 . . . . 0.0 103.688 176.001 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.429 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 56.6 t90 -31.2 131.91 0.25 Allowed Pre-proline 0 N--CA 1.446 -0.644 0 C-N-CA 127.009 2.124 . . . . 0.0 113.347 -171.314 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 1.8 Cg_endo -90.37 9.68 63.07 Favored 'Cis proline' 0 C--N 1.323 -0.811 0 C-N-CA 122.883 -1.715 . . . . 0.0 115.074 4.091 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 29.8 m -112.32 153.01 14.04 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 O-C-N 122.043 -0.41 . . . . 0.0 111.927 -176.2 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 73.4 m -93.39 158.78 15.56 Favored 'General case' 0 N--CA 1.416 -2.15 0 CA-C-O 121.487 0.661 . . . . 0.0 112.42 178.05 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.461 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.1 p -129.81 -175.04 3.48 Favored 'General case' 0 C--N 1.31 -1.145 0 C-N-CA 124.519 1.128 . . . . 0.0 108.562 175.679 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 20.0 ptt180 . . . . . 0 N--CA 1.384 -3.725 0 CA-C-N 119.407 1.003 . . . . 0.0 112.138 -178.027 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 72.4 m . . . . . 0 N--CA 1.441 -0.924 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -88.03 12.98 62.52 Favored Glycine 0 C--N 1.304 -1.201 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.025 -178.057 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -90.23 154.67 19.56 Favored 'General case' 0 N--CA 1.431 -1.401 0 CA-C-O 121.096 0.474 . . . . 0.0 110.013 -179.289 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . 0.401 ' HA ' ' HA ' ' A' ' 24' ' ' VAL . 35.9 p -111.65 158.53 19.16 Favored 'General case' 0 N--CA 1.395 -3.225 0 N-CA-C 106.32 -1.734 . . . . 0.0 106.32 170.449 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.604 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 28.1 p -135.85 50.86 2.07 Favored 'General case' 0 C--N 1.283 -2.304 0 CA-C-O 121.502 0.668 . . . . 0.0 110.056 -177.66 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 40.3 t -62.43 -31.0 50.35 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.36 -178.568 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -74.45 -26.36 68.08 Favored Glycine 0 N--CA 1.446 -0.638 0 N-CA-C 111.338 -0.705 . . . . 0.0 111.338 176.701 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 122.27 0.18 10.46 Favored Glycine 0 N--CA 1.443 -0.875 0 C-N-CA 120.657 -0.782 . . . . 0.0 114.219 177.021 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 15.7 m -148.81 162.59 39.51 Favored 'General case' 0 N--CA 1.432 -1.372 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 -179.664 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 35.9 m -111.82 166.78 10.9 Favored 'General case' 0 C--N 1.281 -2.407 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 177.841 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 36.0 m-80 -83.43 -38.89 21.31 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-O 120.923 0.392 . . . . 0.0 110.022 179.223 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.582 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 13.4 m -79.88 123.85 83.54 Favored Pre-proline 0 N--CA 1.429 -1.509 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 178.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_exo -69.81 -2.92 11.03 Favored 'Trans proline' 0 C--N 1.353 0.809 0 C-N-CA 123.009 2.472 . . . . 0.0 112.898 179.504 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.445 ' H ' HG22 ' A' ' 15' ' ' THR . . . -96.47 -12.19 51.83 Favored Glycine 0 C--N 1.27 -3.134 0 CA-C-N 113.752 -1.567 . . . . 0.0 110.449 177.17 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.582 ' SG ' ' HB ' ' A' ' 15' ' ' THR . 62.3 m -103.7 130.63 51.22 Favored 'General case' 0 N--CA 1.415 -2.198 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 179.659 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 9.6 m -109.26 147.7 32.2 Favored 'General case' 0 C--N 1.282 -2.329 0 N-CA-C 107.928 -1.138 . . . . 0.0 107.928 -177.625 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 46.2 t -83.45 121.15 26.8 Favored 'General case' 0 N--CA 1.403 -2.777 0 CA-C-O 121.629 0.728 . . . . 0.0 111.073 -177.434 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 25.2 t -123.58 72.36 1.13 Allowed 'General case' 0 C--N 1.279 -2.472 0 N-CA-C 103.417 -2.809 . . . . 0.0 103.417 173.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.464 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 36.9 t90 -41.24 133.71 1.95 Allowed Pre-proline 0 N--CA 1.444 -0.729 0 C-N-CA 125.893 1.677 . . . . 0.0 113.411 -168.343 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.464 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 1.6 Cg_endo -92.23 16.81 43.42 Favored 'Cis proline' 0 CA--C 1.538 0.705 0 C-N-CA 122.826 -1.739 . . . . 0.0 114.655 2.113 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.401 ' HA ' ' HA ' ' A' ' 7' ' ' THR . 26.8 m -117.38 151.13 19.3 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.863 0 N-CA-C 113.95 1.093 . . . . 0.0 113.95 -176.11 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.604 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 82.8 m -86.21 148.95 25.42 Favored 'General case' 0 N--CA 1.409 -2.506 0 O-C-N 121.536 -0.727 . . . . 0.0 110.928 176.459 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.494 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.2 p -132.72 -174.51 3.48 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 175.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 3.5 ppt_? . . . . . 0 N--CA 1.379 -3.975 0 CA-C-N 119.524 1.056 . . . . 0.0 110.43 179.368 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.638 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 88.7 m . . . . . 0 N--CA 1.442 -0.852 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -92.42 -16.75 48.55 Favored Glycine 0 N--CA 1.44 -1.096 0 C-N-CA 120.454 -0.879 . . . . 0.0 112.866 -174.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.638 ' OE1' ' HB3' ' A' ' 4' ' ' CYS . 1.0 OUTLIER -90.15 145.94 24.66 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 122.447 -0.443 . . . . 0.0 111.056 -178.786 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . 0.442 HG22 HG12 ' A' ' 24' ' ' VAL . 21.7 p -109.83 157.04 19.6 Favored 'General case' 0 N--CA 1.417 -2.114 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.485 -179.209 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.5 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 19.5 p -126.23 38.85 4.06 Favored 'General case' 0 C--N 1.303 -1.422 0 CA-C-O 121.169 0.509 . . . . 0.0 110.589 -177.05 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 35.5 t -56.12 -35.48 41.97 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 CA-C-N 115.106 -0.952 . . . . 0.0 110.722 -178.427 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -95.4 7.85 68.97 Favored Glycine 0 N--CA 1.441 -1.027 0 C-N-CA 121.089 -0.577 . . . . 0.0 113.053 -179.483 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 152.1 -82.06 0.18 Allowed Glycine 0 N--CA 1.434 -1.477 0 C-N-CA 119.186 -1.483 . . . . 0.0 114.425 178.369 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 7.5 m -153.44 163.89 39.15 Favored 'General case' 0 N--CA 1.428 -1.57 0 N-CA-C 106.867 -1.531 . . . . 0.0 106.867 -171.153 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 76.7 m -99.13 161.56 13.55 Favored 'General case' 0 C--N 1.291 -1.95 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 176.188 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 41.7 m-80 -92.82 -16.51 25.24 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-O 120.99 0.424 . . . . 0.0 110.837 -177.839 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 10.7 m -72.49 114.89 33.98 Favored Pre-proline 0 N--CA 1.438 -1.07 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 178.814 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -70.17 -9.02 25.01 Favored 'Trans proline' 0 C--N 1.351 0.709 0 C-N-CA 122.806 2.337 . . . . 0.0 114.213 -174.204 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -91.74 -15.34 54.94 Favored Glycine 0 C--N 1.261 -3.623 0 CA-C-N 113.988 -1.46 . . . . 0.0 111.234 178.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.568 ' HA ' ' O ' ' A' ' 26' ' ' THR . 82.9 m -118.7 125.29 49.35 Favored 'General case' 0 N--CA 1.415 -2.195 0 CA-C-O 121.639 0.733 . . . . 0.0 110.795 -177.687 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 8.1 m -101.88 156.61 17.42 Favored 'General case' 0 C--N 1.293 -1.871 0 C-N-CA 124.666 1.187 . . . . 0.0 108.521 -176.734 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 51.8 t -88.64 119.64 29.3 Favored 'General case' 0 C--N 1.297 -1.707 0 CA-C-O 121.503 0.668 . . . . 0.0 111.851 -176.696 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 21.1 t -124.76 75.69 1.45 Allowed 'General case' 0 N--CA 1.417 -2.097 0 N-CA-C 103.541 -2.763 . . . . 0.0 103.541 171.11 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.485 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 57.2 t90 -38.0 135.79 0.81 Allowed Pre-proline 0 N--CA 1.436 -1.125 0 C-N-CA 126.063 1.745 . . . . 0.0 113.058 -170.809 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.485 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 1.2 Cg_endo -91.47 9.54 61.59 Favored 'Cis proline' 0 CA--C 1.536 0.618 0 C-N-CA 122.862 -1.724 . . . . 0.0 114.958 3.426 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.442 HG12 HG22 ' A' ' 7' ' ' THR . 25.3 m -113.86 158.09 14.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 C-N-CA 120.102 -0.639 . . . . 0.0 111.725 -175.442 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.5 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 53.4 m -96.86 143.06 28.12 Favored 'General case' 0 N--CA 1.388 -3.528 0 CA-C-O 121.838 0.828 . . . . 0.0 110.442 173.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.568 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 7.9 p -128.19 -170.13 2.19 Favored 'General case' 0 C--N 1.273 -2.742 0 CA-C-N 114.466 -1.243 . . . . 0.0 110.994 -177.558 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 19.1 mtm180 . . . . . 0 N--CA 1.381 -3.914 0 CA-C-O 121.459 0.647 . . . . 0.0 110.77 -169.179 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 99.1 m . . . . . 0 N--CA 1.444 -0.737 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -87.64 9.83 72.24 Favored Glycine 0 C--N 1.314 -0.671 0 N-CA-C 110.581 -1.008 . . . . 0.0 110.581 178.459 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.47 ' HB2' ' HB2' ' A' ' 25' ' ' CYS . 6.2 mm-40 -86.38 154.16 21.39 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 124.14 0.976 . . . . 0.0 108.735 -179.64 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 9.2 p -126.82 153.94 44.97 Favored 'General case' 0 N--CA 1.41 -2.452 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 174.062 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.467 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 25.1 p -133.94 40.38 3.08 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-O 120.92 0.391 . . . . 0.0 110.862 -175.825 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 18.7 t -56.48 -29.17 28.29 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.182 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.345 -179.075 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -79.66 -17.19 76.0 Favored Glycine 0 N--CA 1.445 -0.7 0 CA-C-N 115.612 -0.722 . . . . 0.0 113.392 179.562 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 138.03 -32.07 2.39 Favored Glycine 0 N--CA 1.444 -0.828 0 C-N-CA 119.775 -1.202 . . . . 0.0 114.543 178.874 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 15.7 m -152.32 159.13 43.52 Favored 'General case' 0 C--N 1.31 -1.123 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 -176.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.467 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 32.6 m -89.95 165.66 13.94 Favored 'General case' 0 C--N 1.285 -2.221 0 O-C-N 123.767 0.667 . . . . 0.0 109.599 -179.295 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 14.0 m120 -85.16 -48.98 8.61 Favored 'General case' 0 CA--C 1.503 -0.842 0 CA-C-O 120.884 0.373 . . . . 0.0 110.142 178.079 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 29.1 m -70.52 118.93 69.14 Favored Pre-proline 0 C--N 1.311 -1.077 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 175.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -72.35 -5.1 16.49 Favored 'Trans proline' 0 C--N 1.365 1.421 0 C-N-CA 123.134 2.556 . . . . 0.0 114.164 -173.534 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -90.42 -8.43 66.1 Favored Glycine 0 C--N 1.261 -3.606 0 CA-C-N 114.008 -1.451 . . . . 0.0 110.35 178.703 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.498 ' HB3' ' HB3' ' A' ' 25' ' ' CYS . 67.9 m -107.98 127.39 53.72 Favored 'General case' 0 N--CA 1.409 -2.512 0 CA-C-O 121.41 0.624 . . . . 0.0 110.663 -178.464 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 6.3 m -90.16 148.63 22.85 Favored 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 107.969 -1.122 . . . . 0.0 107.969 -178.241 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 51.5 t -88.97 102.81 15.45 Favored 'General case' 0 N--CA 1.412 -2.332 0 CA-C-O 121.501 0.667 . . . . 0.0 111.183 -178.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.1 p -105.65 64.89 0.7 Allowed 'General case' 0 C--N 1.288 -2.097 0 N-CA-C 106.225 -1.768 . . . . 0.0 106.225 172.244 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.44 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 56.1 t90 -35.74 134.31 0.52 Allowed Pre-proline 0 N--CA 1.443 -0.821 0 C-N-CA 127.358 2.263 . . . . 0.0 113.586 -169.652 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.44 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 1.5 Cg_endo -91.28 10.01 61.09 Favored 'Cis proline' 0 C--N 1.323 -0.777 0 C-N-CA 122.823 -1.741 . . . . 0.0 114.188 2.474 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.9 m -110.81 150.0 13.44 Favored 'Isoleucine or valine' 0 C--O 1.21 -1.019 0 C-N-CA 120.212 -0.595 . . . . 0.0 111.846 -176.426 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.498 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 69.0 m -92.93 141.29 28.58 Favored 'General case' 0 N--CA 1.408 -2.539 0 CA-C-O 121.44 0.638 . . . . 0.0 112.45 178.808 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.455 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 1.7 p -117.83 -177.18 3.19 Favored 'General case' 0 C--N 1.292 -1.903 0 CA-C-N 115.016 -0.993 . . . . 0.0 108.526 175.534 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 4.9 ppt_? . . . . . 0 N--CA 1.387 -3.602 0 CA-C-N 119.669 1.122 . . . . 0.0 112.298 -176.521 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.422 ' SG ' ' HB3' ' A' ' 27' ' ' ARG . 63.4 m . . . . . 0 N--CA 1.443 -0.794 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -89.21 16.62 55.33 Favored Glycine 0 C--N 1.315 -0.608 0 N-CA-C 110.201 -1.16 . . . . 0.0 110.201 178.408 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.466 ' HB2' ' HB2' ' A' ' 25' ' ' CYS . 7.8 mm-40 -91.53 151.44 20.75 Favored 'General case' 0 N--CA 1.425 -1.699 0 C-N-CA 124.433 1.093 . . . . 0.0 110.153 -179.403 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 17.2 p -126.4 152.27 46.57 Favored 'General case' 0 N--CA 1.405 -2.675 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 174.746 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 24.7 p -130.37 37.67 3.84 Favored 'General case' 0 C--N 1.301 -1.513 0 CA-C-O 121.153 0.501 . . . . 0.0 110.934 -175.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 25.7 t -58.46 -37.56 64.89 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.13 0 CA-C-N 114.928 -1.033 . . . . 0.0 109.835 -178.468 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -79.18 1.81 73.62 Favored Glycine 0 CA--C 1.524 0.602 0 CA-C-N 115.55 -0.75 . . . . 0.0 113.608 -179.908 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 124.65 -28.8 5.14 Favored Glycine 0 N--CA 1.44 -1.053 0 C-N-CA 119.956 -1.116 . . . . 0.0 114.168 176.657 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 12.4 t -157.33 172.7 18.14 Favored 'General case' 0 N--CA 1.426 -1.636 0 CA-C-N 117.566 0.683 . . . . 0.0 109.324 -176.641 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 33.4 m -98.81 164.21 12.31 Favored 'General case' 0 C--N 1.276 -2.604 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 -178.581 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 14.6 m-80 -85.23 -42.01 15.07 Favored 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 107.261 -1.385 . . . . 0.0 107.261 178.909 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 14.3 m -77.9 114.74 44.36 Favored Pre-proline 0 N--CA 1.422 -1.868 0 CA-C-N 114.035 -1.439 . . . . 0.0 108.685 177.52 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -73.43 -0.67 9.56 Favored 'Trans proline' 0 N--CA 1.483 0.861 0 C-N-CA 123.662 2.908 . . . . 0.0 113.536 -174.538 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -96.4 -11.83 52.98 Favored Glycine 0 C--N 1.261 -3.6 0 CA-C-N 113.985 -1.462 . . . . 0.0 111.15 177.843 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.404 ' HB3' ' HB3' ' A' ' 25' ' ' CYS . 76.2 m -103.91 127.96 51.41 Favored 'General case' 0 N--CA 1.419 -2.019 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 179.446 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 8.8 m -90.44 153.51 20.34 Favored 'General case' 0 C--N 1.288 -2.093 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 -176.229 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 52.8 t -89.84 116.48 27.96 Favored 'General case' 0 C--N 1.284 -2.241 0 CA-C-O 121.657 0.742 . . . . 0.0 111.247 -177.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 34.4 t -119.35 57.7 0.89 Allowed 'General case' 0 C--N 1.29 -1.984 0 N-CA-C 104.568 -2.382 . . . . 0.0 104.568 176.099 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.412 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 42.5 t90 -29.62 131.86 0.22 Allowed Pre-proline 0 C--N 1.346 0.454 0 C-N-CA 127.261 2.224 . . . . 0.0 113.966 -170.564 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.412 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 2.4 Cg_endo -90.16 6.24 68.11 Favored 'Cis proline' 0 C--N 1.327 -0.56 0 C-N-CA 123.082 -1.632 . . . . 0.0 114.664 3.325 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 26.8 m -108.75 152.57 10.71 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 C-N-CA 120.181 -0.608 . . . . 0.0 112.175 -176.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.466 ' HB2' ' HB2' ' A' ' 6' ' ' GLU . 82.2 m -93.35 144.57 25.2 Favored 'General case' 0 N--CA 1.407 -2.622 0 CA-C-O 121.59 0.71 . . . . 0.0 112.188 178.246 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 3.1 p -116.17 179.14 4.08 Favored 'General case' 0 C--N 1.29 -2.016 0 C-N-CA 124.654 1.181 . . . . 0.0 110.049 178.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.422 ' HB3' ' SG ' ' A' ' 4' ' ' CYS . 0.0 OUTLIER . . . . . 0 N--CA 1.386 -3.672 0 CA-C-O 121.863 0.84 . . . . 0.0 111.856 -176.662 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.493 ' SG ' ' HG3' ' A' ' 27' ' ' ARG . 94.6 m . . . . . 0 N--CA 1.439 -0.988 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -94.58 17.35 59.26 Favored Glycine 0 N--CA 1.446 -0.692 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 176.723 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.415 ' HB2' ' HB2' ' A' ' 25' ' ' CYS . 17.6 mm-40 -90.08 148.44 23.02 Favored 'General case' 0 N--CA 1.42 -1.946 0 CA-C-N 113.888 -1.156 . . . . 0.0 107.884 179.035 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . 0.41 HG22 HG12 ' A' ' 24' ' ' VAL . 3.7 p -127.77 146.81 50.47 Favored 'General case' 0 C--N 1.268 -2.948 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.57 -179.755 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 21.7 p -127.18 35.99 4.49 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-O 121.07 0.462 . . . . 0.0 110.337 -176.579 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 25.2 t -57.25 -35.12 47.6 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 CA-C-N 115.06 -0.973 . . . . 0.0 109.828 -179.42 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -93.12 4.91 75.05 Favored Glycine 0 N--CA 1.437 -1.283 0 CA-C-N 115.526 -0.761 . . . . 0.0 113.171 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 151.43 -79.94 0.2 Allowed Glycine 0 N--CA 1.443 -0.841 0 C-N-CA 119.431 -1.366 . . . . 0.0 114.594 178.942 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 5.1 m -149.75 164.74 34.46 Favored 'General case' 0 N--CA 1.435 -1.187 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 -172.46 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.406 ' SG ' ' HB3' ' A' ' 6' ' ' GLU . 91.7 m -98.58 149.04 23.17 Favored 'General case' 0 C--N 1.285 -2.2 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 175.364 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -95.2 -0.37 53.23 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-O 121.437 0.637 . . . . 0.0 111.409 -179.002 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 56.2 m -85.73 111.19 35.79 Favored Pre-proline 0 N--CA 1.429 -1.509 0 N-CA-C 106.29 -1.744 . . . . 0.0 106.29 171.101 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -68.54 -12.29 34.33 Favored 'Trans proline' 0 C--N 1.36 1.181 0 C-N-CA 123.27 2.646 . . . . 0.0 115.664 -168.828 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -87.16 -15.74 62.02 Favored Glycine 1 C--N 1.251 -4.153 0 CA-C-N 114.65 -1.159 . . . . 0.0 110.571 178.813 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.601 ' HA ' ' O ' ' A' ' 26' ' ' THR . 58.1 m -105.63 125.48 51.03 Favored 'General case' 0 N--CA 1.414 -2.243 0 CA-C-N 115.098 -0.551 . . . . 0.0 110.076 -177.597 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 5.0 m -103.71 148.29 26.23 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 -179.021 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 46.7 t -78.91 125.57 29.54 Favored 'General case' 0 N--CA 1.413 -2.318 0 CA-C-O 122.113 0.958 . . . . 0.0 110.537 -178.262 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 37.5 m -130.66 59.26 1.67 Allowed 'General case' 0 N--CA 1.398 -3.06 0 N-CA-C 105.345 -2.094 . . . . 0.0 105.345 174.806 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.45 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 31.6 t90 -28.08 132.97 0.17 Allowed Pre-proline 0 C--O 1.246 0.877 0 C-N-CA 127.381 2.272 . . . . 0.0 114.348 -171.052 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.45 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 5.1 Cg_exo -88.48 6.94 68.4 Favored 'Cis proline' 0 CA--C 1.54 0.8 0 C-N-CA 123.044 -1.648 . . . . 0.0 114.631 2.328 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.41 HG12 HG22 ' A' ' 7' ' ' THR . 27.5 m -113.79 152.83 15.42 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.137 0 C-N-CA 120.329 -0.548 . . . . 0.0 112.464 -175.479 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.419 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 36.0 m -96.13 145.77 25.22 Favored 'General case' 0 N--CA 1.406 -2.631 0 CA-C-O 122.02 0.914 . . . . 0.0 112.716 176.035 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.601 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 19.6 p -121.51 -162.6 0.98 Allowed 'General case' 0 C--N 1.293 -1.883 0 CA-C-N 114.036 -1.438 . . . . 0.0 108.059 179.672 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.493 ' HG3' ' SG ' ' A' ' 4' ' ' CYS . 78.9 mtt180 . . . . . 0 N--CA 1.397 -3.083 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 177.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.447 ' O ' ' HB ' ' A' ' 32' ' ' VAL . . . . . . . . 0 N--CA 1.428 -1.884 0 N-CA-C 108.804 -1.719 . . . . 0.0 108.804 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -85.28 67.8 3.57 Favored Glycine 0 C--N 1.303 -1.27 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 178.501 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 80.67 -121.08 5.33 Favored Glycine 0 N--CA 1.439 -1.106 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 -176.209 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 77.7 m -141.86 108.11 5.25 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 174.081 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -82.61 8.48 62.0 Favored Glycine 0 C--N 1.308 -0.999 0 C-N-CA 121.432 -0.414 . . . . 0.0 113.168 -176.03 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.416 ' HG3' ' SG ' ' A' ' 25' ' ' CYS . 12.4 pt-20 -90.13 156.67 18.19 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 -179.393 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . 0.415 ' HB ' HG23 ' A' ' 9' ' ' VAL . 5.8 p -107.55 161.7 14.61 Favored 'General case' 0 N--CA 1.409 -2.503 0 CA-C-O 120.739 0.305 . . . . 0.0 110.767 178.715 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.441 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 19.1 p -127.66 35.7 4.47 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -178.622 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.415 HG23 ' HB ' ' A' ' 7' ' ' THR . 29.6 t -52.36 -37.31 23.03 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.987 0 CA-C-N 114.81 -1.086 . . . . 0.0 111.628 -177.559 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -68.95 -37.52 83.52 Favored Glycine 0 N--CA 1.443 -0.846 0 C-N-CA 121.068 -0.587 . . . . 0.0 111.94 177.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 157.05 -20.53 0.43 Allowed Glycine 0 N--CA 1.44 -1.035 0 C-N-CA 119.472 -1.347 . . . . 0.0 115.483 177.646 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 27.6 m -155.89 164.86 37.97 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 -176.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 40.3 m -94.71 164.65 12.86 Favored 'General case' 0 C--N 1.283 -2.312 0 C-N-CA 123.688 0.795 . . . . 0.0 108.949 178.536 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 39.7 m-80 -93.5 -30.86 14.81 Favored 'General case' 0 C--N 1.302 -1.477 0 CA-C-O 121.163 0.506 . . . . 0.0 110.008 -177.595 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.503 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 20.6 m -90.13 120.28 69.22 Favored Pre-proline 0 C--N 1.304 -1.395 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 176.836 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -71.05 -3.56 13.11 Favored 'Trans proline' 0 N--CA 1.485 1.022 0 C-N-CA 123.258 2.639 . . . . 0.0 114.285 -175.626 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -89.0 -11.94 64.41 Favored Glycine 0 C--N 1.269 -3.19 0 CA-C-N 114.176 -1.375 . . . . 0.0 110.117 176.453 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.503 ' SG ' ' HB ' ' A' ' 15' ' ' THR . 34.5 m -103.68 144.67 31.15 Favored 'General case' 0 N--CA 1.423 -1.817 0 CA-C-N 114.761 -0.719 . . . . 0.0 109.25 -179.372 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 14.7 m -112.7 151.33 30.34 Favored 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 179.5 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 52.0 t -89.14 118.69 29.03 Favored 'General case' 0 C--N 1.277 -2.549 0 CA-C-O 121.531 0.682 . . . . 0.0 110.318 -179.34 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 63.0 m -116.54 63.81 0.71 Allowed 'General case' 0 N--CA 1.407 -2.579 0 N-CA-C 104.54 -2.393 . . . . 0.0 104.54 171.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.459 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 40.6 t90 -36.27 132.43 0.61 Allowed Pre-proline 0 N--CA 1.437 -1.082 0 C-N-CA 126.404 1.882 . . . . 0.0 113.592 -170.144 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.459 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 2.8 Cg_endo -90.31 13.56 53.0 Favored 'Cis proline' 0 CA--C 1.547 1.139 0 C-N-CA 122.882 -1.716 . . . . 0.0 114.849 2.039 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.404 HG12 HG22 ' A' ' 7' ' ' THR . 27.6 m -110.91 144.46 18.82 Favored 'Isoleucine or valine' 0 C--O 1.204 -1.316 0 N-CA-C 112.877 0.695 . . . . 0.0 112.877 -176.936 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.441 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 76.5 m -86.19 152.14 23.06 Favored 'General case' 0 N--CA 1.407 -2.578 0 O-C-N 121.164 -0.96 . . . . 0.0 110.693 176.287 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.429 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.6 p -130.83 -176.89 4.14 Favored 'General case' 0 C--N 1.291 -1.951 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 175.164 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 14.4 ttm180 -124.39 128.55 49.23 Favored 'General case' 0 N--CA 1.416 -2.172 0 N-CA-C 106.107 -1.812 . . . . 0.0 106.107 178.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -82.41 67.84 8.61 Favored 'General case' 0 C--N 1.27 -2.855 0 N-CA-C 114.335 1.235 . . . . 0.0 114.335 -172.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.12 5.2 52.65 Favored Glycine 0 CA--C 1.523 0.552 0 CA-C-N 115.833 -0.621 . . . . 0.0 114.285 175.08 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 54.2 mt -78.59 160.36 72.49 Favored Pre-proline 0 C--N 1.304 -1.37 0 C-N-CA 122.974 0.51 . . . . 0.0 110.793 -177.751 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.47 135.89 62.29 Favored 'Trans proline' 0 C--O 1.245 0.836 0 C-N-CA 122.3 2.0 . . . . 0.0 109.887 178.169 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.447 ' HB ' ' O ' ' A' ' 1' ' ' GLY . 5.4 m -95.89 107.06 19.12 Favored 'Isoleucine or valine' 0 N--CA 1.402 -2.867 0 CA-C-O 121.831 0.824 . . . . 0.0 112.992 -174.096 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 4.8 p . . . . . 0 C--N 1.306 -1.305 0 CA-C-O 122.079 0.942 . . . . 0.0 109.77 174.866 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.431 -1.688 0 N-CA-C 110.206 -1.158 . . . . 0.0 110.206 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -95.17 -42.41 3.75 Favored Glycine 0 N--CA 1.439 -1.119 0 C-N-CA 120.817 -0.706 . . . . 0.0 111.485 -179.25 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 144.85 -103.22 0.29 Allowed Glycine 0 N--CA 1.435 -1.401 0 N-CA-C 109.801 -1.32 . . . . 0.0 109.801 -178.229 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 81.4 m -127.58 108.39 10.74 Favored 'General case' 0 C--N 1.278 -2.529 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 175.856 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -76.13 7.12 31.35 Favored Glycine 0 C--N 1.31 -0.881 0 CA-C-N 115.877 -0.601 . . . . 0.0 112.853 -178.165 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -90.56 150.18 21.85 Favored 'General case' 0 N--CA 1.417 -2.122 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 178.823 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 6.6 p -109.7 154.17 23.25 Favored 'General case' 0 N--CA 1.392 -3.372 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.439 178.031 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.509 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 20.0 p -118.06 37.28 4.03 Favored 'General case' 0 CA--C 1.484 -1.575 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -177.807 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.8 t -55.71 -35.64 39.92 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.971 0 CA-C-N 115.002 -0.999 . . . . 0.0 109.912 -178.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -65.7 -26.26 71.99 Favored Glycine 0 N--CA 1.446 -0.693 0 CA-C-N 115.354 -0.839 . . . . 0.0 112.587 178.244 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 137.41 -22.01 3.23 Favored Glycine 0 N--CA 1.437 -1.249 0 C-N-CA 120.849 -0.691 . . . . 0.0 113.917 178.782 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 12.1 m -150.31 158.99 44.76 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 -175.624 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.509 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 61.0 m -95.23 155.94 16.52 Favored 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 176.467 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 40.1 m-80 -88.72 -18.61 27.47 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-O 121.178 0.513 . . . . 0.0 111.194 -178.613 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.554 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 34.0 m -101.14 124.77 40.31 Favored Pre-proline 0 C--N 1.297 -1.684 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 175.316 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -68.57 -13.68 37.85 Favored 'Trans proline' 0 N--CA 1.488 1.151 0 C-N-CA 122.974 2.449 . . . . 0.0 112.907 -178.2 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.429 ' H ' HG22 ' A' ' 15' ' ' THR . . . -84.55 -12.78 74.61 Favored Glycine 0 C--N 1.263 -3.525 0 CA-C-N 113.311 -1.768 . . . . 0.0 110.525 178.633 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.644 ' HA ' ' O ' ' A' ' 26' ' ' THR . 56.1 m -103.51 126.28 50.57 Favored 'General case' 0 N--CA 1.403 -2.792 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 -179.153 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.464 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 1.1 m -89.23 144.03 26.4 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 -177.77 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 53.7 t -88.14 103.26 15.59 Favored 'General case' 0 N--CA 1.421 -1.904 0 C-N-CA 119.602 -0.839 . . . . 0.0 109.887 177.764 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 14.7 m -104.82 58.36 0.69 Allowed 'General case' 0 C--N 1.285 -2.231 0 N-CA-C 104.473 -2.417 . . . . 0.0 104.473 174.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.444 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 42.1 t90 -33.98 132.9 0.38 Allowed Pre-proline 0 N--CA 1.441 -0.893 0 C-N-CA 127.133 2.173 . . . . 0.0 113.495 -169.808 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.444 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 4.5 Cg_exo -89.31 11.32 59.45 Favored 'Cis proline' 0 C--N 1.322 -0.859 0 C-N-CA 122.851 -1.729 . . . . 0.0 114.981 2.203 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 34.8 m -109.68 143.6 19.49 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.765 0 C-N-CA 120.166 -0.614 . . . . 0.0 112.538 -176.458 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.513 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 77.5 m -89.36 147.92 23.8 Favored 'General case' 0 N--CA 1.414 -2.273 0 O-C-N 121.7 -0.625 . . . . 0.0 110.984 177.21 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.644 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.9 p -132.74 -167.31 1.88 Allowed 'General case' 0 C--O 1.195 -1.796 0 C-N-CA 123.923 0.889 . . . . 0.0 109.206 178.069 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.411 ' HB3' ' HB2' ' A' ' 30' ' ' LEU . 98.8 mtt180 -121.96 136.85 54.95 Favored 'General case' 0 N--CA 1.399 -2.996 0 CA-C-N 119.048 0.84 . . . . 0.0 109.51 179.083 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 6.5 p30 -123.05 133.57 54.32 Favored 'General case' 0 C--N 1.288 -2.088 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 177.115 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 61.83 22.66 62.44 Favored Glycine 0 N--CA 1.462 0.377 0 O-C-N 123.483 0.489 . . . . 0.0 112.354 179.246 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.413 ' HA ' ' HD3' ' A' ' 31' ' ' PRO . 71.9 mt -129.59 157.43 76.5 Favored Pre-proline 0 N--CA 1.429 -1.508 0 CA-C-O 120.8 0.333 . . . . 0.0 111.693 -176.717 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.413 ' HD3' ' HA ' ' A' ' 30' ' ' LEU . 1.8 Cg_endo -73.43 137.7 25.97 Favored 'Trans proline' 0 N--CA 1.438 -1.753 0 C-N-CA 122.523 2.148 . . . . 0.0 109.021 174.409 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 24.2 t -96.81 104.06 15.42 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.068 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 -179.712 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 22.0 p . . . . . 0 C--N 1.267 -3.019 0 CA-C-N 114.689 -1.141 . . . . 0.0 108.878 178.986 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.906 0 N-CA-C 110.231 -1.148 . . . . 0.0 110.231 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -102.57 4.05 50.38 Favored Glycine 0 N--CA 1.433 -1.512 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 177.157 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 82.87 -58.27 5.04 Favored Glycine 0 CA--C 1.498 -1.023 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 -177.118 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.444 ' HB3' ' HG2' ' A' ' 6' ' ' GLU . 4.0 m -150.74 134.1 16.28 Favored 'General case' 0 N--CA 1.413 -2.275 0 C-N-CA 125.318 1.447 . . . . 0.0 108.181 175.207 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -88.92 -5.75 73.25 Favored Glycine 0 N--CA 1.439 -1.165 0 N-CA-C 110.123 -1.191 . . . . 0.0 110.123 177.83 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.444 ' HG2' ' HB3' ' A' ' 4' ' ' CYS . 13.0 pt-20 -78.77 147.93 33.16 Favored 'General case' 0 N--CA 1.428 -1.558 0 CA-C-N 114.92 -0.64 . . . . 0.0 109.438 179.689 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 32.2 p -105.01 155.09 19.29 Favored 'General case' 0 N--CA 1.401 -2.907 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.271 -177.178 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.624 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 30.0 p -118.8 41.62 2.98 Favored 'General case' 0 N--CA 1.428 -1.537 0 CA-C-O 121.614 0.721 . . . . 0.0 109.228 -179.104 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 35.4 t -56.57 -36.47 48.23 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.919 0 CA-C-N 114.933 -1.03 . . . . 0.0 111.075 -178.366 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -91.7 3.93 78.66 Favored Glycine 0 CA--C 1.519 0.312 0 N-CA-C 112.025 -0.43 . . . . 0.0 112.025 178.338 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 83.17 42.51 7.98 Favored Glycine 0 N--CA 1.44 -1.066 0 C-N-CA 121.753 -0.26 . . . . 0.0 112.847 179.231 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.3 t -155.09 151.03 27.84 Favored 'General case' 0 N--CA 1.431 -1.377 0 CA-C-O 121.286 0.565 . . . . 0.0 111.227 179.219 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.491 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 82.9 m -138.2 145.85 41.94 Favored 'General case' 0 C--N 1.286 -2.166 0 CA-C-N 113.812 -1.54 . . . . 0.0 108.105 178.696 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 31.6 m-80 -87.18 -39.25 15.66 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-O 121.61 0.719 . . . . 0.0 110.162 -178.505 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 16.0 m -78.52 120.85 82.55 Favored Pre-proline 0 C--N 1.305 -1.366 0 N-CA-C 108.785 -0.821 . . . . 0.0 108.785 178.208 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -72.98 -8.42 22.22 Favored 'Trans proline' 0 C--N 1.365 1.425 0 C-N-CA 122.802 2.335 . . . . 0.0 113.127 -175.501 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -92.97 -6.66 63.21 Favored Glycine 0 C--N 1.265 -3.369 0 CA-C-N 113.45 -1.705 . . . . 0.0 109.881 177.725 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.512 ' HA ' ' O ' ' A' ' 26' ' ' THR . 98.7 m -109.57 125.93 53.05 Favored 'General case' 0 N--CA 1.401 -2.898 0 CA-C-O 122.532 1.158 . . . . 0.0 111.106 179.202 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 3.5 m -100.09 153.23 19.39 Favored 'General case' 0 N--CA 1.401 -2.916 0 C-N-CA 127.153 2.181 . . . . 0.0 107.688 -175.283 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 53.9 t -85.27 117.59 24.3 Favored 'General case' 0 C--N 1.285 -2.198 0 CA-C-O 121.466 0.65 . . . . 0.0 110.364 179.001 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 21.3 t -124.55 74.88 1.36 Allowed 'General case' 0 C--N 1.282 -2.364 0 N-CA-C 103.197 -2.89 . . . . 0.0 103.197 172.47 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.497 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 42.9 t90 -39.56 133.88 1.28 Allowed Pre-proline 0 N--CA 1.431 -1.411 0 CA-C-N 113.858 -1.519 . . . . 0.0 113.096 -171.063 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.497 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 1.4 Cg_endo -92.38 15.27 46.72 Favored 'Cis proline' 0 CA--C 1.541 0.868 0 C-N-CA 122.874 -1.719 . . . . 0.0 114.695 1.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 30.9 m -115.63 146.62 19.82 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 N-CA-C 113.986 1.106 . . . . 0.0 113.986 -175.696 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.624 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 70.0 m -83.8 132.93 34.79 Favored 'General case' 0 N--CA 1.402 -2.846 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 173.309 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.512 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 2.5 p -135.55 -176.57 4.33 Favored 'General case' 0 C--O 1.182 -2.485 0 C-N-CA 124.057 0.943 . . . . 0.0 108.654 -179.779 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.432 ' HB3' ' HB2' ' A' ' 30' ' ' LEU . 57.2 mtp180 -114.72 107.06 14.96 Favored 'General case' 0 N--CA 1.407 -2.585 0 CA-C-N 119.515 1.052 . . . . 0.0 110.009 -177.407 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -68.67 127.75 34.18 Favored 'General case' 0 C--N 1.313 -0.993 0 N-CA-C 111.627 0.232 . . . . 0.0 111.627 179.218 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 60.7 25.94 64.23 Favored Glycine 0 N--CA 1.46 0.287 0 CA-C-N 116.008 -0.542 . . . . 0.0 113.551 175.61 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.432 ' HB2' ' HB3' ' A' ' 27' ' ' ARG . 32.8 mt -125.56 145.66 52.02 Favored Pre-proline 0 C--N 1.301 -1.52 0 N-CA-C 111.923 0.342 . . . . 0.0 111.923 -175.674 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 30' ' ' LEU . 73.9 Cg_exo -49.99 138.24 35.41 Favored 'Trans proline' 0 C--O 1.246 0.912 0 C-N-CA 124.149 3.233 . . . . 0.0 113.335 178.719 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.3 p -70.03 120.74 18.3 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.665 0 CA-C-O 122.231 1.015 . . . . 0.0 112.461 -177.613 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 5.0 t . . . . . 0 C--N 1.281 -2.383 0 CA-C-N 114.101 -1.409 . . . . 0.0 109.828 175.457 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.493 -1.308 0 N-CA-C 110.424 -1.071 . . . . 0.0 110.424 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 147.34 127.97 1.8 Allowed Glycine 0 N--CA 1.42 -2.419 0 N-CA-C 108.889 -1.684 . . . . 0.0 108.889 -177.211 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -76.16 -94.07 0.18 Allowed Glycine 0 N--CA 1.436 -1.308 0 C-N-CA 120.483 -0.865 . . . . 0.0 111.984 -179.53 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 73.2 m -131.02 134.96 47.17 Favored 'General case' 0 C--N 1.29 -2.002 0 N-CA-C 109.665 -0.495 . . . . 0.0 109.665 -179.017 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -88.41 16.9 51.51 Favored Glycine 0 C--N 1.315 -0.612 0 N-CA-C 110.741 -0.944 . . . . 0.0 110.741 177.65 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.437 ' HB2' ' HB2' ' A' ' 25' ' ' CYS . 6.0 mm-40 -90.35 150.63 21.81 Favored 'General case' 0 N--CA 1.432 -1.354 0 C-N-CA 124.018 0.927 . . . . 0.0 109.881 -178.817 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 7.1 p -124.58 151.94 44.15 Favored 'General case' 0 N--CA 1.411 -2.384 0 CA-C-N 116.186 -0.461 . . . . 0.0 109.869 176.025 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.497 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 27.0 p -130.9 41.12 3.4 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-O 121.446 0.641 . . . . 0.0 109.989 -176.507 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 19.4 t -61.87 -32.94 55.64 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 114.965 -1.016 . . . . 0.0 109.533 -179.317 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -85.79 -1.61 87.08 Favored Glycine 0 N--CA 1.442 -0.943 0 CA-C-N 115.452 -0.795 . . . . 0.0 111.78 178.834 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 109.4 -10.14 33.18 Favored Glycine 0 N--CA 1.433 -1.516 0 N-CA-C 114.81 0.684 . . . . 0.0 114.81 176.059 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 1.1 m -137.55 152.57 49.59 Favored 'General case' 0 N--CA 1.43 -1.471 0 CA-C-N 118.773 1.286 . . . . 0.0 110.198 -174.708 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.497 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 82.8 m -106.92 136.39 46.84 Favored 'General case' 0 C--N 1.277 -2.546 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 174.469 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . 0.41 ' HB2' ' OE2' ' A' ' 6' ' ' GLU . 33.9 m-80 -65.54 -44.44 86.85 Favored 'General case' 0 N--CA 1.475 0.778 0 CA-C-O 121.236 0.541 . . . . 0.0 109.816 176.884 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 55.0 m -83.33 112.48 39.35 Favored Pre-proline 0 N--CA 1.43 -1.447 0 N-CA-C 108.852 -0.796 . . . . 0.0 108.852 175.197 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -75.87 -1.39 11.34 Favored 'Trans proline' 0 C--N 1.359 1.096 0 C-N-CA 123.337 2.691 . . . . 0.0 113.781 -174.716 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -86.69 -10.64 72.57 Favored Glycine 0 C--N 1.27 -3.084 0 CA-C-N 113.971 -1.468 . . . . 0.0 110.356 177.14 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.445 ' HA ' ' O ' ' A' ' 26' ' ' THR . 49.9 m -105.92 133.5 50.54 Favored 'General case' 0 N--CA 1.419 -2.006 0 CA-C-N 114.552 -0.824 . . . . 0.0 109.537 -179.053 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.433 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 5.8 m -89.86 151.88 21.54 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 108.299 -1.001 . . . . 0.0 108.299 -177.693 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 50.5 t -88.52 104.71 17.07 Favored 'General case' 0 C--N 1.292 -1.93 0 CA-C-O 122.021 0.915 . . . . 0.0 111.331 179.604 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 42.6 t -107.51 65.59 0.65 Allowed 'General case' 0 C--N 1.285 -2.201 0 N-CA-C 104.22 -2.511 . . . . 0.0 104.22 173.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.444 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 56.7 t90 -36.24 132.63 0.61 Allowed Pre-proline 0 N--CA 1.439 -1.018 0 C-N-CA 125.884 1.673 . . . . 0.0 112.668 -172.171 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.444 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 2.2 Cg_endo -90.23 10.76 60.48 Favored 'Cis proline' 0 CA--C 1.546 1.117 0 C-N-CA 123.017 -1.66 . . . . 0.0 115.294 3.09 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 30.6 m -111.34 153.78 13.03 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.0 0 O-C-N 121.561 -0.712 . . . . 0.0 112.466 -176.611 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.476 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 68.3 m -92.89 135.37 34.2 Favored 'General case' 0 N--CA 1.397 -3.078 0 O-C-N 121.835 -0.541 . . . . 0.0 109.617 175.044 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.445 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 11.8 p -116.45 -174.21 2.52 Favored 'General case' 0 C--N 1.285 -2.23 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.836 -179.558 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.437 ' HB2' ' HB2' ' A' ' 30' ' ' LEU . 0.0 OUTLIER -112.69 149.59 32.68 Favored 'General case' 0 N--CA 1.383 -3.784 0 CA-C-O 121.523 0.677 . . . . 0.0 110.901 -176.79 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -136.14 129.69 32.15 Favored 'General case' 0 C--N 1.266 -3.053 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 174.667 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.13 -33.58 1.09 Allowed Glycine 0 CA--C 1.533 1.205 0 N-CA-C 113.894 0.318 . . . . 0.0 113.894 179.285 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.437 ' HB2' ' HB2' ' A' ' 27' ' ' ARG . 55.9 mt -57.76 142.26 78.63 Favored Pre-proline 0 C--N 1.321 -0.648 0 C-N-CA 124.701 1.2 . . . . 0.0 113.465 -177.703 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_endo -69.27 148.27 67.88 Favored 'Trans proline' 0 N--CA 1.445 -1.374 0 C-N-CA 122.797 2.331 . . . . 0.0 111.931 -176.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 25.7 t -69.51 113.31 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.49 0 N-CA-C 108.269 -1.011 . . . . 0.0 108.269 -179.497 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 14.9 m . . . . . 0 C--N 1.273 -2.737 0 CA-C-N 115.078 -0.965 . . . . 0.0 109.914 -175.789 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.425 -2.042 0 N-CA-C 108.384 -1.887 . . . . 0.0 108.384 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -89.94 -19.62 46.45 Favored Glycine 0 C--N 1.306 -1.086 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.277 -178.103 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -173.27 -139.48 2.9 Favored Glycine 0 CA--C 1.486 -1.729 0 N-CA-C 110.721 -0.952 . . . . 0.0 110.721 -179.025 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 71.9 m -142.02 135.24 29.05 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 178.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -94.93 -2.76 62.45 Favored Glycine 0 C--N 1.308 -1.005 0 C-N-CA 121.227 -0.511 . . . . 0.0 111.869 -176.521 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.443 ' O ' ' HB2' ' A' ' 25' ' ' CYS . 1.6 pm0 -83.82 141.74 31.13 Favored 'General case' 0 N--CA 1.426 -1.673 0 CA-C-O 121.488 0.661 . . . . 0.0 110.87 177.001 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . 0.414 HG22 HG12 ' A' ' 24' ' ' VAL . 22.8 p -106.83 153.57 22.29 Favored 'General case' 0 N--CA 1.404 -2.732 0 CA-C-N 115.279 -0.873 . . . . 0.0 109.765 -179.603 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.467 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 19.5 p -122.01 37.59 4.33 Favored 'General case' 0 CA--C 1.492 -1.277 0 CA-C-O 121.389 0.614 . . . . 0.0 110.268 -177.876 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 16.0 t -60.06 -33.99 55.04 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.204 0 CA-C-N 114.734 -1.121 . . . . 0.0 109.636 -178.646 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -87.73 6.62 83.17 Favored Glycine 0 N--CA 1.439 -1.107 0 CA-C-N 115.258 -0.883 . . . . 0.0 113.087 179.647 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 142.18 -69.01 0.44 Allowed Glycine 0 N--CA 1.438 -1.189 0 C-N-CA 120.131 -1.033 . . . . 0.0 114.502 177.384 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 20.5 m -157.04 163.24 39.27 Favored 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 106.748 -1.575 . . . . 0.0 106.748 -174.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 98.3 m -94.76 158.49 15.48 Favored 'General case' 0 C--N 1.281 -2.384 0 CA-C-O 120.808 0.337 . . . . 0.0 110.493 178.58 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 16.1 m120 -84.39 -26.73 28.15 Favored 'General case' 0 C--N 1.31 -1.144 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.845 -178.64 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 9.1 m -71.22 112.87 15.14 Favored Pre-proline 0 CA--C 1.556 1.175 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 177.243 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -70.8 -10.21 27.28 Favored 'Trans proline' 0 C--N 1.362 1.274 0 C-N-CA 123.293 2.662 . . . . 0.0 115.257 -172.101 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -93.3 -6.06 63.18 Favored Glycine 0 C--N 1.258 -3.753 0 CA-C-N 114.309 -1.314 . . . . 0.0 111.124 179.121 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.506 ' HA ' ' O ' ' A' ' 26' ' ' THR . 60.3 m -108.49 126.01 52.43 Favored 'General case' 0 N--CA 1.422 -1.834 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 1.4 m -95.16 143.9 26.22 Favored 'General case' 0 C--N 1.284 -2.268 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 -178.203 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 41.1 t -87.65 125.94 34.67 Favored 'General case' 0 C--N 1.285 -2.225 0 CA-C-O 121.593 0.711 . . . . 0.0 109.879 -179.873 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 6.4 t -132.22 71.41 1.47 Allowed 'General case' 0 N--CA 1.4 -2.973 0 N-CA-C 103.426 -2.805 . . . . 0.0 103.426 174.53 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.485 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 55.5 t90 -35.69 132.87 0.53 Allowed Pre-proline 0 N--CA 1.433 -1.297 0 C-N-CA 126.319 1.848 . . . . 0.0 112.95 -171.281 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.485 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 1.6 Cg_endo -91.95 10.59 58.15 Favored 'Cis proline' 0 CA--C 1.539 0.729 0 C-N-CA 123.081 -1.633 . . . . 0.0 115.381 4.053 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.414 HG12 HG22 ' A' ' 7' ' ' THR . 34.1 m -118.56 150.03 20.88 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 C-N-CA 119.511 -0.875 . . . . 0.0 112.438 -175.177 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.467 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 64.5 m -95.66 148.56 22.41 Favored 'General case' 0 N--CA 1.398 -3.047 0 CA-C-O 121.704 0.764 . . . . 0.0 111.331 175.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.506 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 0.6 OUTLIER -135.47 -165.23 1.66 Allowed 'General case' 0 C--N 1.284 -2.242 0 CA-C-N 114.518 -1.219 . . . . 0.0 109.975 177.851 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.405 HH11 ' HD3' ' A' ' 27' ' ' ARG . 3.8 ptm180 -108.62 153.48 23.35 Favored 'General case' 0 N--CA 1.389 -3.491 0 CA-C-O 121.746 0.784 . . . . 0.0 110.554 -174.476 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 43.3 m-80 -78.32 -23.4 47.09 Favored 'General case' 0 C--N 1.28 -2.45 0 CA-C-N 114.564 -1.198 . . . . 0.0 108.738 174.634 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 106.37 43.4 1.48 Allowed Glycine 0 N--CA 1.429 -1.814 0 CA-C-N 114.111 -1.404 . . . . 0.0 111.213 -178.152 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 4.4 mp -76.43 166.02 48.26 Favored Pre-proline 0 C--O 1.249 1.04 0 N-CA-C 106.44 -1.689 . . . . 0.0 106.44 178.58 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_exo -46.23 136.37 14.72 Favored 'Trans proline' 0 C--N 1.376 1.999 0 C-N-CA 122.363 2.042 . . . . 0.0 109.707 178.846 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 26.8 t -68.34 112.25 3.19 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 CA-C-O 122.397 1.094 . . . . 0.0 113.374 -168.107 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 12.8 m . . . . . 0 C--N 1.282 -2.357 0 CA-C-N 113.428 -1.714 . . . . 0.0 107.162 174.371 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.497 -1.033 0 N-CA-C 109.946 -1.262 . . . . 0.0 109.946 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 84.5 -73.85 2.59 Favored Glycine 0 C--N 1.298 -1.533 0 N-CA-C 109.989 -1.244 . . . . 0.0 109.989 -175.121 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 153.14 -100.8 0.2 Allowed Glycine 0 N--CA 1.422 -2.258 0 C-N-CA 121.157 -0.544 . . . . 0.0 111.774 179.397 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 65.2 m -118.92 135.92 54.34 Favored 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 -179.231 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -96.25 14.72 64.06 Favored Glycine 0 C--N 1.314 -0.678 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 176.534 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.501 ' HB2' ' HB2' ' A' ' 25' ' ' CYS . 6.7 mm-40 -81.21 149.76 28.92 Favored 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 179.132 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 18.3 p -123.49 150.75 43.54 Favored 'General case' 0 N--CA 1.401 -2.914 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 177.198 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.499 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 30.1 p -127.22 44.85 2.83 Favored 'General case' 0 N--CA 1.427 -1.578 0 CA-C-O 121.231 0.539 . . . . 0.0 109.588 -177.103 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 38.8 t -57.62 -33.82 45.75 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.059 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.894 -178.37 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -81.09 -31.49 34.71 Favored Glycine 0 N--CA 1.444 -0.83 0 N-CA-C 110.803 -0.919 . . . . 0.0 110.803 175.474 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 124.84 14.89 3.31 Favored Glycine 0 N--CA 1.441 -1.006 0 C-N-CA 121.507 -0.378 . . . . 0.0 113.613 178.41 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 12.7 m -139.62 153.77 47.42 Favored 'General case' 0 N--CA 1.424 -1.727 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 -178.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.499 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 41.5 m -122.59 137.93 54.74 Favored 'General case' 0 C--N 1.274 -2.709 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 175.194 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -66.01 -52.44 49.24 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.043 178.188 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 32.8 m -73.39 112.53 16.32 Favored Pre-proline 0 CA--C 1.554 1.122 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 176.57 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -72.86 -4.64 15.74 Favored 'Trans proline' 0 C--N 1.36 1.178 0 C-N-CA 123.438 2.759 . . . . 0.0 114.868 -172.85 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -86.0 -14.77 66.37 Favored Glycine 0 C--N 1.257 -3.822 0 CA-C-N 114.388 -1.278 . . . . 0.0 110.358 177.416 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.541 ' HA ' ' O ' ' A' ' 26' ' ' THR . 22.0 m -103.95 129.94 51.54 Favored 'General case' 0 N--CA 1.419 -1.999 0 CA-C-N 114.952 -0.624 . . . . 0.0 109.658 -179.163 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 4.3 m -95.85 156.48 16.31 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 124.346 1.058 . . . . 0.0 108.151 -178.806 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 42.0 t -83.04 123.76 29.78 Favored 'General case' 0 N--CA 1.423 -1.809 0 CA-C-O 121.61 0.719 . . . . 0.0 110.987 -179.299 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 32.7 t -133.76 69.93 1.46 Allowed 'General case' 0 C--N 1.283 -2.306 0 N-CA-C 104.526 -2.398 . . . . 0.0 104.526 173.831 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.437 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 41.7 t90 -36.53 134.59 0.6 Allowed Pre-proline 0 N--CA 1.443 -0.821 0 C-N-CA 126.258 1.823 . . . . 0.0 113.93 -170.702 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.437 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 1.9 Cg_endo -90.12 8.83 65.17 Favored 'Cis proline' 0 N--CA 1.456 -0.705 0 C-N-CA 122.679 -1.8 . . . . 0.0 114.261 1.277 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 35.9 m -108.88 158.66 8.62 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.928 0 CA-C-O 121.415 0.626 . . . . 0.0 112.548 -175.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.501 ' HB2' ' HB2' ' A' ' 6' ' ' GLU . 84.1 m -95.41 135.52 36.94 Favored 'General case' 0 N--CA 1.405 -2.7 0 O-C-N 121.733 -0.604 . . . . 0.0 109.829 174.453 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.541 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 10.5 p -119.35 -169.46 1.76 Allowed 'General case' 0 C--N 1.286 -2.168 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.83 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 10.5 mtp-105 -110.77 165.04 12.16 Favored 'General case' 0 N--CA 1.392 -3.326 0 CA-C-O 121.878 0.847 . . . . 0.0 110.442 -177.447 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -143.82 105.2 4.27 Favored 'General case' 0 C--N 1.272 -2.794 0 CA-C-N 113.705 -1.589 . . . . 0.0 109.56 177.435 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.08 33.84 69.92 Favored Glycine 0 C--N 1.316 -0.557 0 CA-C-N 115.752 -0.658 . . . . 0.0 112.458 179.429 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 45.7 mt -127.69 147.28 62.01 Favored Pre-proline 0 C--N 1.314 -0.975 0 N-CA-C 112.849 0.685 . . . . 0.0 112.849 -176.274 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_exo -60.78 148.08 93.11 Favored 'Trans proline' 0 C--O 1.247 0.929 0 C-N-CA 123.386 2.724 . . . . 0.0 110.881 176.264 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.4 p -81.81 115.81 25.01 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.737 0 CA-C-O 122.415 1.102 . . . . 0.0 111.467 -179.418 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 18.1 p . . . . . 0 C--N 1.277 -2.586 0 CA-C-N 113.738 -1.574 . . . . 0.0 111.387 -179.442 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.429 -1.81 0 N-CA-C 109.206 -1.557 . . . . 0.0 109.206 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -85.12 69.38 3.31 Favored Glycine 0 CA--C 1.495 -1.17 0 N-CA-C 110.145 -1.182 . . . . 0.0 110.145 177.362 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.417 ' HA3' ' HA ' ' A' ' 26' ' ' THR . . . 84.27 -107.84 3.04 Favored Glycine 0 N--CA 1.413 -2.848 0 N-CA-C 109.409 -1.476 . . . . 0.0 109.409 -175.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.722 ' SG ' ' HG3' ' A' ' 27' ' ' ARG . 78.0 m -133.16 146.73 51.82 Favored 'General case' 0 C--N 1.298 -1.653 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 176.812 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -81.57 -3.47 90.61 Favored Glycine 0 C--N 1.308 -1.007 0 C-N-CA 120.99 -0.624 . . . . 0.0 111.944 -179.501 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -89.62 160.06 16.84 Favored 'General case' 0 N--CA 1.437 -1.096 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 179.602 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . 0.526 ' HB ' HG23 ' A' ' 9' ' ' VAL . 38.0 p -113.88 164.07 14.25 Favored 'General case' 0 N--CA 1.406 -2.647 0 CA-C-O 121.109 0.481 . . . . 0.0 112.271 -174.83 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.495 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 26.1 p -131.41 33.8 4.03 Favored 'General case' 0 N--CA 1.426 -1.663 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 178.034 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.526 HG23 ' HB ' ' A' ' 7' ' ' THR . 21.9 t -57.7 -35.52 51.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 114.74 -1.118 . . . . 0.0 110.01 -178.766 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -82.27 -4.77 90.08 Favored Glycine 0 N--CA 1.444 -0.782 0 CA-C-N 115.684 -0.689 . . . . 0.0 113.063 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 128.46 -24.98 4.87 Favored Glycine 0 N--CA 1.444 -0.771 0 C-N-CA 120.231 -0.985 . . . . 0.0 114.344 177.497 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 15.3 t -156.89 173.03 17.61 Favored 'General case' 0 N--CA 1.431 -1.402 0 CA-C-N 118.277 1.039 . . . . 0.0 110.446 -175.689 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 57.5 m -101.77 175.88 5.41 Favored 'General case' 0 C--N 1.276 -2.612 0 CA-C-N 114.527 -1.215 . . . . 0.0 109.977 -175.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 51.0 m-80 -97.88 -38.32 9.48 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.046 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.422 HG22 ' H ' ' A' ' 17' ' ' GLY . 33.9 m -90.03 126.12 58.28 Favored Pre-proline 0 N--CA 1.429 -1.524 0 CA-C-N 115.505 -0.77 . . . . 0.0 108.979 178.33 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -72.33 -2.34 11.55 Favored 'Trans proline' 0 C--N 1.358 1.043 0 C-N-CA 122.693 2.262 . . . . 0.0 113.416 -177.383 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.422 ' H ' HG22 ' A' ' 15' ' ' THR . . . -93.07 -10.09 60.08 Favored Glycine 0 C--N 1.271 -3.054 0 CA-C-N 113.836 -1.529 . . . . 0.0 110.311 177.176 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.577 ' HB3' ' HB3' ' A' ' 25' ' ' CYS . 80.3 m -104.09 132.37 50.4 Favored 'General case' 0 N--CA 1.42 -1.926 0 CA-C-N 114.96 -0.62 . . . . 0.0 109.472 179.478 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 7.5 m -101.49 156.43 17.47 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 -179.736 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 44.4 t -88.16 123.97 33.35 Favored 'General case' 0 N--CA 1.418 -2.066 0 CA-C-O 121.409 0.623 . . . . 0.0 109.961 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 8.8 t -130.82 62.83 1.6 Allowed 'General case' 0 C--N 1.282 -2.34 0 N-CA-C 103.463 -2.792 . . . . 0.0 103.463 175.121 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.489 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 35.5 t90 -33.28 135.78 0.29 Allowed Pre-proline 0 C--O 1.243 0.732 0 C-N-CA 127.827 2.451 . . . . 0.0 113.821 -170.335 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.489 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 4.4 Cg_exo -88.4 4.98 69.71 Favored 'Cis proline' 0 CA--C 1.534 0.507 0 C-N-CA 123.004 -1.665 . . . . 0.0 114.812 2.183 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 34.1 m -107.82 157.66 7.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 C-N-CA 120.26 -0.576 . . . . 0.0 111.913 -176.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.577 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 93.1 m -91.28 150.33 21.37 Favored 'General case' 0 N--CA 1.404 -2.77 0 CA-C-O 121.305 0.574 . . . . 0.0 111.086 177.063 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.518 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 16.7 p -130.9 -178.65 4.9 Favored 'General case' 0 N--CA 1.421 -1.895 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.624 179.765 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.722 ' HG3' ' SG ' ' A' ' 4' ' ' CYS . 34.4 mtt85 -120.71 120.12 34.78 Favored 'General case' 0 N--CA 1.414 -2.241 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 -177.798 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -79.72 97.44 6.58 Favored 'General case' 0 C--N 1.287 -2.135 0 CA-C-N 115.448 -0.796 . . . . 0.0 112.284 -177.238 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 60.81 44.21 98.29 Favored Glycine 0 C--N 1.331 0.25 0 CA-C-N 115.733 -0.667 . . . . 0.0 112.933 176.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.539 ' HB2' ' HB3' ' A' ' 27' ' ' ARG . 55.0 mt -119.35 157.81 50.38 Favored Pre-proline 0 C--N 1.298 -1.668 0 O-C-N 122.885 -0.185 . . . . 0.0 110.625 -177.529 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 77.1 Cg_exo -50.24 139.47 35.67 Favored 'Trans proline' 0 C--O 1.252 1.21 0 C-N-CA 123.963 3.108 . . . . 0.0 112.033 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.6 p -64.64 112.74 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.186 0 CA-C-O 122.576 1.179 . . . . 0.0 111.597 -177.781 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 6.5 m . . . . . 0 C--N 1.293 -1.848 0 CA-C-N 113.288 -1.778 . . . . 0.0 107.979 -179.201 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.667 0 N-CA-C 112.502 -0.239 . . . . 0.0 112.502 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 117.72 -34.73 4.38 Favored Glycine 0 N--CA 1.432 -1.626 0 N-CA-C 110.909 -0.876 . . . . 0.0 110.909 179.401 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 87.35 -79.71 1.76 Allowed Glycine 0 N--CA 1.435 -1.407 0 N-CA-C 111.381 -0.687 . . . . 0.0 111.381 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 73.7 m -137.33 138.43 39.96 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 178.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -77.78 -6.24 86.94 Favored Glycine 0 C--N 1.312 -0.778 0 C-N-CA 121.212 -0.518 . . . . 0.0 113.163 -177.262 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -86.14 146.94 26.37 Favored 'General case' 0 C--N 1.308 -1.222 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 -179.398 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . 0.458 HG22 HG12 ' A' ' 24' ' ' VAL . 24.9 p -104.39 161.43 14.08 Favored 'General case' 0 N--CA 1.414 -2.255 0 CA-C-O 121.013 0.435 . . . . 0.0 111.891 -179.401 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.471 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 9.2 p -126.63 34.72 4.75 Favored 'General case' 0 CA--C 1.492 -1.255 0 CA-C-O 121.271 0.558 . . . . 0.0 110.27 -178.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.459 ' HA ' ' NE1' ' A' ' 22' ' ' TRP . 5.7 t -65.43 -28.79 45.27 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-N 115.273 -0.876 . . . . 0.0 109.46 -178.698 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -79.76 -15.83 78.58 Favored Glycine 0 C--O 1.241 0.564 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.512 177.814 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 125.98 -18.39 6.63 Favored Glycine 0 N--CA 1.436 -1.361 0 C-N-CA 120.519 -0.848 . . . . 0.0 115.217 175.695 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.5 m -145.67 158.14 43.88 Favored 'General case' 0 N--CA 1.437 -1.092 0 CA-C-N 118.764 1.282 . . . . 0.0 108.172 -175.341 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 62.7 m -99.51 170.85 8.32 Favored 'General case' 0 C--N 1.281 -2.372 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 175.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 26.9 m-80 -101.37 -18.82 15.87 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.468 0.651 . . . . 0.0 110.621 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.576 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 29.2 m -105.58 124.83 35.0 Favored Pre-proline 0 C--N 1.293 -1.888 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 175.561 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -73.29 -3.26 13.38 Favored 'Trans proline' 0 N--CA 1.486 1.078 0 C-N-CA 122.744 2.296 . . . . 0.0 113.098 -177.735 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.409 ' H ' HG22 ' A' ' 15' ' ' THR . . . -94.89 -8.03 59.47 Favored Glycine 0 C--N 1.27 -3.134 0 CA-C-N 113.38 -1.736 . . . . 0.0 109.839 176.419 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.621 ' HA ' ' O ' ' A' ' 26' ' ' THR . 85.0 m -106.12 125.75 51.37 Favored 'General case' 0 N--CA 1.419 -1.998 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.168 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 7.4 m -101.55 160.42 14.46 Favored 'General case' 0 C--N 1.286 -2.168 0 N-CA-C 107.483 -1.302 . . . . 0.0 107.483 -178.839 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 42.1 t -93.11 122.58 35.63 Favored 'General case' 0 N--CA 1.419 -2.013 0 CA-C-O 121.305 0.574 . . . . 0.0 110.911 -177.352 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 49.3 m -123.99 67.69 1.04 Allowed 'General case' 0 N--CA 1.409 -2.483 0 N-CA-C 105.03 -2.211 . . . . 0.0 105.03 171.644 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.465 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 50.4 t90 -37.27 133.69 0.73 Allowed Pre-proline 0 N--CA 1.435 -1.177 0 C-N-CA 126.091 1.757 . . . . 0.0 113.23 -170.157 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 1.9 Cg_endo -89.52 7.07 68.27 Favored 'Cis proline' 0 CA--C 1.55 1.299 0 C-N-CA 122.924 -1.698 . . . . 0.0 115.905 3.32 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.458 HG12 HG22 ' A' ' 7' ' ' THR . 33.3 m -109.52 151.47 11.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 O-C-N 121.581 -0.7 . . . . 0.0 112.421 -175.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.507 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 71.1 m -86.52 147.34 26.0 Favored 'General case' 0 N--CA 1.405 -2.68 0 CA-C-O 121.297 0.57 . . . . 0.0 109.954 175.395 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.621 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 31.0 p -132.6 -169.99 2.35 Favored 'General case' 0 C--N 1.294 -1.829 0 C-N-CA 122.758 0.423 . . . . 0.0 110.257 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 95.9 mtt180 -113.61 148.7 35.73 Favored 'General case' 0 N--CA 1.391 -3.396 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 -178.266 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -125.67 135.98 52.72 Favored 'General case' 0 C--N 1.276 -2.612 0 CA-C-N 114.47 -1.241 . . . . 0.0 109.144 179.804 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 60.57 27.41 66.06 Favored Glycine 0 N--CA 1.462 0.4 0 O-C-N 123.369 0.418 . . . . 0.0 112.446 177.024 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 55.7 mt -129.45 164.38 40.09 Favored Pre-proline 0 C--N 1.299 -1.607 0 CA-C-N 115.566 -0.317 . . . . 0.0 110.807 -175.629 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_exo -54.47 136.62 70.39 Favored 'Trans proline' 0 C--O 1.25 1.121 0 C-N-CA 122.976 2.45 . . . . 0.0 109.76 175.574 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 35.7 t -73.14 115.77 14.47 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.274 0 CA-C-O 122.371 1.081 . . . . 0.0 110.633 -173.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 9.7 m . . . . . 0 C--N 1.268 -2.95 0 CA-C-N 113.184 -1.826 . . . . 0.0 107.187 -179.519 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.426 -1.98 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -97.72 -17.65 30.04 Favored Glycine 0 C--N 1.306 -1.132 0 N-CA-C 111.028 -0.829 . . . . 0.0 111.028 179.125 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -150.6 -172.88 20.2 Favored Glycine 0 N--CA 1.423 -2.198 0 N-CA-C 108.857 -1.697 . . . . 0.0 108.857 179.598 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 88.2 m -103.66 124.21 48.42 Favored 'General case' 0 C--N 1.292 -1.904 0 C-N-CA 119.613 -0.835 . . . . 0.0 112.323 -179.349 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -89.88 23.41 20.43 Favored Glycine 0 C--N 1.316 -0.554 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 175.555 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.491 ' HB2' ' HB2' ' A' ' 25' ' ' CYS . 8.3 mm-40 -90.38 156.76 18.01 Favored 'General case' 0 N--CA 1.437 -1.109 0 C-N-CA 124.181 0.992 . . . . 0.0 110.005 -177.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 21.8 p -126.16 153.54 44.45 Favored 'General case' 0 N--CA 1.41 -2.443 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 174.23 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.428 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 21.6 p -124.79 33.75 5.15 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.781 -0.574 . . . . 0.0 111.005 -178.442 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.431 ' HA ' ' NE1' ' A' ' 22' ' ' TRP . 22.3 t -62.03 -35.98 71.57 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.867 0 CA-C-N 114.786 -1.097 . . . . 0.0 109.193 -179.835 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -71.33 -16.06 75.23 Favored Glycine 0 C--O 1.22 -0.733 0 CA-C-N 115.094 -0.957 . . . . 0.0 112.336 178.747 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 132.66 -23.65 3.97 Favored Glycine 0 N--CA 1.435 -1.428 0 C-N-CA 120.242 -0.98 . . . . 0.0 113.696 177.874 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 20.4 m -157.08 162.27 39.47 Favored 'General case' 0 C--N 1.31 -1.116 0 N-CA-C 107.114 -1.439 . . . . 0.0 107.114 -176.483 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 52.5 m -86.45 140.15 30.24 Favored 'General case' 0 C--N 1.283 -2.301 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 177.163 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 44.8 m-80 -72.0 -44.21 63.83 Favored 'General case' 0 C--N 1.315 -0.93 0 C-N-CA 120.746 -0.382 . . . . 0.0 110.892 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.483 HG21 HG23 ' A' ' 32' ' ' VAL . 27.2 m -76.34 121.08 84.27 Favored Pre-proline 0 CA--C 1.556 1.195 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 172.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_endo -71.24 -1.48 9.69 Favored 'Trans proline' 0 C--N 1.36 1.169 0 C-N-CA 123.551 2.834 . . . . 0.0 114.683 -173.45 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -95.06 2.32 65.9 Favored Glycine 0 C--N 1.261 -3.619 0 CA-C-N 114.506 -1.225 . . . . 0.0 112.003 -179.122 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 32.5 m -112.03 140.77 46.43 Favored 'General case' 0 N--CA 1.426 -1.674 0 CA-C-O 120.908 0.385 . . . . 0.0 111.674 -175.253 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 3.2 m -89.91 145.19 25.31 Favored 'General case' 0 C--N 1.315 -0.909 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 179.324 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 43.2 t -93.09 105.43 17.53 Favored 'General case' 0 C--N 1.29 -1.991 0 C-N-CA 120.073 -0.651 . . . . 0.0 110.369 177.547 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 2.3 p -113.97 65.69 0.66 Allowed 'General case' 0 C--N 1.278 -2.538 0 N-CA-C 106.274 -1.751 . . . . 0.0 106.274 173.444 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.47 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 49.2 t90 -34.83 135.34 0.41 Allowed Pre-proline 0 N--CA 1.446 -0.628 0 C-N-CA 126.985 2.114 . . . . 0.0 113.512 -169.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.47 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 1.8 Cg_endo -89.93 2.42 68.04 Favored 'Cis proline' 0 C--N 1.329 -0.499 0 C-N-CA 122.929 -1.696 . . . . 0.0 114.725 2.875 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.1 m -108.1 146.35 14.13 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 C-N-CA 120.259 -0.576 . . . . 0.0 111.95 -175.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.491 ' HB2' ' HB2' ' A' ' 6' ' ' GLU . 72.3 m -93.27 141.59 28.27 Favored 'General case' 0 N--CA 1.396 -3.162 0 CA-C-O 121.4 0.619 . . . . 0.0 111.5 179.341 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 1.4 p -109.14 -169.61 1.51 Allowed 'General case' 0 C--N 1.283 -2.313 0 CA-C-N 114.736 -1.12 . . . . 0.0 108.683 176.079 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.547 ' HG2' ' H ' ' A' ' 29' ' ' GLY . 39.7 ttp180 -117.45 137.11 52.73 Favored 'General case' 0 N--CA 1.404 -2.73 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 -178.478 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . 0.545 ' HB2' ' CD2' ' A' ' 30' ' ' LEU . 25.1 m-80 -76.61 -14.99 59.94 Favored 'General case' 0 C--N 1.291 -1.955 0 CA-C-O 121.568 0.699 . . . . 0.0 110.537 -178.477 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.547 ' H ' ' HG2' ' A' ' 27' ' ' ARG . . . 118.89 -21.16 9.69 Favored Glycine 0 C--N 1.294 -1.787 0 CA-C-N 115.195 -0.911 . . . . 0.0 111.234 -175.664 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.561 HD23 ' H ' ' A' ' 30' ' ' LEU . 2.6 pt? -75.42 150.33 84.76 Favored Pre-proline 0 C--N 1.323 -0.547 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 174.223 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_exo -66.17 137.13 46.8 Favored 'Trans proline' 0 CA--C 1.481 -2.137 0 C-N-CA 123.168 2.578 . . . . 0.0 115.034 -172.797 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.483 HG23 HG21 ' A' ' 15' ' ' THR . 14.6 p -133.36 160.4 42.37 Favored 'Isoleucine or valine' 0 N--CA 1.388 -3.543 0 CA-C-N 112.102 -2.317 . . . . 0.0 104.747 175.702 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 22.7 m . . . . . 0 C--N 1.265 -3.104 0 CA-C-O 121.351 0.596 . . . . 0.0 110.296 175.895 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.412 ' O ' HG23 ' A' ' 32' ' ' VAL . . . . . . . . 0 N--CA 1.415 -2.757 0 N-CA-C 107.033 -2.427 . . . . 0.0 107.033 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -63.06 -39.09 97.61 Favored Glycine 0 C--N 1.314 -0.646 0 N-CA-C 111.254 -0.738 . . . . 0.0 111.254 -178.726 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -172.83 -168.2 33.81 Favored Glycine 0 N--CA 1.419 -2.49 0 N-CA-C 108.202 -1.959 . . . . 0.0 108.202 178.216 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 61.2 m -103.41 119.65 39.29 Favored 'General case' 0 C--N 1.29 -2.02 0 CA-C-N 117.929 0.864 . . . . 0.0 110.049 179.412 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -84.98 -4.45 87.01 Favored Glycine 0 N--CA 1.443 -0.882 0 CA-C-N 115.699 -0.682 . . . . 0.0 113.978 -175.219 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -86.5 169.45 12.81 Favored 'General case' 0 C--N 1.309 -1.185 0 C-N-CA 119.836 -0.746 . . . . 0.0 111.064 -179.637 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . 0.42 HG22 HG12 ' A' ' 24' ' ' VAL . 7.0 p -120.36 155.52 33.22 Favored 'General case' 0 N--CA 1.401 -2.911 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 178.402 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.513 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 13.4 p -119.06 37.2 4.2 Favored 'General case' 0 CA--C 1.484 -1.587 0 CA-C-O 121.043 0.449 . . . . 0.0 110.571 -176.648 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.7 t -57.69 -34.2 47.02 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 CA-C-N 114.926 -1.034 . . . . 0.0 109.353 -179.612 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -70.62 -8.51 63.4 Favored Glycine 0 N--CA 1.436 -1.321 0 CA-C-N 114.964 -1.017 . . . . 0.0 113.557 179.172 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 144.21 -54.07 0.58 Allowed Glycine 0 N--CA 1.441 -0.979 0 C-N-CA 120.67 -0.776 . . . . 0.0 113.962 176.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 14.7 t -157.61 173.33 17.02 Favored 'General case' 0 N--CA 1.425 -1.72 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -176.226 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.513 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 35.6 m -96.21 137.29 35.49 Favored 'General case' 0 C--N 1.27 -2.867 0 CA-C-N 115.342 -0.844 . . . . 0.0 108.759 -178.158 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 40.8 m-80 -70.47 -47.74 59.13 Favored 'General case' 0 C--N 1.319 -0.755 0 O-C-N 123.199 0.312 . . . . 0.0 111.43 -179.168 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.405 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 42.3 m -69.91 119.56 72.2 Favored Pre-proline 0 N--CA 1.437 -1.079 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 178.774 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 15' ' ' THR . 22.0 Cg_exo -66.87 -9.82 26.14 Favored 'Trans proline' 0 C--N 1.36 1.134 0 C-N-CA 123.458 2.772 . . . . 0.0 113.927 -175.672 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -83.3 -17.27 67.12 Favored Glycine 0 C--N 1.265 -3.392 0 CA-C-N 113.787 -1.551 . . . . 0.0 110.412 177.252 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.493 ' HA ' ' O ' ' A' ' 26' ' ' THR . 47.8 m -108.55 126.68 53.2 Favored 'General case' 0 N--CA 1.416 -2.173 0 N-CA-C 108.096 -1.076 . . . . 0.0 108.096 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 6.8 m -101.22 148.04 25.57 Favored 'General case' 0 C--N 1.274 -2.701 0 N-CA-C 107.459 -1.311 . . . . 0.0 107.459 -175.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 50.3 t -90.78 106.27 18.4 Favored 'General case' 0 C--N 1.275 -2.653 0 CA-C-O 121.702 0.763 . . . . 0.0 110.662 -178.156 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 31.3 t -107.67 67.09 0.68 Allowed 'General case' 0 C--N 1.28 -2.426 0 N-CA-C 102.9 -3.0 . . . . 0.0 102.9 172.81 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.44 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 57.4 t90 -39.39 133.59 1.23 Allowed Pre-proline 0 N--CA 1.433 -1.286 0 CA-C-N 113.405 -1.725 . . . . 0.0 112.326 -171.356 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.44 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 1.9 Cg_endo -90.75 12.17 56.75 Favored 'Cis proline' 0 CA--C 1.543 0.967 0 C-N-CA 122.723 -1.782 . . . . 0.0 115.812 3.721 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.42 HG12 HG22 ' A' ' 7' ' ' THR . 21.0 m -110.66 146.86 15.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 119.071 0.851 . . . . 0.0 113.007 -176.419 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 90.9 m -86.53 140.64 29.71 Favored 'General case' 0 N--CA 1.401 -2.898 0 O-C-N 121.679 -0.638 . . . . 0.0 109.327 174.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.493 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 2.6 p -135.6 -177.3 4.61 Favored 'General case' 0 C--N 1.269 -2.92 0 CA-C-N 115.206 -0.907 . . . . 0.0 109.084 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 12.9 ttm180 -124.79 118.81 27.2 Favored 'General case' 0 N--CA 1.421 -1.89 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 176.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 34.8 p30 -69.8 7.04 0.97 Allowed 'General case' 0 C--N 1.285 -2.205 0 N-CA-C 114.865 1.431 . . . . 0.0 114.865 -172.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 116.92 -4.16 18.96 Favored Glycine 0 C--N 1.3 -1.428 0 C-N-CA 119.659 -1.258 . . . . 0.0 111.429 -177.533 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 28.2 mt -62.36 158.71 46.0 Favored Pre-proline 0 C--O 1.243 0.717 0 CA-C-O 119.35 -0.357 . . . . 0.0 111.034 174.703 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_exo -37.46 137.63 0.34 Allowed 'Trans proline' 0 C--N 1.362 1.278 0 C-N-CA 124.879 3.719 . . . . 0.0 115.472 -175.53 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.412 HG23 ' O ' ' A' ' 1' ' ' GLY . 3.4 p -80.91 99.49 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.782 0 CA-C-O 122.971 1.367 . . . . 0.0 111.172 -178.203 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 18.7 m . . . . . 0 C--N 1.271 -2.834 0 CA-C-N 113.28 -1.782 . . . . 0.0 107.263 179.091 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.441 -0.988 0 N-CA-C 110.597 -1.001 . . . . 0.0 110.597 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -142.32 -140.46 3.75 Favored Glycine 0 N--CA 1.415 -2.736 0 N-CA-C 109.959 -1.256 . . . . 0.0 109.959 177.884 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 107.68 -154.71 16.52 Favored Glycine 0 C--N 1.281 -2.477 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 -176.629 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 3.5 m -150.85 139.32 20.48 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 113.55 0.945 . . . . 0.0 113.55 -176.815 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -103.93 18.39 46.62 Favored Glycine 0 C--N 1.313 -0.739 0 N-CA-C 107.724 -2.15 . . . . 0.0 107.724 169.806 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 23.2 mm-40 -80.99 170.85 15.73 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 113.605 -1.298 . . . . 0.0 109.552 -178.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . 0.457 ' HB ' HG23 ' A' ' 9' ' ' VAL . 16.8 p -122.57 156.5 34.1 Favored 'General case' 0 N--CA 1.402 -2.827 0 CA-C-O 120.791 0.329 . . . . 0.0 111.062 178.825 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 20.5 p -128.22 38.24 4.03 Favored 'General case' 0 CA--C 1.491 -1.294 0 CA-C-O 121.41 0.624 . . . . 0.0 109.601 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.457 HG23 ' HB ' ' A' ' 7' ' ' THR . 11.1 t -58.62 -29.89 40.37 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.007 0 CA-C-N 114.426 -1.261 . . . . 0.0 110.709 -177.16 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -74.1 -22.11 78.24 Favored Glycine 0 N--CA 1.437 -1.256 0 CA-C-N 115.849 -0.614 . . . . 0.0 112.544 179.028 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 149.63 -36.55 0.99 Allowed Glycine 0 N--CA 1.438 -1.226 0 C-N-CA 120.207 -0.997 . . . . 0.0 113.863 179.672 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 8.8 t -158.3 173.65 16.36 Favored 'General case' 0 N--CA 1.423 -1.793 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 -178.429 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 63.2 m -89.75 150.54 22.25 Favored 'General case' 0 C--N 1.268 -2.937 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.134 -177.277 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 13.9 m120 -90.43 -12.23 38.06 Favored 'General case' 0 C--N 1.308 -1.203 0 CA-C-O 121.177 0.513 . . . . 0.0 110.158 177.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 10.4 m -100.37 122.96 48.13 Favored Pre-proline 0 C--N 1.305 -1.335 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 176.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 96.6 Cg_endo -78.39 -1.85 11.97 Favored 'Trans proline' 0 N--CA 1.484 0.949 0 C-N-CA 123.232 2.621 . . . . 0.0 115.926 -169.186 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -102.5 0.02 49.84 Favored Glycine 0 C--N 1.261 -3.634 0 N-CA-C 110.001 -1.24 . . . . 0.0 110.001 178.221 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.44 ' HA ' ' O ' ' A' ' 26' ' ' THR . 56.1 m -118.65 134.15 55.32 Favored 'General case' 0 N--CA 1.402 -2.854 0 CA-C-N 113.75 -1.225 . . . . 0.0 109.041 -175.429 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 10.5 t -109.89 163.86 13.13 Favored 'General case' 0 N--CA 1.426 -1.651 0 C-N-CA 119.584 -0.846 . . . . 0.0 109.639 -178.74 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 48.9 t -92.96 125.06 37.37 Favored 'General case' 0 N--CA 1.387 -3.605 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.117 -174.495 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 46.0 m -128.75 59.85 1.54 Allowed 'General case' 0 N--CA 1.397 -3.121 0 N-CA-C 104.557 -2.386 . . . . 0.0 104.557 173.211 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.435 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 47.7 t90 -31.8 131.49 0.29 Allowed Pre-proline 0 C--O 1.247 0.931 0 C-N-CA 126.851 2.06 . . . . 0.0 113.149 -172.452 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.435 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 2.8 Cg_endo -89.04 6.62 69.08 Favored 'Cis proline' 0 CA--C 1.537 0.644 0 C-N-CA 122.872 -1.72 . . . . 0.0 115.242 2.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 28.9 m -107.76 152.24 9.54 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.004 0 N-CA-C 112.855 0.687 . . . . 0.0 112.855 -176.223 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 94.5 m -88.56 149.4 23.61 Favored 'General case' 0 N--CA 1.402 -2.836 0 CA-C-O 121.452 0.644 . . . . 0.0 110.986 175.71 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.44 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.8 p -125.37 -146.72 0.35 Allowed 'General case' 0 C--N 1.285 -2.236 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 173.761 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 6.6 ptp180 -124.14 147.83 47.65 Favored 'General case' 1 N--CA 1.377 -4.077 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 -176.5 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 26.4 p30 -82.58 67.7 8.74 Favored 'General case' 0 C--N 1.272 -2.801 0 N-CA-C 113.696 0.999 . . . . 0.0 113.696 -177.733 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 66.72 22.7 71.99 Favored Glycine 0 C--N 1.316 -0.575 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.627 179.646 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 44.8 mt -76.8 155.29 83.15 Favored Pre-proline 0 C--N 1.313 -1.012 0 CA-C-N 115.819 -0.191 . . . . 0.0 110.706 179.387 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 75.9 Cg_exo -50.24 137.74 37.94 Favored 'Trans proline' 0 C--O 1.247 0.946 0 C-N-CA 123.602 2.868 . . . . 0.0 112.615 179.855 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 41.9 t -65.62 121.31 14.45 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.622 0 CA-C-N 115.078 -0.965 . . . . 0.0 109.133 -179.402 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 27.5 m . . . . . 0 C--N 1.294 -1.825 0 O-C-N 124.847 1.342 . . . . 0.0 111.659 179.239 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.411 -2.999 0 N-CA-C 105.22 -3.152 . . . . 0.0 105.22 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -73.03 -53.32 7.98 Favored Glycine 0 C--N 1.299 -1.48 0 N-CA-C 110.215 -1.154 . . . . 0.0 110.215 178.414 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -172.53 -173.87 39.41 Favored Glycine 0 N--CA 1.418 -2.553 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 178.669 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 58.5 m -126.42 138.37 53.53 Favored 'General case' 0 C--N 1.286 -2.175 0 CA-C-O 120.764 0.316 . . . . 0.0 110.999 179.634 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -107.94 -6.69 32.1 Favored Glycine 0 N--CA 1.431 -1.661 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 174.853 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -69.59 151.35 46.06 Favored 'General case' 0 C--O 1.25 1.086 0 CA-C-N 115.169 -0.515 . . . . 0.0 110.948 179.389 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 39.9 p -102.62 163.38 12.25 Favored 'General case' 0 N--CA 1.408 -2.571 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.072 -178.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.712 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 29.3 p -129.38 43.42 3.14 Favored 'General case' 0 N--CA 1.425 -1.677 0 CA-C-O 121.465 0.65 . . . . 0.0 109.485 -178.839 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 58.3 t -58.42 -33.14 47.07 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.862 -177.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -90.03 -0.95 76.89 Favored Glycine 0 C--O 1.224 -0.528 0 CA-C-N 116.211 -0.45 . . . . 0.0 112.109 178.762 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 86.72 29.18 24.53 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 121.823 -0.227 . . . . 0.0 113.217 177.752 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 7.0 m -148.52 155.08 40.67 Favored 'General case' 0 N--CA 1.436 -1.131 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 179.196 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.433 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 61.1 m -133.04 156.87 46.58 Favored 'General case' 0 C--N 1.279 -2.464 0 N-CA-C 107.572 -1.269 . . . . 0.0 107.572 176.862 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 33.3 m-80 -84.1 -39.42 19.53 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 -179.787 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 16.2 m -84.79 116.62 66.09 Favored Pre-proline 0 N--CA 1.429 -1.507 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 175.415 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -74.72 -7.67 19.61 Favored 'Trans proline' 0 C--N 1.358 1.07 0 C-N-CA 122.433 2.089 . . . . 0.0 112.758 -175.444 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -90.44 -6.84 67.88 Favored Glycine 0 C--N 1.268 -3.239 0 CA-C-N 113.233 -1.803 . . . . 0.0 110.143 178.368 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.447 ' HA ' ' O ' ' A' ' 26' ' ' THR . 86.8 m -105.28 125.91 51.51 Favored 'General case' 0 N--CA 1.412 -2.361 0 CA-C-O 122.407 1.098 . . . . 0.0 109.679 177.269 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.435 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 6.8 m -93.59 150.72 20.2 Favored 'General case' 0 C--N 1.276 -2.595 0 CA-C-N 113.125 -1.852 . . . . 0.0 108.603 -173.641 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 52.2 t -93.1 105.77 17.82 Favored 'General case' 0 N--CA 1.409 -2.493 0 CA-C-O 121.866 0.841 . . . . 0.0 110.904 -178.374 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 31.1 m -108.68 79.61 1.25 Allowed 'General case' 0 N--CA 1.391 -3.405 0 N-CA-C 103.569 -2.752 . . . . 0.0 103.569 171.074 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.436 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 54.5 t90 -44.31 134.51 4.37 Favored Pre-proline 0 N--CA 1.429 -1.517 0 CA-C-N 113.322 -1.763 . . . . 0.0 112.919 -167.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.436 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 4.0 Cg_endo -95.64 22.96 26.79 Favored 'Cis proline' 0 N--CA 1.458 -0.561 0 C-N-CA 122.969 -1.68 . . . . 0.0 114.597 3.15 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 29.9 m -120.68 144.22 30.25 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.968 0 N-CA-C 114.057 1.132 . . . . 0.0 114.057 -175.712 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.712 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 56.1 m -86.05 129.87 34.71 Favored 'General case' 0 N--CA 1.414 -2.268 0 O-C-N 121.791 -0.568 . . . . 0.0 109.616 176.212 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.447 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 1.3 p -135.78 -170.82 2.71 Favored 'General case' 0 C--N 1.287 -2.119 0 C-N-CA 123.541 0.737 . . . . 0.0 109.828 178.439 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 70.8 mtp180 -112.69 129.14 56.51 Favored 'General case' 0 N--CA 1.396 -3.145 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 177.729 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 11.0 p30 -79.37 21.22 0.49 Allowed 'General case' 0 C--N 1.281 -2.378 0 N-CA-C 112.89 0.7 . . . . 0.0 112.89 -177.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.31 33.08 32.99 Favored Glycine 0 C--N 1.315 -0.627 0 C-N-CA 119.727 -1.225 . . . . 0.0 111.679 -177.308 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.577 HD23 ' H ' ' A' ' 30' ' ' LEU . 2.5 pt? -101.18 169.82 7.3 Favored Pre-proline 0 C--N 1.298 -1.636 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.56 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 81.1 Cg_exo -49.01 162.43 0.41 Allowed 'Trans proline' 0 C--N 1.369 1.613 0 C-N-CA 123.428 2.752 . . . . 0.0 113.961 178.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 34.7 t -67.98 107.75 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 CA-C-O 122.23 1.014 . . . . 0.0 110.973 -175.387 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 8.9 t . . . . . 0 C--N 1.275 -2.658 0 CA-C-N 113.96 -1.473 . . . . 0.0 107.275 177.549 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.429 -1.8 0 N-CA-C 108.152 -1.979 . . . . 0.0 108.152 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -70.71 -38.57 66.98 Favored Glycine 0 CA--C 1.498 -0.978 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 177.696 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -142.0 -148.88 5.09 Favored Glycine 0 N--CA 1.415 -2.746 0 N-CA-C 107.703 -2.159 . . . . 0.0 107.703 175.474 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 96.4 m -129.83 143.44 50.81 Favored 'General case' 0 C--N 1.285 -2.225 0 CA-C-N 117.31 0.555 . . . . 0.0 110.209 178.293 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -85.65 4.01 86.36 Favored Glycine 0 N--CA 1.447 -0.581 0 N-CA-C 110.788 -0.925 . . . . 0.0 110.788 179.677 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 74.6 mm-40 -89.6 146.82 24.3 Favored 'General case' 0 N--CA 1.421 -1.909 0 CA-C-N 114.79 -0.705 . . . . 0.0 110.816 -179.511 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 32.6 p -123.71 150.81 43.87 Favored 'General case' 0 N--CA 1.392 -3.335 0 N-CA-C 106.185 -1.783 . . . . 0.0 106.185 174.4 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.43 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 24.4 p -123.99 38.35 4.21 Favored 'General case' 0 C--N 1.289 -2.022 0 CA-C-N 118.63 0.65 . . . . 0.0 110.254 -177.521 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 13.6 t -61.76 -40.48 87.04 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 CA-C-N 114.494 -1.23 . . . . 0.0 108.306 178.791 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -73.78 -22.24 78.42 Favored Glycine 0 N--CA 1.441 -1.032 0 CA-C-N 114.902 -1.045 . . . . 0.0 111.022 177.127 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 120.4 -6.94 11.57 Favored Glycine 0 N--CA 1.436 -1.302 0 C-N-CA 121.255 -0.498 . . . . 0.0 113.876 177.211 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 6.1 m -136.51 155.25 50.23 Favored 'General case' 0 N--CA 1.429 -1.492 0 CA-C-N 118.047 0.924 . . . . 0.0 108.936 -176.336 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 57.6 m -113.99 143.33 44.92 Favored 'General case' 0 C--N 1.279 -2.463 0 N-CA-C 106.154 -1.795 . . . . 0.0 106.154 175.676 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 33.4 m-80 -68.09 -39.36 82.88 Favored 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 119.053 0.842 . . . . 0.0 110.656 177.395 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 9.9 m -94.1 113.19 60.04 Favored Pre-proline 0 N--CA 1.426 -1.671 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 176.358 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -76.33 -1.89 12.0 Favored 'Trans proline' 0 C--N 1.354 0.828 0 C-N-CA 122.668 2.245 . . . . 0.0 112.534 -178.727 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -79.59 -14.41 81.26 Favored Glycine 0 C--N 1.284 -2.33 0 CA-C-N 113.105 -1.861 . . . . 0.0 108.936 175.166 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.536 ' HA ' ' O ' ' A' ' 26' ' ' THR . 63.7 m -103.14 127.33 50.47 Favored 'General case' 0 N--CA 1.406 -2.653 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.115 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.43 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 10.3 m -89.9 148.86 22.9 Favored 'General case' 0 C--N 1.279 -2.493 0 CA-C-N 114.876 -1.056 . . . . 0.0 108.633 -177.129 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 50.5 t -84.64 115.15 22.49 Favored 'General case' 0 C--N 1.269 -2.897 0 CA-C-O 121.461 0.648 . . . . 0.0 110.453 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 16.6 t -120.26 68.24 0.84 Allowed 'General case' 0 C--N 1.287 -2.152 0 N-CA-C 103.728 -2.693 . . . . 0.0 103.728 172.85 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.448 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 51.3 t90 -35.92 133.08 0.56 Allowed Pre-proline 0 N--CA 1.441 -0.904 0 CA-C-N 113.108 -1.86 . . . . 0.0 112.969 -170.417 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.448 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 1.6 Cg_endo -91.63 14.46 49.62 Favored 'Cis proline' 0 CA--C 1.541 0.855 0 C-N-CA 123.145 -1.606 . . . . 0.0 115.343 2.517 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 28.9 m -115.65 152.6 17.3 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.019 0 O-C-N 121.182 -0.949 . . . . 0.0 112.36 -177.629 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.43 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 59.6 m -95.73 139.32 32.14 Favored 'General case' 0 N--CA 1.403 -2.81 0 O-C-N 121.77 -0.581 . . . . 0.0 109.543 177.123 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.536 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 20.1 p -125.49 -173.29 2.79 Favored 'General case' 0 C--N 1.29 -1.989 0 C-N-CA 123.119 0.568 . . . . 0.0 111.345 -179.157 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 53.8 ttt180 -118.2 123.0 44.41 Favored 'General case' 0 N--CA 1.417 -2.095 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 -177.619 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 10.2 p30 -89.94 25.25 2.16 Favored 'General case' 0 C--N 1.279 -2.496 0 CA-C-N 115.028 -0.987 . . . . 0.0 113.052 -173.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 92.59 4.8 65.46 Favored Glycine 0 C--N 1.305 -1.161 0 C-N-CA 118.837 -1.649 . . . . 0.0 112.131 -178.42 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.438 ' HB3' ' HD2' ' A' ' 31' ' ' PRO . 17.6 mt -69.88 171.26 7.66 Favored Pre-proline 0 C--N 1.315 -0.928 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 174.016 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.438 ' HD2' ' HB3' ' A' ' 30' ' ' LEU . 61.8 Cg_exo -47.49 161.49 0.28 Allowed 'Trans proline' 0 C--N 1.36 1.161 0 C-N-CA 123.703 2.935 . . . . 0.0 112.188 176.689 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 24.6 m -60.33 115.18 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.415 -2.208 0 N-CA-C 114.262 1.208 . . . . 0.0 114.262 -170.244 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.452 HG21 ' SG ' ' A' ' 18' ' ' CYS . 1.3 m . . . . . 0 C--N 1.305 -1.336 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 173.454 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.427 -1.929 0 N-CA-C 109.278 -1.529 . . . . 0.0 109.278 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -80.2 58.45 4.61 Favored Glycine 0 C--N 1.31 -0.904 0 CA-C-N 116.976 0.388 . . . . 0.0 113.061 -177.317 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 93.34 -106.05 3.37 Favored Glycine 0 N--CA 1.43 -1.746 0 N-CA-C 111.825 -0.51 . . . . 0.0 111.825 179.294 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 98.1 m -152.82 154.65 35.57 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 179.246 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -107.19 5.64 36.16 Favored Glycine 0 C--N 1.31 -0.892 0 C-N-CA 120.465 -0.874 . . . . 0.0 112.443 -178.295 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -88.73 166.43 14.06 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.779 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . 0.43 ' HB ' HG23 ' A' ' 9' ' ' VAL . 24.4 p -112.49 163.25 14.68 Favored 'General case' 0 N--CA 1.415 -2.194 0 N-CA-C 112.15 0.426 . . . . 0.0 112.15 -175.79 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.462 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 21.4 p -137.13 36.01 2.55 Favored 'General case' 0 CA--C 1.497 -1.073 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 179.58 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.43 HG23 ' HB ' ' A' ' 7' ' ' THR . 15.4 t -60.8 -35.4 64.15 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.084 0 CA-C-N 114.719 -1.128 . . . . 0.0 109.4 -177.867 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -74.27 -17.27 79.63 Favored Glycine 0 N--CA 1.44 -1.044 0 CA-C-N 115.132 -0.94 . . . . 0.0 112.935 178.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 141.49 -33.43 1.98 Allowed Glycine 0 N--CA 1.435 -1.402 0 C-N-CA 119.992 -1.099 . . . . 0.0 113.795 179.848 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 9.0 t -153.58 172.8 16.64 Favored 'General case' 0 N--CA 1.424 -1.745 0 CA-C-N 117.771 0.785 . . . . 0.0 109.845 -174.726 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 58.1 m -94.75 176.35 6.31 Favored 'General case' 0 C--N 1.274 -2.687 0 CA-C-N 114.475 -1.239 . . . . 0.0 110.042 -177.391 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 26.8 m-80 -100.55 -36.43 9.18 Favored 'General case' 0 C--N 1.307 -1.243 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 178.588 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.507 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 25.8 m -90.69 121.86 67.69 Favored Pre-proline 0 N--CA 1.427 -1.607 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 177.179 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.443 ' HD3' ' HA ' ' A' ' 15' ' ' THR . 13.6 Cg_exo -69.66 -3.58 12.22 Favored 'Trans proline' 0 N--CA 1.488 1.157 0 C-N-CA 123.132 2.555 . . . . 0.0 113.458 -177.506 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -90.3 -14.22 59.08 Favored Glycine 0 C--N 1.255 -3.949 0 CA-C-N 113.719 -1.582 . . . . 0.0 110.283 176.458 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.589 ' HA ' ' O ' ' A' ' 26' ' ' THR . 57.8 m -103.55 129.97 50.86 Favored 'General case' 0 N--CA 1.396 -3.128 0 N-CA-C 107.575 -1.269 . . . . 0.0 107.575 179.254 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.556 ' OG1' ' HB3' ' A' ' 28' ' ' ASN . 25.1 m -114.78 155.5 26.61 Favored 'General case' 0 C--N 1.281 -2.389 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 -179.13 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 38.2 t -83.48 128.15 34.28 Favored 'General case' 0 N--CA 1.409 -2.521 0 CA-C-O 122.251 1.024 . . . . 0.0 113.065 -171.477 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.8 m -128.26 65.32 1.39 Allowed 'General case' 0 N--CA 1.402 -2.833 0 N-CA-C 104.401 -2.444 . . . . 0.0 104.401 170.149 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.426 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 37.9 t90 -33.67 134.87 0.33 Allowed Pre-proline 0 N--CA 1.442 -0.849 0 C-N-CA 127.433 2.293 . . . . 0.0 113.918 -170.92 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.426 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 4.6 Cg_exo -88.96 12.01 57.51 Favored 'Cis proline' 0 CA--C 1.544 0.98 0 C-N-CA 122.894 -1.711 . . . . 0.0 114.403 0.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.7 m -114.38 150.49 16.36 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.889 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -175.254 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.463 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 95.5 m -86.14 151.6 23.53 Favored 'General case' 0 N--CA 1.41 -2.435 0 CA-C-O 121.74 0.781 . . . . 0.0 112.206 178.39 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.589 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.0 p -129.27 -164.44 1.4 Allowed 'General case' 0 C--N 1.298 -1.642 0 C-N-CA 124.609 1.164 . . . . 0.0 108.331 175.559 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 17.3 ttm180 -122.62 135.27 54.56 Favored 'General case' 0 N--CA 1.407 -2.603 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 -178.277 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . 0.556 ' HB3' ' OG1' ' A' ' 19' ' ' THR . 1.1 t30 -131.88 129.6 40.57 Favored 'General case' 0 C--N 1.26 -3.29 0 N-CA-C 113.72 1.008 . . . . 0.0 113.72 -177.042 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 65.44 22.47 69.52 Favored Glycine 0 CA--C 1.499 -0.962 0 CA-C-N 114.956 -1.02 . . . . 0.0 112.884 173.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 68.4 mt -129.96 161.41 59.92 Favored Pre-proline 0 C--N 1.298 -1.654 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 -175.596 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -56.84 137.71 82.69 Favored 'Trans proline' 0 C--O 1.242 0.721 0 C-N-CA 123.35 2.7 . . . . 0.0 111.15 176.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 32.4 t -85.28 117.66 30.76 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.018 0 CA-C-O 121.914 0.864 . . . . 0.0 109.639 -177.263 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 24.6 m . . . . . 0 C--N 1.27 -2.861 0 N-CA-C 105.912 -1.885 . . . . 0.0 105.912 176.294 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.782 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 78.41 -53.25 3.89 Favored Glycine 0 CA--C 1.519 0.297 0 N-CA-C 111.883 -0.487 . . . . 0.0 111.883 -176.271 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -154.94 -138.59 2.62 Favored Glycine 0 N--CA 1.422 -2.239 0 N-CA-C 108.61 -1.796 . . . . 0.0 108.61 177.806 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 85.3 m -111.55 107.97 17.32 Favored 'General case' 0 C--N 1.29 -2.02 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 175.427 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -80.06 13.9 23.53 Favored Glycine 0 C--N 1.314 -0.675 0 CA-C-N 116.117 -0.492 . . . . 0.0 112.927 -176.382 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -91.56 162.13 14.66 Favored 'General case' 0 C--N 1.306 -1.288 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 178.762 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 25.3 p -114.74 163.48 15.42 Favored 'General case' 0 N--CA 1.411 -2.385 0 N-CA-C 110.374 -0.232 . . . . 0.0 110.374 -179.739 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 16.9 p -134.2 41.2 2.98 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-O 121.229 0.538 . . . . 0.0 110.185 -179.036 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 23.2 t -59.94 -29.89 44.26 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.042 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.619 -176.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -83.09 -8.14 86.02 Favored Glycine 0 N--CA 1.441 -0.995 0 CA-C-N 115.769 -0.65 . . . . 0.0 112.903 -179.786 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 139.82 -39.61 1.49 Allowed Glycine 0 N--CA 1.443 -0.885 0 C-N-CA 120.214 -0.993 . . . . 0.0 113.777 178.2 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 13.5 t -155.6 173.23 17.01 Favored 'General case' 0 N--CA 1.423 -1.802 0 CA-C-N 117.354 0.577 . . . . 0.0 109.649 -176.807 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 32.2 m -91.87 173.11 8.03 Favored 'General case' 0 C--N 1.274 -2.713 0 CA-C-N 114.815 -1.084 . . . . 0.0 109.578 -175.048 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 36.3 m-80 -93.27 -36.63 12.47 Favored 'General case' 0 CA--C 1.496 -1.097 0 N-CA-C 110.059 -0.348 . . . . 0.0 110.059 177.017 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.48 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 17.6 m -84.63 124.26 73.38 Favored Pre-proline 0 C--N 1.297 -1.675 0 N-CA-C 108.131 -1.062 . . . . 0.0 108.131 176.304 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_endo -72.86 -1.53 10.58 Favored 'Trans proline' 0 C--N 1.359 1.098 0 C-N-CA 123.05 2.5 . . . . 0.0 113.425 -176.194 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -97.63 -4.05 58.2 Favored Glycine 0 C--N 1.265 -3.407 0 CA-C-N 113.964 -1.471 . . . . 0.0 110.152 177.782 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.48 ' SG ' ' HB ' ' A' ' 15' ' ' THR . 60.3 m -108.66 125.84 52.32 Favored 'General case' 0 N--CA 1.409 -2.518 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 178.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 8.6 m -91.45 151.39 20.82 Favored 'General case' 0 C--N 1.291 -1.959 0 N-CA-C 107.74 -1.208 . . . . 0.0 107.74 -177.213 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 46.6 t -90.17 127.73 36.18 Favored 'General case' 0 N--CA 1.411 -2.415 0 CA-C-O 121.388 0.613 . . . . 0.0 109.565 179.501 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 22.6 t -128.71 56.8 1.63 Allowed 'General case' 0 C--N 1.28 -2.448 0 N-CA-C 103.688 -2.708 . . . . 0.0 103.688 176.001 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.429 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 56.6 t90 -31.2 131.91 0.25 Allowed Pre-proline 0 N--CA 1.446 -0.644 0 C-N-CA 127.009 2.124 . . . . 0.0 113.347 -171.314 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 1.8 Cg_endo -90.37 9.68 63.07 Favored 'Cis proline' 0 C--N 1.323 -0.811 0 C-N-CA 122.883 -1.715 . . . . 0.0 115.074 4.091 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 29.8 m -112.32 153.01 14.04 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 O-C-N 122.043 -0.41 . . . . 0.0 111.927 -176.2 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 73.4 m -93.39 158.78 15.56 Favored 'General case' 0 N--CA 1.416 -2.15 0 CA-C-O 121.487 0.661 . . . . 0.0 112.42 178.05 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.461 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.1 p -129.81 -175.04 3.48 Favored 'General case' 0 C--N 1.31 -1.145 0 C-N-CA 124.519 1.128 . . . . 0.0 108.562 175.679 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.504 ' HB2' ' HB2' ' A' ' 30' ' ' LEU . 20.0 ptt180 -119.29 139.78 51.36 Favored 'General case' 0 N--CA 1.384 -3.725 0 CA-C-N 119.407 1.003 . . . . 0.0 112.138 -178.027 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 8.7 p30 -122.42 109.61 14.6 Favored 'General case' 0 C--N 1.277 -2.546 0 CA-C-N 114.705 -1.134 . . . . 0.0 109.244 173.224 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 67.0 31.99 79.58 Favored Glycine 0 C--O 1.244 0.744 0 CA-C-N 115.893 -0.594 . . . . 0.0 113.538 177.89 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.504 ' HB2' ' HB2' ' A' ' 27' ' ' ARG . 35.2 mt -107.93 147.42 35.43 Favored Pre-proline 0 C--N 1.31 -1.148 0 O-C-N 122.388 -0.478 . . . . 0.0 112.199 -179.506 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 30' ' ' LEU . 2.9 Cg_exo -69.12 148.6 69.54 Favored 'Trans proline' 0 N--CA 1.449 -1.092 0 C-N-CA 122.616 2.211 . . . . 0.0 109.668 175.001 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 13.1 t -74.38 100.05 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 CA-C-O 121.769 0.795 . . . . 0.0 109.201 -177.842 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 3.8 m . . . . . 0 C--N 1.272 -2.767 0 CA-C-N 114.105 -1.407 . . . . 0.0 109.788 -177.286 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.791 0 N-CA-C 110.346 -1.102 . . . . 0.0 110.346 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.91 -75.02 1.92 Allowed Glycine 0 N--CA 1.445 -0.75 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 -177.234 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.453 ' HA2' ' HE ' ' A' ' 27' ' ' ARG . . . -141.86 -92.43 0.19 Allowed Glycine 0 N--CA 1.419 -2.44 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 178.219 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 72.4 m -143.51 141.43 30.74 Favored 'General case' 0 C--N 1.291 -1.966 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 173.652 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -88.03 12.98 62.52 Favored Glycine 0 C--N 1.304 -1.201 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.025 -178.057 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -90.23 154.67 19.56 Favored 'General case' 0 N--CA 1.431 -1.401 0 CA-C-O 121.096 0.474 . . . . 0.0 110.013 -179.289 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . 0.401 ' HA ' ' HA ' ' A' ' 24' ' ' VAL . 35.9 p -111.65 158.53 19.16 Favored 'General case' 0 N--CA 1.395 -3.225 0 N-CA-C 106.32 -1.734 . . . . 0.0 106.32 170.449 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.604 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 28.1 p -135.85 50.86 2.07 Favored 'General case' 0 C--N 1.283 -2.304 0 CA-C-O 121.502 0.668 . . . . 0.0 110.056 -177.66 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 40.3 t -62.43 -31.0 50.35 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.36 -178.568 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -74.45 -26.36 68.08 Favored Glycine 0 N--CA 1.446 -0.638 0 N-CA-C 111.338 -0.705 . . . . 0.0 111.338 176.701 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 122.27 0.18 10.46 Favored Glycine 0 N--CA 1.443 -0.875 0 C-N-CA 120.657 -0.782 . . . . 0.0 114.219 177.021 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 15.7 m -148.81 162.59 39.51 Favored 'General case' 0 N--CA 1.432 -1.372 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 -179.664 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 35.9 m -111.82 166.78 10.9 Favored 'General case' 0 C--N 1.281 -2.407 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 177.841 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 36.0 m-80 -83.43 -38.89 21.31 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-O 120.923 0.392 . . . . 0.0 110.022 179.223 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.582 ' HB ' ' SG ' ' A' ' 18' ' ' CYS . 13.4 m -79.88 123.85 83.54 Favored Pre-proline 0 N--CA 1.429 -1.509 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 178.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_exo -69.81 -2.92 11.03 Favored 'Trans proline' 0 C--N 1.353 0.809 0 C-N-CA 123.009 2.472 . . . . 0.0 112.898 179.504 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.445 ' H ' HG22 ' A' ' 15' ' ' THR . . . -96.47 -12.19 51.83 Favored Glycine 0 C--N 1.27 -3.134 0 CA-C-N 113.752 -1.567 . . . . 0.0 110.449 177.17 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.582 ' SG ' ' HB ' ' A' ' 15' ' ' THR . 62.3 m -103.7 130.63 51.22 Favored 'General case' 0 N--CA 1.415 -2.198 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 179.659 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 9.6 m -109.26 147.7 32.2 Favored 'General case' 0 C--N 1.282 -2.329 0 N-CA-C 107.928 -1.138 . . . . 0.0 107.928 -177.625 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 46.2 t -83.45 121.15 26.8 Favored 'General case' 0 N--CA 1.403 -2.777 0 CA-C-O 121.629 0.728 . . . . 0.0 111.073 -177.434 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 25.2 t -123.58 72.36 1.13 Allowed 'General case' 0 C--N 1.279 -2.472 0 N-CA-C 103.417 -2.809 . . . . 0.0 103.417 173.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.464 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 36.9 t90 -41.24 133.71 1.95 Allowed Pre-proline 0 N--CA 1.444 -0.729 0 C-N-CA 125.893 1.677 . . . . 0.0 113.411 -168.343 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.464 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 1.6 Cg_endo -92.23 16.81 43.42 Favored 'Cis proline' 0 CA--C 1.538 0.705 0 C-N-CA 122.826 -1.739 . . . . 0.0 114.655 2.113 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.401 ' HA ' ' HA ' ' A' ' 7' ' ' THR . 26.8 m -117.38 151.13 19.3 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.863 0 N-CA-C 113.95 1.093 . . . . 0.0 113.95 -176.11 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.604 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 82.8 m -86.21 148.95 25.42 Favored 'General case' 0 N--CA 1.409 -2.506 0 O-C-N 121.536 -0.727 . . . . 0.0 110.928 176.459 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.494 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 17.2 p -132.72 -174.51 3.48 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 175.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.453 ' HE ' ' HA2' ' A' ' 3' ' ' GLY . 3.5 ppt_? -123.82 160.26 27.76 Favored 'General case' 0 N--CA 1.379 -3.975 0 CA-C-N 119.524 1.056 . . . . 0.0 110.43 179.368 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 7.8 p30 -132.8 134.46 44.71 Favored 'General case' 0 C--N 1.265 -3.069 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 -179.144 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 60.77 22.78 60.22 Favored Glycine 0 C--O 1.227 -0.3 0 O-C-N 123.573 0.546 . . . . 0.0 112.861 178.799 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.442 ' HA ' ' HD3' ' A' ' 31' ' ' PRO . 46.0 mt -118.2 145.88 38.05 Favored Pre-proline 0 N--CA 1.424 -1.738 0 O-C-N 122.602 -0.352 . . . . 0.0 111.881 -176.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.442 ' HD3' ' HA ' ' A' ' 30' ' ' LEU . 6.4 Cg_exo -66.73 162.06 39.05 Favored 'Trans proline' 0 N--CA 1.451 -0.986 0 C-N-CA 122.777 2.318 . . . . 0.0 110.296 176.096 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 16.7 t -75.68 112.22 13.04 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 -179.031 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 9.1 t . . . . . 0 C--N 1.278 -2.515 0 CA-C-N 114.614 -1.175 . . . . 0.0 108.214 179.015 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.433 -1.523 0 N-CA-C 109.821 -1.311 . . . . 0.0 109.821 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -67.89 -39.36 89.54 Favored Glycine 0 C--N 1.314 -0.669 0 CA-C-N 116.976 0.388 . . . . 0.0 112.207 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -170.9 -130.81 1.26 Allowed Glycine 0 N--CA 1.437 -1.274 0 N-CA-C 109.261 -1.536 . . . . 0.0 109.261 179.287 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.638 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 88.7 m -104.7 162.94 12.86 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 174.708 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -92.42 -16.75 48.55 Favored Glycine 0 N--CA 1.44 -1.096 0 C-N-CA 120.454 -0.879 . . . . 0.0 112.866 -174.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.638 ' OE1' ' HB3' ' A' ' 4' ' ' CYS . 1.0 OUTLIER -90.15 145.94 24.66 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 122.447 -0.443 . . . . 0.0 111.056 -178.786 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . 0.442 HG22 HG12 ' A' ' 24' ' ' VAL . 21.7 p -109.83 157.04 19.6 Favored 'General case' 0 N--CA 1.417 -2.114 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.485 -179.209 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.5 ' HB3' ' SG ' ' A' ' 25' ' ' CYS . 19.5 p -126.23 38.85 4.06 Favored 'General case' 0 C--N 1.303 -1.422 0 CA-C-O 121.169 0.509 . . . . 0.0 110.589 -177.05 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 35.5 t -56.12 -35.48 41.97 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 CA-C-N 115.106 -0.952 . . . . 0.0 110.722 -178.427 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -95.4 7.85 68.97 Favored Glycine 0 N--CA 1.441 -1.027 0 C-N-CA 121.089 -0.577 . . . . 0.0 113.053 -179.483 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 152.1 -82.06 0.18 Allowed Glycine 0 N--CA 1.434 -1.477 0 C-N-CA 119.186 -1.483 . . . . 0.0 114.425 178.369 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 7.5 m -153.44 163.89 39.15 Favored 'General case' 0 N--CA 1.428 -1.57 0 N-CA-C 106.867 -1.531 . . . . 0.0 106.867 -171.153 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 76.7 m -99.13 161.56 13.55 Favored 'General case' 0 C--N 1.291 -1.95 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 176.188 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 41.7 m-80 -92.82 -16.51 25.24 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-O 120.99 0.424 . . . . 0.0 110.837 -177.839 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 10.7 m -72.49 114.89 33.98 Favored Pre-proline 0 N--CA 1.438 -1.07 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 178.814 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -70.17 -9.02 25.01 Favored 'Trans proline' 0 C--N 1.351 0.709 0 C-N-CA 122.806 2.337 . . . . 0.0 114.213 -174.204 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -91.74 -15.34 54.94 Favored Glycine 0 C--N 1.261 -3.623 0 CA-C-N 113.988 -1.46 . . . . 0.0 111.234 178.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.568 ' HA ' ' O ' ' A' ' 26' ' ' THR . 82.9 m -118.7 125.29 49.35 Favored 'General case' 0 N--CA 1.415 -2.195 0 CA-C-O 121.639 0.733 . . . . 0.0 110.795 -177.687 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 8.1 m -101.88 156.61 17.42 Favored 'General case' 0 C--N 1.293 -1.871 0 C-N-CA 124.666 1.187 . . . . 0.0 108.521 -176.734 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 51.8 t -88.64 119.64 29.3 Favored 'General case' 0 C--N 1.297 -1.707 0 CA-C-O 121.503 0.668 . . . . 0.0 111.851 -176.696 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 21.1 t -124.76 75.69 1.45 Allowed 'General case' 0 N--CA 1.417 -2.097 0 N-CA-C 103.541 -2.763 . . . . 0.0 103.541 171.11 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.485 ' CG ' ' HA ' ' A' ' 23' ' ' PRO . 57.2 t90 -38.0 135.79 0.81 Allowed Pre-proline 0 N--CA 1.436 -1.125 0 C-N-CA 126.063 1.745 . . . . 0.0 113.058 -170.809 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.485 ' HA ' ' CG ' ' A' ' 22' ' ' TRP . 1.2 Cg_endo -91.47 9.54 61.59 Favored 'Cis proline' 0 CA--C 1.536 0.618 0 C-N-CA 122.862 -1.724 . . . . 0.0 114.958 3.426 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.442 HG12 HG22 ' A' ' 7' ' ' THR . 25.3 m -113.86 158.09 14.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 C-N-CA 120.102 -0.639 . . . . 0.0 111.725 -175.442 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.5 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 53.4 m -96.86 143.06 28.12 Favored 'General case' 0 N--CA 1.388 -3.528 0 CA-C-O 121.838 0.828 . . . . 0.0 110.442 173.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.568 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 7.9 p -128.19 -170.13 2.19 Favored 'General case' 0 C--N 1.273 -2.742 0 CA-C-N 114.466 -1.243 . . . . 0.0 110.994 -177.558 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.412 ' HB3' ' HB2' ' A' ' 30' ' ' LEU . 19.1 mtm180 -99.84 151.58 21.12 Favored 'General case' 0 N--CA 1.381 -3.914 0 CA-C-O 121.459 0.647 . . . . 0.0 110.77 -169.179 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 7.1 p30 -133.62 112.75 11.71 Favored 'General case' 0 C--N 1.266 -3.055 0 CA-C-N 113.652 -1.613 . . . . 0.0 106.773 169.563 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.0 -33.45 2.65 Favored Glycine 0 CA--C 1.533 1.163 0 CA-C-N 116.337 -0.392 . . . . 0.0 112.929 179.902 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.412 ' HB2' ' HB3' ' A' ' 27' ' ' ARG . 62.9 mt -60.91 149.75 79.88 Favored Pre-proline 0 C--O 1.243 0.742 0 N-CA-C 113.792 1.034 . . . . 0.0 113.792 -178.481 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -76.61 162.73 32.68 Favored 'Trans proline' 0 N--CA 1.444 -1.414 0 C-N-CA 123.377 2.718 . . . . 0.0 111.578 -179.183 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.5 t -84.26 98.8 6.04 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.69 0 CA-C-O 121.736 0.779 . . . . 0.0 109.774 -177.436 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 8.2 m . . . . . 0 C--N 1.274 -2.694 0 CA-C-N 115.031 -0.986 . . . . 0.0 109.486 179.017 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.733 0 N-CA-C 111.904 -0.479 . . . . 0.0 111.904 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 89.39 -81.88 1.46 Allowed Glycine 0 N--CA 1.43 -1.728 0 N-CA-C 108.939 -1.664 . . . . 0.0 108.939 -176.042 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.502 ' HA2' ' HG3' ' A' ' 27' ' ' ARG . . . -115.79 -102.76 2.36 Favored Glycine 0 N--CA 1.426 -1.979 0 N-CA-C 109.305 -1.518 . . . . 0.0 109.305 176.651 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 99.1 m -140.82 152.52 45.22 Favored 'General case' 0 C--N 1.295 -1.768 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 176.334 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -87.64 9.83 72.24 Favored Glycine 0 C--N 1.314 -0.671 0 N-CA-C 110.581 -1.008 . . . . 0.0 110.581 178.459 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.47 ' HB2' ' HB2' ' A' ' 25' ' ' CYS . 6.2 mm-40 -86.38 154.16 21.39 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 124.14 0.976 . . . . 0.0 108.735 -179.64 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 9.2 p -126.82 153.94 44.97 Favored 'General case' 0 N--CA 1.41 -2.452 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 174.062 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.467 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 25.1 p -133.94 40.38 3.08 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-O 120.92 0.391 . . . . 0.0 110.862 -175.825 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 18.7 t -56.48 -29.17 28.29 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.182 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.345 -179.075 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -79.66 -17.19 76.0 Favored Glycine 0 N--CA 1.445 -0.7 0 CA-C-N 115.612 -0.722 . . . . 0.0 113.392 179.562 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 138.03 -32.07 2.39 Favored Glycine 0 N--CA 1.444 -0.828 0 C-N-CA 119.775 -1.202 . . . . 0.0 114.543 178.874 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 15.7 m -152.32 159.13 43.52 Favored 'General case' 0 C--N 1.31 -1.123 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 -176.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.467 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 32.6 m -89.95 165.66 13.94 Favored 'General case' 0 C--N 1.285 -2.221 0 O-C-N 123.767 0.667 . . . . 0.0 109.599 -179.295 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 14.0 m120 -85.16 -48.98 8.61 Favored 'General case' 0 CA--C 1.503 -0.842 0 CA-C-O 120.884 0.373 . . . . 0.0 110.142 178.079 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 29.1 m -70.52 118.93 69.14 Favored Pre-proline 0 C--N 1.311 -1.077 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 175.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -72.35 -5.1 16.49 Favored 'Trans proline' 0 C--N 1.365 1.421 0 C-N-CA 123.134 2.556 . . . . 0.0 114.164 -173.534 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -90.42 -8.43 66.1 Favored Glycine 0 C--N 1.261 -3.606 0 CA-C-N 114.008 -1.451 . . . . 0.0 110.35 178.703 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.498 ' HB3' ' HB3' ' A' ' 25' ' ' CYS . 67.9 m -107.98 127.39 53.72 Favored 'General case' 0 N--CA 1.409 -2.512 0 CA-C-O 121.41 0.624 . . . . 0.0 110.663 -178.464 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 6.3 m -90.16 148.63 22.85 Favored 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 107.969 -1.122 . . . . 0.0 107.969 -178.241 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 51.5 t -88.97 102.81 15.45 Favored 'General case' 0 N--CA 1.412 -2.332 0 CA-C-O 121.501 0.667 . . . . 0.0 111.183 -178.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.1 p -105.65 64.89 0.7 Allowed 'General case' 0 C--N 1.288 -2.097 0 N-CA-C 106.225 -1.768 . . . . 0.0 106.225 172.244 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.44 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 56.1 t90 -35.74 134.31 0.52 Allowed Pre-proline 0 N--CA 1.443 -0.821 0 C-N-CA 127.358 2.263 . . . . 0.0 113.586 -169.652 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.44 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 1.5 Cg_endo -91.28 10.01 61.09 Favored 'Cis proline' 0 C--N 1.323 -0.777 0 C-N-CA 122.823 -1.741 . . . . 0.0 114.188 2.474 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.9 m -110.81 150.0 13.44 Favored 'Isoleucine or valine' 0 C--O 1.21 -1.019 0 C-N-CA 120.212 -0.595 . . . . 0.0 111.846 -176.426 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.498 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 69.0 m -92.93 141.29 28.58 Favored 'General case' 0 N--CA 1.408 -2.539 0 CA-C-O 121.44 0.638 . . . . 0.0 112.45 178.808 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.455 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 1.7 p -117.83 -177.18 3.19 Favored 'General case' 0 C--N 1.292 -1.903 0 CA-C-N 115.016 -0.993 . . . . 0.0 108.526 175.534 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.502 ' HG3' ' HA2' ' A' ' 3' ' ' GLY . 4.9 ppt_? -119.17 154.96 32.48 Favored 'General case' 0 N--CA 1.387 -3.602 0 CA-C-N 119.669 1.122 . . . . 0.0 112.298 -176.521 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -140.66 127.68 20.75 Favored 'General case' 0 C--N 1.274 -2.69 0 CA-C-N 114.426 -1.261 . . . . 0.0 109.957 177.414 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 65.66 34.19 88.23 Favored Glycine 0 N--CA 1.449 -0.489 0 N-CA-C 111.35 -0.7 . . . . 0.0 111.35 -178.616 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 47.5 mt -129.46 160.32 64.94 Favored Pre-proline 0 C--N 1.309 -1.184 0 N-CA-C 112.443 0.535 . . . . 0.0 112.443 -177.719 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -61.19 148.58 92.48 Favored 'Trans proline' 0 C--O 1.251 1.147 0 C-N-CA 123.3 2.666 . . . . 0.0 111.55 176.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 5.7 m -81.91 98.61 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.399 -3.022 0 CA-C-O 122.088 0.947 . . . . 0.0 110.952 179.171 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 10.0 t . . . . . 0 N--CA 1.42 -1.96 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 178.63 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.796 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -125.56 25.94 5.54 Favored Glycine 0 N--CA 1.436 -1.302 0 N-CA-C 110.624 -0.991 . . . . 0.0 110.624 178.85 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 145.35 -94.63 0.17 Allowed Glycine 0 N--CA 1.437 -1.247 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 178.745 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.422 ' SG ' ' HB3' ' A' ' 27' ' ' ARG . 63.4 m -131.56 151.48 51.56 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 173.842 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -89.21 16.62 55.33 Favored Glycine 0 C--N 1.315 -0.608 0 N-CA-C 110.201 -1.16 . . . . 0.0 110.201 178.408 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.466 ' HB2' ' HB2' ' A' ' 25' ' ' CYS . 7.8 mm-40 -91.53 151.44 20.75 Favored 'General case' 0 N--CA 1.425 -1.699 0 C-N-CA 124.433 1.093 . . . . 0.0 110.153 -179.403 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 17.2 p -126.4 152.27 46.57 Favored 'General case' 0 N--CA 1.405 -2.675 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 174.746 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 24.7 p -130.37 37.67 3.84 Favored 'General case' 0 C--N 1.301 -1.513 0 CA-C-O 121.153 0.501 . . . . 0.0 110.934 -175.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 25.7 t -58.46 -37.56 64.89 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.13 0 CA-C-N 114.928 -1.033 . . . . 0.0 109.835 -178.468 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -79.18 1.81 73.62 Favored Glycine 0 CA--C 1.524 0.602 0 CA-C-N 115.55 -0.75 . . . . 0.0 113.608 -179.908 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 124.65 -28.8 5.14 Favored Glycine 0 N--CA 1.44 -1.053 0 C-N-CA 119.956 -1.116 . . . . 0.0 114.168 176.657 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 12.4 t -157.33 172.7 18.14 Favored 'General case' 0 N--CA 1.426 -1.636 0 CA-C-N 117.566 0.683 . . . . 0.0 109.324 -176.641 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 33.4 m -98.81 164.21 12.31 Favored 'General case' 0 C--N 1.276 -2.604 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 -178.581 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 14.6 m-80 -85.23 -42.01 15.07 Favored 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 107.261 -1.385 . . . . 0.0 107.261 178.909 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 14.3 m -77.9 114.74 44.36 Favored Pre-proline 0 N--CA 1.422 -1.868 0 CA-C-N 114.035 -1.439 . . . . 0.0 108.685 177.52 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -73.43 -0.67 9.56 Favored 'Trans proline' 0 N--CA 1.483 0.861 0 C-N-CA 123.662 2.908 . . . . 0.0 113.536 -174.538 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -96.4 -11.83 52.98 Favored Glycine 0 C--N 1.261 -3.6 0 CA-C-N 113.985 -1.462 . . . . 0.0 111.15 177.843 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.404 ' HB3' ' HB3' ' A' ' 25' ' ' CYS . 76.2 m -103.91 127.96 51.41 Favored 'General case' 0 N--CA 1.419 -2.019 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 179.446 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 8.8 m -90.44 153.51 20.34 Favored 'General case' 0 C--N 1.288 -2.093 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 -176.229 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 52.8 t -89.84 116.48 27.96 Favored 'General case' 0 C--N 1.284 -2.241 0 CA-C-O 121.657 0.742 . . . . 0.0 111.247 -177.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 34.4 t -119.35 57.7 0.89 Allowed 'General case' 0 C--N 1.29 -1.984 0 N-CA-C 104.568 -2.382 . . . . 0.0 104.568 176.099 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.412 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 42.5 t90 -29.62 131.86 0.22 Allowed Pre-proline 0 C--N 1.346 0.454 0 C-N-CA 127.261 2.224 . . . . 0.0 113.966 -170.564 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.412 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 2.4 Cg_endo -90.16 6.24 68.11 Favored 'Cis proline' 0 C--N 1.327 -0.56 0 C-N-CA 123.082 -1.632 . . . . 0.0 114.664 3.325 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 26.8 m -108.75 152.57 10.71 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 C-N-CA 120.181 -0.608 . . . . 0.0 112.175 -176.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.466 ' HB2' ' HB2' ' A' ' 6' ' ' GLU . 82.2 m -93.35 144.57 25.2 Favored 'General case' 0 N--CA 1.407 -2.622 0 CA-C-O 121.59 0.71 . . . . 0.0 112.188 178.246 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 3.1 p -116.17 179.14 4.08 Favored 'General case' 0 C--N 1.29 -2.016 0 C-N-CA 124.654 1.181 . . . . 0.0 110.049 178.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.422 ' HB3' ' SG ' ' A' ' 4' ' ' CYS . 0.0 OUTLIER -120.4 149.58 42.13 Favored 'General case' 0 N--CA 1.386 -3.672 0 CA-C-O 121.863 0.84 . . . . 0.0 111.856 -176.662 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 6.9 p30 -132.57 118.43 19.2 Favored 'General case' 0 C--N 1.266 -3.046 0 N-CA-C 106.521 -1.659 . . . . 0.0 106.521 172.899 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.43 -33.57 1.36 Allowed Glycine 0 CA--C 1.535 1.285 0 CA-C-N 116.187 -0.461 . . . . 0.0 113.474 -178.235 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 53.0 mt -68.15 154.61 93.71 Favored Pre-proline 0 C--N 1.318 -0.787 0 N-CA-C 113.55 0.944 . . . . 0.0 113.55 -178.47 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_exo -61.55 137.05 66.85 Favored 'Trans proline' 0 C--O 1.25 1.103 0 C-N-CA 122.921 2.414 . . . . 0.0 110.398 176.038 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.4 p -64.94 114.14 2.33 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.277 0 CA-C-O 122.286 1.041 . . . . 0.0 111.087 -178.505 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 28.6 m . . . . . 0 C--N 1.27 -2.888 0 CA-C-N 114.141 -1.39 . . . . 0.0 108.206 178.95 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.9 0 N-CA-C 110.09 -1.204 . . . . 0.0 110.09 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -107.1 25.48 22.02 Favored Glycine 0 C--N 1.304 -1.198 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 178.103 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 108.46 -83.79 0.35 Allowed Glycine 0 N--CA 1.429 -1.814 0 N-CA-C 110.097 -1.201 . . . . 0.0 110.097 179.757 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.493 ' SG ' ' HG3' ' A' ' 27' ' ' ARG . 94.6 m -135.95 154.16 51.19 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.361 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -94.58 17.35 59.26 Favored Glycine 0 N--CA 1.446 -0.692 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 176.723 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.415 ' HB2' ' HB2' ' A' ' 25' ' ' CYS . 17.6 mm-40 -90.08 148.44 23.02 Favored 'General case' 0 N--CA 1.42 -1.946 0 CA-C-N 113.888 -1.156 . . . . 0.0 107.884 179.035 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . 0.41 HG22 HG12 ' A' ' 24' ' ' VAL . 3.7 p -127.77 146.81 50.47 Favored 'General case' 0 C--N 1.268 -2.948 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.57 -179.755 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 21.7 p -127.18 35.99 4.49 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-O 121.07 0.462 . . . . 0.0 110.337 -176.579 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 25.2 t -57.25 -35.12 47.6 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 CA-C-N 115.06 -0.973 . . . . 0.0 109.828 -179.42 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -93.12 4.91 75.05 Favored Glycine 0 N--CA 1.437 -1.283 0 CA-C-N 115.526 -0.761 . . . . 0.0 113.171 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 151.43 -79.94 0.2 Allowed Glycine 0 N--CA 1.443 -0.841 0 C-N-CA 119.431 -1.366 . . . . 0.0 114.594 178.942 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 5.1 m -149.75 164.74 34.46 Favored 'General case' 0 N--CA 1.435 -1.187 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 -172.46 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.406 ' SG ' ' HB3' ' A' ' 6' ' ' GLU . 91.7 m -98.58 149.04 23.17 Favored 'General case' 0 C--N 1.285 -2.2 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 175.364 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -95.2 -0.37 53.23 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-O 121.437 0.637 . . . . 0.0 111.409 -179.002 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 56.2 m -85.73 111.19 35.79 Favored Pre-proline 0 N--CA 1.429 -1.509 0 N-CA-C 106.29 -1.744 . . . . 0.0 106.29 171.101 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -68.54 -12.29 34.33 Favored 'Trans proline' 0 C--N 1.36 1.181 0 C-N-CA 123.27 2.646 . . . . 0.0 115.664 -168.828 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -87.16 -15.74 62.02 Favored Glycine 1 C--N 1.251 -4.153 0 CA-C-N 114.65 -1.159 . . . . 0.0 110.571 178.813 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.601 ' HA ' ' O ' ' A' ' 26' ' ' THR . 58.1 m -105.63 125.48 51.03 Favored 'General case' 0 N--CA 1.414 -2.243 0 CA-C-N 115.098 -0.551 . . . . 0.0 110.076 -177.597 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 5.0 m -103.71 148.29 26.23 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 -179.021 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 46.7 t -78.91 125.57 29.54 Favored 'General case' 0 N--CA 1.413 -2.318 0 CA-C-O 122.113 0.958 . . . . 0.0 110.537 -178.262 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 37.5 m -130.66 59.26 1.67 Allowed 'General case' 0 N--CA 1.398 -3.06 0 N-CA-C 105.345 -2.094 . . . . 0.0 105.345 174.806 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.45 ' HA ' ' HA ' ' A' ' 23' ' ' PRO . 31.6 t90 -28.08 132.97 0.17 Allowed Pre-proline 0 C--O 1.246 0.877 0 C-N-CA 127.381 2.272 . . . . 0.0 114.348 -171.052 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.45 ' HA ' ' HA ' ' A' ' 22' ' ' TRP . 5.1 Cg_exo -88.48 6.94 68.4 Favored 'Cis proline' 0 CA--C 1.54 0.8 0 C-N-CA 123.044 -1.648 . . . . 0.0 114.631 2.328 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.41 HG12 HG22 ' A' ' 7' ' ' THR . 27.5 m -113.79 152.83 15.42 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.137 0 C-N-CA 120.329 -0.548 . . . . 0.0 112.464 -175.479 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.419 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 36.0 m -96.13 145.77 25.22 Favored 'General case' 0 N--CA 1.406 -2.631 0 CA-C-O 122.02 0.914 . . . . 0.0 112.716 176.035 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.601 ' O ' ' HA ' ' A' ' 18' ' ' CYS . 19.6 p -121.51 -162.6 0.98 Allowed 'General case' 0 C--N 1.293 -1.883 0 CA-C-N 114.036 -1.438 . . . . 0.0 108.059 179.672 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.493 ' HG3' ' SG ' ' A' ' 4' ' ' CYS . 78.9 mtt180 -123.36 162.24 23.13 Favored 'General case' 0 N--CA 1.397 -3.083 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 177.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -139.25 135.36 33.81 Favored 'General case' 0 C--N 1.273 -2.718 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 178.157 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 60.96 16.7 48.67 Favored Glycine 0 N--CA 1.464 0.556 0 O-C-N 123.306 0.379 . . . . 0.0 113.078 179.555 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 57.7 mt -129.21 157.61 75.53 Favored Pre-proline 0 C--N 1.298 -1.67 0 C-N-CA 122.314 0.246 . . . . 0.0 111.007 -174.784 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 22.7 Cg_exo -62.07 137.2 65.31 Favored 'Trans proline' 0 C--O 1.254 1.278 0 C-N-CA 122.261 1.974 . . . . 0.0 109.735 175.154 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 28.2 t -87.58 114.29 26.22 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.565 0 CA-C-O 121.567 0.699 . . . . 0.0 109.407 -176.683 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 11.0 t . . . . . 0 C--N 1.262 -3.234 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 176.27 . . . . . . . . 0 0 . 1 stop_ save_